

BEST AVAILABLE COPY

WO0164922

Publication Title:

HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS

Abstract:

Abstract of WO0164922

Alternative and improved approaches to the heterologous expression of the proteins of *Neisseria meningitidis* and *Neisseria gonorrhoeae*. These approaches typically affect the level of expression, the ease of purification, the cellular localisation, and/or the immunological properties of the expressed protein. Data supplied from the esp@cenet database
- Worldwide

Courtesy of <http://v3.espacenet.com>

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
7 September 2001 (07.09.2001)

PCT

(10) International Publication Number
WO 01/64922 A2

(51) International Patent Classification⁷: **C12N 15/70**,
C07K 14/22, 19/00

Siena (IT). **PIZZA, Mariagrazia** [IT/IT]; Chiron SpA,
Via Fiorentina, 1, I-53100 Siena (IT).

(21) International Application Number: **PCT/IB01/00452**

(74) Agents: **HALLYBONE, Huw, George et al.**; Carpmaels
& Ransford, 43 Bloomsbury Square, London WC1A 2RA
(GB).

(22) International Filing Date: 28 February 2001 (28.02.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
0004695.3 28 February 2000 (28.02.2000) GB
0027675.8 13 November 2000 (13.11.2000) GB

(81) Designated States (*national*): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX,
MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,
TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(71) Applicant (*for all designated States except US*): **CHIRON**
SPA [IT/IT]; Via Fiorentina 1, I-53100 Siena (IT).

(84) Designated States (*regional*): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(72) Inventors; and


(75) Inventors/Applicants (*for US only*): **ARICO, Maria**,
Beatrice [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100
Siena (IT). **COMANDUCCI, Maurizio** [IT/IT]; Chiron
SpA, Via Fiorentina 1, I-53100 Siena (IT). **GALEOTTI**,
Cesira [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100
Siena (IT). **MASIGNANI, Vega** [IT/IT]; Chiron SpA, Via
Fiorentina 1, I-53100 Siena (IT). **GUILIANI, Marzia**,
Monica [IT/IT]; Chiron SpA, Via Fiorentina 1, I-53100

Published:

— without international search report and to be republished
upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guid-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.

(54) Title: HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS



(57) Abstract: Alternative and improved approaches to the heterologous expression of the proteins of *Neisseria meningitidis* and *Neisseria gonorrhoeae*. These approaches typically affect the level of expression, the ease of purification, the cellular localisation, and/or the immunological properties of the expressed protein.

HETEROLOGOUS EXPRESSION OF NEISSERIAL PROTEINS

All documents cited herein are incorporated by reference in their entirety.

TECHNICAL FIELD

This invention is in the field of protein expression. In particular, it relates to the heterologous
5 expression of proteins from *Neisseria* (e.g. *N.gonorrhoeae* or, preferably, *N.meningitidis*).

BACKGROUND ART

International patent applications WO99/24578, WO99/36544, WO99/57280 and
WO00/22430 disclose proteins from *Neisseria meningitidis* and *Neisseria gonorrhoeae*.
These proteins are typically described as being expressed in *E.coli* (i.e. heterologous
10 expression) as either N-terminal GST-fusions or C-terminal His-tag fusions, although other
expression systems, including expression in native *Neisseria*, are also disclosed.

It is an object of the present invention to provide alternative and improved approaches for
the heterologous expression of these proteins. These approaches will typically affect the
level of expression, the ease of purification, the cellular localisation of expression, and/or the
15 immunological properties of the expressed protein.

DISCLOSURE OF THE INVENTION

Nomenclature herein

The 2166 protein sequences disclosed in WO99/24578, WO99/36544 and WO99/57280 are
referred to herein by the following SEQ# numbers:

Application	Protein sequences	SEQ# herein
WO99/24578	Even SEQ IDs 2-892	SEQ#s 1-446
WO99/36544	Even SEQ IDs 2-90	SEQ#s 447-491
WO99/57280	Even SEQ IDs 2-3020	SEQ#s 492-2001
	Even SEQ IDs 3040-3114	SEQ#s 2002-2039
	SEQ IDs 3115-3241	SEQ#s 2040-2166

20 In addition to this SEQ# numbering, the naming conventions used in WO99/24578,
WO99/36544 and WO99/57280 are also used (e.g. 'ORF4', 'ORF40', 'ORF40-1' etc. as
used in WO99/24578 and WO99/36544; 'm919', 'g919' and 'a919' etc. as used in
WO99/57280).

The 2160 proteins NMB0001 to NMB2160 from Tettelin *et al.* [*Science* (2000) 287:1809-1815] are referred to herein as SEQ#s 2167-4326 [see also WO00/66791].

The term 'protein of the invention' as used herein refers to a protein comprising:

- (a) one of sequences SEQ#s 1-4326; or
- 5 (b) a sequence having sequence identity to one of SEQ#s 1-4326; or
- (c) a fragment of one of SEQ#s 1-4326.

The degree of 'sequence identity' referred to in (b) is preferably greater than 50% (*eg.* 60%, 70%, 80%, 90%, 95%, 99% or more). This includes mutants and allelic variants [*e.g.* see WO00/66741]. Identity is preferably determined by the Smith-Waterman homology search
10 algorithm as implemented in the MPSRCH program (Oxford Molecular), using an affine gap search with parameters *gap open penalty=12* and *gap extension penalty=1*. Typically, 50% identity or more between two proteins is considered to be an indication of functional equivalence.

The 'fragment' referred to in (c) should comprise at least *n* consecutive amino acids from
15 one of SEQ#s 1-4326 and, depending on the particular sequence, *n* is 7 or more (*eg.* 8, 10, 12, 14, 16, 18, 20, 25, 30, 35, 40, 50, 60, 70, 80, 90, 100 or more). Preferably the fragment comprises an epitope from one of SEQ#s 1-4326. Preferred fragments are those disclosed in WO00/71574 and WO01/04316.

Preferred proteins of the invention are found in *N.meningitidis* serogroup B.

- 20 Preferred proteins for use according to the invention are those of serogroup B *N.meningitidis* strain 2996 or strain 394/98 (a New Zealand strain). Unless otherwise stated, proteins mentioned herein are from *N.meningitidis* strain 2996. It will be appreciated, however, that the invention is not in general limited by strain. References to a particular protein (*e.g.* '287', '919' *etc.*) may be taken to include that protein from any strain.

25 ***Non-fusion expression***

In a first approach to heterologous expression, no fusion partner is used, and the native leader peptide (if present) is used. This will typically prevent any 'interference' from fusion partners and may alter cellular localisation and/or post-translational modification and/or folding in the heterologous host.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) no fusion partner is used, and (b) the protein's native leader peptide (if present) is used.

5 The method will typically involve the step of preparing an vector for expressing a protein of the invention, such that the first expressed amino acid is the first amino acid (methionine) of said protein, and last expressed amino acid is the last amino acid of said protein (*i.e.* the codon preceding the native STOP codon).

This approach is preferably used for the expression of the following proteins using the native leader peptide: 111, 149, 206, 225-1, 235, 247-1, 274, 283, 286, 292, 401, 406, 502-1, 503,
10 519-1, 525-1, 552, 556, 557, 570, 576-1, 580, 583, 664, 759, 907, 913, 920-1, 936-1, 953, 961, 983, 989, Orf4, Orf7-1, Orf9-1, Orf23, Orf25, Orf37, Orf38, Orf40, Orf40.1, Orf40.2, Orf72-1, Orf76-1, Orf85-2, Orf91, Orf97-1, Orf119, Orf143.1, NMB0109 and NMB2050. The suffix 'L' used herein in the name of a protein indicates expression in this manner using the native leader peptide.

15 Proteins which are preferably expressed using this approach using no fusion partner and which have no native leader peptide include: 008, 105, 117-1, 121-1, 122-1, 128-1, 148, 216, 243, 308, 593, 652, 726, 926, 982, Orf83-1 and Orf143-1.

Advantageously, it is used for the expression of ORF25 or ORF40, resulting in a protein which induces better anti-bactericidal antibodies than GST- or His-fusions.

20 This approach is particularly suited for expressing lipoproteins.

Leader-peptide substitution

In a second approach to heterologous expression, the native leader peptide of a protein of the invention is replaced by that of a different protein. In addition, it is preferred that no fusion partner is used. Whilst using a protein's own leader peptide in heterologous hosts can often
25 localise the protein to its 'natural' cellular location, in some cases the leader sequence is not efficiently recognised by the heterologous host. In such cases, a leader peptide known to drive protein targeting efficiently can be used instead.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is replaced by the leader peptide from a
30 different protein and, optionally, (b) no fusion partner is used.

The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; manipulating said nucleic acid to remove nucleotides that encode the protein's leader peptide and to introduce nucleotides that encode a different protein's leader peptide. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector. The expressed protein will consist of the replacement leader peptide at the N-terminus, followed by the protein of the invention minus its leader peptide.

The leader peptide is preferably from another protein of the invention (*e.g.* one of SEQ#s 1-4326), but may also be from an *E.coli* protein (*e.g.* the OmpA leader peptide) or an *Erwinia carotovora* protein (*e.g.* the PelB leader peptide), for instance.

10 A particularly useful replacement leader peptide is that of ORF4. This leader is able to direct lipidation in *E.coli*, improving cellular localisation, and is particularly useful for the expression of proteins 287, 919 and Δ G287. The leader peptide and N-terminal domains of 961 are also particularly useful.

Another useful replacement leader peptide is that of *E.coli* OmpA. This leader is able to direct membrane localisation of *E.coli*. It is particularly advantageous for the expression of ORF1, resulting in a protein which induces better anti-bactericidal antibodies than both fusions and protein expressed from its own leader peptide.

Another useful replacement leader peptide is MKKYLEFSAA. This can direct secretion into culture medium, and is extremely short and active. The use of this leader peptide is not restricted to the expression of Neisserial proteins – it may be used to direct the expression of any protein (particularly bacterial proteins).

Leader-peptide deletion

In a third approach to heterologous expression, the native leader peptide of a protein of the invention is deleted. In addition, it is preferred that no fusion partner is used.

25 Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is deleted and, optionally, (b) no fusion partner is used.

The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; manipulating said nucleic acid to remove nucleotides that encode the protein's leader peptide. The resulting nucleic acid may be inserted into an expression vector, or may

already be part of an expression vector. The first amino acid of the expressed protein will be that of the mature native protein.

This method can increase the levels of expression. For protein 919, for example, expression levels in *E.coli* are much higher when the leader peptide is deleted. Increased expression
5 may be due to altered localisation in the absence of the leader peptide.

The method is preferably used for the expression of 919, ORF46, 961, 050-1, 760 and 287.

Domain-based expression

In a fourth approach to heterologous expression, the protein is expressed as domains. This may be used in association with fusion systems (*e.g.* GST or His-tag fusions).

10 Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) at least one domain in the protein is deleted and, optionally, (b) no fusion partner is used.

The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; manipulating said nucleic acid to remove at least one domain from within the
15 protein. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector. Where no fusion partners are used, the first amino acid of the expressed protein will be that of a domain of the protein.

A protein is typically divided into notional domains by aligning it with known sequences in databases and then determining regions of the protein which show different alignment
20 patterns from each other.

The method is preferably used for the expression of protein 287. This protein can be notionally split into three domains, referred to as A B & C (see Figure 5). Domain B aligns strongly with IgA proteases, domain C aligns strongly with transferrin-binding proteins, and domain A shows no strong alignment with database sequences. An alignment of
25 polymorphic forms of 287 is disclosed in WO00/66741.

Once a protein has been divided into domains, these can be (a) expressed singly (b) deleted from with the protein *e.g.* protein ABCD → ABD, ACD, BCD *etc.* or (c) rearranged *e.g.* protein ABC → ACB, CAB *etc.* These three strategies can be combined with fusion partners is desired.

ORF46 has also been notionally split into two domains – a first domain (amino acids 1-433) which is well-conserved between species and serogroups, and a second domain (amino acids 433-608) which is not well-conserved. The second domain is preferably deleted. An alignment of polymorphic forms of ORF46 is disclosed in WO00/66741.

- 5 Protein 564 has also been split into domains (Figure 8), as have protein 961 (Figure 12) and protein 502 (amino acids 28-167 of the MC58 protein).

Hybrid proteins

- 10 In a fifth approach to heterologous expression, two or more (*e.g.* 3, 4, 5, 6 or more) proteins of the invention are expressed as a single hybrid protein. It is preferred that no non-Neisserial fusion partner (*e.g.* GST or poly-His) is used.

This offers two advantages. Firstly, a protein that may be unstable or poorly expressed on its own can be assisted by adding a suitable hybrid partner that overcomes the problem. Secondly, commercial manufacture is simplified – only one expression and purification need be employed in order to produce two separately-useful proteins.

- 15 Thus the invention provides a method for the simultaneous heterologous expression of two or more proteins of the invention, in which said two or more proteins of the invention are fused (*i.e.* they are translated as a single polypeptide chain).

- 20 The method will typically involve the steps of: obtaining a first nucleic acid encoding a first protein of the invention; obtaining a second nucleic acid encoding a second protein of the invention; ligating the first and second nucleic acids. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector.

Preferably, the constituent proteins in a hybrid protein according to the invention will be from the same strain.

- 25 The fused proteins in the hybrid may be joined directly, or may be joined via a linker peptide *e.g.* via a poly-glycine linker (*i.e.* G_n where $n = 3, 4, 5, 6, 7, 8, 9, 10$ or more) or via a short peptide sequence which facilitates cloning. It is evidently preferred not to join a ΔG protein to the C-terminus of a poly-glycine linker.

The fused proteins may lack native leader peptides or may include the leader peptide sequence of the N-terminal fusion partner.

The method is well suited to the expression of proteins orf1, orf4, orf25, orf40, Orf46/46.1, orf83, 233, 287, 292L, 564, 687, 741, 907, 919, 953, 961 and 983.

The 42 hybrids indicated by 'X' in the following table of form $\text{NH}_2\text{-A-B-COOH}$ are preferred:

$\downarrow \text{A} \quad \text{B} \rightarrow$	ORF46.1	287	741	919	953	961	983
ORF46.1		X	X	X	X	X	X
287	X		X	X	X	X	X
741	X	X		X	X	X	X
919	X	X	X		X	X	X
953	X	X	X	X		X	X
961	X	X	X	X	X		X
983	X	X	X	X	X	X	

- 5 Preferred proteins to be expressed as hybrids are thus ORF46.1, 287, 741, 919, 953, 961 and 983. These may be used in their essentially full-length form, or poly-glycine deletions (ΔG) forms may be used (*e.g.* $\Delta\text{G-287}$, ΔGTbp2 , ΔG741 , ΔG983 *etc.*), or truncated forms may be used (*e.g.* $\Delta\text{1-287}$, $\Delta\text{2-287}$ *etc.*), or domain-deleted versions may be used (*e.g.* 287B, 287C, 287BC, ORF46₁₋₄₃₃, ORF46₄₃₃₋₆₀₈, ORF46, 961c *etc.*).
- 10 Particularly preferred are: (a) a hybrid protein comprising 919 and 287; (b) a hybrid protein comprising 953 and 287; (c) a hybrid protein comprising 287 and ORF46.1; (d) a hybrid protein comprising ORF1 and ORF46.1; (e) a hybrid protein comprising 919 and ORF46.1; (f) a hybrid protein comprising ORF46.1 and 919; (g) a hybrid protein comprising ORF46.1, 287 and 919; (h) a hybrid protein comprising 919 and 519; and (i) a hybrid protein
- 15 comprising ORF97 and 225. Further embodiments are shown in Figure 14.

Where 287 is used, it is preferably at the C-terminal end of a hybrid; if it is to be used at the N-terminus, if is preferred to use a ΔG form of 287 is used (*e.g.* as the N-terminus of a hybrid with ORF46.1, 919, 953 or 961).

Where 287 is used, this is preferably from strain 2996 or from strain 394/98.

- 20 Where 961 is used, this is preferably at the N-terminus. Domain forms of 961 may be used.

Alignments of polymorphic forms of ORF46, 287, 919 and 953 are disclosed in WO00/66741. Any of these polymorphs can be used according to the present invention.

Temperature

In a sixth approach to heterologous expression, proteins of the invention are expressed at a low temperature.

Expressed Neisserial proteins (*e.g.* 919) may be toxic to *E.coli*, which can be avoided by
5 expressing the toxic protein at a temperature at which its toxic activity is not manifested.

Thus the present invention provides a method for the heterologous expression of a protein of the invention, in which expression of a protein of the invention is carried out at a temperature at which a toxic activity of the protein is not manifested.

A preferred temperature is around 30°C. This is particularly suited to the expression of 919.

10 ***Mutations***

As discussed above, expressed Neisserial proteins may be toxic to *E.coli*. This toxicity can be avoided by mutating the protein to reduce or eliminate the toxic activity. In particular, mutations to reduce or eliminate toxic enzymatic activity can be used, preferably using site-directed mutagenesis.

15 In a seventh approach to heterologous expression, therefore, an expressed protein is mutated to reduce or eliminate toxic activity.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which protein is mutated to reduce or eliminate toxic activity.

The method is preferably used for the expression of protein 907, 919 or 922. A preferred
20 mutation in 907 is at Glu-117 (*e.g.* Glu→Gly); preferred mutations in 919 are at Glu-255 (*e.g.* Glu→Gly) and/or Glu-323 (*e.g.* Glu→Gly); preferred mutations in 922 are at Glu-164 (*e.g.* Glu→Gly), Ser-213 (*e.g.* Ser→Gly) and/or Asn-348 (*e.g.* Asn→Gly).

Alternative vectors

In a eighth approach to heterologous expression, an alternative vector used to express the
25 protein. This may be to improve expression yields, for instance, or to utilise plasmids that are already approved for GMP use.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which an alternative vector is used. The alternative vector is preferably pSM214, with no fusion partners. Leader peptides may or may not be included.

This approach is particularly useful for protein 953. Expression and localisation of 953 with its native leader peptide expressed from pSM214 is much better than from the pET vector.

pSM214 may also be used with: Δ G287, Δ 2-287, Δ 3-287, Δ 4-287, Orf46.1, 961L, 961, 961(MC58), 961c, 961c-L, 919, 953 and Δ G287-Orf46.1.

- 5 Another suitable vector is pET-24b (Novagen; uses kanamycin resistance), again using no fusion partners. pET-24b is preferred for use with: Δ G287K, Δ 2-287K, Δ 3-287K, Δ 4-287K, Orf46.1-K, Orf46A-K, 961-K (MC58), 961a-K, 961b-K, 961c-K, 961c-L-K, 961d-K, Δ G287-919-K, Δ G287-Orf46.1-K and Δ G287-961-K.

Multimeric form

- 10 In a ninth approach to heterologous expression, a protein is expressed or purified such that it adopts a particular multimeric form.

This approach is particularly suited to protein 953. Purification of one particular multimeric form of 953 (the monomeric form) gives a protein with greater bactericidal activity than other forms (the dimeric form).

- 15 Proteins 287 and 919 may be purified in dimeric forms.

Protein 961 may be purified in a 180kDa oligomeric form (e.g. a tetramer).

Lipidation

In a tenth approach to heterologous expression, a protein is expressed as a lipidated protein.

- 20 Thus the invention provides a method for the heterologous expression of a protein of the invention, in which the protein is expressed as a lipidated protein.

This is particularly useful for the expression of 919, 287, ORF4, 406, 576-1, and ORF25. Polymorphic forms of 919, 287 and ORF4 are disclosed in WO00/66741.

The method will typically involve the use of an appropriate leader peptide without using an N-terminal fusion partner.

- 25 *C-terminal deletions*

In an eleventh approach to heterologous expression, the C-terminus of a protein of the invention is mutated. In addition, it is preferred that no fusion partner is used.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) the protein's C-terminus region is mutated and, optionally, (b) no fusion partner is used.

5 The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; manipulating said nucleic acid to mutate nucleotides that encode the protein's C-terminus portion. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector. The first amino acid of the expressed protein will be that of the mature native protein.

The mutation may be a substitution, insertion or, preferably, a deletion.

10 This method can increase the levels of expression, particularly for proteins 730, ORF29 and ORF46. For protein 730, a C-terminus region of around 65 to around 214 amino acids may be deleted; for ORF46, the C-terminus region of around 175 amino acids may be deleted; for ORF29, the C-terminus may be deleted to leave around 230-370 N-terminal amino acids.

Leader peptide mutation

15 In a twelfth approach to heterologous expression, the leader peptide of the protein is mutated. This is particularly useful for the expression of protein 919.

Thus the invention provides a method for the heterologous expression of a protein of the invention, in which the protein's leader peptide is mutated.

20 The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; and manipulating said nucleic acid to mutate nucleotides within the leader peptide. The resulting nucleic acid may be inserted into an expression vector, or may already be part of an expression vector.

Poly-glycine deletion

25 In a thirteenth approach to heterologous expression, poly-glycine stretches in wild-type sequences are mutated. This enhances protein expression.

The poly-glycine stretch has the sequence (Gly)_n, where $n \geq 4$ (e.g. 5, 6, 7, 8, 9 or more). This stretch is mutated to disrupt or remove the (Gly)_n. This may be by deletion (e.g. CGGGGS → CGGGS, CGGS, CGS or CS), by substitution (e.g. CGGGGS → CGXGGS, CGXXGS, CGXGXS etc.), and/or by insertion (e.g. CGGGGS → CGGXGGS, CGXGGGS, etc.).

This approach is not restricted to Neisserial proteins – it may be used for any protein (particularly bacterial proteins) to enhance heterologous expression. For Neisserial proteins, however, it is particularly suitable for expressing 287, 741, 983 and Tbp2. An alignment of polymorphic forms of 287 is disclosed in WO00/66741.

- 5 Thus the invention provides a method for the heterologous expression of a protein of the invention, in which (a) a poly-glycine stretch within the protein is mutated.

The method will typically involve the steps of: obtaining nucleic acid encoding a protein of the invention; and manipulating said nucleic acid to mutate nucleotides that encode a poly-glycine stretch within the protein sequence. The resulting nucleic acid may be inserted into
10 an expression vector, or may already be part of an expression vector.

Conversely, the opposite approach (*i.e.* introduction of poly-glycine stretches) can be used to suppress or diminish expression of a given heterologous protein.

Heterologous host

Whilst expression of the proteins of the invention may take place in the native host (*i.e.* the
15 organism in which the protein is expressed in nature), the present invention utilises a heterologous host. The heterologous host may be prokaryotic or eukaryotic. It is preferably *E.coli*, but other suitable hosts include *Bacillus subtilis*, *Vibrio cholerae*, *Salmonella typhi*, *Salmonella typhimurium*, *Neisseria meningitidis*, *Neisseria gonorrhoeae*, *Neisseria lactamica*, *Neisseria cinerea*, *Mycobacteria* (*e.g.* *M.tuberculosis*), yeast *etc.*

Vectors etc.

As well as the methods described above, the invention provides (a) nucleic acid and vectors useful in these methods (b) host cells containing said vectors (c) proteins expressed or expressable by the methods (d) compositions comprising these proteins, which may be suitable as vaccines, for instance, or as diagnostic reagents, or as immunogenic compositions
25 (e) these compositions for use as medicaments (*e.g.* as vaccines) or as diagnostic reagents (f) the use of these compositions in the manufacture of (1) a medicament for treating or preventing infection due to Neisserial bacteria (2) a diagnostic reagent for detecting the presence of Neisserial bacteria or of antibodies raised against Neisserial bacteria, and/or (3) a reagent which can raise antibodies against Neisserial bacteria and (g) a method of treating a

patient, comprising administering to the patient a therapeutically effective amount of these compositions.

Sequences

5 The invention also provides a protein or a nucleic acid having any of the sequences set out in the following examples. It also provides proteins and nucleic acid having sequence identity to these. As described above, the degree of 'sequence identity' is preferably greater than 50% (eg. 60%, 70%, 80%, 90%, 95%, 99% or more).

Furthermore, the invention provides nucleic acid which can hybridise to the nucleic acid disclosed in the examples, preferably under "high stringency" conditions (eg. 65°C in a
10 0.1xSSC, 0.5% SDS solution).

The invention also provides nucleic acid encoding proteins according to the invention.

It should also be appreciated that the invention provides nucleic acid comprising sequences complementary to those described above (eg. for antisense or probing purposes).

Nucleic acid according to the invention can, of course, be prepared in many ways (eg. by
15 chemical synthesis, from genomic or cDNA libraries, from the organism itself *etc.*) and can take various forms (eg. single stranded, double stranded, vectors, probes *etc.*).

In addition, the term "nucleic acid" includes DNA and RNA, and also their analogues, such as those containing modified backbones, and also peptide nucleic acids (PNA) *etc.*

BRIEF DESCRIPTION OF DRAWINGS

20 Figures 1 and 2 show constructs used to express proteins using heterologous leader peptides.

Figure 3 shows expression data for ORF1, and Figure 4 shows similar data for protein 961.

Figure 5 shows domains of protein 287, and Figures 6 & 7 show deletions within domain A.

Figure 8 shows domains of protein 564.

Figure 9 shows the *PhoC* reporter gene driven by the 919 leader peptide, and Figure 10
25 shows the results obtained using mutants of the leader peptide.

Figure 11 shows insertion mutants of protein 730 (A: 730-C1; B: 730-C2).

Figure 12 shows domains of protein 961.

Figure 13 shows SDS-PAGE of ΔG proteins. Dots show the main recombinant product.

Figure 14 shows 26 hybrid proteins according to the invention.

MODES FOR CARRYING OUT THE INVENTION

Example 1 – 919 and its leader peptide

- 5 Protein 919 from *N.meningitidis* (serogroup B, strain 2996) has the following sequence:

```

1  MKKYLFRAAL YGIAAAILAA CQSKSIQTFP QPDTSVINGP DRPVGIPDPA
51 GTTVGGGGAV YTVVPHLSLP HWAAQDFAKS LQSFRLGCAN LKNRQGWQDV
101 CAQAFQTPVH SFQAKQFFER YFTPWQVAGN GSLAGTVTGY YEPVLKGDDR
151 RTAQARFPIY GIPDDFISVP LPAGLRSGKA LVRIQTGKN SGTIDNTGGT
10  201 HTADLSRFPI TARTTAIKGR FEGRSFLPYH TRNQINGGAL DGKAPILGYA
251 EDPVELFFMH IQGSGRLKTP SGKYIRIGYA DKNEHPYVSI GRYMADKGYL
301 KLGQTSMQGI KAYMRQNPQR LAEVLGQNPS YIFFRELAGS SNDGPVGALG
351 TPLMGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG
401 AVRVDYFWGY GDEAGELAGK QKTGTGYVWQL LPNGMKPEYR P*
```

- 15 The leader peptide is underlined.

The sequences of 919 from other strains can be found in Figures 7 and 18 of WO00/66741.

Example 2 of WO99/57280 discloses the expression of protein 919 as a His-fusion in *E.coli*.

The protein is a good surface-exposed immunogen.

Three alternative expression strategies were used for 919:

- 20 1) 919 without its leader peptide (and without the mature N-terminal cysteine) and without any fusion partner ('919^{untagged}):

```

1  QSKSIQTFP QPDTSVINGP DRPVGIPDPA GTTVGGGGAV YTVVPHLSLP
50 HWAAQDFAKS LQSFRLGCAN LKNRQGWQDV CAQAFQTPVH SFQAKQFFER
100 YFTPWQVAGN GSLAGTVTGY YEPVLKGDDR RTAQARFPIY GIPDDFISVP
25  150 LPAGLRSGKA LVRIQTGKN SGTIDNTGGT HTADLSRFPI TARTTAIKGR
200 FEGRSFLPYH TRNQINGGAL DGKAPILGYA EDPVELFFMH IQGSGRLKTP
250 SGKYIRIGYA DKNEHPYVSI GRYMADKGYL KLGQTSMQGI KAYMRQNPQR
300 LAEVLGQNPS YIFFRELAGS SNDGPVGALG TPLMGEYAGA VDRHYITLGA
350 PLFVATAHPV TRKALNRLIM AQDTGSAIKG AVRVDYFWGY GDEAGELAGK
30  400 QKTGTGYVWQL LPNGMKPEYR P*
```

The leader peptide and cysteine were omitted by designing the 5'-end amplification primer downstream from the predicted leader sequence.

- 2) 919 with its own leader peptide but without any fusion partner ('919L'); and
35 3) 919 with the leader peptide (MKTFFKTLSSAAALALILAA) from ORF4 ('919Lorf4').

```

1  MKTFFKTLSS AAALALILAA CQSKSIQTFP QPDTSVINGP DRPVGIPDPA
50 GTTVGGGGAV YTVVPHLSLP HWAAQDFAKS LQSFRLGCAN LKNRQGWQDV
100 CAQAFQTPVH SFQAKQFFER YFTPWQVAGN GSLAGTVTGY YEPVLKGDDR
150 RTAQARFPIY GIPDDFISVP LPAGLRSGKA LVRIQTGKN SGTIDNTGGT
40  200 HTADLSRFPI TARTTAIKGR FEGRSFLPYH TRNQINGGAL DGKAPILGYA
250 EDPVELFFMH IQGSGRLKTP SGKYIRIGYA DKNEHPYVSI GRYMADKGYL
300 KLGQTSMQGI KSYMQRNPQR LAEVLGQNPS YIFFRELAGS SNDGPVGALG
```

-14-

350 TPLMGEYAGA VDRHYITLGA PLFVATAHPV TRKALNRLIM AQDTGSAIKG
 400 AVRVDYFWGY GDEAGELAGK QKTTGYVWQL LPNGMKPEYR P*

To make this construct, the entire sequence encoding the ORF4 leader peptide was included in the 5'-primer as a tail (primer 919Lorf4 For). A *NheI* restriction site was generated by a double nucleotide change in the sequence coding for the ORF4 leader (no amino acid changes), to allow different genes to be fused to the ORF4 leader peptide sequence. A stop codon was included in all the 3'-end primer sequences.

All three forms of the protein were expressed and could be purified.

The '919L' and '919Lorf4' expression products were both lipidated, as shown by the incorporation of [³H]-palmitate label. 919^{untagged} did not incorporate the ³H label and was located intracellularly.

919Lorf4 could be purified more easily than 919L. It was purified and used to immunise mice. The resulting sera gave excellent results in FACS and ELISA tests, and also in the bactericidal assay. The lipoprotein was shown to be localised in the outer membrane.

919^{untagged} gave excellent ELISA titres and high serum bactericidal activity. FACS confirmed its cell surface location.

Example 2 – 919 and expression temperature

Growth of *E.coli* expressing the 919Lorf4 protein at 37°C resulted in lysis of the bacteria. In order to overcome this problem, the recombinant bacteria were grown at 30°C. Lysis was prevented without preventing expression.

Example 3 – mutation of 907, 919 and 922

It was hypothesised that proteins 907, 919 and 922 are murein hydrolases, and more particularly lytic transglycosylases. Murein hydrolases are located on the outer membrane and participate in the degradation of peptidoglycan.

The purified proteins 919^{untagged}, 919Lorf4, 919-His (*i.e.* with a C-terminus His-tag) and 922-His were thus tested for murein hydrolase activity [Ursinus & Holtje (1994) *J.Bact.* 176:338-343]. Two different assays were used, one determining the degradation of insoluble murein sacculus into soluble muropeptides and the other measuring breakdown of poly(MurNAc-GlcNAc)_{n>30} glycan strands.

The first assay uses murein sacculi radiolabelled with meso-2,6-diamino-3,4,5-[³H]pimelic acid as substrate. Enzyme (3–10 µg total) was incubated for 45 minutes at 37°C in a total volume of 100µl comprising 10mM Tris-maleate (pH 5.5), 10mM MgCl₂, 0.2% v/v Triton X-100 and [³H]A₂pm labelled murein sacculi (about 10000cpm). The assay mixture was placed on ice for 15 minutes with 100 µl of 1% w/v N-acetyl-N,N,N-trimethylammonium for 15 minutes and precipitated material pelleted by centrifugation at 10000g for 15 minutes. The radioactivity in the supernatant was measured by liquid scintillation counting. *E.coli* soluble lytic transglycosylase Slt70 was used as a positive control for the assay; the negative control comprised the above assay solution without enzyme.

10 All proteins except 919-His gave positive results in the first assay.

The second assay monitors the hydrolysis of poly(MurNAc-GlcNAc)glycan strands. Purified strands, poly(MurNAc-GlcNAc)_{n>30} labelled with N-acetyl-D-1-[³H]glucosamine were incubated with 3µg of 919L in 10 mM Tris-maleate (pH 5.5), 10 mM MgCl₂ and 0.2% v/v Triton X-100 for 30 min at 37°C. The reaction was stopped by boiling for 5 minutes and the pH of the sample adjusted to about 3.5 by addition of 10µl of 20% v/v phosphoric acid. Substrate and product were separated by reversed phase HPLC on a Nucleosil 300 C₁₈ column as described by Harz *et. al.* [*Anal. Biochem.* (1990) 190:120-128]. The *E.coli* lytic transglycosylase Mlt A was used as a positive control in the assay. The negative control was performed in the absence of enzyme.

20 By this assay, the ability of 919Lorf4 to hydrolyse isolated glycan strands was demonstrated when anhydrodisaccharide subunits were separated from the oligosaccharide by HPLC.

Protein 919Lorf4 was chosen for kinetic analyses. The activity of 919Lorf4 was enhanced 3.7-fold by the addition of 0.2% v/v Triton X-100 in the assay buffer. The presence of Triton X-100 had no effect on the activity of 919^{untagged}. The effect of pH on enzyme activity was determined in Tris-Maleate buffer over a range of 5.0 to 8.0. The optimal pH for the reaction was determined to be 5.5. Over the temperature range 18°C to 42°C, maximum activity was observed at 37°C. The effect of various ions on murein hydrolase activity was determined by performing the reaction in the presence of a variety of ions at a final concentration of 10mM. Maximum activity was found with Mg²⁺, which stimulated activity 2.1-fold. Mn²⁺ and Ca²⁺ also stimulated enzyme activity to a similar extent while the addition Ni²⁺ and EDTA had no significant effect. In contrast, both Fe²⁺ and Zn²⁺ significantly inhibited enzyme activity.

The structures of the reaction products resulting from the digestion of unlabelled *E.coli* murein sacculus were analysed by reversed-phase HPLC as described by Glauner [*Anal. Biochem.* (1988) 172:451-464]. Murein sacculi digested with the muramidase Cellosyl were used to calibrate and standardise the Hypersil ODS column. The major reaction products
5 were 1,6 anhydrodisaccharide tetra and tri peptides, demonstrating the formation of 1,6 anhydromuraminic acid intramolecular bond.

These results demonstrate experimentally that 919 is a murein hydrolase and in particular a member of the lytic transglycosylase family of enzymes. Furthermore the ability of 922-His to hydrolyse murein sacculi suggests this protein is also a lytic transglycosylase.

10 This activity may help to explain the toxic effects of 919 when expressed in *E.coli*.

In order to eliminate the enzymatic activity, rational mutagenesis was used. 907, 919 and 922 show fairly low homology to three membrane-bound lipidated murein lytic transglycosylases from *E.coli*:

- 919 (441aa) is 27.3% identical over 440aa overlap to *E.coli* MLTA (P46885);
15 922 (369aa) is 38.7% identical over 310aa overlap to *E.coli* MLTB (P41052); and
907-2 (207aa) is 26.8% identical over 149aa overlap to *E.coli* MLTC (P52066).

907-2 also shares homology with *E.coli* MLTD (P23931) and Slt70 (P03810), a soluble lytic transglycosylase that is located in the periplasmic space. No significant sequence homology can be detected among 919, 922 and 907-2, and the same is true among the corresponding
20 MLTA, MLTB and MLTC proteins.

Crystal structures are available for Slt70 [1QTEA; 1QTEB; Thunnissen *et al.* (1995) *Biochemistry* 34:12729-12737] and for Slt35 [1LTM; 1QUS; 1QUT; van Asselt *et al.* (1999) *Structure Fold Des* 7:1167-80] which is a soluble form of the 40kDa MLTB.

The catalytic residue (a glutamic acid) has been identified for both Slt70 and MLTB.

25 In the case of Slt70, mutagenesis studies have demonstrated that even a conservative substitution of the catalytic Glu505 with a glutamine (Gln) causes the complete loss of enzymatic activity. Although Slt35 has no obvious sequence similarity to Slt70, their catalytic domains shows a surprising similarity. The corresponding catalytic residue in MLTB is Glu162.

-17-

Another residue which is believed to play an important role in the correct folding of the enzymatic cleft is a well-conserved glycine (Gly) downstream of the glutamic acid. Recently, Terrak *et al.* [*Mol.Microbiol.* (1999) 34:350-64] have suggested the presence of another important residue which is an aromatic amino acid located around 70-75 residues downstream of the catalytic glutamic acid.

Sequence alignment of Slr70 with 907-2 and of MLTB with 922 were performed in order to identify the corresponding catalytic residues in the MenB antigens.

The two alignments in the region of the catalytic domain are reported below:

907-2/Slr70:

```

10      90      100      110      ▼120      130      140
      907-2.pep  ERRRLLVNIQYESSRAG--LDTQIVLGLIEVESAFRQYVAISGVGARGLMQVMPFWKNYIG
      | | | | : : : : : : : : : : | | | | | : : :
      slty_ecoli  ERFPLAYNDLFKRYTSGKEIPQSYAMAIARQESAWNPKVKSPVGASGLMQIMPGTATHTV
      480      490      500      ▲ 510      520      530
                                GLU505

```

922/MLTB

```

20      150      160      ▼ 170      180      190      200
      922.pep    VAQKYGVPAELIVAVIGIETNYGKNTGSFRVADALATLGFDYPRRAGFFQKELVELLKLA
      : | | | | : : : : : : : : : : | : | : | : | : | : | : | : | : | : |
      mltb_ecoli  AWQVYGVPPPIIVGIIIGVETRWGRVMGKTRILDALATLSFNYPRAEYFSGELETFLMLA
      150      160      ▲ 170      180      190      200
                                GLU162

25      210      220      230      240      250      260
      922.pep    KEEGGDVFAFKGSYAGAMGMPQFMPSSYRKWAVDYDGDGHRDIWGNVDVAASVANYMKQ
      : : | | : : | : | : | : | : | : | : | : | : | : | : | : | : | : |
      mltb_ecoli  RDEQDDPLNLKGSFAGAMGYGQFMPSSYKQYAVDFSGDGHINLWDPV-DAIGSVANYFKA
      210      220      230      240      250      260

```

From these alignments, it results that the corresponding catalytic glutamate in 907-2 is Glu117, whereas in 922 is Glu164. Both antigens also share downstream glycines that could have a structural role in the folding of the enzymatic cleft (in bold), and 922 has a conserved aromatic residue around 70aa downstream (in bold).

In the case of protein 919, no 3D structure is available for its *E.coli* homologue MLTA, and nothing is known about a possible catalytic residue. Nevertheless, three amino acids in 919 are predicted as catalytic residues by alignment with MLTA:

919/MLTA

```

40      240      250      ▼ 260 □ □ 270 □      280      290
      919.pep    ALDGKAPILGYAEDPVELFFMHIIQSGRLKTPSGKYIRI-GYADKNEHPYVSIGRYMADK
      | : | | : : | : : : : : | : | : | : : : : : | : | : | : : : :
      mlta_ecoli  ALSDKY-ILAYSNSLMDNFIMDVQGSYIDFGDGSPLNFFSYAGKNHAYRSIGKVLIDR
      170      180      190      200      210

```

-18-

		300	310	320 ▼	330 □ □	340	350 ◊	0
919.pep		GYLKL	QTSMQGIKSYMRQNPQ	RLAEVL	GQNPSYIFFRELAGSSNDGPV	GALGTPLMG		
		:	: : : : : : : : :	: : : :	: :	: :		
5	mlta_ecoli.p	GEVKKEDMSMQAIRHWGETHSEAEVRELLEQNPSFVFFKPQSFA	----	PVKGASAVPLVG				
		220	230	240	250	260	270	
		360 ▼	o	380	390	400	410 ◊	
919.pep		EYAGAVDRHYITLGAPLFVATAHPVTRKALN	----	RLIMAQDTGSAIKGAVRVDYFWGY				
10	mlta_ecoli.p	RASVASDRSTIIPPGTTLAEVPLLDNNGKFNGQYELRLMVALDVGGAIKQ	----	HFDTYQGI				
		280	290	300	310	320	330	
		420	o					
919.pep		GDEAGELAGKQKTTGYVWQLLP						
15	mlta_ecoli.p	GPEAGHRAGWYNHYGRVWLKT						
		340	350					

The three possible catalytic residues are shown by the symbol ▼:

- 20 1) Glu255 (Asp in MLTA), followed by three conserved glycines (Gly263, Gly265 and Gly272) and three conserved aromatic residues located approximately 75-77 residues downstream. These downstream residues are shown by □.
- 2) Glu323 (conserved in MLTA), followed by 2 conserved glycines (Gly347 and Gly355) and two conserved aromatic residues located 84-85 residues downstream (Tyr406 or Phe407). These downstream residues are shown by ◊.
- 25 3) Asp362 (instead of the expected Glu), followed by one glycine (Gly 369) and a conserved aromatic residue (Trp428). These downstream residues are shown by o.

Alignments of polymorphic forms of 919 are disclosed in WO00/66741.

- Based on the prediction of catalytic residues, three mutants of the 919 and one mutant of 907, containing each a single amino acid substitution, have been generated. The glutamic acids in position 255 and 323 and the aspartic acids in position 362 of the 919 protein and the glutamic acid in position 117 of the 907 protein, were replaced with glycine residues using PCR-based SDM. To do this, internal primers containing a codon change from Glu or Asp to Gly were designed:

Primers	Sequences	Codon change
919-E255 for 919-E255 rev	CGAAGACCCCGTC <u>Ggt</u> CTTTTTTTTATG GTGCATAAAAAAAAGacCGACGGGGTCT	GAA → Ggt
919-E323 for 919-E323 rev	AACGCCTCGCC <u>Ggt</u> GTTTTGGGTCA TTTGACCCAAAAACacCGGCGAGGCG	GAA → Ggt
919-D362 for 919-D362 rev	TGCCGGCGCAGTC <u>Ggt</u> CGGCACTACA TAATGTAGTGCCGacCGACTGCGCCG	GAC → Ggt
907-E117 for 907-E117 rev	TGATTGAGGTGG <u>gt</u> AGCGCGTTCCG GGCGGAACGCGCTacCCACCTCAAT	GAA → Ggt

Underlined nucleotides code for glycine; the mutated nucleotides are in lower case.

To generate the 919-E255, 919-E323 and 919-E362 mutants, PCR was performed using 20ng of the pET 919-Lorf4 DNA as template, and the following primer pairs:

- 1) Orf4L for / 919-E255 rev
- 2) 919-E255 for / 919L rev
- 3) Orf4L for / 919-E323 rev
- 4) 919-E323 for / 919L rev
- 5) Orf4L for / 919-D362 rev
- 6) 919-D362 for / 919L rev

- 10 The second round of PCR was performed using the product of PCR 1-2, 3-4 or 5-6 as template, and as forward and reverse primers the "Orf4L for" and "919L rev" respectively.

For the mutant 907-E117, PCR have been performed using 200ng of chromosomal DNA of the 2996 strain as template and the following primer pairs:

- 7) 907L for / 907-E117 rev
- 8) 907-E117 for / 907L rev

The second round of PCR was performed using the products of PCR 7 and 8 as templates and the oligos "907L for" and "907L rev" as primers.

- 20 The PCR fragments containing each mutation were processed following the standard procedure, digested with *Nde*I and *Xho*I restriction enzymes and cloned into pET-21b+ vector. The presence of each mutation was confirmed by sequence analysis.

Mutation of Glu117 to Gly in 907 is carried out similarly, as is mutation of residues Glu164, Ser213 and Asn348 in 922.

The E255G mutant of 919 shows a 50% reduction in activity; the E323G mutant shows a 70% reduction in activity; the E362G mutant shows no reduction in activity.

Example 4 – multimeric form

287-GST, 919^{untagged} and 953-His were subjected to gel filtration for analysis of quaternary
 5 structure or preparative purposes. The molecular weight of the native proteins was estimated using either FPLC Superose 12 (H/R 10/30) or Superdex 75 gel filtration columns (Pharmacia). The buffers used for chromatography for 287, 919 and 953 were 50 mM Tris-HCl (pH 8.0), 20 mM Bicine (pH 8.5) and 50 mM Bicine (pH 8.0), respectively.

10 Additionally each buffer contained 150-200 mM NaCl and 10% v/v glycerol. Proteins were dialysed against the appropriate buffer and applied in a volume of 200µl. Gel filtration was performed with a flow rate of 0.5 – 2.0 ml/min and the eluate monitored at 280nm. Fractions were collected and analysed by SDS-PAGE. Blue dextran 2000 and the molecular weight standards ribonuclease A, chymotrypsin A ovalbumin, albumin (Pharmacia) were used to calibrate the column. The molecular weight of the sample was estimated from a calibration
 15 curve of K_{av} vs. $\log M_r$ of the standards. Before gel filtration, 287-GST was digested with thrombin to cleave the GST moiety.

The estimated molecular weights for 287, 919 and 953-His were 73 kDa, 47 kDa and 43 kDa respectively. These results suggest 919 is monomeric while both 287 and 953 are principally dimeric in their nature. In the case of 953-His, two peaks were observed during gel filtration.
 20 The major peak (80%) represented a dimeric conformation of 953 while the minor peak (20%) had the expected size of a monomer. The monomeric form of 953 was found to have greater bactericidal activity than the dimer.

Example 5 – pSM214 and pET-24b vectors

953 protein with its native leader peptide and no fusion partners was expressed from the pET
 25 vector and also from pSM214 [Velati Bellini *et al.* (1991) *J. Biotechnol.* 18, 177-192].

The 953 sequence was cloned as a full-length gene into pSM214 using the *E. coli* MM294-1 strain as a host. To do this, the entire DNA sequence of the 953 gene (from ATG to the STOP codon) was amplified by PCR using the following primers:

	953L for/2 CCGGAATTCTTATGAAAAAATCATCTTCGCCGC	Eco RI
30	953L rev/2 GCCCAAGCTTTTATTGTTTGGCTGCCTCGATT	Hind III

which contain *EcoRI* and *HindIII* restriction sites, respectively. The amplified fragment was digested with *EcoRI* and *HindIII* and ligated with the pSM214 vector digested with the same two enzymes. The ligated plasmid was transformed into *E.coli* MM294-1 cells (by incubation in ice for 65 minutes at 37° C) and bacterial cells plated on LB agar containing 20µg/ml of chloramphenicol.

Recombinant colonies were grown over-night at 37°C in 4 ml of LB broth containing 20 µg/ml of chloramphenicol; bacterial cells were centrifuged and plasmid DNA extracted as and analysed by restriction with *EcoRI* and *HindIII*. To analyse the ability of the recombinant colonies to express the protein, they were inoculated in LB broth containing 20µg/ml of chloramphenicol and let to grown for 16 hours at 37°C. Bacterial cells were centrifuged and resuspended in PBS. Expression of the protein was analysed by SDS-PAGE and Coomassie Blue staining.

Expression levels were unexpectedly high from the pSM214 plasmid.

Oligos used to clone sequences into pSM-214 vectors were as follows:

ΔG287 (pSM-214)	Fwd	CCGGAATTCCTTATG-TCGCCCAGATGTTAAATCGGCGGA	EcoRI
	Rev	GCCCAAGCTT-TCAATCCTGCTCTTTTTTGCCG	HindIII
Δ2 287 (pSM-214)	Fwd	CCGGAATTCCTTATG-AGCCAAGATATGGCGGCAGT	EcoRI
	Rev	GCCCAAGCTT-TCAATCCTGCTCTTTTTTGCCG	HindIII
Δ3 287 (pSM-214)	Fwd	CCGGAATTCCTTATG-TCCGCCGAATCCGCAAATCA	EcoRI
	Rev	GCCCAAGCTT-TCAATCCTGCTCTTTTTTGCCG	HindIII
Δ4 287 (pSM-214)	Fwd	CCGGAATTCCTTATG-GGAAGGGTTGATTTGGCTAATG	EcoRI
	Rev	GCCCAAGCTT-TCAATCCTGCTCTTTTTTGCCG	HindIII
Orf46.1 (pSM-214)	Fwd	CCGGAATTCCTTATG-TCAGATTTGGCAAACGATTCTT	EcoRI
	Rev	GCCCAAGCTT-TTACGTATCATATTTACAGTGCTTC	HindIII
ΔG287-Orf46.1 (pSM-214)	Fwd	CCGGAATTCCTTATG-TCGCCCAGATGTTAAATCGGCGGA	EcoRI
	Rev	GCCCAAGCTT-TTACGTATCATATTTACAGTGCTTC	HindIII
919 (pSM-214)	Fwd	CCGGAATTCCTTATG-CAAAGCAAGAGCATCCAAACCT	EcoRI
	Rev	GCCCAAGCTT-TTACGGGCGGTATTCGGGCT	HindIII
961L (pSM-214)	Fwd	CCGGAATTCATATG-AAACACTTTCCATCC	EcoRI
	Rev	GCCCAAGCTT-TTACCACTCGTAATTGAC	HindIII
961 (pSM-214)	Fwd	CCGGAATTCATATG-GCCACAAGCGACGAC	EcoRI
	Rev	GCCCAAGCTT-TTACCACTCGTAATTGAC	HindIII
961c L pSM-214	Fwd	CCGGAATTCCTTATG-AAACACTTTCCATCC	EcoRI
	Rev	GCCCAAGCTT-TCAACCCACGTTGTAAGGTTG	HindIII
961c pSM-214	Fwd	CCGGAATTCCTTATG-GCCACAACGACGACG	EcoRI
	Rev	GCCCAAGCTT-TCAACCCACGTTGTAAGGTTG	HindIII
953 (pSM-214)	Fwd	CCGGAATTCCTTATG-GCCACCTACAAAGTGGACGA	EcoRI
	Rev	GCCCAAGCTT-TTATTGTTTGGCTGCCTCGATT	HindIII

These sequences were manipulated, cloned and expressed as described for 953L.

For the pET-24 vector, sequences were cloned and the proteins expressed in pET-24 as described below for pET21. pET2 has the same sequence as pET-21, but with the kanamycin resistance cassette instead of ampicillin cassette.

5 Oligonucleotides used to clone sequences into pET-24b vector were:

ΔG 287 K	Fwd	CGCGGATCCGCTAGC-CCCGATGTAAATCGGC §	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC *	XhoI
Δ2 287 K	Fwd	CGCGGATCCGCTAGC-CAAGATATGGCGGCAGT §	NheI
Δ3 287 K	Fwd	CGCGGATCCGCTAGC-GCCGAATCCGCAAATCA §	NheI
Δ4 287 K	Fwd	CGCGCTAGC-GGAAGGGTTGATTTGGCTAATGG §	NheI
Orf46.1 K	Fwd	GGAATTCCATATG-GGCATTTCCCGCAAAATATC	NdeI
	Rev	CCCGCTCGAG-TTACGTATCATATTTACGTGC	XhoI
Orf46A K	Fwd	GGAATTCCATATG-GGCATTTCCCGCAAAATATC	NdeI
	Rev	CCCGCTCGAG-TTATTCTATGCCTTGTGCGGCAT	XhoI
961 K (MC58)	Fwd	CGCGGATCCCATATG-GCCACAAGCGACGACGA	NdeI
	Rev	CCCGCTCGAG-TTACCACTCGTAATTGAC	XhoI
961a K	Fwd	CGCGGATCCCATATG-GCCACAAACGACG	NdeI
	Rev	CCCGCTCGAG-TCATTTAGCAATATTATCTTTGTTC	XhoI
961b K	Fwd	CGCGGATCCCATATG-AAAGCAAACAGTGCCGAC	NdeI
	Rev	CCCGCTCGAG-TTACCACTCGTAATTGAC	XhoI
961c K	Fwd	CGCGGATCCCATATG-GCCACAAACGACG	NdeI
	Rev	CCCGCTCGAG-TTAACCCACGTTGTAAGGT	XhoI
961cL K	Fwd	CGCGGATCCCATATG-ATGAAACACTTTCCATCC	NdeI
	Rev	CCCGCTCGAG-TTAACCCACGTTGTAAGGT	XhoI
961d K	Fwd	CGCGGATCCCATATG-GCCACAAACGACG	NdeI
	Rev	CCCGCTCGAG-TCAGTCTGACACTGTTTTATCC	XhoI
ΔG 287-919 K	Fwd	CGCGGATCCGCTAGC-CCCGATGTAAATCGGC	NheI
	Rev	CCCGCTCGAG-TTACGGGCGGTATTCCG	XhoI
ΔG 287-Orf46.1 K	Fwd	CGCGGATCCGCTAGC-CCCGATGTAAATCGGC	NheI
	Rev	CCCGCTCGAG-TTACGTATCATATTTACGTGC	XhoI
ΔG 287-961 K	Fwd	CGCGGATCCGCTAGC-CCCGATGTAAATCGGC	NheI
	Rev	CCCGCTCGAG-TTACCACTCGTAATTGAC	XhoI

* This primer was used as a Reverse primer for all the 287 forms.

§ Forward primers used in combination with the ΔG278 K reverse primer.

Example 6 – ORF1 and its leader peptide

ORF1 from *N.meningitidis* (serogroup B, strain MC58) is predicted to be an outer membrane
10 or secreted protein. It has the following sequence:

1 MKITDKRTTE THRKAPKTGR IRFSPAYLAI CLSFGILPQA WAGHTYFGIN

51 YQYYRDFAEK KGKFAVGAKD IEVYNKKGEL VGKSMTKAPM IDFSVVSRRNG
 101 VAALVGDQYI VSAHNGGYN NVDFGAEGRN PDQHRFTYKI VKRNNYKAGT
 151 KGHYPYGGDYH MPRLHKFVTD AEPVEMTSYM DGRKYIDQNN YPDRVRIGAG
 201 RQYWRSEDEDE PNNRESSYHI ASAYSWLVG GNTFAQNGSGG GTVNLGSEKI
 5 KHSFYGFLPT GGSFGDSGSP MFIYDAQKQK WLINGVLQGT NPYIGKSNNGF
 301 QLVRKDWFYD EIFAGDTHSV FYEPRQNGKY SFNDDNNGTG KINAKHEHNS
 351 LPNRLKTRTV QLFNVSLSET AREPVYHAAG GVNSYRPRLN NGENISFIDE
 401 GKGEILITSN INQAGGLYF QGDFTVSPEN NETWQAGGVH ISEDSTVTWK
 451 VNGVANDRLS KIGKGTLVH VQ AKGENQGSIS VGDGTVILDQ QADDKGGKQA
 10 501 FSEIGLVSGR GTVQLNADNQ FNPDKLYFGF RGGRLDLNGH SLSFHRIONT
 551 DEGAMIVNHN QDKESTVTIT GNKDIATTGN NNSLDSKKEI AYNGWFGKED
 601 TTKTNGRLNL VYQPAEDRT LLLSGGTNLN GNITQTNGKL FFSGRPTPHA
 651 YNHLNDHWSQ KEGIPRGEIV WDNDWINRTF KAENFQIKGG QAVVSRNVAK
 701 VKGDWHLNSH AQAVFGVAPH QSHTICTRSD WTGLTNCVEK TITDDKVIAS
 15 751 LTKTDISGNV DLADHAHLNL TGLATLNGNL SANGDTRYTV SHNATQNGNL
 801 SLVGNAQATF NQATLNGNTS ASGNASFNLS DHAVQNGSLT LSGNAKANVS
 851 HSALENGVSL ADKAVFHFES SRFTGQISGG KDTALHLKDS EWTLPSTGTEL
 901 GNLNLDNATI TLNSAYRHDA AGAQTGSATD APRRRSRRSR RSLSVTPPT
 951 SVESRFTLT VNGKLNQGT FRFMSELFY RSDKLKLAES SEGTYTLAVN
 20 1001 NTGNEPASLE QLTVEGKDN KPLSENLFNT LQNEHVDAGA WRYQLIRKDG
 1051 EFRHLNVPKE QELSDKLGA EAKKQAEKDN AQSLDALIAA GRDAVEKTES
 1101 VAEPARQAGG ENVGIMQAE EKKRVQADKD TALAKQREAE TRPATTAFFR
 1151 ARRARRDLPQ LQPQPQPQ RDLISRYANS GLSEFSATLN SVFAVQDELD
 1201 RVFAEDRRNA VWTSGIRDTH HYRSQDFRAY RQQTDLRQIG MQKNLGSGRV
 25 1251 GILFSHNRTE NTFDDGIGNS ARLAHGAVFG QYGIDRFYIG ISAGAGFSSG
 1301 SLSDGIGGKI RRRVLHYGIQ ARYRAGFGGF GIEPHIGATR YFVQKADYRY
 1351 ENVNIATPGL AFNRYRAGIK ADYSFKPAQH ISITPYLSLS YTTDAASGKVR
 1401 TRVNTAVLAQ DFGKTRSAEW GVNAEIKGFT LSLHAAAAGK PQLEAQHSAG
 1451 IKLGYRW*

30 The leader peptide is underlined.

A polymorphic form of ORF1 is disclosed in WO99/55873.

Three expression strategies have been used for ORF1:

- 1) ORF1 using a His tag, following WO99/24578 (ORF1-His);
- 2) ORF1 with its own leader peptide but without any fusion partner ('ORF1L'); and
- 35 3) ORF1 with the leader peptide (MKKTAIAIAVALAGFATVAQA) from *E.coli* OmpA ('Orf1LOmpA'):

40 MKKTAIAIAVALAGFATVAQAASAGHTYFGINYYRDFAEKKGKFAVGAKDIEVYNKKGELVGKSMTKAPMIDFSV
 VSRNGVAALVGDQYIVSAHNGGYNVDFGAEGRNPDQHRFTYKIVKRNNYKAGTKGHYPYGGDYHMPRLHKFVTD
 PVEMTSYMDGRKYIDQNNYPDRVRIGAGRQYWRSEDEPNNRESSYHIASAYSWLVG GNTFAQNGSGGGT
 45 IKHSPYGFPLPTGGSFGDSGSPMFIYDAQKQKWLINGVLQGTGNPYIGKSNNGFQLVRKDWFYDEIFAGDTHSVFYEP
 NGKYSFNDDNNGTGKINAKHEHNSLPNRLKTRTVQLFNVSLSETAREPVYHAAGGVNSYRPRLNNGENISFIDE
 ELILTSNINQAGGLYFQGDFTVSPENNETWQAGGVHISEDSTVTWKVNGVANDRLSKIGKGTLVHQA
 50 KGENQGSIS VGDGTVILDQ QADDKGGKQA FSEIGLVSGRGTVQLNADNQFNPDKLYFGFRGGRLDLNGH
 SLSFHRIONTDEGAMIV NHNQDKESTVTITGNKDIATTGNNSLDSKKEIAYNGWFGKEDTTKTNGRLNLVYQ
 45 PAEDRTLLLSGGTNLNGNIT QTNGKLFPSGRPTPHAYNHLNDHWSQKEGIPRGEIVWDNDWINRTFKAENFQIKGG
 QAVVSRNVAKVGKDWHLNSHA QAVFGVAPHQSHTICTRSDWTGLTNCVEKTITDDKVIASLTKTDISGNVDLADHAHLNL
 TGLATLNGNLSANGDTRY TVSHNATQNGNLSLVGNAQATFNQATLNGNTSASGNASFNLSDHAVQNGSLTSGNAKANVS
 50 HSALENGVSLADKAV FHFESSRFTGTGQISGGKDTALHLKDSWTLPSTGTELGNLNLDNATITLNSAYRHDAAGAGQ
 TGSATDAPRRRSRRSRRS LLSVTPPTSVESRFTLT VNGKLNQGTFRFMSELFYRSDKLKLAESSEGTYTLAVNNTGNEPASLE
 55 QLTVEGKD NKPLSENLFNTLQNEHVDAGAWRYQLIRKDG EFRHLNVPKEQELSDKLGA EAKKQAEKDN AQSLDALIAA
 AGRDAVE KTESVAEPARQAGGENVGIMQAE EKKRVQADKD TALAKQREAE TRPATTAFFRARRARRDLPQLQPQPQPQ
 RDLISRYANSGLSEFSATLNSVFAVQDELD RVFAEDRRNAVWTSGIRDTHHYRSQDFRAYRQQTDLRQIGMQKNLGSGRV
 55 GILFSHNRTE NTFDDGIGNS ARLAHGAVFG QYGIDRFYIG ISAGAGFSSGSLSDGIGKIRRRVLHYGIQARYRAGF
 GGFGIEPHIGATRYFVQKADYRYENVNIATPGLAFNRYRAGIKADYSFKPAQHISITPYLSLSYTTDAASGKVRTRVN
 TAVLAQDFGKTRSAEWGVNAEIKGFTLSLHAAAAGK PQLEAQHSAGIKLGYRW*

To make this construct, the clone pET911LOmpA (see below) was digested with the *NheI* and *XhoI* restriction enzymes and the fragment corresponding to the vector carrying the OmpA leader sequence was purified (pETLOmpA). The ORF1 gene coding for the mature protein was amplified using the oligonucleotides ORF1-For and ORF1-Rev (including the *NheI* and *XhoI* restriction sites, respectively), digested with *NheI* and *XhoI* and ligated to the purified pETOmpA fragment (see Figure 1). An additional AS dipeptide was introduced by the *NheI* site.

All three forms of the protein were expressed. The His-tagged protein could be purified and was confirmed as surface exposed, and possibly secreted (see Figure 3). The protein was used to immunise mice, and the resulting sera gave excellent results in the bactericidal assay.

ORF1LOmpA was purified as total membranes, and was localised in both the inner and outer membranes. Unexpectedly, sera raised against ORF1LOmpA show even better ELISA and anti-bactericidal properties than those raised against the His-tagged protein.

ORF1L was purified as outer membranes, where it is localised.

Example 7 – protein 911 and its leader peptide

Protein 911 from *N.meningitidis* (serogroup B, strain MC58) has the following sequence:

```

1  MKKNILEFWV GLFVLIGAAA VAFLAFRVAG GAAFGGSDKT YAVYADFGDI
51 GGLKVNAPVK SAGVLVGRVG AIGLDPKSYQ ARVRLDLGK YQFSSDVSAQ
101 ILTSGLLGEQ YIGLQQGGDT ENLAAGDTIS VTSSAMVLEN LIGKFMTSFA
151 EKNADGGNAE KAAE*
```

The leader peptide is underlined.

Three expression strategies have been used for 911:

- 1) 911 with its own leader peptide but without any fusion partner ('911L');
 - 2) 911 with the leader peptide from *E.coli* OmpA ('911LOmpA').
- To make this construct, the entire sequence encoding the OmpA leader peptide was included in the 5'- primer as a tail (primer 911LOmpA Forward). A *NheI* restriction site was inserted between the sequence coding for the OmpA leader peptide and the 911 gene encoding the predicted mature protein (insertion of one amino acid, a serine), to allow the use of this construct to clone different genes downstream the OmpA leader peptide sequence.
- 3) 911 with the leader peptide (MKYLLPTAAAGLLLAQPAMA) from *Erwinia carotovora* PelB ('911LpelB').

-25-

To make this construct, the 5'-end PCR primer was designed downstream from the leader sequence and included the *NcoI* restriction site in order to have the 911 fused directly to the PelB leader sequence; the 3'- end primer included the STOP codon. The expression vector used was pET22b+ (Novagen), which carries the coding sequence for the PelB leader peptide. The *NcoI* site introduces an additional methionine after the PelB sequence.

All three forms of the protein were expressed. ELISA titres were highest using 911L, with 919LOmpA also giving good results.

Example 8 – ORF46

The complete ORF46 protein from *N.meningitidis* (serogroup B, strain 2996) has the following sequence:

```

1  LGISRKISLI LSILAVCLPM HAHASDLAND SFIRQVLDRO HFEPDGKYHL
51  FGSRGELAER SGHIGLGKIQ SHQLGNLMIQ QAAIKGNIGY IVRFSDHGHE
101 VHSPPFDNHAS HSDSDEAGSP VDGFSLYRIH WDGYEHHPAD GYDGPQGGGY
151 PAPKGARDIY SYDIKVAQN IRLNLTNRS TGQRLADRPH NAGSMLTQGV
201 GDGFKRATRY SPELDRSGNA AEAFTGTADI VKNIIGAAGE IVGAGDAVQG
251 ISEGSNIAVM HGLGLLSTEN KMARINDLAD MAQLKDYAAA AIRDWAVQNP
301 NAAQGIEAVS NIFMAAIPK GIGAVRGKYG LGGITAHPIK RSQMGAIALP
351 KGKSAVSDNF ADAAYAKYPS PYHSRNIRSN LEQRYGKENI TSSTVPPSNG
20  401 KNVKLADQRH PKTGVPFDGK GFPNFEKHVK YDTKLDIQEL SGGGIPKAKP
451 VSDAKPRWEV DRKLNKLTTR EQVEKNVQEI RGNKNNSNFS QHAQLEREIN
501 KLSADEINF ADGMGKFTDS MNDKAFSRLV KSVKENGFTN PVVEYVEING
551 KAYIVRGNNR VFAAEYLGRI HELKFKKVDF PVPNTSWKNP TDVLNESGNV
25  601 KRPRYRSK*
```

The leader peptide is underlined.

The sequences of ORF46 from other strains can be found in WO00/66741.

Three expression strategies have been used for ORF46:

- 1) ORF46 with its own leader peptide but without any fusion partner ('ORF46-2L');
- 2) ORF46 without its leader peptide and without any fusion partner ('ORF46-2'), with the leader peptide omitted by designing the 5'-end amplification primer downstream from the predicted leader sequence:

```

1  SDLANDSFIR QVLDROHFEP DGKYHLFGSR GELAERSGHI GLGKIQSHQL
51  GNLMIQQAII KGNIGYIVRF SDHGHEVHSP FDNHASHSDS DEAGSPVDGF
35  101 SLYRIHWDGY EHHPADGYDG PQGGGYPAK GARDIYSYDI KGVAQNIRLN
151 LTNDRSTGQR LADRPHNAGS MLTQGVGDGF KRATRYSPEL DRSGNAAEAF
201 NGTADIVKNI IGAAGEIVGA GDAVQGISEG SNIAVMHGLG LLSTENKMAR
251 INDLADMAQL KDYAAAAIRD WAVQNPNAAQ GIEAVSNIFM AAIPKIGIGA
301 VRGKYGLGGI TAHPIKRSQM GAIALPKGKS AVSDNFADAA YAKYPSPYHS
40  351 RNIRSNLEQR YGKENITSST VPPSNGKNVK LADQRHPKTG VPPDGKGFPN
401 FEKHVKYDTK LDIQELSGGG IPKAKPVSDA KPRWEVDRLK NKLTTREQVE
451 KNVQEIRNGN KNSNFSQHAQ LEREINKLKS ADEINFADGM GKFTDSMNDK
501 AFSRLVKSVM ENGFTNPVVE YVEINGKAYI VRGNNRVFAA EYLGRIRHEK
551 FKKVDFPVPN TSWKNPTDVL NESGNVCRPR YRSK*
```

- 3) ORF46 as a truncated protein, consisting of the first 433 amino acids ('ORF46.1L'), constructed by designing PCR primers to amplify a partial sequence corresponding to aa 1-433.

5 A STOP codon was included in the 3'-end primer sequences.

ORF46-2L is expressed at a very low level to *E.coli*. Removal of its leader peptide (ORF46-2) does not solve this problem. The truncated ORF46.1L form (first 433 amino acids, which are well conserved between serogroups and species), however, is well-expressed and gives excellent results in ELISA test and in the bactericidal assay.

- 10 ORF46.1 has also been used as the basis of hybrid proteins. It has been fused with 287, 919, and ORF1. The hybrid proteins were generally insoluble, but gave some good ELISA and bactericidal results (against the homologous 2996 strain):

Protein	ELISA	Bactericidal Ab
Orf1-Orf46.1-His	850	256
919-Orf46.1-His	12900	512
919-287-Orf46-His	n.d.	n.d.
Orf46.1-287His	150	8192
Orf46.1-919His	2800	2048
Orf46.1-287-919His	3200	16384

- For comparison, 'triple' hybrids of ORF46.1, 287 (either as a GST fusion, or in Δ G287 form) and 919 were constructed and tested against various strains (including the homologous 2996 strain) *versus* a simple mixture of the three antigens. FCA was used as adjuvant:

	2996	BZ232	MC58	NGH38	F6124	BZ133
Mixture	8192	256	512	1024	>2048	>2048
ORF46.1-287-919his	16384	256	4096	8192	8192	8192
Δ G287-919-ORF46.1his	8192	64	4096	8192	8192	16384
Δ G287-ORF46.1-919his	4096	128	256	8192	512	1024

Again, the hybrids show equivalent or superior immunological activity.

Hybrids of two proteins (strain 2996) were compared to the individual proteins against various heterologous strains:

	1000	MC58	F6124 (MenA)
ORF46.1-His	<4	4096	<4
ORF1-His	8	256	128
ORF1—ORF46.1-His	1024	512	1024

Again, the hybrid shows equivalent or superior immunological activity.

Example 9 – protein 961

The complete 961 protein from *N.meningitidis* (serogroup B, strain MC58) has the following sequence:

```

5      1  MSMKHFPAKV LTTAILATFC SGALAATSDD DVKKAATVAI VAAYNNGQEI
      51  NGFKAGETIY DIGEDGTITQ KDATAADVEA DDFKGLGLKK VVTNLTKTVN
     101  ENKQNVDAKV KAAESEIEKL TTKLADTDAA LADTDAALDE TTNALNKLGE
     151  NITTFARETK TNIVKIDEKL EAVADTVDKH AEA FN DIADS LDETNTKADE
     201  AVKTANEAKQ TAEETKQNV D AKVKAETA A GKAEAAAGTA NTAADKAEAV
    10  251  AAKVTDIKAD IATNKADIAK NSARIDSLDK NVANLRKETR QGLAEQAALS
     301  GLFPYPNVGR FNVTAAVGGY KSESAVAIGT GFRFTENFAA KAGVAVGTSS
     351  GSSAAYHGVV NYEW*
```

The leader peptide is underlined.

15 Three approaches to 961 expression were used:

- 1) 961 using a GST fusion, following WO99/57280 ('GST961');
- 2) 961 with its own leader peptide but without any fusion partner ('961L'); and
- 3) 961 without its leader peptide and without any fusion partner ('961^{untagged}'), with the leader peptide omitted by designing the 5'-end PCR primer downstream from the predicted leader sequence.

All three forms of the protein were expressed. The GST-fusion protein could be purified and antibodies against it confirmed that 961 is surface exposed (Figure 4). The protein was used to immunise mice, and the resulting sera gave excellent results in the bactericidal assay. 961L could also be purified and gave very high ELISA titres.

25 Protein 961 appears to be phase variable. Furthermore, it is not found in all strains of *N.meningitidis*.

Example 10 – protein 287

Protein 287 from *N.meningitidis* (serogroup B, strain 2996) has the following sequence:

```

30      1  MFERSVIAMA CIFALSACGG GGGGSPDVKS ADTLSKPAAP VVAEKETEVR
      51  EDAPQAGSQG QGAPSTQGSQ DMAAVSAENT GNGGAATTDK PKNEDEGPQN
     101  DMPQNSAESA NQTGNNQPAD SSDSAPASNP APANGGSNFG RVDLANGVLI
     151  DGPSQNTILT HCKGDSCNGD NLLDEEAPSK SEFENLNESE RIEKYKKDGK
```

-28-

5 201 SDKFTNLVAT AVQANGTNKY VIIYKDKSAS SSSARFRSA RSRRSLPAEM
 251 PLIPVNQADT LIVDGEAVSL TGHSGNIFAP EGNYRYLTYG AEKLPGGSYA
 301 LRVQGEPAKG EMLAGTAVYN GEVLHFHTEN GRPYPTRGRF AAKVDFGSKS
 351 VDGIIDSGDD LHMGTOQKFA AIDGNGFKGT WTENGGGDVS GRFYGPAGEE
 401 VAGKYSYRPT DAEKGFGVVF AGKKEQD*

The leader peptide is shown underlined.

The sequences of 287 from other strains can be found in Figures 5 and 15 of WO00/66741.

Example 9 of WO99/57280 discloses the expression of 287 as a GST-fusion in *E.coli*.

10 A number of further approaches to expressing 287 in *E.coli* have been used, including:

- 1) 287 as a His-tagged fusion ('287-His');
- 2) 287 with its own leader peptide but without any fusion partner ('287L');
- 3) 287 with the ORF4 leader peptide and without any fusion partner ('287L_{Orf4}'); and
- 4) 287 without its leader peptide and without any fusion partner ('287^{untagged}');

15 1 CGGGGGGSPD VKSADTLSPK AAPVVAEKET EVKEDAPQAG SQGGGAPSTQ
 51 GSQDMAAVSA ENTGNGGAAT TDKPKNEDEG PQNDMPQNSA ESANQTGNNO
 101 PADSSDSAPA SNPAPANGGS NFGRVDLANG VLIDGPSQNI TLTHCKGDSC
 151 NGDNLLDEEA PSKSEFENLN ESERIEKYKK DGKSDKFTNL VATAVQANGT
 201 NKYVVIYKDK SASSSSARFR RSARSRRSLP AEMPLIPVNO ADTLIVDGEA
 251 VSLTGHSGNI FAPEGNYRYL TYGAEKLPQG SYALRVQGEF AKGEMLAGTA
 301 VYNGEVLHFFH TENGRPYPTR GRFAAKVDFG SKSVDGIIDS GDDLHMGTOQ
 351 FKAAIDGNLF KGTWTENGGG DVSGRFYGPA GEEVAGKYSY RPTDAEKGGF
 401 GVFAGKKEQD *

25 All these proteins could be expressed and purified.

'287L' and '287L_{Orf4}' were confirmed as lipoproteins.

As shown in Figure 2, '287L_{Orf4}' was constructed by digesting 919L_{Orf4} with *NheI* and *XhoI*. The entire ORF4 leader peptide was restored by the addition of a DNA sequence coding for the missing amino acids, as a tail, in the 5'-end primer (287L_{Orf4} for), fused to
 30 287 coding sequence. The 287 gene coding for the mature protein was amplified using the oligonucleotides 287L_{Orf4} For and Rev (including the *NheI* and *XhoI* sites, respectively), digested with *NheI* and *XhoI* and ligated to the purified pET_{Orf4} fragment.

Example 11 – further non-fusion proteins with/without native leader peptides

A similar approach was adopted for *E.coli* expression of further proteins from WO99/24578,
 35 WO99/36544 and WO99/57280.

The following were expressed without a fusion partner: 008, 105, 117-1, 121-1, 122-1, 128-1, 148, 216, 243, 308, 593, 652, 726, 982, and Orf143-1. Protein 117-1 was confirmed as surface-exposed by FACS and gave high ELISA titres.

The following were expressed with the native leader peptide but without a fusion partner:
5 111, 149, 206, 225-1, 235, 247-1, 274, 283, 286, 292, 401, 406, 502-1, 503, 519-1, 525-1, 552, 556, 557, 570, 576-1, 580, 583, 664, 759, 907, 913, 920-1, 926, 936-1, 953, 961, 983, 989, Orf4, Orf7-1, Orf9-1, Orf23, Orf25, Orf37, Orf38, Orf40, Orf40.1, Orf40.2, Orf72-1, Orf76-1, Orf85-2, Orf91, Orf97-1, Orf119, Orf143.1. These proteins are given the suffix 'L'.

His-tagged protein 760 was expressed with and without its leader peptide. The deletion of
10 the signal peptide greatly increased expression levels. The protein could be purified most easily using 2M urea for solubilisation.

His-tagged protein 264 was well-expressed using its own signal peptide, and the 30kDa protein gave positive Western blot results.

All proteins were successfully expressed.

15 The localisation of 593, 121-1, 128-1, 593, 726, and 982 in the cytoplasm was confirmed.

The localisation of 920-1L, 953L, ORF9-1L, ORF85-2L, ORF97-1L, 570L, 580L and 664L in the periplasm was confirmed.

The localisation of ORF40L in the outer membrane, and 008 and 519-1L in the inner membrane was confirmed. ORF25L, ORF4L, 406L, 576-1L were all confirmed as being
20 localised in the membrane.

Protein 206 was found not to be a lipoprotein.

ORF25 and ORF40 expressed with their native leader peptides but without fusion partners, and protein 593 expressed without its native leader peptide and without a fusion partner, raised good anti-bactericidal sera. Surprisingly, the forms of ORF25 and ORF40 expressed
25 without fusion partners and using their own leader peptides (*i.e.* 'ORF25L' and 'ORF40L') give better results in the bactericidal assay than the fusion proteins.

Proteins 920L and 953L were subjected to N-terminal sequencing, giving HRVWVETAH and ATYKVDEYHANARFAF, respectively. This sequencing confirms that the predicted leader peptides were cleaved and, when combined with the periplasmic location, confirms that the

proteins are correctly processed and localised by *E.coli* when expressed from their native leader peptides.

The N-terminal sequence of protein 519.1L localised in the inner membrane was MEFFTILLA, indicating that the leader sequence is not cleaved. It may therefore function as both an
5 uncleaved leader sequence and a transmembrane anchor in a manner similar to the leader peptide of PBP1 from *N.gonorrhoeae* [Ropp & Nicholas (1997) *J. Bact.* 179:2783-2787.]. Indeed the N-terminal region exhibits strong hydrophobic character and is predicted by the Tmpred. program to be transmembrane.

Example 12 – lipoproteins

10 The incorporation of palmitate in recombinant lipoproteins was demonstrated by the method of Kraft *et. al.* [*J. Bact.* (1998) 180:3441-3447.]. Single colonies harbouring the plasmid of interest were grown overnight at 37°C in 20 ml of LB/Amp (100µg/ml) liquid culture. The culture was diluted to an OD₅₅₀ of 0.1 in 5.0 ml of fresh medium LB/Amp medium containing 5 µC/ml [³H] palmitate (Amersham). When the OD₅₅₀ of the culture reached 0.4-
15 0.8, recombinant lipoprotein was induced for 1 hour with IPTG (final concentration 1.0 mM). Bacteria were harvested by centrifugation in a bench top centrifuge at 2700g for 15 min and washed twice with 1.0 ml cold PBS. Cells were resuspended in 120µl of 20 mM Tris-HCl (pH 8.0), 1 mM EDTA, 1.0% w/v SDS and lysed by boiling for 10 min. After centrifugation at 13000g for 10 min the supernatant was collected and proteins precipitated
20 by the addition of 1.2 ml cold acetone and left for 1 hour at -20 °C. Protein was pelleted by centrifugation at 13000g for 10 min and resuspended in 20-50µl (calculated to standardise loading with respect to the final O.D of the culture) of 1.0% w/v SDS. An aliquot of 15 µl was boiled with 5µl of SDS-PAGE sample buffer and analysed by SDS-PAGE. After electrophoresis gels were fixed for 1 hour in 10% v/v acetic acid and soaked for 30 minutes
25 in Amplify solution (Amersham). The gel was vacuum-dried under heat and exposed to Hyperfilm (Kodak) overnight -80 °C.

Incorporation of the [³H] palmitate label, confirming lipidation, was found for the following proteins: Orf4L, Orf25L, 287L, 287LOrf4, 406.L, 576L, 926L, 919L and 919LOrf4.

Example 13 – domains in 287

30 Based on homology of different regions of 287 to proteins that belong to different functional classes, it was split into three 'domains', as shown in Figure 5. The second domain shows

homology to IgA proteases, and the third domain shows homology to transferrin-binding proteins.

Each of the three 'domains' shows a different degree of sequence conservation between *N.meningitidis* strains – domain C is 98% identical, domain A is 83% identical, whilst domain B is only 71% identical. Note that protein 287 in strain MC58 is 61 amino acids longer than that of strain 2996. An alignment of the two sequences is shown in Figure 7, and alignments for various strains are disclosed in WO00/66741 (see Figures 5 and 15 therein).

The three domains were expressed individually as C-terminal His-tagged proteins. This was done for the MC58 and 2996 strains, using the following constructs:

- 10 287a-MC58 (aa 1-202), 287b-MC58 (aa 203-288), 287c-MC58 (aa 311-488).
 287a-2996 (aa 1-139), 287b-2996 (aa 140-225), 287c-2996 (aa 250-427).

To make these constructs, the stop codon sequence was omitted in the 3'-end primer sequence. The 5' primers included the *NheI* restriction site, and the 3' primers included a *XhoI* as a tail, in order to direct the cloning of each amplified fragment into the expression
 15 vector pET21b+ using *NdeI-XhoI*, *NheI-XhoI* or *NdeI-HindIII* restriction sites.

All six constructs could be expressed, but 287b-MC8 required denaturation and refolding for solubilisation.

Deletion of domain A is described below ('Δ4 287-His').

Immunological data (serum bactericidal assay) were also obtained using the various domains
 20 from strain 2996, against the homologous and heterologous MenB strains, as well as MenA (F6124 strain) and MenC (BZ133 strain):

	2996	BZ232	MC58	NGH38	394/98	MenA	MenC
287-His	32000	16	4096	4096	512	8000	16000
287(B)-His	256	-	-	-	-	16	-
287(C)-His	256	-	32	512	32	2048	>2048
287(B-C)-His	64000	128	4096	64000	1024	64000	32000

Using the domains of strain MC58, the following results were obtained: .

	MC58	2996	BZ232	NGH38	394/98	MenA	MenC
287-His	4096	32000	16	4096	512	8000	16000
287(B)-His	128	128	-	-	-	-	128
287(C)-His	-	16	-	1024	-	512	-
287(B-C)-His	16000	64000	128	64000	512	64000	>8000

Example 14 – deletions in 287

As well as expressing individual domains, 287 was also expressed (as a C-terminal His-tagged protein) by making progressive deletions within the first domain. These

Four deletion mutants of protein 287 from strain 2996 were used (Figure 6):

- 5 1) '287-His', consisting of amino acids 18-427 (*i.e.* leader peptide deleted);
- 2) 'Δ1 287-His', consisting of amino acids 26-427;
- 3) 'Δ2 287-His', consisting of amino acids 70-427;
- 4) 'Δ3 287-His', consisting of amino acids 107-427; and
- 5) 'Δ4 287-His', consisting of amino acids 140-427 (=287-bc).
- 10 The 'Δ4' protein was also made for strain MC58 ('Δ4 287MC58-His'; aa 203-488).

The constructs were made in the same way as 287a/b/c, as described above.

All six constructs could be expressed and protein could be purified. Expression of 287-His was, however, quite poor.

Expression was also high when the C-terminal His-tags were omitted.

- 15 Immunological data (serum bactericidal assay) were also obtained using the deletion mutants, against the homologous (2996) and heterologous MenB strains, as well as MenA (F6124 strain) and MenC (BZ133 strain):

	2996	BZ232	MC58	NGH38	394/98	MenA	MenC
287-his	32000	16	4096	4096	512	8000	16000
Δ1 287-His	16000	128	4096	4096	1024	8000	16000
Δ2 287-His	16000	128	4096	>2048	512	16000	>8000
Δ3 287-His	16000	128	4096	>2048	512	16000	>8000
Δ4 287-His	64000	128	4096	64000	1024	64000	32000

The same high activity for the Δ4 deletion was seen using the sequence from strain MC58.

As well as showing superior expression characteristics, therefore, the mutants are immunologically equivalent or superior.

Example 15 – poly-glycine deletions

The 'Δ1 287-His' construct of the previous example differs from 287-His and from 5 '287^{untagged}', only by a short N-terminal deletion (GGGGGGS). Using an expression vector which replaces the deleted serine with a codon present in the *Nhe* cloning site, however, this amounts to a deletion only of (Gly)₆. Thus, the deletion of this (Gly)₆ sequence has been shown to have a dramatic effect on protein expression.

The protein lacking the N-terminal amino acids up to GGGGGG is called 'ΔG 287'. In strain 10 MC58, its sequence (leader peptide underlined) is:

➡ ΔG287

```

1  MFKRSVIAMA CIFALSACGG GGGGSPDVKS ADTLSKPAAP VVSEKETEAQ
51  EDAPQAGSQG QGAPSAQGSQ DMAAVSEENT GNCGAVTADN PKNEDEVAQN
101 DMPQNAAGTD SSTPNHTPDP NMLAGNMENQ ATDAGESSQP ANQPDMANAA
151 DGMQGGDDPSA GGQNAGNTAA QGANQAGNNQ AAGSSDPIPA SNPAPANGGS
201 NFGRVDLANG VLIDGPSQNI TLTHCKGDSC SGNNFLDEEV QLKSEFEKLS
251 DADKISNYKK DGKNDKFVGL VADSVQMKGI NQYIIFYKPK PTSFARFRRS
301 ARSRRSLPAE MPLIPVNQAD TLIVDGEAVS LTGHSGNIFA PEGNYRYLTY
351 GAEKLPGGSY ALRVQGEPAK GEMLAGAAVY NGEVLHPHTE NGRPYPTRGR
401 FAAKVDFGSK SVDGIIDSGD DLHMGTKQFK AAIDGNGFGK TWTENGSGDV
451 SGKFGYPAGE EVAGKYSYRP TDAEKGFGV FAGKKEQD*
```

ΔG287, with or without His-tag ('ΔG287-His' and 'ΔG287K', respectively), are expressed at very good levels in comparison with the '287-His' or '287^{untagged}'.

25 On the basis of gene variability data, variants of ΔG287-His were expressed in *E.coli* from a number of MenB strains, in particular from strains 2996, MC58, 1000, and BZ232. The results were also good.

It was hypothesised that poly-Gly deletion might be a general strategy to improve expression. Other MenB lipoproteins containing similar (Gly)_n motifs (near the N-terminus, 30 downstream of a cysteine) were therefore identified, namely Tbp2 (NMB0460), 741 (NMB 1870) and 983 (NMB1969):

➡ ΔGTbp2

```

TBP2
1  MNNPLVNQAA MVLPVFLLSA CLGGGGSFDL DSVDTEAPRP APKYQDVFSF
35 51  KPQAQKDQGG YGFAMRLKRR NWYPQAKEDF VKLDESDWEA TGLPDEPKEL
101 PKRQKSVIEK VETDSDDNNIY SSPYLKPSNH QNGNTGNGIN QPKNQAKDYE
151 NFKYVYSGWF YKHAKREFNL KVEPKSAKNG DDGYIFYHKG EPSRQLPASG
201 KITYKGVWHF ATDTKKGQKF REIIQPSKSQ GDRYSGFSGD DGEEYSNKNK
251 STLTDGQEGY GFTSNLEVDF HNKKLTKGLI RNNANTDNNQ ATTTQYYSLF
301 AQVTGNRFNG KATATDKPQQ NSETKEHPFV SDSSSLSGGF FGPQGEELGF
40 351 RFLSDDQKVA VVGSAKTKDK PANGNTAAAS GGTDAAASNG AAGTSSENGK
401 LTTVLDAVEL KLGDKEVQKL DNFSNAAQLV VDGIMIPLLP EASESGNNQA
451 NQGTNGGTAF TRKFDHTPES DKKDAQAGTQ TNGAQTASNT AGDTNGKTKT
```

-34-

5	501	YEVEVCCSNL	NYLKYGMLTR	KNSKSAMQAG	ESSSQADAKT	EQVEQSMFLQ
	551	GBRTDEKEIP	SEQNIVYRGS	WYGYIANDKS	TSWSGNASNA	TSGNRAEFTV
	601	NFADKKITGT	LTADNRQEAT	FTIDGNIKDN	GFEGTAKTAE	SGFDLDQSNT
	651	TRTPRAYITD	AKVQGGFYGP	KAEELGGWFA	YPGDKQTKNA	TNAGNSSSAT
	701	VVFGAKRQQP	VR*			
	741			ΔG741		
	1	VNRTAFCCLS	LTALILTAC	SSGGGGVAAD	IGAGLADALT	APLDHKDKGL
10	51	QSLTLDQSVR	KNEKLKLAAG	GAEKTYNGND	SLNTGKLKND	KVSRFDFIRQ
	101	IEVDGQLITL	ESGEFQVYKQ	SHSALTAFQT	EQIQDSEHSG	KMVAKRQFRI
	151	GDIAGEHTSF	DKLPEGGRAT	YRGTAFGSDD	AGGKLTYYTID	FAAQQNGKI
	201	EHLKSPELNV	DLAAADIKPD	GKRHAVISGS	VLYNQAEKGS	YSLGIFGGA
	251	QEVAGSAEVK	TVNGIRHIGL	AAQ*		
15	983			ΔG983		
	1	MRTTPTFPTK	TFKPTAMALA	VATTLTSLCLG	GGGGGTSAPD	FNAGGTGIGS
	51	NSRATTAKSA	AVSYAGIKNE	MCKDRSMLCA	GRDDVAVTDR	DAKINAPPPN
	101	LHTGDFPNPN	DAYKNLINLK	PAIEAGYTGR	GVEVGIVDTG	ESVGSISFPE
	151	LYGRKEHGYN	ENYKNYTAYM	RKEAPEDGGG	KDIEASFDD	AVIETAKPT
20	201	DIRHVKEIGH	IDLVSHIIGG	RSVDGRPAGG	IAPDATLHIM	NTNDETKNEM
	251	MVAATRNAAV	KLGERGVRIV	NNSFGTTSRA	GTADLFQIAN	SEEQYRQALL
	301	DYSGGDKTDE	GIRLMQQSDY	GNLSYHIRNK	NMLFIFSTGN	DAQAQPNTYA
	351	LLPFYEKDAQ	KGIITVAGVD	RSGERFKREM	YGEFGTEPLE	YGSNHCGITA
	401	MWCLSAPYEA	SVRFTRTNPI	QIAGTSFSAP	IVTGTAALLL	QKYPWMSNDN
25	451	LRTLLTTAQ	DIGAVGVDSK	FGWGLLDAGK	AMNGPASFPF	GDFTADTKGT
	501	SDIAYSFRND	ISGTGGLIKK	GGSQLQLHGN	NTYTGKTIIE	GGSLVLYGNN
	551	KSDMRVETKG	ALIYNGAASG	GSLNSDGIVY	LADTDQSGAN	ETVHIKGSLO
	601	LDGKGTLYTR	LKLLKVDGT	AIIGGKLYMS	ARGKGAGYLN	STGRRVPFLS
	651	AAKIGQDYSF	FTNIETDGGL	LASLDSVEKT	AGSEGDLSY	YVRRGNAART
30	701	ASAAHSAPA	GLKHAVEQGG	SNLENLMVEL	DASESSATPE	TVETAAADRT
	751	DMPGIRPYGA	TFRAAAAVQH	ANAADGVRIK	NSLAATVYAD	STAAHADMQG
	801	RLKAVSDGL	DHNGTGLRVI	AQTQQDGGTW	EQGGVEGKMR	GSTQTVGIAA
	851	KTGENTTAAA	TLGMGRSTWS	ENSANAKTDS	ISLFAGIRHD	AGDIGYLKGL
	901	FSYGRYKNSI	SRSTGADEHA	EGSVNGTLMQ	LGALGGVNVP	FAATGDLTVE
35	951	GGLRYDLLKQ	DAFAEKGSAL	GWSGNSLITEG	TLVGLAGLKL	SQPLSDKAVL
	1001	FATAGVERDL	NGRDYTVTGG	FTGATAATGK	TGARNMPHTR	LVAGLGADVE
	1051	FGNGWNGLAR	YSYAGSKQYG	NHSGRVGVGY	RF*	

Tbp2 and 741 genes were from strain MC58; 983 and 287 genes were from strain 2996.

- 40 These were cloned in pET vector and expressed in *E.coli* without the sequence coding for their leader peptides or as "ΔG forms", both fused to a C-terminal His-tag. In each case, the same effect was seen – expression was good in the clones carrying the deletion of the poly-glycine stretch, and poor or absent if the glycines were present in the expressed protein:

ORF	Express.	Purification	Bact. Activity
287-His(2996)	+/-	+	+
'287 ^{untagged} '(2996)	+/-	nd	nd
Δ G287-His(2996)	+	+	+
Δ G287K(2996)	+	+	+
Δ G287-His(MC58)	+	+	+
Δ G287-His(1000)	+	+	+
Δ G287-His(BZ232)	+	+	+
Tbp2-His(MC58)	+/-	nd	nd
Δ GTbp2-His(MC58)	+	+	
741-His(MC58)	+/-	nd	nd
Δ G741-His(MC58)	+	+	
983-His (2996)			
Δ G983-His (2996)	+	+	

SDS-PAGE of the proteins is shown in Figure 13.

Δ G287 and hybrids

Δ G287 proteins were made and purified for strains MC58, 1000 and BZ232. Each of these gave high ELISA titres and also serum bactericidal titres of >8192. Δ G287K, expressed from pET-24b, gave excellent titres in ELISA and the serum bactericidal assay. Δ G287-ORF46.1K may also be expressed in pET-24b.

Δ G287 was also fused directly in-frame upstream of 919, 953, 961 (sequences shown below) and ORF46.1:

<u>ΔG287-919</u>	
1	ATGGCTAGCC CCGATGTTAA ATCGGCGGAC ACGCTGTCAA AACCGGCCGC
51	TCCTGTTGTT GCTGAAAAAG AGACAGAGGT AAAAGAAGAT GCGCCACAGG
101	CAGGTTCTCA AGGACAGGGC GCGCCATCCA CACAAGGCAG CCAAGATATG
151	GCGGCAGTTT CGGCAGAAAA TACAGGCAAT GGCGGTGCGG CAACAACGGA
201	CAAAACCAAA AATGAAGACG AGGGACCGCA AAATGATATG CCGCAAAATT
251	CCGCCGAATC CGCAAATCAA ACAGGGAACA ACCAACC CGC GATTTCTTCA
301	GATTCGCCCC CCGCGTCAAA CCCTGCACCT GCGAATGGCG GTAGCAATTT
351	TGGAAGGGTT GATTTGGCTA ATGGCGTTTT GATTGATGGG CCGTCGCAAA
401	ATATAACGTT GACCCACTGT AAAGGCGATT CTTGTAATGG TGATAATTTA
451	TTGGATGAAG AAGCACCCTC AAAATCAGAA TTTGAAAAAT TAAATGAGTC
501	TGAACGAATT GAGAAATATA AGAAAGATGG GAAAAGCGAT AAATTTACTA
551	ATTTGGTTGC GACAGCAGTT CAAGCTAATG GAACCTAACAA ATATGTCATC
601	ATTTATAAAG ACAAGTCCGC TTCATCTTCA TCTGCGCGAT TCAGGCGTTC
651	TGCACGGTCG AGGAGGTCGC TTCCTGCCGA GATGCCGCTA ATCCCCGTCA
701	ATCAGGCGGA TACGCTGATT GTCGATGGGG AAGCGGTGAG CCTGACGGGG
751	CATTCCGGCA ATATCTTCGC GCCCGAAGGG AATTACCGGT ATCTGACTTA
801	CGGGGCGGAA AAATTGCCCG GCGGATCGTA TGCCCTCCGT GTGCAAGGCG
851	AACCGGCAAA AGGCGAAATG CTTGCTGGCA CGGCCGTGTA CAACGGCGAA
901	GTGCTGCATT TTCATACGGA AAACGGCCGT CCGTACCCGA CTAGAGGCAG
951	GTTTGCCGCA AAAGTCGATT TCGGCAGCAA ATCTGTGGAC GGCATTATCG
1001	ACAGCGGCGA TGATTTGCAT ATGGGTACGC AAAAATTCAA AGCCGCCATC

-36-

1051 GATGGAAACG GCTTTAAGGG GACTTGGACG GAAAATGGCG GCGGGGATGT
 1101 TTCCGGAAGG TTTTACGGCC CGGCCGCGCA GGAAGTGGCG GGAAAATACA
 1151 GCTATCGCCC GACAGATGCG GAAAAGGGCG GATTGCGCGT GTTTGCCGGC
 1201 AAAAAAGAGC AGGATGGATC CGGAGGAGGA GGATGCCAAA GCAAGAGCAT
 1251 CCAAACCTTT CCGCAACCCG ACACATCCGT CATCAACGGC CCGGACCGGC
 1301 CGGTGCGCAT CCCCACCCG GCCGGAACGA CGGTGCGCGG CCGCGGGGCC
 1351 GTCTATACCG TTGTACCGCA CCTGTCCCTG CCCCACTGGG CGGCGCAGGA
 1401 TTTGCGCCAA AGCCTGCAAT CCTTCCGCCT CGGCTGCGCC AATTTGAAAA
 1451 ACCGCCAAGG CTGGCAGGAT GTGTGCGCCC AAGCCTTTCA AACCCCGTC
 1501 CATTCCTTTC AGGCAAAACA GTTTTTTGAA CGCTATTTC ACGCGTGGCA
 1551 GGTTCGAGGC AACGGAAGCC TTGCCGGTAC GGTTACCGGC TATTACGAGC
 1601 CGGTGCTGAA GGGCGACGAC AGGCGGACGG CACAAGCCCG CTTCCTGATT
 1651 TACGGTATT CCGACGATTT TATCTCCGTC CCCCTGCCTG CCGGTTCGCG
 1701 GAGCGGAAAA GCCCTTGCTC GCATCAGGCA GACGGGAAAA AACAGCGGCA
 1751 CAATCGACAA TACCGGCGGC ACACATACCG CCGACCTCTC CCGATTCCCC
 1801 ATCACC CGCGC GCACAACGGC AATCAAAGGC AGGTTTGAAG GAAGCGCTT
 1851 CCTCCCCTAC CACACGCGCA ACCAAATCAA CGGCGGCGCG CTTGACGGCA
 1901 AAGCCCCGAT ACTCGGTTAC GCCGAAGACC CCGTCGAACT TTTTTCATG
 1951 CACATCCAAG GCTCGGGCCG TCTGAAAACC CCGTCCGGCA AATACATCCG
 2001 CATCGGCTAT GCCGACAAA ACGAACATCC CTACGTTTCC ATCGGACGCT
 2051 ATATGGCGGA CAAAGGCTAC CTCAAGCTCG GGCAGACCTC GATGCAGGGC
 2101 ATCAAAGCCT ATATGCGGCA AAATCCGCAA CGCCTCGCGG AAGTTTGGG
 2151 TCAAAACCCC AGCTATATCT TTTTCCGCGA GCTTGCCGGA AGCAGCAATG
 2201 ACGGTCCCCT CCGCGCACTG GGCACGCCGT TGATGGGGGA ATATGCCGGC
 2251 GCAGTCGACC GGCATACAT TACCTTGCGG GCGCCCTTAT TTGTGCGCAC
 2301 CGCCCATCCG GTTACCCGCA AAGCCCTCAA CCGCCTGATT ATGGCGCAGG
 2351 ATACCGGCAG CGCGATTAAA GGCAGCGTGC GCGTGGATTA TTTTGGGGA
 2401 TACGGCGACG AAGCCGGCGA ACTTCCCGGC AAACAGAAAA CCACGGGTTA
 2451 CGTCTGGCAG CTCCTACCCA ACGGTATGAA GCCCGAATAC CGCCCGTAAC
 2501 TCGAG

1 MASPDVKSAD TLSKPAAPVV AEKETEVED APQAGSQGG APSTQGSQDM
 51 AAVSAENTGN GGAATTDKPK NEDEGPQNDM PQNSAESANQ TGNNQPADSS
 101 DSAPASNAP ANGGSNFRV DLANGVLIDG PSQNTLTHC KGDSCNGDNL
 151 LDEEAPSKSE FENLNESERI EKYKKGKSD KFTNLVATAV QANGTNKYVI
 201 IYKDKSASS SARFRRSARS RRSPLAEMPL IPVNQADTLI VDGEAVSLTG
 251 HSGNIFAPEG NYRYLTYGAE KLPGGSYALR VQGEPAKGEM LAGTAVYNGE
 301 VLHPHTENGR PYPTRGRFAA KVDFGSKSVD GIIDSGDDLH MGTQKFKAAI
 351 DNGFGKGTWT ENGGGDVSGR FYGPAGEEVA GKYSYRPTDA BKGGFVVFAG
 401 KKEQDGS GGGG GCQSKSIQTF PQPDTSVING PDRFVGIPDP AGTTVGGGGA
 451 VYTVPHLSL PHWAAQDFAK SLQSPRLGCA NLKNRQGWQD VCAQAFQTPV
 501 HSFQAKOFFE RYFTPWQVAG NGSLAGTVTG YYEPVLKGDD RRTAQARFPI
 551 YGIPDDFISV PLPAGLRSGK ALVRIQTGK NSGTIDNTGG THTADLSRFP
 601 ITARTAIKG RFEGSRFLPY HTRNQINGGA LDGKAPILGY AEDPVELFFM
 651 HIQSGSRLKT PSKYIRIGY ADKNEHPYVS IGRYMAKGY LKLGQTSMQG
 701 IKAYMRQNPQ RLAEVLGQNP SYIFFRELAG SSNDGPVGAL GTPLMGEYAG
 751 AVDRHYITLG APLFVATAHP VTRKALNRLI MAQDTGSAIK GAVRVDFYWG
 801 YGDEAGELAG KQKTTGYVWQ LLPNGMKPEY RP*

ΔG287-953

1 ATGGCTAGCC CCGATGTTAA ATCGGCGGAC ACGCTGTCAA AACCGGCCCGC
 51 TCCGTGTTGTT GCTGAAAAAG AGACAGAGGT AAAAGAAGAT GCGCCACAGG
 101 CAGGTTCTCA AGGACAGGGC GCGCCATCCA CACAAGGCAG CCAAGATATG
 151 GCGGCAGTTT CCGCAGAAAA TACAGGCAAT GGCGGTGCGG CAACAACGGA
 201 CAAACCCAAA AATGAAGACG AGGGACCGCA AAATGATATG CCGCAAAATT
 251 CCGCCGAATC CGCAAATCAA ACAGGGAACA ACCAACCCGC CGATTCTTCA
 301 GATTCCGCCC CCGCGTCAA CCCTGCACCT GCGAATGGCG GTAGCAATTT
 351 TGGAAGGGTT GATTGCGCTA ATGGCGTTT GATTGATGG CCGTCGCAAA
 401 ATATAACGTT GACCCACTGT AAAGGCGATT CTTGTAATGG TGATAATTTA
 451 TTGGATGAAG AAGCACCCTC AAAATCAGAA TTTGAAAATT TAAATGAGTC
 501 TGAACGAATT GAGAAATATA AGAAAGATGG GAAAAGCGAT AAATTTACTA
 551 ATTTGGTTGC GACAGCATTT CAAGCTAATG GAACATAACA ATATGTCATC
 601 ATTTATAAAG ACAAGTCCGC TTCATCTTCA TCTGCGCGAT TCAGGCGTTC
 651 TGCACGGTCG AGGAGGTCGC TTCTGCCGA GATGCCGCTA ATCCCGTCA
 701 ATCAGGCGGA TACGCTGATT GTCGATGGGG AAGCGGTCAG CCTGACGGGG
 751 CATTCGGCA ATATCTTCGC GCCCGAAGGG AATTACCGGT ATCTGACTTA

-37-

5	801	CGGGGCGGAA	AAATTGCCCG	GCGGATCGTA	TGCCCTCCGT	GTGCAAGGCG
	851	AACCGGCAAA	AGGCGAAATG	CTTGCTGGCA	CGGCCGTGTA	CAACGGCGAA
	901	GTGCTGCATT	TTCATACGGA	AAACGGCCGT	CCGTACCCGA	CTAGAGGCAG
	951	GTTTGCCGCA	AAAGTCGATT	TCGGCAGCAA	ATCTGTGGAC	GGCATTATCG
	1001	ACAGCGGCGA	TGATTTGCAT	ATGGGTACGC	AAAAATTCAA	AGCCGCCATC
	1051	GATGGAAACG	GCTTTAAGGG	GACTTGGACG	GAAAATGGCG	GCGGGGATGT
	1101	TTCCGGAAGG	TTTTACGGCC	CGGCCGCGA	GGAAGTGGCG	GGAAATACA
	1151	GCTATCGCCC	GACAGATGCG	GAAAAGGGCG	GATTCGGCGT	GTTTGCCGGC
10	1201	AAAAAAGAGC	AGGATGGATC	CGGAGGAGGA	GGAGCCACCT	ACAAAGTGGA
	1251	CGAATATCAC	GCCAACGCCC	GTTCGCCAT	CGACCATTTC	AACACCAGCA
	1301	CCAACGTCGG	CGGTTTTCAC	GGTCTGACCG	GTTCCGTCGA	GTTCGACCAA
	1351	GCAAAACGCG	ACGGTAAAT	CGACATCACC	ATCCCCGTTG	CCAACCTGCA
	1401	AAGCGGTTTC	CAACACTTTA	CCGACCACCT	GAAATCAGCC	GACATCTTCG
	1451	ATGCCGCCCA	ATATCCGGAC	ATCCGCTTTG	TTTCCACCAA	ATTCAACTTC
15	1501	AACGGCAAAA	AACTGGTTTC	CGTTGACGGC	AACCTGACCA	TGCACGGCAA
	1551	AACCGCCCCC	GTCAAACTCA	AAGCCGAAAA	ATTCAACTGC	TACCAAAGCC
	1601	CGATGGCGAA	AACCGAAGTT	TGCGCGGGCG	ACTTCAGCAC	CACCATCGAC
	1651	CGCACCAAAT	GGGGCGTGGA	CTACCTCGTT	AACGTTGGTA	TGACCAAAAG
20	1701	CGTCCGCATC	GACATCCAAA	TCGAGGCAGC	CAACAATAA	CTCGAG
	1	MASPDVKSAD	TLSPKPAAPVV	AEKETEVKED	APQAGSQGGG	APSTQGSQDM
	51	AAVSAENTGN	GGAATTDKPK	NEDEGPQNDM	PQNSAESANQ	TGNNQPADSS
	101	DSAPASNAP	ANGGSNFRV	DLANGVLIDG	PSQNTLTHC	KGDSNGNDNL
25	151	LDEEAPSKSE	FENLNESERI	EKYKDKGKSD	KFTNLVATAV	QANGTNKYVI
	201	IYKDKSASSS	SARFRRSARS	RRSLPAEMPL	IPVNQADTLI	VDGEAVSLTG
	251	HSGNIFAPEG	NYRYLTYGAE	KLPGGSYALR	VQGEPAKGEM	LAGTAVYNGE
	301	VLHFHTENGR	PYPTRGRFAA	KVDFGSKSVD	GIIDSGDDLH	MGTQKFKAAL
	351	DGNFGKGTWT	ENGSGDVSGR	FYGPAGEEVA	GKYSYRPTDA	EKGGFVGFAG
30	401	KKEQDGSQGG	GATYKVDEYH	ANARPAIDHF	NTSTNVGGFY	GLTGSVEFDQ
	451	AKRDGKIDIT	IPVANLQSGS	QHFTDHLKSA	DIFDAAQYPD	IRFVSTKFNF
	501	NGKILVSVDG	NLTMHGKTAP	VKLKAEKFNC	YQSPMAKTEV	CGGDFSTTID
	551	RTKWGVVDLV	NVGMTKSVRI	DIQIEAAKQ*		
35	<u>AG287-961</u>					
	1	ATGGCTAGCC	CCGATGTTAA	ATCGGCGGAC	ACGCTGTCAA	AACCGGCCGC
	51	TCCTGTGTGT	GCTGAAAAAG	AGACAGAGGT	AAAAGAAGAT	GCGCCACAGG
	101	CAGGTTCTCA	AGGACAGGGC	GCGCCATCCA	CACAAGGCAG	CCAAGATATG
40	151	GCGGCAGTTT	CGGCAGAAAA	TACAGGCAAT	GGCGGTGCGG	CAACACGGA
	201	CAAAACCAAA	AATGAAGACG	AGGGACCGCA	AAATGATATG	CCGCAAAATT
	251	CCGCCGAATC	CGCAAATCAA	ACAGGGAACA	ACCAACCCGC	CGATTCTTCA
	301	GATTTCGCCC	CCGCGTCAAA	CCCTGCACCT	GCGAATGGCG	GTAGCAATTT
	351	TGGAAGGGTT	GATTTGGCTA	ATGGCGTTTT	GATTGATGGG	CCGTCGCAAA
45	401	ATATAACGTT	GACCCACTGT	AAAGGCGATT	CTTGTAATGG	TGATAATTTA
	451	TTGATGAAG	AAGCACCGTC	AAAATCAGAA	TTTGAAAAAT	TAAATGAGTC
	501	TGAACGAATT	GAGAAATATA	AGAAAGATGG	GAAAAGCGAT	AAATTTACTA
	551	ATTTGGTTGC	GACAGCAGTT	CAAGCTAATG	GAACATAACA	ATATGTCATC
	601	ATTTATAAAG	ACAAAGTCCGC	TTTATCTTCA	TCTGCGCGAT	TCAGGCGTTC
50	651	TGCACGGTCG	AGGAGGTCGC	TTCTTGCCGA	GATGCCGCTA	ATCCCCGTCA
	701	ATCAGGCGGA	TACGCTGATT	GTCGATGGGG	AAGCGGTCAG	CCTGACGGGG
	751	CATTCCGGCA	ATATCTTCGC	GCCCCAAGGG	AATTACCGGT	ATCTGACTTA
	801	CGGGGCGGAA	AAATTGCCCG	GCGGATCGTA	TGCCCTCCGT	GTGCAAGGCG
	851	AACCGGCAAA	AGGCGAAATG	CTTGCTGGCA	CGGCCGTGTA	CAACGGCGAA
55	901	GTGCTGCATT	TTCATACGGA	AAACGGCCGT	CCGTACCCGA	CTAGAGGCAG
	951	GTTTGCCGCA	AAAGTCGATT	TCGGCAGCAA	ATCTGTGGAC	GGCATTATCG
	1001	ACAGCGGCGA	TGATTTGCAT	ATGGGTACGC	AAAAATTCAA	AGCCGCCATC
	1051	GATGGAAACG	GCTTTAAGGG	GACTTGGACG	GAAAATGGCG	GCGGGGATGT
	1101	TTCCGGAAGG	TTTTACGGCC	CGGCCGCGA	GGAAGTGGCG	GGAAATACA
	1151	GCTATCGCCC	GACAGATGCG	GAAAAGGGCG	GATTCGGCGT	GTTTGCCGGC
60	1201	AAAAAAGAGC	AGGATGGATC	CGGAGGAGGA	GGAGCCACAA	ACGACGACGA
	1251	TGTTAAAAAA	GCTGCCACTG	TGGCCATTGC	TGCTGCCTAC	AACAATGGCC
	1301	AAGAAATCAA	CGGTTTCAAA	GCTGGAGAGA	CCATCTACGA	CATTGATGAA
	1351	GACGGCACAA	TTACCAAAAA	AGACGCAACT	GCAGCCGATG	TTGAAGCCGA
	1401	CGACTTTTAA	GGTCTGGGTC	TGAAAAAAGT	CGTGACTAAC	CTGACCAAAA
65	1451	CCGTCGAATG	AAACAAACAA	AACGTCGATG	CCAAAGTAAA	AGCTGCAGAA
	1501	TCTGAAATAG	AAAAGTTAAC	AACCAAGTTA	GCAGACACTG	ATGCCGCTTT
	1551	AGCAGATACT	GATGCCGCTC	TGGATGCAAC	CACCAACGCC	TTGAATAAAT

-38-

1601 TGGGAGAAAA TATAACGACA TTTGCTGAAG AGACTAAGAC AAATATCGTA
 1651 AAAATTGATG AAAAATTAGA AGCCGTGGCT GATACCGTCG ACAAGCATGC
 1701 CGAAGCATTC AACGATATCG CCGATTTCATT GGATGAAACC AACACTAAGG
 1751 CAGACGAAGC CGTCAAAACC GCCAATGAAG CCAAACAGAC GGCCGAAGAA
 1801 ACCAAACAAA ACGTTCGATGC CAAAGTAAAA GCTGCAGAAA CTGCAGCAGG
 1851 CAAAGCCGAA GCTGCCGCTG GCACAGCTAA TACTGCAGCC GACAAGGCCG
 1901 AAGCTGTTCG TGCAAAAGTT ACCGACATCA AAGCTGATAT CGCTACGAAC
 1951 AAAGATAATA TTGCTAAAAA AGCAAACAGT GCCGACGTGT ACACCAGAGA
 2001 AGAGTCTGAC AGCAAATTTG TCAGAATTGA TGGTCTGAAC GCTACTACCG
 2051 AAAAATTGGA CACACGCTTG GCTTCTGCTG AAAAATCCAT TGCCGATCAC
 2101 GATACTCGCC TGAACGGTTT GGATAAAACA GTGTCAGACC TGCCCAAAGA
 2151 AACCCGCCAA GGCCTTGCAG AACAAGCCGC GCTCTCCGGT CTGTTCCAAC
 2201 CTTACAACGT GGGTCGGTTC AATGTAACGG CTGCAGTCGG CGGCTACAAA
 2251 TCCGAATCGG CAGTCGCCAT CGGTACCGGC TTCCCGTTTA CCGAAAACTT
 2301 TGCCGCCAAA GCAGGCGTGG CAGTCGGCAC TTCGTCCGGT TCTTCCGCAG
 2351 CCTACCATGT CGGCGTCAAT TACGAGTGGT AACTCGAG

 1 MASPDVKSAD TLSKPAAPVV AEKETEVKED APQAGSQGQG APSTQGSQDM
 51 AAVSAENTGN GGAATTDKPK NEDEGPQNDM PQNSAESANQ TGNNQPADSS
 101 DSAPASNPAP ANGGSNFRGV DLANGVLIDG PSQNIITLTHC KGDSNCGDNL
 151 LDEEAPSKSE FENLNESERI EKYKKGKSD KFTNLVATAV QANGTNKYVI
 201 IYKDKSASSS SARFRRSARS RRSIPAEMPL IPVNQADTLI VDGEAVSLTG
 251 HSGNIFAPEG NYRYLTYGAE KLPGGSYALR VQGEPAKGEM LAGTAVYNGE
 301 VLHFHTENGR PYPTRGRFAA KVDFGSKSVD GIIDSGDDLH MGTQKFKAAI
 351 DGNFGKGTWT ENGGGDVSGR FYGPAGEEVA GKYSYRPTDA EKGFGVVFAG
 401 KKEQDGSGGG GATNDDDVKK AATVAIAAAY NNGQEINGFK AGETIYDIDE
 451 DGTITTKDAT AADVEADDFK GLGLKKVVTN LTKTVNENKQ NVDKVKAAE
 501 SEIEKLTTKL ADTDAALADT DAALDATTNA LNKLGENTTT FAEETKTNIV
 551 KIDEKLEAVA DTVDKHAEAF NDIADSLDET NTKADEAVKT ANEAKQTAE
 601 TKQNVDAVK AAETAAGKAE AAAGTANTAA DKAEAVAAKV TDIKADIATN
 651 KDNIAKKANS ADVYTRESD SKFVRIDGLN ATTEKLDTRL ASAEKSIADH
 701 DTRLNGLDKT VSDLRKETRQ GLAEQAALSG LFQPYNVGRF NVTAAGVGYK
 751 SESAVAIGTG FRFTENFAAK AGVAVGTSSG SSAAYHGVN YEW*

	ELISA	Bactericidal
ΔG287-953-His	3834	65536
ΔG287-961-His	108627	65536

35 The bactericidal efficacy (homologous strain) of antibodies raised against the hybrid proteins was compared with antibodies raised against simple mixtures of the component antigens (using 287-GST) for 919 and ORF46.1:

	Mixture with 287	Hybrid with ΔG287
919	32000	128000
ORF46.1	128	16000

Data for bactericidal activity against heterologous MenB strains and against serotypes A and C were also obtained:

-39-

	919		ORF46.1	
Strain	Mixture	Hybrid	Mixture	Hybrid
NGH38	1024	32000	-	16384
MC58	512	8192	-	512
BZ232	512	512	-	-
MenA (F6124)	512	32000	-	8192
MenC (C11)	>2048	>2048	-	-
MenC (BZ133)	>4096	64000	-	8192

The hybrid proteins with Δ G287 at the N-terminus are therefore immunologically superior to simple mixtures, with Δ G287-ORF46.1 being particularly effective, even against heterologous strains. Δ G287-ORF46.1K may be expressed in pET-24b.

The same hybrid proteins were made using New Zealand strain 394/98 rather than 2996:

5	<u>AG287NZ-919</u>					
	1	ATGGCTAGCC	CCGATGTCAA	GTCGGCGGAC	ACGCTGTCAA	AACCTGCCCGC
	51	CCCTGTTGTT	TCTGAAAAAG	AGACAGAGGC	AAAGGAAGAT	GCGCCACAGG
	101	CAGGTTCTCA	AGGACAGGGC	GCGCCATCCG	CACAAGGCGG	TCAAGATATG
	151	GCGGCGGTTT	CGGAAGAAAA	TACAGGCAAT	GGCGGTGCGG	CAGCAACGGA
10	201	CAAAACCCAAA	AATGAAGACG	AGGGGGCGCA	AAATGATATG	CCGCAAAATG
	251	CCGCCGATAC	AGATAGTTTG	ACACCGAATC	ACACCCCGGC	TTCGAATATG
	301	CCGGCCGGAA	ATATGGAAAA	CCAAGCACCG	GATGCCGGGG	AATCGGAGCA
	351	GCCGGCAAAC	CAACCCGATA	TGGCAAATAC	GGCGGACGGA	ATGCAGGGTG
	401	ACGATCCGTC	GGCAGGCGGG	GAAAATGCCG	GCAATACGGC	TGCCCCAAGGT
15	451	ACAAATCAAG	CCGAAAACAA	TCAAACCGCC	GGTTCTCAAA	ATCCTGCCTC
	501	TTCAACCAAT	CCTAGCGCCA	CGAATAGCGG	TGGTGATTTT	GGAAGGACGA
	551	ACGTGGGCAA	TTCTGTTGTG	ATTGACGGGC	CGTCGCAAAA	TATAACGTTG
	601	ACCCACTGTA	AAGGCGATTC	TTGTAGTGGC	AATAATTTCT	TGGATGAAGA
	651	AGTACAGCTA	AAATCAGAAT	TTGAAAAATT	AAGTGATGCA	GACAAAATAA
20	701	GTAATTACAA	GAAAGATGGG	AAGAATGACG	GGAAGAATGA	TAAATTTGTC
	751	GGTTTGGTTG	CCGATAGTGT	GCAGATGAAG	GGAATCAATC	AATATATTAT
	801	CTTTTATAAA	CCTAAACCCA	CTTCATTTGC	GCGATTTAGG	CGTTCTGCAC
	851	GGTCGAGGCG	GTCGCTTCCG	GCCGAGATGC	CGCTGATTCC	CGTCAATCAG
	901	GCGGATACGC	TGATTGTCTGA	TGGGGAAGCG	GTCAGCCTGA	CGGGGCATTC
25	951	CGGCAATATC	TTCCGCGCCG	AAGGGAATTA	CCGGTATCTG	ACTTACGGGG
	1001	CGGAAAAATT	GCCCGCGGGA	TCGTATGCCC	TCCGTGTTCA	AGGCGAACCT
	1051	TCAAAAGGCG	AAATGCTCGC	GGGCACGGCA	GTGTACAACG	GCGAAGTGCT
	1101	GCATTTTCAT	ACGGAAAACG	GCCGTCCGTC	CCCGTCCAGA	GGCAGGTTTG
	1151	CCGCAAAAAGT	CGATTTCCGGC	AGCAAATCTG	TGGACGGCAT	TATCGACAGC
30	1201	GGCGATGGTT	TGCATATGGG	TACGCAAAAA	TTCAAAGCCG	CCATCGATGG
	1251	AAACGGCTTT	AAGGGGACTT	GGACGGAAAA	TGGCGGCGGG	GATGTTTCCG
	1301	GAAAGTTTFA	CGGCCCGGCC	GGCGAGGAAG	TGGCGGGAAA	ATACAGCTAT
	1351	CGCCCAACAG	ATGCGGAAAA	GGGCGGATTC	GGCGTGTTTG	CCGGCAAAAA
	1401	AGAGCAGGAT	GGATCCGGAG	GAGGAGGATG	CCAAAGCAAG	AGCATCCAAA
35	1451	CCTTTCCGCA	ACCCGACACA	TCCGTCATCA	ACGGCCCGGA	CCGGCCGGTC
	1501	GGCATCCCCG	ACCCCGCCGG	AACGACGGTC	GGCGGCGGCG	GGGCCGTCTA
	1551	TACCGTTGTA	CCGCACCTGT	CCCTGCCCCA	CTGGGCGGCG	CAGGATTTCC
	1601	CCAAAAGCCT	GCAATCCTTC	CGCCTCGGCT	GCGCCAATTT	GAAAAACCGC
	1651	CAAGGCTGGC	AGGATGTGTG	CGCCCAAGCC	TTTCAAACCC	CCGTCCATTC
40	1701	CTTTTCAGGCA	AAACAGTTTT	TTGAACGCTA	TTTCACGCGG	TGGCAGGTTG
	1751	CAGGCAACCG	AAGCCTTGCC	GGTACGGTTA	CCGGCTATTA	CGAGCCGGTG
	1801	CTGAAGGGCG	ACGACAGGCG	GACGGCACAA	GCCCGCTTCC	CGATTTACGG
	1851	TATTTCCGAC	GATTTTATCT	CCGTCCCCCT	GCCTGCCGGT	TTGCGGAGCG
	1901	GAAAAGCCCT	TGTCCGCATC	AGGCAGACGG	GAAAAAACAG	CGGCACAATC
45	1951	GACAATACCG	GCGGCACACA	TACCGCCGAC	CTCTCCCGAT	TCCCCATCAC
	2001	CGCGCGCACA	ACGGCAATCA	AAGGCAGGTT	TGAAGGAAGC	CGCTTCCTCC

-40-

	2051	CCTACCACAC	GCGCAACCAA	ATCAACGGCG	GCGCGCTTGA	CGGCAAAGCC
	2101	CCGATACTCG	GTTACGCCGA	AGACCCCGTC	GAACTTTTTT	TTATGCACAT
	2151	CCAAGGCTCG	GGCCGTCTGA	AAACCCCGTC	CGGCAAATAC	ATCCGCATCG
5	2201	GCTATGCCGA	CAAAAACGAA	CATCCCTACG	TTTCCATCGG	ACGCTATATG
	2251	GCGGACAAAG	GCTACCTCAA	GCTCGGGCAG	ACCTCGATGC	AGGGCATCAA
	2301	AGCCTATATG	CGGCAAAATC	CGCAACGCCT	CGCCGAAGTT	TTGGGTCAAA
	2351	ACCCACAGTA	TATCTTTTTT	CFCGAGCTTG	CCGGAAGCAG	CAATGACGGT
	2401	CCCGTCGGCG	CACTGGGCAC	GCCGTGTATG	GGGGAATATG	CCGGCGCAGT
10	2451	CGACCGGCAC	TACATTACCT	TGGGCGCGCC	CTTATTTGTC	GCCACCGCCC
	2501	ATCCGGTTAC	CCGCAAGGCC	CTCAACCGCC	TGATTATGGC	GCAGGATACC
	2551	GGCAGCGCGA	TTAAAGGCGC	GGTGC GCGTG	GATTATTTTT	GGGGATACGG
	2601	CGACGAAGCC	GGCGAACTTG	CCGGCAAACA	GAAAACCACG	GGTTACGTCT
	2651	GGCAGCTCCT	ACCCAACGGT	ATGAAGCCCG	AATACCGCCC	GTAAGGCTT
15	1	MASPDVKSAD	TLSKPAAPVV	SEKETEAKED	APQAGSQGQG	APSAQGGQDM
	51	AAVSEENTGN	GGAAATDKPK	NEDEGAQNDM	PQNAADTDSL	TPNHTPASNM
	101	PAGNMENQAP	DAGESEQPAN	QPDMAANTADG	MOGDDPSAGG	ENAGNTAAQG
	151	TNQAENQTA	GSQNPAASSTN	PSATNSGGDF	GRTNVGNSVV	IDGPSQNTIL
20	201	THCKGDSGSG	NNFLDEEVQL	KSEFEKLSDA	DKISNYKKDG	KNDGKNDKRV
	251	GLVADSVQMK	GINQYIIFYK	PKPTSFARFR	RSARSRRSLP	AEMPLIPVNO
	301	ADTLIVDGEA	VSLTGHSGNI	FAPEGNYRYL	TYGAELKPGG	SYALRVQGEF
	351	SKGEMLAGTA	VYNGEVLHFH	TENGRPSPSR	GRFAAKVDFG	SKSVDGIIDS
	401	GDGLHMGTOK	FKAIDGNF	KGTWTENGFG	DVSGKFYQPA	GEEVAGKYSY
	451	RPTDAEKGGF	GVFAGKKEQD	GSGGGGQSK	SIQTFPQPD	SVINGPDRPV
25	501	GIPDPAGTTV	GGGAVYTVV	PHLSLPHWAA	QDFAKSLQSF	RLGCANLKNR
	551	QWQDVCAQA	FQTPVHSFQA	KQFFERYFTP	WQVAGNGSLA	GTVTGYEYEPV
	601	LKGDDRRTAQ	ARFPIYGIPD	DFISVPLPAG	LRSGKALVRI	RQTGKNSGTI
	651	DNTGGTHTAD	LSRFPITART	TAIKGRFEFS	RFLPYHTRNQ	INGGALDGKA
	701	PILGYAEDPV	ELFFMHIGGS	GRKTPPSGKY	IRIGYADKNE	HPVVSIGRYM
30	751	ADKGYLKLGO	TSMQGIKAYM	RQNPORLAEV	LGQNPSYIFF	RELAGSNDG
	801	PVGALGTPLM	GEYAGAVDRH	YITLGAPLFV	ATAHPVTRKA	LNRLIMAQDT
	851	GSAIKGAVRV	DYFWGYGDEA	GELAGKQKTT	GYVWQLLPNG	MKPEYRP*
35	<u>AG287NZ-953</u>					
	1	ATGGCTAGCC	CCGATGTCAA	GTCGGCGGAC	ACGCTGTCAA	AACCTGCCGC
	51	CCCTGTTGTT	TCTGAAAAAG	AGACAGAGGC	AAAGGAAGAT	GCGCCACAGG
	101	CAGGTTCTCA	AGGACAGGGC	GCGCCATCCG	CACAAGGCGG	TCAAGATATG
40	151	GCGGCGGTTT	CGGAAGAAAA	TACAGGCAAT	GGCGGTGCGG	CAGCAACGGA
	201	CAAAACCCAA	AATGAAGACG	AGGGGGCGCA	AAATGATATG	CCGCAAAATG
	251	CCGCCGATAC	AGATAGTTTG	ACACCGGAATC	ACACCCCGGC	TTCGAATATG
	301	CCGGCCGGAA	ATATGGAAAA	CCAAGCACCG	GATGCCGGGG	AATCGGAGCA
	351	GCCGGCAAAC	CAACCGGATA	TGGCAAATAC	GCGCGACGGA	ATGCAGGGTG
	401	ACGATCCGTC	GGCAGGCGGG	GAAAATGCCG	GCAATACGGC	TGCCCAAGGT
45	451	ACAAATCAAG	CCGAAAACAA	TCAAACCGCC	GGTTCTCAAA	ATCCTGCCTC
	501	TTCAACCAAT	CCTAGCGCCA	CGAATAGCGG	TGGTGATTTT	GGAAGGACGA
	551	ACCTGGGCAA	TTCTGTTGTG	ATTGACGGGC	CGTCGCAAAA	TATAACGTTG
	601	ACCCACTGTA	AAGGCGATTTC	TTGTAGTGGC	AATAATTTCT	TGGATGAAGA
	651	AGTACAGCTA	AAATCAGAAT	TTGAAAAATT	AAGTGATGCA	GACAAAATAA
50	701	GTAATTACAA	GAAAGATGGG	AAGAATGACG	GGAAGAATGA	TAAATTTGTC
	751	GGTTTGGTTG	CCGATAGTGT	GCAGATGAAG	GGAATCAATC	AATATATTAT
	801	CTTTTATAAA	CCTAAACCCA	CTTCATTTGC	GCGATTTAGG	CGTTCTGCAC
	851	GGTCGAGGCG	GTCGCTTCCG	GCCGAGATGC	CGCTGATTCC	CGTCAATCAG
	901	GCGGATACGC	TGATTGTCTGA	TGGGGAAGCG	GTCAGCCTGA	CGGGGCATTC
55	951	CGGCAATATC	TTCGCGCCCG	AAGGGAATTA	CCGGTATCTG	ACTTACGGGG
	1001	CGGAAAAATT	GCCCGGCGGA	TCGTATGCCC	TCCGTGTTCA	AGGCGAACCT
	1051	TCAAAGGGCG	AAATGCTCGC	GGGCACGGCA	GTGTACAACG	GCGAAGTGCT
	1101	GCAATTTTCAT	ACGGAAAAACG	GCCGTCCGTC	CCCGTCCAGA	GGCAGGTTTG
	1151	CCGCAAAAGT	CGATTTCCGC	AGCAAATCTG	TGGACGGCAT	TATCGACAGC
60	1201	GGCGATGGTT	TGCATATGGG	TACGCAAAAA	TTCAAAGCCG	CCATCGATGG
	1251	AAACGGCTTT	AAGGGGACTT	GGACGAAAAA	TGGCGGCGGG	GATGTTTCCG
	1301	GAAAGTTTTA	CGGCCCGGCC	GGCGAGGAAG	TGGCGGGAAA	ATACAGCTAT
	1351	GCCCCAACAG	ATGCGGAAAA	GGGCGGATTC	GGCGTGTGTT	CCGGCAAAAA
	1401	AGACGAGGAT	GGATCCGGAG	GAGGAGGAGC	CACCTACAAA	GTGGACGAAT
65	1451	ATCACGCCAA	CGCCCGTTTC	GCCATCGACC	ATTTCAACAC	CAGCACCAAC
	1501	GTCGGCGGTT	TTTACGGTCT	GACCGGTTCC	GTCGAGTTCC	ACCAAGCAAA
	1551	ACGCACGGT	AAAATCGACA	TCACCATCCC	CGTTGCCAAC	CTGCAAGCG

1601	GTTCGCAACA	CTTTACCGAC	CACCTGAAAT	CAGCCGACAT	CTTCGATGCC
1651	GCCCAATATC	CGGACATCCG	CTTTGTTTCC	ACCAAATTCA	ACTTCAACGG
1701	CAAAAAACTG	GTTTCCGTTG	ACGGCAACCT	GACCATGCAC	GGCAAAACCG
1751	CCCCCGTCAA	ACTCAAAGCC	GAAAAATTCA	ACTGCTACCA	AAGCCCGATG
1801	GCGAAAACCG	AAGTTTGC GG	CGGCGACTTC	AGCACCACCA	TCGACCGCAC
1851	CAAAATGGGGC	GTGGACTACC	TCGTTAACGT	TGGTATGACC	AAAAGCGTCC
1901	GCATCGACAT	CCAAATCGAG	GCAGCCAAAC	AATAAAAGCT	T
1	MASPDVKSAD	TLSPKPAAPVV	SEKETEAKED	APQAGSQGGQ	APSAQGGQDM
51	AAVSEENTGN	GGAAATDKPK	NEDEGAQN DM	PQNAADTDSL	TPNH TPASNM
101	PAGNMENQAP	DAGESEQPAN	QPD MANTADG	MQGDDPSAGG	ENAGNTAAQG
151	THQAENQTA	GSQN PASSTN	PSATNSGGDF	GRTNVGN SVV	IDGPSQNTL
201	THCKGDSCSG	NNFLDEEVQL	KSEFEKLSDA	DKISNYKKDG	KNDGKNDK FV
251	GLVADSVQMK	GINQYIIFYK	PKPTS FARFR	RSARSRRSLP	AEMPLIPV NQ
301	ADTLIVDGEA	VSLTGHSGNI	FAPEGNYRYL	TYGAEKLPGG	SYALRVQGEF
351	SKGEMLAGTA	VYNGEVLH FH	TENGRPSPSR	GRFAAKVDFG	SKSVDGIIDS
401	GDGLHMGTOK	FKAAIDGNF	KGTWTENGGG	DVSGKFYGPA	GEEVAGKYSY
451	RPTDAEKGGF	GVFAGKKEQD	SGSGGGATYK	VDEYHANARF	AIDHFN TSTN
501	VGGFYGLTGS	VEFDQAKRDG	KIDITIPVAN	LQSGSQHFTD	HLKSADIFDA
551	AQYPDIFRVS	TKFNFN GKKL	VSVDGNLTMH	GKTAPVKLKA	EKFNCYQSPM
601	AKTEVCGGDF	STTIDRTKWG	VDYLVN VGMT	KSVRIDIQIE	AAKQ*

25	1	ATGGCTAGCC	CCGATGTCAA	GTCGGCGGAC	ACGCTGTCAA	AACCTGCCGC
	51	CCCTGTGTGT	TCTGAAAAAG	AGACAGAGGC	AAAGGAAGAT	GCGCCACAGG
	101	CAGGT TCTCA	AGGACAGGGC	GCGCCATCCG	CACAAGGCGG	TCAAGATATG
	151	GCGGCGGTTT	CGGAAGAAAA	TACAGGCAAT	GGCGGTGCGG	CAGCAACGGA
	201	CAAAACCAAA	AATGAAGACG	AGGGGGCGCA	AAATGATATG	CCGCAAAATG
30	251	CCGCCGATAC	AGATAGTTTG	ACACCGAATC	ACACCCCGGC	TTCGAATATG
	301	CCGCCCGGAA	ATATGGA AAA	CCAAGCACCG	GATGCCGGGG	AATCGGAGCA
	351	GCCGGCAAAC	CAACCGGATA	TGGCAAATAC	GGCGGACGGA	ATGCAGGGTG
	401	ACGATCCGTC	GGCAGGCGGG	GAAAA TGCCG	GCAATACGGC	TGCCCAAGGT
	451	ACAAATCAAG	CCGAAAACAA	TCAAACCGCC	GGTTCTCAA	ATCCTGCCCTC
35	501	TTCAACCAAT	CCTAGCGCCA	CGAATAGCGG	TGGTGATTTT	GGAAGGACGA
	551	ACGTGGGCAA	TTCTGTTGTG	ATTGACGGGC	CGTCGCAAAA	TATAACCTTG
	601	ACCCACTGTA	AAGGCGATTC	TTGTAGTGGC	AATAATTTCT	TGGATGAAGA
	651	AGTACAGCTA	AAATCAGAAT	TTGAAAAATT	AAGTGATGCA	GACAAAAATA
40	701	GTAATTACAA	GAAAGATGGG	AAGAATGACG	GGAAGAATGA	TAAATTTGTC
	751	GGTTTGGTTG	CCGATAGTGT	GCAGATGAAG	GGAATCAATC	AATATATTAT
	801	CTTTTATAAA	CCTAAACCCA	CTTCATTTGC	GCGATTTAGG	CGTTCTGCAC
	851	GGTCGAGGCG	GTCGCTTCCG	GCCGAGATGC	CGCTGATTCC	CGTCAATCAG
	901	GCGGATACGC	TGATTGTCTGA	TGGGGAAGCG	GTCAGCCTGA	CGGGGCATTC
45	951	CGGCAATATC	TTCCGCGCCG	AAGGGAATTA	CCGGTATCTG	ACTTACGGGG
	1001	CGGAAAAATT	GCCC GGCGGA	TCGTATGCCC	TCCGTGTTCA	AGGCGAACCT
	1051	TCAAAAGGCG	AAATGCTCGC	GGGCACGGCA	GTGTACAACG	GCGAAGTGCT
	1101	GCAPTTTTCAT	ACGGAAAAACG	GCCGTCCGTC	CCCGTCCAGA	GGCAGGTTTG
	1151	CCGCAAAAGT	CGATTTCCGC	AGCAAATCTG	TGGACGGCAT	TATCGACAGC
	1201	GGCGATGGTT	TGCATATGGG	TACGCAAAAA	TTCAAAGCCG	CCATCGATGG
50	1251	AAACGCTTTT	AAGGGGACTT	GGACGAAAAA	TGGCGGCGGG	GATGTTTCCG
	1301	GAAAGTTTTA	CGGCCCGGCC	GGCGAGGAAG	TGGCGGGAAG	ATACAGCTAT
	1351	CGCCCAACAG	ATGCGGAAAA	GGGCGGATTC	GGCGTGTTTG	CCGGCAAAAA
	1401	AGAGCAGGAT	GGATCCGGAG	GAGGAGGAGC	CACAAACGAC	GACGATGTTA
55	1451	AAAAAGCTGC	CACTGTGGCC	ATTGCTGCTG	CCTACAACAA	TGGCCAAGAA
	1501	ATCAACGGTT	TCAAAGCTGG	AGAGACCATC	TACGACATTG	ATGAAGACGG
	1551	CACAATTACC	AAAAAAGACG	CAACTGCAGC	CGATGTTGAA	GCCGACGACT
	1601	TTAAAGGTCT	GGGTCTGAAA	AAAGTCGTGA	CTAACCTGAC	CAAAACCGTC
	1651	AATGAAAAACA	AACAAAACGT	CGATGCCAAA	GTAAGAGCTG	CAGAATCTGA
	1701	AATAGAAAAG	TTAACAACCA	AGTTAGCAGA	CACTGATGCC	GCTTTAGCAG
60	1751	ATACTGATGC	CGCTCTGGAT	GCAACCACCA	ACGCCTTGAA	TAAATTTGGGA
	1801	GAAAAATATA	CGACATTTGC	TGAAGAGACT	AAGACAAATA	TCGTAAAAAT
	1851	TGATGAAAAA	TTAGAAGCCG	TGGCTGATAC	CGTCGACAAG	CATGCCGAAG
	1901	CATTCAACGA	TATCGCCGAT	TCATTGGATG	AAACCAACAC	TAAGGCAGAC
	1951	GAAAGCCGTC	AAACCGCCAA	TGAAGCCAAA	CAGACGGCCG	AAGAAACCAA
65	2001	ACAAAACGTC	GATGCCAAAG	TAAAAGCTGC	AGAAACTGCA	GCAGGCAAGG
	2051	CCGAAGCTGC	CGCTGGCACA	GCTAATACTG	CAGCCGACAA	GGCCGAAGCT
	2101	GTCGCTGCAA	AAGTTACCGA	CATCAAAGCT	GATATCGCTA	CGAACAAAGA

-42-

2151 TAATATTGCT AAAAAAGCAA ACAGTGCCGA CGTGACACC AGAGAAGAGT
 2201 CTGACAGCAA ATTTGTCAGA ATTGATGGTC TGAACGCTAC TACCGAAAAA
 2251 TTGGACACAC GCTTGGCTTC TGCTGAAAAA TCCATTGCCG ATCAGGATAC
 5 2301 TCGCCTGAAC GGTTTGGATA AAACAGTGTC AGACCTGCCG AAAGAAACCC
 2351 GCCAAGGCCT TGCAGAACAA GCCGCGCTCT CCGGTCGTGT CCAACCTTAC
 2401 AACGTGGGTC GGTTCATGT AACGGCTGCA GTCGGCGGCT ACAAATCCGA
 2451 ATCGGCAGTC GCCATCGGTA CCGGCTCCG CTTTACCGAA AACTTTGCCG
 2501 CCAAAGCAGG CGTGGCAGTC GGCACCTCGT CCGGTTCTTC CGCAGCCTAC
 10 2551 CATGTCGGCG TCAATTACGA GTGGTAAAAG CTT

 1 MASPDVKSAD TLSKPAAPVV SEKETEAKED APQAGSQGG APSAQGGQDM
 51 AAVSEENTGN GGAAATDKPK NEDEGAQNDM PQNAADTDSL TPNHTPASNM
 101 PAGNMENQAP DAGESEQPAN QPDMANTADG MQGDDPSAGG ENAGNTAAQG
 151 TNQAENNQTA GSQNPASSTN PSATNSGGDF GRITNVGNSV IDGPSQNTIL
 15 201 THCKGDS CSG NNFLDEEVQL KSEFEKLSDA DKISNYKKDG KNDGKNDKFV
 251 GLVADSVQMK GINQYIIFYK PKPTSFARFR RSARSRRSLP AEMPLIPVNQ
 301 ADTLIVDGEA VSLTGHSGNI FAPEGNYRYL TYGAEKLP GG SYALRVQGEP
 351 SKGEMLAGTA VYNGEVLHFH TENGRPSPSR GRFAAKVDFG SKSVDGIIDS
 401 SKGLHMGTOK FKAAIDGNFG KGTWTENGGG DVSGKFYGPA GEEVAGKYSY
 20 451 RPTDAEKGGF GVFAGKKEQD GSGGGGATND DDVKAATVA IAAAYNNGQE
 501 INGFKAGETI YDIDEDGTIT KKDATAADVE ADDFKGLGLK KVVNTLTKTV
 551 NENKQNVDAK VKAAESEIEK LTTKLADTDA ALADTDAALD ATTNALNKLK
 601 ENITTFAEET KTNIVKIDEK LEAVADTVDK HAEAFNDIAD SLDETNTKAD
 651 EAVKTANEAK QTAETKQNV DAKVKAETA AGKAEAAAGT ANTAADKAEA
 25 701 VAAKVTDIKA DIATNKDNIA KKANSADVYT REESDSKFVR IDGLNATTEK
 751 LDTRLASA EK SIADHDTRLN GLDKTVSDLR KETROGLAEQ AALSGLFPY
 801 NVGRFNVTA VGGYKSESAV AIGTGFRFTE NFAAKAGVAV GTSSGSSAAY
 851 HVG VNYEW*

30 *ΔG983 and hybrids*

Bactericidal titres generated in response to Δ G983 (His-fusion) were measured against various strains, including the homologous 2996 strain:

	2996	NGH38	BZ133
Δ G983	512	128	128

Δ G983 was also expressed as a hybrid, with ORF46.1, 741, 961 or 961c at its C-terminus:

Δ G983-ORF46.1

35 1 ATGACTTCTG CGCCCGACTT CAATGCAGGC GGTACCGGTA TCGGCAGCAA
 51 CAGCAGAGCA ACAACAGCGA AATCAGCAGC AGTATCTTAC GCCGGTATCA
 101 AGAACGAAAT GTGCAAAGAC AGAAGCATGC TCTGTGCCGG TCGGGATGAC
 151 GTTCGCGGTTA CAGACAGGGA TGCCAAAATC AATGCCCCCC CCCCGAATCT
 40 201 GCATACCGGA GACTTTCCAA ACCCAAATGA CGCATACAAG AATTTGATCA
 251 ACCTCAAACC TGCAATTGAA GCAGGCTATA CAGGACGCGG GGTAGAGGTA
 301 GGTATCGTCG ACACAGGCGA ATCCGTCGGC AGCATATCCT TTCCCGAACT
 351 GTATGGCAGA AAAGAACACG GCTATAACGA AAATTACAAA AACTATACGG
 401 CGTATATGCG GAAGGAAGCG CCTGAAGACG GAGGCGGTAA AGACATTGAA
 451 GCTTCTTTTCG ACGATGAGGC CGTTATAGAG ACTGAAGCAA AGCCGACGGA
 45 501 TATCCGCCAC GTAAAAGAAA TCGGACACAT CGATTTGGTC TCCCATATTA
 551 TTGGCGGGCG TTCCGTGGAC GGCAGACCTG CAGGCGGTAT TGCGCCCGAT
 601 GCGACGCTAC ACATAATGAA TACGAATGAT GAAACCAAGA ACGAAATGAT
 651 GGTTCAGGCC ATCCGCAATG CATGGGTCAA GCTGGGCGAA CGTGGCGTGC
 701 GCATCGTCAA TAACAGTTT TGAACAACAT CGAGGCGAG CACTGCCGAC
 50 751 CTTTTCCTTCC TAGCCAATTC GGAGGAGCAG TACCGCCAAG CGTTGCTCGA
 801 CTATTCCGGC GGTGATAAAA CAGACGAGGG TATCCGCCTG ATGCAACAGA
 851 GCGATTACGG CAACCTGTCC TACCACATCC GTAATAAAAA CATGCTTTTC
 901 ATCTTTTCGA CAGGCAATGA CGCACAAAGT CAGCCCAACA CATATGCCCT
 951 ATTGCCATTT TATGAAAAAG ACGCTCAAAA AGGCATTATC ACAGTCGCAG
 55 1001 CGGTAGACCG CAGTGGAGAA AAGTTCAAAC GGGAAATGTA TGGAGAACCG
 1051 GGTACAGAAC CGCTTGAGTA TGGCTCCAAC CATTGCGGAA TTACTGCCAT
 1101 GTGGTGCCCTG TCGGCACCCCT ATGAAGCAAG CGTCCGTTTC ACCCGTACAA

	1151	ACCCGATTCA	AATTGCCGGA	ACATCCTTTT	CCGCACCCAT	CGTAACCGGC
	1201	ACGGCGGCTC	TGCTGTGCA	GAAATACCCG	TGGATGAGCA	ACGACAACCT
	1251	GCGTACCACG	TTGCTGACGA	CGGCTCAGGA	CATCGGTGCA	GTCGGCGTGG
5	1301	ACAGCAAGTT	CGGCTGGGGA	CTGCTGGATG	CGGGTAAGGC	CATGAACGGA
	1351	CCCGCGTCCT	TTCCGTTCCG	CGACTTTACC	GCCGATACGA	AAGGTACATC
	1401	CGATATTGCC	TACTCCTTCC	GTAACGACAT	TTCAGGCACG	GGCGGCCTGA
	1451	TCAAAAAAGG	CGGCAGCCAA	CTGCAACTGC	ACGGCAACAA	CACCTATACG
	1501	GGCAAAACCA	TTATCGAAGG	CGGTTGCTG	GTGTTGTACG	GCAACAACAA
10	1551	ATCGGATATG	CGCGTCGAAA	CCAAAGGTGC	GCTGATTAT	AACGGGGCGG
	1601	CATCCGGCGG	CAGCCTGAAC	AGCGACGGCA	TTGTCTATCT	GGCAGATACC
	1651	GACCAATCCG	GCGCAACGA	AACCGTACAC	ATCAAAGGCA	GTCTGCAGCT
	1701	GGACGGCAAA	GGTACGCTGT	ACACACGTTT	GGGCAAACTG	CTGAAAGTGG
	1751	ACGGTACGGC	GATTATCGGC	GGCAAGCTGT	ACATGTCCGC	ACGCGGCAAG
15	1801	GGGGCAGGCT	ATCTCAACAG	TACCGGACGA	CGTGTTCCTT	TCCTGAGTGC
	1851	CGCCAAAATC	GGGCAGGATT	ATTCTTTCTT	CACAAACATC	GAAACCGACG
	1901	GCGGCCTGCT	GGCTTCCTTC	GACAGCGTCG	AAAAAACAGC	GGGCAGTGAA
	1951	GGCGACACGC	TGTCCATTAT	TGTCCGTCGC	GGCAATGCGG	CACGGACTGC
	2001	TTCCGGCAGCG	GCACATTCCG	CGCCCGCCCG	TCTGAAACAC	GCCGTAGAAC
20	2051	AGGGCGGCAG	CAATCTGGAA	AACCTGATGG	TCGAACTGGA	TGCTCCGAA
	2101	TCATCCGCAA	CACCCGAGAC	GGTTGAAACT	GCGGCAGCCG	ACCGCACAGA
	2151	TATGCCGGGC	ATCCGCCCTT	ACGGCGCAAC	TTTCCGCGCA	GCGCGAGCCG
	2201	TACAGCATGC	GAATGCCGCC	GACGGTGTAC	GCATCTTCAA	CAGTCTCGCC
	2251	GCTACCGTCT	ATGCCGACAG	TACCGCCGCC	CATGCCGATA	TGCAGGGACG
25	2301	CCGCCTGAAA	CCCGTATCGG	ACGGTTGGA	CCACAACGGC	ACGGGTCTGC
	2351	GCGTCATCGC	GCAAACCCAA	CAGGACGGTG	GAACGTGGGA	ACAGGGCGGT
	2401	GTTGAAGGCA	AAATGCGCGG	CAGTACCCAA	ACCGTCGCGA	TTGCGCGGAA
	2451	AACCGGCGAA	AATACGACAG	CAGCCGCCAC	ACTGGGCATG	GGACGCAGCA
	2501	CATGGAGCGA	AAACAGTGCA	AATGCAAAAA	CCGACAGCAT	TAGTCTGTCT
30	2551	GCAGGCATAC	GGCAGCATGC	GGGCGATATC	GGCTATCTCA	AAGGCTGTCT
	2601	CTCTACGGA	CGCTACAAAA	ACAGCATCAG	CCGACGACCC	GGTGCAGACG
	2651	AACATGCGGA	AGGCAGCGTC	AACGGCACGC	TGATGCAGCT	GGGCGCACTG
	2701	GCGGGTGTCA	ACGTTCCGTT	TGCCGCAACG	GGAGATTGGA	CGGTGGAAGG
	2751	CGGTCTGCGC	TACGACCTGC	TCAAACAGGA	TGCATTTCGCC	GAAAAAGGCA
35	2801	GTGCTTTGGG	CTGGAGCGGC	AACAGCCTCA	CTGAAGGCAC	GCTGGTCGGA
	2851	CTCGCGGGTC	TGAAGCTGTC	GCAACCCCTG	AGCGATAAAG	CCGTCTGTCT
	2901	TGCAACGGCG	GGCGTGGAAC	GCGACCTGAA	CGGACGCGAC	TACACGGTAA
	2951	CGGGCGGCTT	TACCGGCGCG	ACTGCAGCAA	CCGGCAAGAC	GGGGGCACGC
	3001	AATATGCCGC	ACACCCGTCT	GGTTGCCGGC	CTGGGCGCGG	ATGTGCAATT
40	3051	CGGCAACGGC	TGGAACGGCT	TGGCACGTTA	CAGCTACGCC	GGTTCCAAAC
	3101	AGTACGGCAA	CCACAGCGGA	CGAGTCGGCG	TAGGCTACCG	GTTCCTCGAC
	3151	GGTGGCGGAG	GCACTGGATC	CTCAGATTTG	GCAAACGATT	CTTTTATCCG
	3201	GCAGGTTCTC	GACCGTCAGC	ATTTGCAACC	CGACGGGAAA	TACCACCTAT
	3251	TCGGCAGCAG	GGGGGAACTT	GCCGAGCGCA	GCGGCCATAT	CGGATTGGGA
45	3301	AAAAACAAA	GCCATCAGTT	GGGCAACCTG	ATGATTCAAC	AGGCGGCCAT
	3351	TAAAGGAAAT	ATCGGCTACA	TTGTCCGCTT	TTCCGATCAC	GGGCACGAAG
	3401	TCCATTCCCC	CTTCGACAAC	CATGCCTCAC	ATTCCGATTG	TGATGAAGCC
	3451	GGTAGTCCCG	TTGACGGATT	TAGCCTTTAC	CGCATCCATT	GGGACGGATA
	3501	CGAACACCAT	CCCGCCGACG	GCTATGACGG	GCCACAGGGC	GGCGGCTATC
50	3551	CCGCTCCCAA	AGGCGCGAGG	GATATATACA	GCTACGACAT	AAAAGGCGTT
	3601	GCCCAAAATA	TCCGCCTCAA	CCTGACCGAC	AACCGCAGCA	CCGGACAACG
	3651	GCTTGCCGAC	CGTTTCCACA	ATGCCGGTAG	TATGCTGACG	CAAGGAGTAG
	3701	GCGACGGATT	CAAACGCGCC	ACCCGATACA	GCCCCGAGCT	GGACAGATCG
	3751	GGCAATGCCG	CCGAAGCCTT	CAACGGCACT	GCAGATATCG	TTAAAAACAT
55	3801	CATCGGCGCG	GCAGGAGAAA	TTGTGCGCGC	AGGCGATGCC	GTGCAGGGCA
	3851	TAAGCGAAGG	CTCAAACATT	GCTGTCATGC	ACGGCTTGGG	TCTGCTTTCC
	3901	ACCGAAAACA	AGATGGCGCG	CATCAACGAT	TTGGCAGATA	TGGCGCAACT
	3951	CAAAGACTAT	GCCGCAGCAG	CCATCCGCGA	TTGGGCAGTC	CAAAACCCCA
	4001	ATGCCGCACA	AGGCATAGAA	GCCGTCAGCA	ATATCTTTAT	GGCAGCCATC
60	4051	CCCATCAAAG	GGATTGGAGC	TGTTGCGGGA	AAATACGGCT	TGGGCGGCAT
	4101	CACGGCACAT	CCTATCAAGC	GGTCGAGAT	GGGCGCGATC	GCATTGCCGA
	4151	AAGGGAAATC	CGCCGTCAGC	GACAATTTTG	CCGATGCGGC	ATACGCCAAA
	4201	TACCCGTCCC	CTTACCATTG	CCGAAATATC	CGTTCAAAC	TGGAGCAGCG
	4251	TTACGGCAAA	GAAAACATCA	CCTCCTCAAC	CGTGCCGCGG	TCAAACGGCA
65	4301	AAAAATGTCAA	ACTGGCAGAC	CAACGCCACC	CGAAGACAGG	CGTACCGTTT
	4351	GACGGTAAAG	GGTTTCCGAA	TTTGTGAGAAG	CACGTGAAAT	ATGATACGCT
	4401	CGAGCACCAC	CACCACCACC	ACTGA		

1 MTSAPDFNAG GTGIGSNSRA TTAKSAAVSY AGIKNEMCKD RSMLCAGRDD
 51 VAVTDRDAKI NAPPPNLHTG DFPNPNDAYK NLINLKPAIE AGYTGRGVEV
 101 GIVDTGESVG SISFPELYGR KEHGYNENYK NYTAYMRKEA PEDGGGKDIE
 151 ASFDDEAVIE TEAKPTDIRH VKEIGHIDL V SHIIGGRSVD GRPAGGIAPD
 201 ATLHIMNTND ETKNEMMVAA IRNAWVKLGE RGVRIVNN SF GTTSRAGTAD
 251 LFQIANSEEQ YRQALLDYSG GDKTDEGIRL MQQSDYGNLS YHIRNKNMLF
 301 IFSTGNDAQA QPNTYALLPF YEKDAQKGII TVAGVDRSGE KFKREMYGEP
 351 GTEPLEYGSN HCGITAMWCL SAPYEASVRF TRTNPIQIAG TSFSAPIVITG
 401 TAALLLQKYP WMSNDNLRTT LLTTAQDIGA VGVDSKFGWG LLDAGKAMNG
 10 451 PASFFPGDFT ADTKGTS DIA YSFRNDISGT GGLIKKGGSQ LQLHGNNTYT
 501 GKTIIEGGS L VLYGNNKSDM RVETKCALIY NGAASGGS LN SDGIVYLADT
 551 DQSGANETVH IKGSLQLDGK GTLYTRLGKL LKVDGTAIIG GKLYMSARGK
 601 GAGYLNSTGR RVPFLSAAKI GDYSFFTNI ETDGGLLASL DSVEKTAGSE
 15 651 GDTLSYYVRR GNAARTASAA AHSAPAGLKH AVEQGGSNLE NLMVELDASE
 701 SSATPETVET AAADRTDMPG IRPYGATFRA AAHVQHANA DGVRIFNSLA
 751 ATVYADSTAA HADMQRRLK AVSDGLDHNG TGLRVIAQTQ QDGGTWEQGG
 801 VEGKMRGSTQ TVGIAAKTGE NTTAAATLGM GRSTWSEN SA NAKTDSISLF
 851 AGIRHDAGDI GYLKGLFSYG RYKNSISRST GADEHAEGSV NGTLMQLGAL
 901 GGVNVFFAAT GDLTVEGGLR YDLLKQDAFA EKGSALGWSG NSLTEGTLVG
 20 951 LAGLKLSQLP SDKAVLFATA GVERDLNGRD YTVTGGFTGA TAATGKTGAR
 1001 NMPHTRLVAG LGADVEFGNG WNGLYRSYSA GSKQYGNHSG RVGVGYRFLD
 1051 GGGGTGSSDL ANDSFIRQVL DRQHFEPDGK YHLFSGRGEL AERSGHIGLG
 1101 KIQSHQLGNL MIQQAIIKGN IGYIVRFS DH GHEVHSPFDN HASHSDSDEA
 1151 GSPVDGFSLY RIHWDGYEHH PADGYDGPQG GGYPA PKGAR DIYSYDIKGV
 25 1201 AQNIRLNLTD NRSTGQRLAD RFHNAGSMLT QGVGDGFKRA TRYSPELDRS
 1251 GNAAEAFNGT ADIVKNIIGA AGEIVGAGDA VQGISEGSNI AVMHGLGLLS
 1301 TENKMARIND LADMAQLKDY AAAAIRDWAV QNPNAAQGIE AVSNIFMAAI
 1351 PIKGIAGVRG KYGLGGITAH PIKRSQMGAI ALPKGKS AVS DNFADAAYAK
 1401 YPSFYHSRNI RSNLEQRYGK ENITSSTVPP SNGKNVKLAD QRHPKTGVFP
 30 1451 DGKGFPNF EK HVKYDTLEHH HHHH*

AG983-741

1 ATGACTTCTG CGCCCGACTT CAATGCAGGC GGTACCGGTA TCGGCAGCAA
 35 51 CAGCAGAGCA ACAACAGCGA AATCAGCAGC AGTATCTTAC GCCGGTATCA
 101 AGAACGAAAT GTGCAAAGAC AGAAGCATGC TCTGTGCCGG TCGGGATGAC
 151 GTTGCGGTTA CAGACAGGGA TGCCAAAATC AATGCCCCC CCCC GAATCT
 201 GCATACCGGA GACTTTC CAA ACCCAAATGA CGCATACAAG AATTGTATCA
 251 ACCTCAAACC TGCAATTGAA GCAGGCTATA CAGGACGCGG GG TAGAGGTA
 40 301 GGTATCGTCG ACACAGGCGA ATCCGTCGGC AGCATATCCT TTCCCGA ACT
 351 GTATGGCAGA AAAGAACACG GCTATAACGA AAATTACAAA AACTATACCG
 401 CGTATATGCG GAAGGAAGCG CCTGAAGACG GAGGCGGTAA AGACATTGAA
 451 GCTTCTTTTCG ACGATGAGGC CGTTATAGAG ACTGAAGCAA AGCCGACGGA
 501 TATCCGCCAC GTAAAAGAAA TCGGACACAT CGATTTGGTC TCCCATATTA
 45 551 TTGGCGGGCG TTCCGTGGAC GGCAGACCTG CAGGCGGTAT TGCGCCCGAT
 601 GCGACGCTAC ACATAATGAA TACGAATGAT GAAACCAAGA ACGAAATGAT
 651 GGTTCAGGCC ATCCGCAATG CATGGGTCAA GCTGGGCGAA CGTGGCGTGC
 701 GCATCGTCAA TAACAGTTT GGAACAACAT CGAGGGCAGG CACTGCCGAC
 751 CTTTTC CAAA TAGCCAATTC GGAGGAGCAG TACCGCCAAG CGTTGCTCGA
 50 801 CTATTCCGGC GGTGATAAAA CAGACGAGGG TATCCGCCTG ATGCAACAGA
 851 GCGATTACGG CAACCTGTCC TACCACATCC GTAATAAAAA CATGCTTTTC
 901 ATCTTTTCGA CAGGCAATGA CGCACAAGCT CAGCCCAACA CATATGCCCT
 951 ATTGCCATTT TATGAAAAAG ACGCTCAAAA AGGCATTATC ACAGTCGCAG
 1001 GCGTAGACCG CAGTGGAGAA AAGTTCAAAC GGGAAATGTA TGGAGAACCG
 55 1051 GGTACAGAAC CGCTTGAGTA TGGCTCCAAC CATTCGCGAA TTA CTGCCAT
 1101 GTGGTGCC TGCGGCACCT ATGAAGCAAG CGTCCGTTTC ACCCGTACAA
 1151 ACCCGATTCA AATTGCCGGA ACATCCTTTT CCGCACCCAT CGTAACCGGC
 1201 ACGGCGGCTC TGCTGTGCA GAAATACCCG TGGATGAGCA ACGACAACCT
 1251 GCGTACCACG TTGCTGACGA CGGCTCAGGA CATCGGTGCA GTCGGCGTGG
 60 1301 ACAGCAAGTT CGGCTGGGGA CTGCTGGATG CGGGTAAGGC CATGAACGGA
 1351 CCCGCGTCCT TTCCGTTCCG CGACTTTACC GCCGATACGA AAGGTACATC
 1401 CGATATTGCC TACTCCTTCC GTAACGACAT TTCAGGCACG GGCGGCCTGA
 1451 TCAAAAAAGG CGGCAGCCAA CTGCAACTGC ACGGCAACAA CACCTATACG
 1501 GGCAAAACCA TTATCGAAGG CGGTTCCGCTG GTGTGTACG GCAACAACAA
 65 1551 ATCGGATATG CGGCTCGAAA CCAAAGGTGC GCTGATTTAT AACGGGGCGG
 1601 CATCCGGCGG CAGCCTGAAC AGCGACGGCA TTGTCTATCT GGCAGATACC
 1651 GACCAATCCG GCGCAAACGA AACCGTACAC ATCAAAGGCA GTCTGCAGCT

	1701	GGACGGCAAA	GGTACGCTGT	ACACACGTTT	GGGCAAACTG	CTGAAAGTGG
	1751	ACGGTACGGC	GATTATCGGC	GGCAAGCTGT	ACATGTCCGC	ACGCGGCAAG
	1801	GGGGCAGGCT	ATCTCAACAG	TACCGGACGA	CGTGTTCCTT	TCCTGAGTGC
5	1851	CGCCAAAATC	GGGCAGGATT	ATTCTTCTTT	CACAAACATC	GAAACCGACG
	1901	GCGGCCTGCT	GGCTTCCCTC	GACAGCGTCG	AAAAAACAGC	GGGCAGTGAA
	1951	GCGGACACGC	TGTCCCTATTA	TGTCCGTCCG	GGCAATGCGG	CACGGACTGC
	2001	TTCGGCAGCG	GCACATTCCG	CGCCCGCCGG	TCTGAAACAC	GCCGTAGAAC
	2051	AGGGCGGCAG	CAATCTGGAA	AACCTGATGG	TCGAACTGGA	TGCCTCCGAA
10	2101	TCATCCGCAA	CACCCGAGAC	GGTTGAAACT	GCGGCAGCCG	ACCGCACAGA
	2151	TATGCCGGGC	ATCCGCCCTT	ACGGCGCAAC	TTTCCGCGCA	GCGGCAGCCG
	2201	TACAGCATGC	GAATGCCGCC	GACGGTGTAC	GCATCTTCAA	CAGTCTCGCC
	2251	GCTACCGTCT	ATGCCGACAG	TACCGCCGCC	CATGCCGATA	TGCAGGGACG
	2301	CCGCCTGAAA	GCCGTATCGG	ACGGGTTGGA	CCACAACGGC	ACGGGTCTGC
15	2351	GCGTCATCGC	GCAAACCCAA	CAGGACGGTG	GAACGTGGGA	ACAGGGCGGT
	2401	GTTGAAGGCA	AAATGCGCGG	CAGTACCCAA	ACCGTCGGCA	TTGCCCGGAA
	2451	AACCGGCGAA	AATACGACAG	CAGCCGCCAC	ACTGGGCAATG	GGACGCGACA
	2501	CATGGAGCGA	AAACAGTGCA	AATGCAAAAA	CCGACAGCAT	TAGTCTGTCT
	2551	GCGGCATATC	GGCAGCATGC	GGGCGATATC	GGCTATCTCA	AAGGCCCTGTT
20	2601	CTCCTACGGA	CGCTACAAAA	ACAGCATCAG	CCGACGACCC	GGTGCAGGAC
	2651	AACATGCGGA	AGGCAGCGTC	AACGGCACGC	TGATGCAGCT	GGGCGCACTG
	2701	GCGGGTGTCA	ACGTTCCGTT	TGCCGCAACG	GGAGATTTGA	CGGTGCAAGG
	2751	CGGTCTGCGC	TACGACCTGC	TCAAACAGGA	TGCATTTCGCC	GAAAAAGGCA
	2801	GTCCTTTGGG	CTGGAGCGGC	AACAGCCTCA	CTGAAGGCAC	GCTGGTCCGA
25	2851	CTCGCGGGTC	TGAAGCTGTC	GCAACCCCTG	AGCGATAAAG	CCGTCTCTGTT
	2901	TGCAACGGCG	GGCGTGGAAC	GCGACCTGAA	CGGACGCGAC	TACACGGTAA
	2951	CGGGCGGCTT	TACCGGCGCG	ACTGCAGCAA	CCGGCAAGAC	GGGGGCACGC
	3001	AATATGCCGC	ACACCCGTCT	GGTTGCCGGC	CTGGGCGCGG	ATGTGCAATT
	3051	CGGCAACGGC	TGGAACGGCT	TGGCACGTTA	CAGCTACGCC	GGTTCCAAAC
30	3101	AGTACGGCAA	CCACAGCCGA	CGAGTCGGCG	TAGGCTACCG	GTTCTCTCGAG
	3151	GGATCCGGAG	GGGGTGGTGT	CGCCGCCGAC	ATCGGTGCGG	GGCTTGCCGA
	3201	TGCACTAACC	GCACCGCTCG	ACCATAAAGA	CAAAGGTTTG	CAGTCTTTGA
	3251	CGCTGGATCA	GTCCGTCAGG	AAAAACGAGA	AACTGAAGCT	GGCGGCACAA
	3301	GGTGCGGAAA	AAACTTATGG	AAACGGTGAC	AGCCTCAATA	CGGGCAAATT
35	3351	GAAGAACGAC	AAGGTACGCC	GTTTCGACTT	TATCCGCCAA	ATCGAAGTGG
	3401	ACGGGCAGCT	CATTACCTTG	GAGAGTGGAG	AGTTCCAAAGT	ATACAAACAA
	3451	AGCCATTCCG	CCTTAACCGC	CTTTCAGACC	GAGCAAATAC	AAGATTCGGA
	3501	GCATTCGGG	AAGATGGTTG	CGAAACGCCA	GTTTCAGAAATC	GGCGACATAG
	3551	CGGGCGAACA	TACATCTTTT	GACAAGCTTC	CCGAAGGCGG	CAGGGCGACA
40	3601	TATCGCGGGA	CGGCGTTCGG	TTCAGACGAT	GCCGGCGGAA	AACTGACCTA
	3651	CACCATAGAT	TTCGCCGCGA	AGCAGGGAAA	CGGCAAAATC	GAACATTTGA
	3701	AATCGCCAGA	ACTCAATGTC	GACCTGGCCG	CCGCCGATAT	CAAGCCGGAT
	3751	GGAAAACGCC	ATGCCGTCAT	CAGCGGTTCC	GTCTTTTACA	ACCAAGCCGA
	3801	GAAAGGCAGT	TACTCCCTCG	GTATCTTTGG	CGGAAAAGCC	CAGGAAAGTTG
45	3851	CCGGCAGCGC	GGAAGTGAAA	ACCGTAAACG	GCATACGCCA	TATCGGCCTT
	3901	GCCGCCAAGC	AACTCGAGCA	CCACCACCAC	CACCACTGA	
	1	MTSAPDFNAG	GTGIGSNSRA	TTAKSAAVSY	AGIKNEMCKD	RSMLCAGRDD
	51	VAVTDRDAKI	NAPPPNLHTG	DFPNPNDAYK	NLNLKPAIE	AGYTGGRVVEV
50	101	GIVDTGBSVG	SISFPELYGR	KEHGYNENYK	NYTAYMRKEA	PEDGGGKDIE
	151	ASFDDEAVIE	TEAKPTDIRH	VKEIGHIDL	SHIIGGRSVD	GRPAGGIAPD
	201	ATLHIMNTND	ETKNEMMVAA	IRNAWVKLGE	RGVRIVNNSF	GTTSRAGTAD
	251	LFQIANSEEQ	YRQALLDYS	GDKTDEGIRL	MQQSDYGNLS	YHIRNKNMLF
	301	IFSTGNDAQA	QPNTYALLPF	YEKDAQKGII	TVAGVDRSGE	KFKREMYGEP
55	351	GTEPLEYGSN	HCGITAMWCL	SAPYEASVRF	TRTNPIQIAG	TSFSAPIVTG
	401	TAALLLQKYP	WMSNDNLRTT	LLTTAQDIGA	VGVDSKFGWG	LLDAGKAMNG
	451	PASFPPGDFT	ADTKGTS DIA	YSFRNDISGT	GGLIKKGSQ	LQLHGNNTYT
	501	PKTIIEGGSL	VLYGNKSDM	RVETKALITY	NGAASGGSLN	SDGIVYLADT
	551	DQSGANETVH	IKGSLQLDGK	GTLYTRLGKL	LKVDGTAIIG	GKLYMSARGK
60	601	GAGYLNSTGR	RVPFLSAAKI	GQDYSFFTNI	ETDGGLLASL	DSVEKTAGSE
	651	GDTLSSYYVRR	GNAARTASAA	AHSAPAGLKH	AVEQGGSNLE	NLMVELDASE
	701	SSATPETVET	AAADRTDMPG	IRPYGATFRA	AAAVQHANA	DGVRIFNSLA
	751	ATVYADSTAA	HADMQRRLK	AVSDGLDHNG	TGLRVIAQTQ	QDGGTWEQGG
	801	VEGMGRGSTQ	TVGIAAKTGE	NTTAAATLGM	GRSTWSENSA	NAKTDSISLF
	851	AGIRHDAGDI	GYLKGLFSYG	RYKNSISRST	GADEHAEBSV	NGTLMQLGAL
65	901	GGVNVPPAAT	GDLTVEGGLR	YDLLKQDAFA	EKGSALGWSG	NSLTEGTLVG
	951	LAGLKLSQLP	SDKAVLFATA	GVERDLNGRD	YTVTGGFTGA	TAATGKTGAR
	1001	NMPHTRLVAG	LGADVEFGNG	WNGLARYSYA	GSKQYGNHSG	RVGVGYRPLE

1051 GSGGGGVAAD IGAGLADALT APLDHKDKGL QSLTLDQSVR KNEKLKLAHQ
 1101 GAEKTYGNGD SLNTGKLNKD KVSRLFDFIRQ IEVDGQLITL ESGEFQVYKQ
 1151 SHSALTAFQT BQIQDSEHSG KMKVAKRQFRI GDIAGEHTSF DKLPEGGRAT
 1201 YRGTAFGSDD AGGKLTFTID FAAKQGNKGI EHLKSPELNV DLAAADIKPD
 1251 GKRHAVISGS VLYNQAEKGS YSLGIFGGKA QEVAGSAEVK TVNGIRHIGL
 1301 AAKQLEHHHH HH*

AG983-961

10 1 ATGACTTCTG CGCCCGACTT CAATGCAGGC GGTACCGGTA TCGGCAGCAA
 51 CAGCAGAGCA ACAACAGCGA AATCAGCAGC AGTATCTTAC GCCGGTATCA
 101 AGAACGAAAT GTGCAAAGAC AGAAGCATGC TCTGTGCCGG TCGGGATGAC
 151 GTTGC GGTTA CAGACAGGGA TGCCAAAATC AATGCCCCCC CCCC GAATCT
 201 GCATACCGGA GACTTTCCAA ACCCAAATGA CGCATACAAG AATTTGATCA
 15 251 ACCTCAAACC TGCAATTGAA GCAGGCTATA CAGGACGCGG GGTAGAGGTA
 301 GGTATCGTCG ACACAGGCGA ATCCGTCGGC AGCATATCCT TTCCCGAACT
 351 GTATGGCAGA AAAGAACACG GCTATAACGA AAATTACAAA AACTATACGG
 401 CGTATATGCG GAAGGAAGCG CCTGAAGACG GAGGCGGTAA AGACATGAA
 451 GCTTCTTTTCG ACGATGAGGC CGTTATAGAG ACTGAAGCAA AGCCGACGGA
 20 501 TATCCGCCAC GTAAAAGAAA TCGGACACAT CGATTTGGTC TCCCATATTA
 551 TTGGCGGGCG TTCCGTGGAC GGCAGACCTG CAGGCGGTAT TGCGCCCGAT
 601 GCGACGCTAC ACATAATGAA TACGAATGAT GAAACCAAGA ACGAAATGAT
 651 GGTTCGAGCC ATCCGCAATG CATGGGTCAA GCTGGCGGAA CGTGGCGTGC
 701 GCATCGTCAA TAACAGTTTT GGAACAACAT CGAGGGCAGG CACTGCCGAC
 25 751 CTTTTCCAAA TAGCCAATTC GGAGGAGCAG TACCGCCAAG CGTTGCTCGA
 801 CTATTCCGGC GGTGATAAAA CAGACGAGGG TATCCGCCTG ATGCAACAGA
 851 GCGATTACGG CAACCTGTCC TACCACATCC GTAATAAAAA CATGCTTTTC
 901 ATCTTTTCGA CAGGCAATGA CGCACAAGCT CAGCCCAACA CATATGCCCT
 951 ATTGCCATTT TATGAAAAAG ACGCTCAAAA AGGCATTATC ACAGTCGCAG
 30 1001 GCGTAGACCG CAGTGGAGAA AAGTTCAAAC GGGAAATGTA TGGAGAACCG
 1051 GGTACAGAAC CGCTTGAGTA TGGCTCCAAC CATTGCGGAA TTAGTGCCAT
 1101 GTGGTGCCCTG TCGGCACCCT ATGAAGCAAG CGTCCGTTTC ACCCGTACAA
 1151 ACCCGATTCA AATTGCCGGA ACATCCTTTT CCGCACCCAT CGTAACCGGC
 1201 ACGGCGGCTC TGCTGTGCA GAAATACCCG TGGATGAGCA ACGACAACCT
 35 1251 GCGTACCACG TTGCTGACGA CGGCTCAGGA CATCGGTGCA GTCGGCGTGG
 1301 ACAGCAAGTT CGGCTGGGGA CTGCTGGATG CGGGTAAGGC CATGAACGGA
 1351 CCCGCGTCCT TTCCGTTCCG CGACTTTACC GCCGATACGA AAGGTACATC
 1401 CGATATTGCC TACTCCTTCC GTAACGACAT TTCAGGCACG GCGGCGCTGA
 1451 TCAAAAAAGG CCGCAGCCAA CTGCAACTGC ACGGCAACAA CACCTATACG
 40 1501 GGCAAAACCA TTATCGAAGG CGGTTCGCTG GTGTTGTACG GCAACAACAA
 1551 ATCGGATATG CGCGTCGAAA CCAAAGGTGC GCTGATTTAT AACGGGGCGG
 1601 CATCCGGCGG CAGCCTGAAC AGCGACGGCA TTGTCTATCT GGCAGATACC
 1651 GACCAATCCG GCGCAAAACGA AACCCTACAC ATCAAAGGCA GTCTGCAGCT
 45 1701 GGACGGCAAA GGTACGCTGT ACACACGTTT GGGCAACTG CTGAAAGTGG
 1751 ACGGTACGGC GATTATCGGC GGCAAGCTGT ACATGTCGGC ACGCGGCAAG
 1801 GGGCAGGCT ATCTCAACAG TACCGGACGA CGTGTTCCTT TCCTGAGTGC
 1851 CGCCAAAATC GGGCAGGATT ATTCTTTCTT CACAAACATC GAAACCGACG
 1901 GCGGCTGCT GGCTTCCCTC GACAGCGTCG AAAAAACAGC GGGCAGTGAA
 1951 GGCACACGCG TGTCTTATTA TGTCCGTCGC GGCAATGCGG CACGGACTGC
 50 2001 TTCGGCAGCG GCACATTCG CGCCCGCCGG TCTGAAACAC GCCGTAGAAC
 2051 AGGCGGGCAG CAATCTGGAA AACCTGATGG TCGAACTGGA TGCCTCCGAA
 2101 TCATCCGCAA CACCCGAGAC GGTGAAACT GCGGCAGCCG ACCGCACAGA
 2151 TATGCCGGGC ATCCGCCCTT ACGGCGCAAC TTTCCGCGCA GCGGCAGCCG
 2201 TACAGCATGC GAATGCCGCC GACGGGTGAC GCATCTTCAA CAGTCTCGCC
 55 2251 GCTACCGTCT ATGCCGACAG TACCGCCGCC CATGCCGATA TGCAGGACG
 2301 CCGCCTGAAA GCCGTATCGG ACGGGTTGGA CCACAACGGC ACGGGTCTGC
 2351 CGGTATCGC GCAAACCCAA CAGGACGGTG GAACGTGGGA ACAGGCGGCT
 2401 GTTGAAGGCA AAATGCGCGG CAGTACCCAA ACCGTCCGCA TTGCCCGGAA
 2451 AACC GGCGAA AATACGACAG CAGCCGCCAC ACTGGGCATG GGACGCAGCA
 60 2501 CATGGAGCGA AAACAGTGCA AATGCAAAAA CCGACAGCAT TAGTCTGTTT
 2551 GCAGGCATAC GGCACGATGC GGGCGATATC GGCTATCTCA AAGGCTGTGT
 2601 CTCTTACGGA CGCTACAAAA ACAGCATCAG CCGCAGCACC GGTGCGGACG
 2651 AACATGCGGA AGGCAGCGTC AACGGCACGC TGATGCAGCT GGGCGCATC
 2701 GGCGGTGTCA ACGTTCCGTT TGCCGCAACG GGAGATTTGA CGGTGGAAGG
 65 2751 CGGTCTGCGC TACGACCTGC TCAAACAGGA TGCATTGCGC GAAAAAGGCA
 2801 GTGCTTTGGG CTGGAGCGGC AACAGCCTCA CTGAAGGCAC GCTGGTCGGA
 2851 CTCGCGGGTC TGAAGCTGTC GCAACCCCTG ACGGATAAAG CCGTCTCTGT

-47-

5	2901	TGCAACGGCG	GGCGTGGAAC	GCGACCTGAA	CGGACGCGAC	TACACGGTAA
	2951	CGGGCGGCTT	TACCGGCGCG	ACTGCAGCAA	CCGGCAAGAC	GGGGGCACGC
	3001	AATATGCCGC	ACACCCGTCT	GGTTGCCGGC	CTGGGCGCGG	ATGTGCAATT
	3051	CGGCAACGGC	TGGAACGGCT	TGGCACGTTA	CAGCTACGCC	GGTTCCAAAC
	3101	AGTACGGCAA	CCACAGCGGA	CGAGTCGGCG	TAGGCTACCG	GTTCCTCGAG
	3151	GGTGGCGGAG	GCACCTGGATC	CGCCACAAAC	GACGACGATG	TTAAAAAGC
	3201	TGCCACTGTG	GCCATTGCTG	CTGCCTACAA	CAATGGCCAA	GAAATCAACG
	3251	GTTTCAAAGC	TGGAGAGACC	ATCTACGACA	TTGATGAAGA	CGGCACAATT
10	3301	ACCAAAAAAG	ACGCAACTGC	AGCCGATGTT	GAAGCCGACG	ACTTTAAAGG
	3351	TCTGGGTCTG	AAAAAAGTCG	TGACTAACCT	GACCAAAACC	GTCAATGAAA
	3401	ACAAACAAAA	CGTCGATGCC	AAAGTAAAG	CTGCAGAATC	TGAAATAGAA
	3451	AAGTTAACAA	CCAAGTTAGC	AGACACTGAT	GCCGCTTTAG	CAGATACTGA
	3501	TGCCGCTCTG	GATGCAACCA	CCAACGCCTT	GAATAAATTG	GGAGAAAAATA
15	3551	TAACGACATT	TGCTGAAGAG	ACTAAGACAA	ATATCGTAAA	AATTGATGAA
	3601	AAATTAGAAG	CCGTGGCTGA	TACCGTCGAC	AAGCATGCCG	AAGCATTCAA
	3651	CGATATCGCC	GATTCATTGG	ATGAAACCAA	CACTAAGGCA	GACGAGCCG
	3701	TCAAAACCGC	CAATGAAGCC	AAACAGACGG	CCGAAGAAAC	CAACAAAAAC
	3751	TCGATGCCA	AAGTAAAGC	TGCAGAAACT	GCAGCAGGCA	AAGCCGAAGC
20	3801	TGCCGCTGGC	ACAGCTAATA	CTGCAGCCGA	CAAGGCCGAA	GCTGTCGCTG
	3851	CAAAAGTTAC	CGACATCAAA	GCTGATATCG	CTACGAACAA	AGATAATATT
	3901	GCTAAAAAAG	CAAACAGTGC	CGACGTGTAC	ACCAGAGAAG	AGTCTGACAG
	3951	CAAAATTTGTC	AGAATTGATG	GTCTGAACGC	TACTACCGAA	AAATTTGGACA
	4001	CACGCTTGGC	TTCTGCTGAA	AAATCCATTG	CCGATCACGA	TACTCGCCTG
25	4051	AACGGTTTGG	ATAAACACAGT	GTCAGACCTG	CGCAAAGAAA	CCCGCCAAGG
	4101	CCTTGCAGAA	CAAGCCGCGC	TCTCCGGTCT	GTTCACACCT	TACAACGTGG
	4151	GTCGGTTCAA	TGTAACGGCT	GCAGTCGGCG	GCTACAAATC	CGAATCGGCA
	4201	GTCGCCATCG	GTACCGGCTT	CCGCTTTACC	GAAACCTTTG	CCGCCAAAGC
	4251	AGGCGTGGCA	GTCGGCACTT	CGTCCGGTTC	TTCCGCAGCC	TACCATGTCTG
30	4301	GCGTCAATTA	CGAGTGGCTC	GAGCACCACC	ACCACCACCA	CTGA
	1	MTSAPDFNAG	GTGIGSNSRA	TTAKSAAVSY	AGIKNEMCKD	RSMLCAGRDD
	51	VAVTDRDAKI	NAPPPNLHTG	DFPNPNDAYK	NLINLKPAIE	AGYTGRGVEV
	101	GIVDTGESVG	SISFPELYGR	KEHGYNENYK	NYTAYMRKEA	PEDGGGKDIE
35	151	ASFDDAEVIE	TEAKPTDIRH	VKEIGHIDL	SHIIGRSVD	GRPAGGIAPD
	201	ATLHIMTND	ETKNEMVAA	IRNAWKLGE	RGVRIVNNSF	GTTSRAGTAD
	251	LFQIANSEEQ	YRQALLDYS	GDKTDEGIRL	MQQSDYGNLS	YHIRNKNMLF
	301	IFSTGNDAQA	QPNTYALLPF	YEKDAQKGI	TVAGVDRSGE	KFKREMYGEP
	351	GTEPLEYGSN	HCGITAMWCL	SAPYBASVRF	TRTNPIQIAG	TSFSAPIVTG
40	401	TAALLLQKYP	WMSNDNLRTT	LLTTAQDIGA	VGVDKSKFGW	LLDAGKAMNG
	451	PASFFPGDFT	ADTKGTS DIA	YSFRNDISGT	GGLIKKGGSQ	LQLHGNNTYT
	501	GKTIIEGGS	VLYGNNKSDM	RVETRGALY	NGAASGGSLN	SDGIVYLADT
	551	DQSGANETVH	IKGSLQLDGK	GTLYTRLGKL	LKVDGTAIIG	GKLYMSARGK
	601	GAGYLNSTGR	RVFFLSAAKI	GQDYSFFTNI	ETDGGLLASL	DSVEKTAGSE
45	651	GDTLSEYVRR	GNAARTASAA	AHSAPAGLKH	AVEQGGSNLE	NLMVELDASE
	701	SSATPETVET	AAADRTDMPG	IRPYGATFRA	AAAVQHANA	DGVRIFNLSA
	751	ATVYADSTAA	HADMQRRLK	AVSDGLDHNG	TGLRVIAQTQ	QDGGTWEQGG
	801	VEGMRGSTQ	TVGIAAKTGE	NTTAAATLGM	GRSTWSENSA	NAKTDSISLF
	851	AGIRHDAGDI	GYLKGLFSYG	RYKNSISRST	GADEHAEGSV	NGTLMQLGAL
50	901	GGVNVFFAAT	GDLTVEGGLR	YDLLQDAFA	EKGSALGWSG	NSLTEGTLVG
	951	LAGLKLSQLP	SDKAVLFATA	GVERDLNGRD	YTVTGGFTGA	TAATGKTGAR
	1001	NMPHTRLVAG	LGADVEFGNG	WNLARYSYA	GSKQYGNHSG	RVGVGYRFLE
	1051	GGGGTGSATN	DDDVKKAATV	AIAAAYNNGQ	EINGFKAGET	IYDIDEDGTI
	1101	TKKDATAADV	EADDFKGLGL	KKVVNTLTKT	VNENKQNVDA	KVKAABSEIE
55	1151	KLTTKLADTD	AALADTDAA	DATTNALNKL	GENITTFARE	TKTNIVKIDE
	1201	KLEAVADTV	KHAEAFNDIA	DSLDETNTKA	DEAVKTANEA	KQTAEETKQN
	1251	VDAVKAAET	AAGKAEAAAG	TANTAADKAE	AVAAKVTDIK	ADIATNKDNI
	1301	AKKANSADV	TREESDSKFV	RIDGLNATTE	KLDTRLASAE	KSIADHDTRL
	1351	NGLDKTVSDL	RKETRQGLAE	QAALSGLFQP	YNVGRFNVTA	AVGGYKSESA
60	1401	VAIGTGFRFT	ENPAKAGVA	VGTSSGSSAA	YHVGVNVEWL	EHHHHHH*

AG983-961c

65	1	ATGACTTCTG	CGCCCGACTT	CAATGCAGGC	GGTACCGGTA	TCGGCAGCAA
	51	CAGCAGAGCA	ACAACAGCGA	AATCAGCAGC	AGTATCTTAC	GCCGGTATCA
	101	AGAACGAAAT	GTGCAAAGAC	AGAAGCATGC	TCTGTGCCGG	TCGGGATGAC
	151	GTTGCGGTTA	CAGACAGGGA	TGCCAAAATC	AATGCCCCC	CCCCGAATCT
	201	GCATACCGGA	GACTTTCCAA	ACCCAAATGA	CGCATACAAG	AATTTGATCA

5 251 ACCTCAAACC TGCAATTGAA GCAGGCTATA CAGGACGCGG GGTAGAGGTA
 301 GGTATCGTCG ACACAGGCGA ATCCGTCGGC AGCATATCCT TTCCCGAACT
 351 GTATGGCAGA AAAGAACACG GCTATAACGA AAATTACAAA AACTATACGG
 401 CGTATATGCG GAAGGAAGCG CCTGAAGACG GAGGCGGTAA AGACATTGAA
 451 GCTTCTTTTCG ACGATGAGGC CGTTATAGAG ACTGAAGCAA AGCCGACGGA
 501 TATCCGCCAC GTAAAAGAAA TCGGACACAT CGATTTGGTC TCCCATATTA
 551 TTGGCGGGCG TTCCGTGGAC GGCAGACCTG CAGGCGGTAT TGCGCCCGAT
 601 GCGACGCTAC ACATAATGAA TACGAATGAT GAAACCAAGA ACGAAATGAT
 10 651 GGTTCGAGCC ATCCGCAATG CATGGGTCAA GCTGGGCGAA CGTGGCGTGC
 701 GCATCGTCAA TAACAGTTTTT GGAACAACAT CGAGGGCAGG CACTGCCGAC
 751 CTTTTCCAAA TAGCCAATTC GGAGGAGCAG TACCGCCAAG CGTTGCTCGA
 801 CTATTCCGGC GGTGATAAAA CAGACGAGGG TATCCGCCTG ATGCAACAGA
 851 GCGATTACGG CAACCTGTCC TACCACATCC GTAATAAAAA CATGCTTTTC
 15 901 ATCTTTTCGA CAGGCAATGA CGCACAAAGCT CAGCCCAACA CATATGCCCT
 951 ATTGCCATTT TATGAAAAAG ACGCTCAAAA AGGCATTATC ACAGTCGCAG
 1001 GCGTAGACCG CAGTGGAGAA AAGTTCAAAC GGGAAATGTA TGGAGAACCG
 1051 GGTACAGAAC CGCTTGAGTA TGGCTCCAAC CATTCGCGAA TFACTGCCAT
 1101 GTGGTGCCTG TCGGCACCTT ATGAAGCAAG CGTCCGTTTC ACCCGTACAA
 1151 ACCCGATTCA AATTGCCGGA ACATCCTTTT CCGCACCCAT CGTAACCCGC
 20 1201 ACGGCGGCTC TGCTGCTGCA GAAATACCCG TGGATGAGCA ACGACAACCT
 1251 GCGTACCACG TTGCTGACGA CGGCTCAGGA CATCGGTGCA GTCGGCGTGG
 1301 ACAGCAAGTT CGGCTGGGGA CTGCTGGATG CGGGTAAGGC CATGAACGGA
 1351 CCCGCTCCTT TTCCGTTCCG CGACTTTACC GCCGATACGA AAGGTACATC
 1401 CGATATTGCC TACTCCTTCC GTAACGACAT TTCAGGCACG GGCGGCCTGA
 25 1451 TCAAAAAGG CGGCAGCCAA CTGCAACTGC ACGGCAACAA CACCTATACG
 1501 GGCAAAACCA TTATCGAAGG CGGTTTCGCTG GTGTTGTACG GCAACAACAA
 1551 ATCGGATATG CGGTCGAAA CCAAAGGTGC GCTGATTTAT AACGGGGCGG
 1601 CATCCGGCGG CAGCCTGAAC AGCGACGGCA TTGTCTATCT GGCAGATACC
 1651 GACCAATCCG GCGCAAACGA AACCGTACAC ATCAAAGGCA GTCTGCAGCT
 30 1701 GGACGGCAAA GGTACGCTGT ACACACGTTT GGGCAAACTG CTGAAAAGTGG
 1751 ACGGTACGGC GATTATCGGC GGCAAGCTGT ACATGTCGGC ACGCGGCAAG
 1801 GGGGCAGGCT ATCTCAACAG TACCGGACGA CGTGTTCCTT TCCTGAGTGC
 1851 CGCCAAAATC GGGCAGGATT ATTCTTTCTT CACAAACATC GAAACCGACG
 35 1901 CGCGCTGTCT GGCTTCCCTC GACAGCGTCG AAAAAACAGC GGGCAGTGAA
 1951 GGCACACGCG TGTCTATTAT TGTCCGTCGC GGCAATGCGG CACGGACTGC
 2001 TTCGGCAGCG GCACATTCCG CGCCCGCCGG TCTGAAACAC GCCGTAGAAC
 2051 AGGGCGGCAG CAATCTGGAA AACCTGATGG TCGAACTGGA TGCCTCCGAA
 2101 TCATCCGCAA CACCCGAGAC GGTGAAACT GCGGCAGCCG ACCGCACAGA
 40 2151 TATGCCGGGC ATCCGCCCTT ACGGCGCAAC TTTCGCGCA GCGGCAGCCG
 2201 TACAGCATGC GAATGCCGCC GACGGGTGAC GCATCTTCAA CAGTCTCGCC
 2251 GCTACCGTCT ATGCCGACAG TACCGCCGCC CATGCCGATA TGCAGGGACG
 2301 CCGCTGAAA GCCGTATCGG ACGGGTTGGA CCACAACGGC ACGGGTCTGC
 2351 GCGTCATCGC GCAAACCCAA CAGGACGGTG GAACGTGGGA ACAGGGCGGT
 45 2401 GTTGAAGGCA AAATGCGCGG CAGTACCCAA ACCGTCGGCA TTGCCGCGAA
 2451 AACCGGCGAA AATACGACAG CAGCCGCCAC ACTGGGCATG GGACGCAGCA
 2501 ATGGAGCGA AAACAGTGCA AATGCAAAAA CCGACAGCAT TAGTCTGTTT
 2551 GCAGGCATAC GGCACGATGC GGGCGATATC GGCTATCTCA AAGGCCTGTT
 2601 CTCCTACGGA CGCTACAAAA ACAGCATCAG CCGCAGCACC GGTGCGGACG
 50 2651 AACATGCGGA AGGCAGCGTC AACGGCACGC TGATGCAGCT GGGCGCACTG
 2701 GGCGGTGTCA ACGTTCCGTT TGCCGCAACG GGAGATTTGA CGGTGCAAGG
 2751 CGGTCTGCGC TACGACCTGC TCAAACAGGA TGCATTGCCC GAAAAAGGCA
 2801 GTGCTTTGGG CTGGAGCGGC AACAGCCTCA CTGAAGGCAC GCTGGTCGGA
 2851 CTCGCGGGTC TGAAGCTGTC GCAACCCTTG AGCGATAAAG CCGTCTGTTT
 55 2901 TGCAACGGCG GCGGTGGAAC GCGACCTGAA CCGACGCGAC TACACGGTAA
 2951 CGGGCGGCTT TACCGGCGCG ACTGCAGCAA CCGGCAAGAC GGGGGCACGC
 3001 AATATGCCGC ACACCCGTCT GGTGCGCGGC CTGGGCGCGG ATGTCGAATT
 3051 CGGCAACGGC TGAACGGCT TGGCACGTTA CAGCTACGCC GGTTCCAAAC
 3101 AGTACGGCAA CCACAGCGGA CGAGTCGCGC TAGGCTACCG GTTCCTCGAG
 3151 GGTGGCGGAG GCACTGGATC CGCCACAAAC GACGACGATG TTAATAAAGC
 60 3201 TGCCACTGTG GCCATTGCTG CTGCC'TACAA CAATGGCCAA GAAATCAACG
 3251 GTTTCAAAGC TGAGAGAGAC ATCTACGACA TTGATGAAGA CGGCACAATT
 3301 ACCAAAAAAG ACGCAACTGC AGCCGATGTT GAAGCCGACG ACTTTAAAGG
 3351 TCTGGGTCTG AAAAAAGTCG TGACTAACCT GACCAAAACC GTCAATGAAA
 3401 ACAAACAAAA CGTCGATGCC AAAGTAAAG CTGCAGAATC TGAATAAGAA
 65 3451 AAGTTAACAA CCAAGTTAGC AGACACTGAT GCCGCTTTAG CAGATACTGA
 3501 TGCCGCTCTG GATGCAACCA CCAACGCCTT GAATAAATTG GGAGAAAATA
 3551 TAACGACATT TGCTGAAGAG ACTAAGACAA ATATCGTAAA AATTGATGAA

	3601	AAATTAGAAG	CCGTGGCTGA	TACCGTCGAC	AAGCATGCCG	AAGCATTCAA
	3651	CGATATCGCC	GATTCATTGG	ATGAAACCAA	CACTAAGGCA	GACGAAGCCG
	3701	TCAAACCGC	CAATGAAGCC	AAACAGACGG	CCGAAGAAAC	CAAACAAAAC
5	3751	GTCGATGCCA	AAGTAAAAGC	TGCAGAAACT	GCAGCAGGCA	AAGCCGAAGC
	3801	TGCCGCTGGC	ACAGCTAATA	CTGCAGCCGA	CAAGGCCGAA	GCTGTCGCTG
	3851	CAAAAGTTAC	CGACATCAAA	GCTGATATCG	CTACGAACAA	AGATAATATT
	3901	GCTAAAAAAG	CAAACAGTGC	CGACGTGTAC	ACCAGAGAAG	AGTCTGACAG
	3951	CAAAATTTGTC	AGAATTGATG	GTCTGAACGC	TACTACCGAA	AAATTTGGACA
10	4001	CACGCTTGGC	TTCTGCTGAA	AAATCCATTG	CCGATCACGA	TACTCGCCTG
	4051	AACGGTTTGG	ATAAAACAGT	GTCAGACCTG	CGCAAAGAAA	CCCGCCAAGG
	4101	CCTTCGAGAA	CAAGCCGCGC	TCTCCGGTCT	GTTCCAACCT	TACAACGTGG
	4151	GTCTCGAGCA	CCACCACCAC	CACCACTGA		
15	1	MTSAPDFNAG	GTGIGSNSRA	TTAKSAAVSY	AGIKNEMCKD	RSMLCAGRDD
	51	VAVTDRDAKI	NAPPPNLTG	DFPNPNDAYK	NLINLKPAIE	AGYTGRGVEV
	101	GIVDTGESVG	SISFPELYGR	KEHGYNYENYK	NYTAYMRKEA	PEDGGGKDIE
	151	ASFDDEAVIE	TEAKPTDIRH	VKEIGHIDL	SHIIGGRSVD	GRPAGGIAPD
	201	ATLHIMTND	ETKNEMMVAA	IRNAWVKLGE	RGVRIVNNSF	GTTSRAGTAD
20	251	LFQIANSEEQ	YRQALLDYS	GDKTDEGIRL	MQQSDYGNLS	YHIRNKNMLF
	301	IFSTGNDQA	QPNTYALLPF	YEKDAQKGII	TVAGVDRSGE	KFKREMYGEP
	351	GTEPLEYGSN	HCGITAMWCL	SAPYEASVRF	TRTNPIQIAG	TSFSAPIVTG
	401	TAALLLQKYP	WMSNDNLRTT	LLTTAQDIGA	VGVDSKFGWG	LLDAGKAMNG
	451	PASFFPGDFT	ADTKGTS DIA	YSFRNDISGT	GGLIKKGGSQ	LQLHGNNTYT
25	501	GKTIIEGSL	VLYGNKSDM	RVETKGALIV	NGAASGGS LN	SDGIVYLADT
	551	DQSGANETVH	IKGSLQLDGK	GTLYTRLGKL	LKVDGTAIIG	GKLYMSARGK
	601	GAGYLNSTGR	RVPFLSAAKI	GQDYSFFTNI	ETDGGLLASL	DSVEKTAGSE
	651	GDTLSSYYVRR	GNAARTASAA	AHSAPAGLKH	AVEQGGSNLE	NLMVELDASE
	701	SSATPETVET	AAADRTDMPG	IRPYGATFRA	AAAVQHANA	DGVRIFNLSA
30	751	ATVYADSTAA	HADMQRRLK	AVSDGLDHNG	TGLRVIAQTQ	QDGGTWEQGG
	801	VEGMRGSTQ	TVGIAAKTGE	NTTAAATLGM	GRSTWSENSA	NAKTDSISLF
	851	AGIRHDAGDI	GYLKGLFSYG	RYKNSISRST	GADEHAEGSV	NGTLMQLGAL
	901	GGVNVFFAAT	GDLTVEGGLR	YDLLKQDAFA	EKGSALGWSG	NSLTEGTLVG
	951	LAGLKLSQLP	SDKAVLFATA	GVERDLNGRD	YTVTGGFTGA	TAATGKTGAR
35	1001	NMPHTRLVAG	LGADVEFGNG	WNLGLARYSYA	GSKQYGNHSG	RVGVGYRFLE
	1051	GGGTGGSATN	DDVVKKAATV	AIAAAYNNGQ	EINGFKAGET	IYDIDEIDGTI
	1101	TKKDATAADV	EADDFKGLGL	KKVVTNLTKT	VNENKQNVDA	KVKAASEEIE
	1151	KLTTKLADTD	AALADTDAA	DATTNALNKL	GENITTFABE	TKTNIVKIDE
	1201	KLEAVADTV	KHABAFNDIA	DSLDETNTKA	DEAVKTANEA	KQTAEETKQ
40	1251	VDAKVKAET	AAGKAEAAAG	TANTAADKAE	AVAAKVTDIK	ADIATNKDNI
	1301	AKKANSADVY	TREESDSKRV	RIDGLNATTE	KLDTRLASAE	KSIADHDTRL
	1351	NGLDKTVSDL	RKETRQGLAE	QAALSGLFQP	YNVGLHEHHH	HH*

ΔG741 and hybrids

Bactericidal titres generated in response to ΔG741 (His-fusion) were measured against various strains, including the homologous 2996 strain:

	2996	MC58	NGH38	F6124	BZ133
ΔG741	512	131072	>2048	16384	>2048

As can be seen, the ΔG741-induced anti-bactericidal titre is particularly high against heterologous strain MC58.

ΔG741 was also fused directly in-frame upstream of proteins 961, 961c, 983 and ORF46.1:

	ΔG741-961					
50	1	ATGGTCGCCG	CCGACATCGG	TGCGGGGCTT	GCCGATGCAC	TAACCGCACC
	51	GCTCGACCAT	AAAGACAAAG	GTTTGACAGTC	TTTGACGCTG	GATCAGTCCG
	101	TCAGGAAAAA	CGAGAAACTG	AAGCTGGCGG	CACAAGGTGC	GGAAAAAAT
	151	TATGGAAACG	GTGACAGCCT	CAATACGGGC	AAATTGAAGA	ACGACAAGGT
	201	CAGCCGTTTC	GACTTTATCC	GCCAAATCGA	AGTGGACGGG	CAGCTCATTA

-50-

5 251 CCTTGGAGAG TGGAGAGTTC CAAGTATACA AACAAAGCCA TTCCGCCTTA
 301 ACCGCCTTTC AGACCGAGCA AATACAAGAT TCGGAGCATT CCGGGAAGAT
 351 GGTTCGCAAA CGCCAGTTCA GAATCGGCGA CATAGCGGGC GAACATACAT
 401 CTTTGTGACAA GCTTCCCGAA GCGCGCAGGG CGACATATCG CCGGACGGCG
 10 451 TTCCGGTTCAG ACGATGCCGG CGGAAAACCTG ACCTACACCA TAGATTTCGC
 501 CGCCAAGCAG GGAACCGGCA AAATCGAACA TTTGAAATCG CCAGAACTCA
 551 ATGTCGACCT GGCCGCGGCC GATATCAAGC CGGATGGAAA ACGCCATGCC
 601 GTCATCAGCG GTTCCGTCCT TTACAACCAA GCCGAGAAAG GCAGTTACTC
 651 CCTCGGTATC TTTGGCGGAA AAGCCCAGGA AGTTGCCGGC AGCGCGGAAG
 10 701 TGAAAACCGT AAACGGCATA CGCCATATCG GCCTTGCCGC CAAGCAACTC
 751 GAGGGTGGCG GAGGCACTGG ATCCGCCACA AACGACGACG ATGTTAAAAA
 801 AGCTGCCACT GTGGCCATTG CTGCTGCCTA CAACAATGGC CAAGAAATCA
 851 ACGGTTTCAA AGCTGGAGAG ACCATCTACG ACATTGATGA AGACGGCACA
 15 901 ATTACCAAAA AAGACGCAAC TGCAGCCGAT GTTGAAGCCG ACGACTTTAA
 951 AGGTCTGGGT CTGAAAAAAG TCGTGAATAA CCTGACCAAA ACCGTCAATG
 1001 AAAACAAACA AAACGTCGAT GCCAAAGTAA AAGCTGCAGA ATCTGAAATA
 1051 GAAAAGTTAA CAACCAAGTT AGCAGACACT GATGCCGCTT TAGCAGATAC
 1101 TGATGCCGCT CTGGATGCAA CCACCAACGC CTTGAATAAA TTGGGAGAAA
 1151 ATATAACGAC ATTTGCTGAA GAGACTAAGA CAAATATCGT AAAAAATTGAT
 20 1201 GAAAAATTAG AAGCCGTGGC TGATACCGTC GACAAGCATG CCGAAGCATT
 1251 CAACGATATC GCCGATTTCAT TGGATGAAAC CAACACTAAG GCAGACGAAG
 1301 CCGTCAAAAC CGCCAATGAA GCCAAACAGA CGGCCGAAGA AACCACAAAC
 1351 AACGTCGATG CCAAAGTAAA AGCTGCAGAA ACTGCAGCAG GCAAAGCCGA
 1401 AGCTGCCGCT GGCACAGCTA ATACTGCAGC CGACAAGGCC GAAGCTGTCT
 25 1451 CTCGAAAAGT TACCGACATC AAAGCTGATA TCGCTACGAA CAAAGATAAT
 1501 ATTGCTAAAA AAGCAAACAG TGCCGACGTG TACACCAGAG AAGAGTCTGA
 1551 CAGCAAATTT GTCAGAAATG ATGGTCTGAA CGCTACTACC GAAAAATTGG
 1601 ACACACGCTT GGCTTCTGCT GAAAAATCCA TTGCCGATCA CGATACTCGC
 1651 CTGAACGGTT TGGATAAAAC AGTGTGAGAC CTGCGCAAAG AAACCCGCCA
 30 1701 AGGCTTTCGA GAACAAGCCG CGCTCTCCGG TCTGTTCCAA CCTTACAACG
 1751 TGGGTCGGTT CAATGTAACG GCTGCAGTCG GCGGCTACAA ATCCGAATCG
 1801 GCAGTCGCCA TCGGTACCGG CTTCCGCTTT ACCGAAAACCT TTGCCGCCAA
 1851 AGCAGGCGTG GCAGTCGCCA CTTCTCCGG TTCTTCCGCA GCCTACCATG
 1901 TCGGCGTCAA TTACGAGTGG CTCGAGCACC ACCACCACCA CCACTGA
 35 1 MVAADIGAGL ADALTAPLDH KDKGLQSLTL DQSVRKNEKL KLAAQGAKEK
 51 YNGDLSLNTG KLKNDKVSFR DFIRQIEVDG QLITLESGEF QVYKQSHSAL
 101 TAFQTEQIQD SEHSGKMVAK RQFRIGDIAG EHTSFDKLPE GGRATYRGTA
 151 FGSDDAGGKL TYTIDFAKQ GNGKIEHLKS PELNVDLAAA DIKPDGKRHA
 40 201 VISGSVLYNQ AEKGSYSLGI FGGKAQEVAG SAEVKTVNGI RHIGLAAKQL
 251 EGGGTTGSAT NDDDVKKAAAT VAIAAAYNNG QEINGFKAGE TIYDIDEDGT
 301 ITKKDATAAD VEADDFKGLG LKKVVTNLTK TVNENKQNV D AKVKAASEI
 351 EKLTTKLADT DAALADTDAA LDATTNALNK LGENITTFAB ETKTNIIVKID
 401 EKLEAVADTV DKHAEAFNDI ADSLDETNTK ADEAVKTANE AKQTAEETKQ
 45 451 NVDKVKAAE TAAGKAEAAA GTANTAADKA EAVAAKVTDI KADIATNKDN
 501 IAKKANSADV YTREESDSKF VRIDGLNATT EKLDTRLASA EKSIADHDTR
 551 LNLGLDKTVSD LRKETRQGLA EQAALSGLFQ PYNVGRFNVT AAVGGYKSES
 601 AVAIGTGFRF TENFAAKAGV AVGTSSGSSA AYHVGUNYEW LEHHHHHH*

AG741-961c

55 1 ATGTCGCCCG CCGACATCGG TGCGGGGCTT GCCGATGCAC TAACCGCACC
 51 GCTCGACCAT AAAGACAAAG GTTTGCAGTC TTTGACGCTG GATCAGTCCG
 101 TCAGGAAAAA CGAGAACTG AAGCTGGCGG CACAAGGTGC GGAAAAAACT
 151 TATGGAACCG GTGACAGCCT CAATACGGGC AAATTGAAGA ACGACAAGGT
 201 CAGCCGTTTC GACTTTATCC GCCAAATCGA AGTGGACGGG CAGCTCATTA
 251 CCTTGGAGAG TGGAGAGTTC CAAGTATACA AACAAAGCCA TTCCGCCTTA
 301 ACCGCCTTTC AGACCGAGCA AATACAAGAT TCGGAGCATT CCGGGAAGAT
 351 GGTTCGCAAA CGCCAGTTCA GAATCGGCGA CATAGCGGGC GAACATACAT
 60 401 CTTTGTGACAA GCTTCCCGAA GCGCGCAGGG CGACATATCG CCGGACGGCG
 451 TTCCGGTTCAG ACGATGCCGG CGGAAAACCTG ACCTACACCA TAGATTTCGC
 501 CGCCAAGCAG GGAACCGGCA AAATCGAACA TTTGAAATCG CCAGAACTCA
 551 ATGTCGACCT GGCCGCGGCC GATATCAAGC CGGATGGAAA ACGCCATGCC
 601 GTCATCAGCG GTTCCGTCCT TTACAACCAA GCCGAGAAAG GCAGTTACTC
 65 651 CCTCGGTATC TTTGGCGGAA AAGCCCAGGA AGTTGCCGGC AGCGCGGAAG
 701 TGAAAACCGT AAACGGCATA CGCCATATCG GCCTTGCCGC CAAGCAACTC
 751 GAGGGTGGCG GAGGCACTGG ATCCGCCACA AACGACGACG ATGTTAAAAA

-51-

5	801	AGCTGCCACT	GTGGCCATTG	CTGCTGCCTA	CAACAATGGC	CAAGAAATCA
	851	ACGGTTTCAA	AGCTGGAGAG	ACCATCTACG	ACATTGATGA	AGACGGCACA
	901	ATTACCAAAA	AAGACGCAAC	TGCAGCCGAT	GTTGAAGCCG	ACGACTTTAA
	951	AGGTCTGGGT	CTGAAAAAAG	TCGTGACTAA	CCTGACCAAA	ACCGTCAATG
	1001	AAAACAAACA	AAACGTCGAT	GCCAAAGTAA	AAGCTGCAGA	ATCTGAAATA
	1051	AAAAAGTTAA	CAACCAAGTT	AGCAGACACT	GATGCCGCTT	TAGCAGATAC
	1101	TGATGCCGCT	CTGGATGCAA	CCACCAACGC	CTTGAATAAA	TTGGGAGAAA
	1151	ATATAACGAC	ATTTGCTGAA	GAGACTAAGA	CAAATATCGT	AAAAATTGAT
	1201	GAAAAATTAG	AAGCCGTGGC	TGATACCGTC	GACAAGCATG	CCGAAGCATT
10	1251	CAACGATATC	GCCGATTTCAT	TGGATGAAAC	CAACACTAAG	GCAGACGAAG
	1301	CCGTCAAAAC	CGCCAATGAA	GCCAAACAGA	CGGCCGAAGA	AACCAAAACA
	1351	AACGTCGATG	CCAAAGTAAA	AGCTGCAGAA	ACTGCAGCAG	GCAAAGCCGA
	1401	AGTGCCCGCT	GGCACAGCTA	ATACTGCAGC	CGACAAGGCC	GAAGCTGTCTG
	1451	CTGCAAAAGT	TACCGACATC	AAAGCTGATA	TCGCTACGAA	CAAAGATAAT
15	1501	ATTGCTAAAA	AAGCAAACAG	TGCCGACGTG	TACACCAGAG	AAGAGTCTGA
	1551	CAGCAAATTT	GTCAGAAATG	ATGGTCTGAA	CGCTACTACC	GAAAAATTGG
	1601	ACACACGCTT	GGCTTCTGCT	GAAAAATCCA	TTGCCGATCA	CGATACTCGC
	1651	CTGAACGGTT	TGGATAAAAC	AGTGTCTAGC	CTGCCGAAAG	AAACCCGCCA
20	1701	AGGCCTTGCA	GAACAAGCCG	CGCTCTCCGG	TCTGTTCCAA	CCTTACAACG
	1751	TGGGTCTCGA	GCACCACCAC	CACCACCCT	GA	
	1	MVAADIGAGL	ADALTAPLDH	KDKGLQSLTL	DQSVRKNEKL	KLAAQGAETK
	51	YNGDGLNTG	KLKNDKVSFR	DFIRQIEVDG	QLITLESGEF	QVYKQSHSAL
25	101	TAFQTEQIQD	SEHSGKMWAK	RQFRIGDIAG	EHTSFDKLPE	GGRATYRGTA
	151	FGSDDAGGKL	TYTIDFAAKQ	GNGKIEHLKS	PELNVDLAAA	DIKPDGKRHA
	201	VISGSVLYNQ	AEKGSYSLGI	FGGKAQEVAG	SAEVKTVNGI	RHIGLAAKQL
	251	EGGGGTGSAT	NDDDVKKAAT	VAIAAAYNNG	QINGFKAGE	TIYDIDEDGT
	301	ITKKDATAAD	VEADDFKGLG	LKKVVTNLTK	TVNENKQNV	AKVKAASEI
30	351	EKLTTKLADT	DAALADTDAA	LDATTNALNK	LGENTTTFAE	ETKTNIVKID
	401	EKLEAVADTV	DKHAEAFNDI	ADSLDETNTK	ADEAVKTANE	AKQTAEETKQ
	451	NVDKVKAAE	TAAGKAEAAA	GTANTAADKA	EAVAANKVTDI	KADIATNKDN
	501	IAKKANSADV	YTREESDSKF	VRIDGLNATT	EKLDTRLASA	EKSIADHDTR
	551	LNGLDKTVSD	LRKETRQGLA	EQAALSGLFQ	PYNVGLEHHH	HHH*
35						
		AG741-983				
	1	ATGGTCGCCG	CCGACATCGG	TGCGGGGCTT	GCCGATGCAC	TAACCGCACC
	51	GCTCGACCAT	AAAGACAAAG	GTTTGCAGTC	TTTGACGCTG	GATCAGTCCG
40	101	TCAGGAAAAA	CGAGAACTG	AAGCTGGCGG	CACAAGGTGC	GGAAAAAACT
	151	TATGGAAACG	GTGACAGCCT	CAATACGGGC	AAATTGAAGA	ACGACAAGGT
	201	CAGCGTTTTC	GACTTTATCC	GCCAAATCGA	AGTGGACGGG	CAGCTCATTA
	251	CCTTGGAGAG	TGGAGAGTTC	CAAGTATACA	AACAAAGCCA	TTCCGCCTTA
	301	ACCGCCTTTC	AGACCGAGCA	AATACAAGAT	TCGGAGCAIT	CCGGGAAGAT
	351	GGTTTGCAAA	CGCCAGTTCA	GAATCGGCGA	CATAGCGGGC	GAACATACAT
45	401	CTTTTGACAA	GCTTCCCGAA	GGCGGCGAGG	CGACATATCG	CGGGACGGCG
	451	TTCCGGTTCAG	ACGATGCCGG	CGGAAAACCTG	ACCTACACCA	TAGATTTCGC
	501	CGCCAAGCAG	GGAAACGGCA	AAATCGAACA	TTTGAAATCG	CCAGAACCTCA
	551	ATGTCGACCT	GGCCGCCGCC	GATATCAAGC	CGGATGGAAA	ACGCCATGCC
50	601	GTCAATCAGCG	GTTCCGTCTT	TTACAACCAA	GCCGAGAAAG	GCAGTTACTC
	651	CCTCGGTATC	TTTGGCGGAA	AAGCCAGGGA	AGTTGCCGGC	AGCGCGGAAG
	701	TGAAAACCGT	AAACGGCATA	CGCCATATCG	GCCTTGCCGC	CAAGCAACTC
	751	GAGGGATCCG	GCGGAGGCGG	CACCTCTGCG	CCCGACTTCA	ATGCAGGCGG
	801	TACCGGTATC	GCAGGCAACA	GCAGAGCAAC	AACAGCGAAA	TCAGCAGCAG
55	851	TATCTTACGC	CGGTATCAAG	AACGAAATGT	GCAAAGACAG	AAGCATGCTC
	901	TGTGCCGGTC	GGGATGACGT	TGCGGTTACA	GACAGGGATG	CCAAAATCAA
	951	TGCCCCCCCC	CCGAATCTGC	ATACCGGAGA	CTTTCCAAAC	CCAAATGACG
	1001	CATACAAGAA	TTTGATCAAC	CTCAAACCTG	CAATTGAAGC	AGGCTATACA
	1051	GGACCGGGGG	TAGAGGTAGG	TATCGTCGAC	ACAGGCGAAT	CCGTCCGGCAG
60	1101	CATATCCTTT	CCCGAACTGT	ATGGCAGAAA	AGAACACGGC	TATAACGAAA
	1151	ATTACAAAAA	CTATACGGCG	TATATGCGGA	AGGAAGCGCC	TGAAGACGGA
	1201	GGCGGTAAAG	ACATTGAAGC	TTCTTTTCGAC	GATGAGGCCG	TTATAGAGAC
	1251	TGAAGCAAAAG	CCGACGGATA	TCCGCCACGT	AAAAGAAATC	GGACACATCG
	1301	ATTTGGTCTC	CCATATTATT	GGCGGGCGTT	CCGTGGACGG	CAGACCTGCA
	1351	GGCGGTATTG	CGCCCGATGC	GACGCTACAC	ATAATGAATA	CGAATGATGA
65	1401	AACCAAGAAC	GAAATGATGG	TTGCAGCCAT	CCGCAATGCA	TGGGTCAAGC
	1451	TGGGCGAAGC	TGGCGTGGCG	ATCGTCAATA	ACAGTTTGGG	AACAACATCG
	1501	AGGGCAGGCA	CTGCCGACCT	TTTCCAAATA	GCCAATTCCG	AGGAGCAGTA

-52-

5	1551	CCGCCAAGCG	TTGCTCGACT	ATTCCGGCGG	TGATAAAACA	GACGAGGGTA	
	1601	TCCGCCTGAT	GCAACAGAGC	GATTACGGCA	ACCTGTCCTA	CCACATCCGT	
	1651	AATAAAACA	TGCTTTTCAT	CTTTTCGACA	GGCAATGACG	CACAAGCTCA	
	1701	GCCCAACACA	TATGCCCTAT	TGCCATTTTA	TGAAAAAGAC	GCTCAAAAAG	
	1751	GCATTATCAC	AGTCGCAGGC	GTAGACCGCA	GTGGAGAAAT	GTTCAAACGG	
10	1801	GAAATGTATG	GAGAACCGGG	TACAGAACCG	CTTGAGTATG	GCTCCAACCA	
	1851	TTGCGGAATT	ACTGCCATGT	GGTGCCTGTC	GGCACCCCTAT	GAAGCAAGCG	
	1901	TCCGTTTTCAC	CCGTACAAAC	CCGATTCAAA	TTGCCGGAAC	ATCCTTTTCC	
	1951	GCACCCATCG	TAACCGGCAC	GGCGGCTCTG	CTGCTGCAGA	AATACCCGTG	
	2001	GATGAGCAAC	GACAACCTGC	GTACCACGTT	GCTGACGAGC	GCTCAGGACA	
15	2051	TCGGTGCAGT	CAGCGTGGAC	AGCAAGTTCG	GCTGGGGACT	GCTGGATGCG	
	2101	GGTAAGGCCA	TGAACGGACC	CGCGTCCTTT	CCGTTCCGGC	ACTTTACCGC	
	2151	CGATACGAAA	GGTACATCCG	ATATTGCCTA	CTCCTTCCGT	AACGACATTT	
	2201	CAGGCACGGG	CGGCCTGATC	AAAAAAGGCG	GCAGCCAACT	GCAACTGCAC	
	2251	GGCAACAACA	CCTATACGGG	CAAAACCATT	ATCGAAGGCG	GTTCCGCTGGT	
20	2301	GTGTACGGC	AACAACAAAT	CGGATATGCG	CGTCGAAACC	AAAGGTGCGC	
	2351	TGATTTATAA	CGGGGCGGCA	TCCGGCGGCA	GCCTGAACAG	CGACGGCATT	
	2401	GTCATCTCGG	CAGATACCGA	CCAATCCGGC	GCAAACGAAA	CCGTACACAT	
	2451	CAAAGGCAGT	CTGCAGCTGG	ACGGCAAAGG	TACGCTGTAC	ACACGTTTGG	
	2501	GCAAACCTGCT	GAAAGTGGAC	GGTACGGCGA	TTATCGGCGG	CAAGCTGTAC	
25	2551	ATGTCGGCAC	GCGGCAAGGG	GGCAGGCTAT	CTCAACAGTA	CCGGACGACG	
	2601	TGTTCCCTTC	CTAGGTGCCG	CCAAAATCGG	GCAGGATTAT	TCTTTCTTCA	
	2651	CAAACTGCTA	AACGACGGC	GGCCTGCTGG	TCTCCCTCGA	CAGCGTCGAA	
	2701	AAAACAGCGG	GCAGTGAAGG	CGACACGCTG	TCCTATTATG	TCCGTCGCGG	
	2751	CAATGCGGCA	CGGACTGCTT	CGGCAGCGGC	ACATTCCGCG	CCCGCCGGTC	
30	2801	TGAAACACGC	CGTAGAACAG	GGCGGCAGCA	ATCTGGAAAA	CCTGATGGTC	
	2851	GAACTGGATG	CCTCCGAATC	ATCCGCAACA	CCCGAGACGG	TTGAAACTGC	
	2901	GGCAGCCGAC	CGCACAGATA	TGCCGGGCAT	CCGCCCTTAC	GGCGCAACTT	
	2951	TCCGCGCAGC	GGCAGCCGTA	CAGCATGCGA	ATGCCCGCGA	CGGTGTACGC	
	3001	ATCTTCAACA	GTCTCGCCGC	TACCGTCTAT	GCCGACAGTA	CCGCCGCCCA	
35	3051	TGCCGATATG	CAGGGACGCC	GCCTGAAAGC	CGTATCGGAC	GGGTGGGACC	
	3101	ACAACGGCAC	GGGTCTGCGC	GTCATCGCGC	AAACCCAACA	GGACGGTGGA	
	3151	ACGTGGGAAC	AGGGCGGTGT	TGAAGGCAAA	ATGCGCGGCA	GTACCCAAAC	
	3201	CGTCGGCATT	GCCGCGAAAA	CCGGCGAAAA	TACGACAGCA	GCCGCCACAC	
	3251	TGGGCATGGG	ACGCAGCACA	TGGAGCGAAA	ACAGTGCAAA	TGCAAAAACC	
40	3301	GACAGCATTA	GTCTGTTTGC	AGGCATACGG	CACGATGCGG	GCGATATCGG	
	3351	CTATCTCAAA	GGCCTGTTCT	CCTACGGACG	CTACAAAAAC	AGCATCAGCC	
	3401	GCAGCACCGG	TGCGGACGAA	CATGCGGAAG	GCAGCGTCAA	CGGCACGCTG	
	3451	ATGCAGCTGG	GCGCACTGGG	CGGTGTCAAC	GTTCCGTTTG	CCGCAACGGG	
	3501	AGATTTGACG	GTCGAAGGCG	GTCGCGCTA	CGACCTGCTC	AAACAGGATG	
45	3551	CATTTCGCCA	AAAAGGCAGT	GCTTTGGGCT	GGAGCGGCAA	CAGCCTCACT	
	3601	GAAGGCACGC	TGGTCGGACT	CGCGGGTCTG	AAGCTGTCCG	AACCCTTGAG	
	3651	CGATAAAGCC	GTCCTGTTTG	CAACGGCGGG	CGTGGAACGC	GACCTGAACG	
	3701	GACGCGACTA	CACGGTAACG	GCGCGCTTTA	CCGGCGCGAC	TGCAGCAACC	
	3751	GGCAAGACCG	GGGCACGCAA	TATGCCGCAC	ACCCGTCTGG	TTGCCGGCCT	
50	3801	GGGCGCGGAT	GTCGAATTTC	GCAACGGCTG	GAACGGCTTG	GCACGTTACA	
	3851	GCTACGCCGG	TTCCAACACG	TACGGCAACC	ACAGCGGACG	AGTCGGCGTA	
	3901	GGCTACCGGT	TCCTCGAGCA	CCACCACCAC	CACCACCTGA		
	51	1	MVAADIGAGL	ADALTAPLDH	KDKGLQSLTL	DQSVRKNEKL	KLAAQGAKEK
	55	51	YNGDSLNTG	KLKNDKVSFR	DFIRQIEVDG	QLITLESGEF	QVYKQSHSAL
55	101	TAFQTEBIQD	SEHSGKMVAK	RQFRIGDIAG	EHTSFDKLPE	GGRATYRGTA	
	151	FGSDDAGGKL	TYTIDFAAKQ	GNGKIEHLKS	PELNVDLAAA	DIKPDGKRHA	
	201	VISGSVLYNQ	AEKGSYSLGI	FGGKAQEVAG	SAEVKTVNGI	RHIGLAAKQL	
	251	EGSGGGTSGS	PDFNAGGTGI	GSNSRATTAK	SAVSYAGIK	NEMCKDRSML	
	301	CAGRDDVAVT	DRDAKINAPP	PNLHTGDFPN	PNDAYKNLIN	LKPAIBAGYT	
60	351	GRGVEVGIVD	TGESVGSISF	PELYGRKEHG	YNENYKNYTA	YMRKEAPEDG	
	401	GGKDIEASFD	DEAVIETBAK	PTDIRHVKEI	GHIDLVSIII	GGRSVDGRPA	
	451	GGIAPDATHL	IMNTNDETGN	EMMVAAIRNA	WVKLGERGVR	IVNNSFGTTS	
	501	RAGTADLFQI	ANSEEQYRQA	LLDYSGGDKT	DEGIRLIITVAG	DYGNLSYHIR	
	551	NKNMLFIFST	GNDAAQAQNT	YALLPFYEKD	AQKGIIITVAG	VDRSGEKFKR	
65	601	EMYGEPGTEP	LEYGSNHCGI	TAMWCLSAPY	EASVRFTRTN	PIQIAGTSFS	
	651	APIVTGTAAL	LLQKYPWMSN	DNLRTTLLTT	AQDIGAVGVD	SKFGWGLLDA	
	701	GKAMNGPASF	PFGDFTADTK	GTSDIAYSFR	NDISGTGGLI	KKGGSQQLQH	
	751	GNNYTYGKTI	IEGGSVLVYG	NNKSDMRVET	KGALIYNGAA	SGGSLNSDGI	
	801	VYLADTDQSG	ANETVHIKGS	LQLDGKGTLY	TRLGKLLKVD	GTAIIGKLY	
	851	MSARGKGAGY	LNSTGRRVFP	LSAAKIGODY	SFTTNIETDG	GLLASLDSVB	

-53-

901 KTAGSEGDITL SYVVRGNAA RTASAAHSA PAGLKHAVEQ GGSNLENLMV
 951 ELDASESSAT PETVETAAAD RTDMPGIRPY GATFRAAAV QHANAADGVR
 1001 IFNSLAATVY ADSTAAHADM QGRRRLKAVSD GLDHNGTGLR VIAQTQDDGG
 1051 TWEQGGVEGK MRGSTQTVGI AAKTGENTTA AATLGMGRST WSENSANAKT
 1101 DSISLFAGIR HDAGDIGYLK GLFSYGRYKN SISRSTGADE HAEGSVNGTL
 1151 MQLGALGGVN VPFAATGDLT VEGGLRYDLL KQDAFABKGS ALGWSGNSLT
 1201 EGTLLVGLAGL KLSQPLSDKA VLFATAGVER DLNGRDYTVT GGFTGATAAT
 1251 GKTGARNMPH TRLVAGLGAD VEFNGWNGL ARYSYAGSKQ YGNHSGRVGV
 1301 GYRFLEHHHH HH*

AG741-ORF46.1

1 ATGGTCGCCG CCGACATCGG TCGGGGGCTT GCCGATGCAC TAACCGCACC
 51 GCTCGACCAT AAAGACAAAG GTTTCAGTC TTTGACGCTG GATCAGTCCG
 101 TCAGGAAAAA CGAGAACTG AAGCTGGCGG CACAAGGTGC GGAAAAAACT
 151 TATGGAACG GTGACAGCCT CAATACGGGC AAATTGAAGA ACGACAAGGT
 201 CAGCCGTTTC GACTTTATCC GCCAAATCGA AGTGGACGGG CAGCTCATTA
 251 CCTTGGAGAG TGGAGAGTTC CAAGTATACA AACAAAGCCA TTCCGCCTTA
 301 ACCGCCTTTC AGACCGAGCA AATACAAGAT TCGGAGCATT CCGGGAAGAT
 351 GGTTCGAAA CGCCAGTTCA GAATCGGCGA CATAGCGGGC GAACATACAT
 201 401 CTTTTGACAA GCTTCCCGAA GCGGCGAGGG CGACATATCG CCGGACGGCG
 451 TTCGGTTTCAG ACATGCGCGG CGGAAAACG ACCTACACCA TAGATTTTCGC
 501 CGCCAAGCAG GGAACCGGCA AAATCGAACA TTTGAAATCG CCAGAACTCA
 551 ATGTCGACCT GGCCGCCGCC GATATCAAGC CGGATGGAAA ACGCCATGCC
 601 GTCATCAGCG GTTCCGTCCT TTACAACCAA GCCGAGAAAG GCAGTTACTC
 251 651 CCTCGGTATC TTTGGCGGAA AAGCCAGGA AGTTGCCGGC AGCGCGGAAG
 701 TGAAAACCGT AAACGGCATA CGCCATATCG GCCTTGCCGC CAAGCAACTC
 751 GACGGTGGCG GAGGCACTGG ATCCTCAGAT TTGGCAAACG ATTCCTTTTAT
 801 CCGGCAGGTT CTCGACCGTC AGCATTTCGA ACCCGACGGG AAATACCACC
 851 TATTCGGCAG CAGGGGGGAA CTGCGGAGC GCAGCGGCA TATCGGATTG
 301 901 GGAAAAATAC AAAGCCATCA GTTGGGCAAC CTGATGATT CACAGCGGGC
 951 CATTAAGGA AATATCGGCT ACATTGTCCG CTTTTCGGAT CACGGGCACG
 1001 AAGTCCATTC CCCCTTCGAC AACCATGCCT CACATTCCGA TTCTGATGAA
 1051 GCCGGTAGTC CCGTTGACGG ATTTAGCCTT TACCGCATCC ATTTGGGACGG
 1101 ATACGAACAC CATCCCGCCG ACGGCTATGA CGGGCCACAG GCGGGCGGCT
 351 1151 ATCCCGCTCC CAAAGCGCGG AGGATATAT ACAGCTACGA CATAAAGGC
 1201 GTTGCCCAA ATATCCGCCT CAACCTGACC GACAACCGCA GCACCGGACA
 1251 ACGGCTTGCC GACCGTTTCC ACAATGCCGG TAGTATGCTG ACGCAAGGAG
 1301 TAGGCGACGG ATTCAAACGC GCCACCCGAT ACAGCCCCGA GCTGGACAGA
 1351 TCGGGCAATG CCGCCGAAGC CTCAACGGC ACTGCAGATA TCGTTAAAAA
 401 1401 CATCATCGGC GCGGCAGGAG AAATTGTCGG CGCAGGCGAT GCCGTGCAGG
 1451 GCATAAGCGA AGGCTCAAAC ATTGCTGTCA TGCACGGCTT GGGTCTGCTT
 1501 TCCACCGAAA ACAAGATGGC GCGCATCAAC GATTGTGGCAG ATATGGCGCA
 1551 ACTCAAAGAC TATGCCGCGC CAGCCATCCG CGATTGGGCA GTCCAAACC
 1601 CCAATGCCGC ACAAGGCATA GAAGCCGTCA GCAATATCTT TATGGCAGCC
 451 1651 ATCCCATCA AAGGGATTGG AGCTGTTCGG GGAAAATACG GCTTGGGCGG
 1701 CATCAGGCA CATCCTATCA AGCGGTGCGA GATGGGCGCG ATCGCATTCG
 1751 CGAAAGGGAA ATCCGCCGTC AGCGACAATT TTGCCGATGC GGCATACGCC
 1801 AAATACCCGT CCCCTTACCA TTCCCGAAAT ATCCGTTCAA ACTTGGAGCA
 1851 GCGTTACGGC AAAGAAAACA TCACCTCCTC AACCGTGCCG CCGTCAAACG
 501 1901 GCAAAAATGT CAAACTGGCA GACCAACGCC ACCCGAAGAC AGGCGTACCG
 1951 TTTGACGGTA AAGGGTTTCC GAATTTTGAG AAGCACGTGA AATATGATAC
 2001 GCTCGAGCAC CACCACCACC ACCACTGA

1 MVAADIGAGL ADALTAPLDH KDRGLQSLTL DQSVRKNEKL KLAAQGAET
 55 51 YNGDLSLNTG KLKNDKVSFR DFIRQIEVDG QLITLESGEF QVYKQSHSAL
 101 TAFQTEQIQD SEHSGKMAV RQFRIGDIAG EHTSFDKLE GGRATYRGT
 151 FGSDDAGKX TYTIDFAKQ GNGKIEHLKS PELNVDLAAA DIKPDGKRHA
 201 VISGSVLYNQ AEKGSYSLGI FGGKAQEVAG SAEVKTVNGI RHIGLAAKQL
 251 DGGGGTSSD LANDSFIRQV LDRQHFEPPD KYHLFGSRGE LAERSGHIGL
 60 301 GKIQSHQLGN LMIQQAIAKG NIGYIVRFSH HGHEVHSPFD NHASHSDSDE
 351 AGSPVDGFSL YRIHWDGYEH HPADGYDGPQ GGGYPAPKGA RDIYSYDIK
 401 VAQNIRLNL TNRSTGQRLA DRFHNAGSML TQGVGDGFKR ATRYSPELDR
 451 SGNAAEAFNG TADIVKNIIG AAGEIVGAGD AVQGISSESN IAVMHGLGLL
 501 STENKMARIN DLADMAQLKD YAAAIRDWA VQNPNAQGI EAVSNIFMAA
 65 551 IPIKIGAVR GYGLGGITA HPIKRSQMGAL IALPKGKSAV SDNFADAAYA
 601 KYPSPYHSRN IRSNLEQRYG KENITSSTVP PSNGKNVKLA DQRHPKTGVP
 651 FDGKGFPNFE KHVKYDTLEH HHHHH*

Example 16 – C-terminal fusions ('hybrids') with 287/ Δ G287

According to the invention, hybrids of two proteins A & B may be either NH₂-A-B-COOH or NH₂-B-A-COOH. The effect of this difference was investigated using protein 287 either C-terminal (in '287-His' form) or N-terminal (in Δ G287 form – sequences shown above) to 919, 953 and ORF46.1. A panel of strains was used, including homologous strain 2996. FCA was used as adjuvant:

	287 & 919		287 & 953		287 & ORF46.1	
Strain	Δ G287-919	919-287	Δ G287-953	953-287	Δ G287-46.1	46.1-287
2996	128000	16000	65536	8192	16384	8192
BZ232	256	128	128	<4	<4	<4
1000	2048	<4	<4	<4	<4	<4
MC58	8192	1024	16384	1024	512	128
NGH38	32000	2048	>2048	4096	16384	4096
394/98	4096	32	256	128	128	16
MenA (F6124)	32000	2048	>2048	32	8192	1024
MenC (BZ133)	64000	>8192	>8192	<16	8192	2048

Better bactericidal titres are generally seen with 287 at the N-terminus (in the Δ G form)

When fused to protein 961 [NH₂- Δ G287-961-COOH – sequence shown above], the resulting protein is insoluble and must be denatured and renatured for purification. Following renaturation, around 50% of the protein was found to remain insoluble. The soluble and insoluble proteins were compared, and much better bactericidal titres were obtained with the soluble protein (FCA as adjuvant):

	2996	BZ232	MC58	NGH38	F6124	BZ133
Soluble	65536	128	4096	>2048	>2048	4096
Insoluble	8192	<4	<4	16	n.d.	n.d.

Titres with the insoluble form were, however, improved by using alum adjuvant instead:

Insoluble	32768	128	4096	>2048	>2048	2048
------------------	-------	-----	------	-------	-------	------

Example 17 – N-terminal fusions ('hybrids') to 287

Expression of protein 287 as full-length with a C-terminal His-tag, or without its leader peptide but with a C-terminal His-tag, gives fairly low expression levels. Better expression is achieved using a N-terminal GST-fusion.

As an alternative to using GST as an N-terminal fusion partner, 287 was placed at the C-terminus of protein 919 ('919-287'), of protein 953 ('953-287'), and of proteins ORF46.1 ('ORF46.1-287'). In both cases, the leader peptides were deleted, and the hybrids were direct in-frame fusions.

- 5 To generate the 953-287 hybrid, the leader peptides of the two proteins were omitted by designing the forward primer downstream from the leader of each sequence; the stop codon sequence was omitted in the 953 reverse primer but included in the 287 reverse primer. For the 953 gene, the 5' and the 3' primers used for amplification included a *NdeI* and a *BamHI* restriction sites respectively, whereas for the amplification of the 287 gene the 5' and the 3' primers included a *BamHI* and a *XhoI* restriction sites respectively. In this way a sequential directional cloning of the two genes in pET21b+, using *NdeI-BamHI* (to clone the first gene) and subsequently *BamHI-XhoI* (to clone the second gene) could be achieved.

- 15 The 919-287 hybrid was obtained by cloning the sequence coding for the mature portion of 287 into the *XhoI* site at the 3'-end of the 919-His clone in pET21b+. The primers used for amplification of the 287 gene were designed for introducing a *SalI* restriction site at the 5'- and a *XhoI* site at the 3'- of the PCR fragment. Since the cohesive ends produced by the *SalI* and *XhoI* restriction enzymes are compatible, the 287 PCR product digested with *SalI-XhoI* could be inserted in the pET21b-919 clone cleaved with *XhoI*.

The ORF46.1-287 hybrid was obtained similarly.

- 20 The bactericidal efficacy (homologous strain) of antibodies raised against the hybrid proteins was compared with antibodies raised against simple mixtures of the component antigens:

	Mixture with 287	Hybrid with 287
919	32000	16000
953	8192	8192
ORF46.1	128	8192

Data for bactericidal activity against heterologous MenB strains and against serotypes A and C were also obtained for 919-287 and 953-287:

	919		953		ORF46.1	
Strain	Mixture	Hybrid	Mixture	Hybrid	Mixture	Hybrid
MC58	512	1024	512	1024	-	1024
NGH38	1024	2048	2048	4096	-	4096
BZ232	512	128	1024	16	-	-
MenA (F6124)	512	2048	2048	32	-	1024
MenC (C11)	>2048	n.d.	>2048	n.d.	-	n.d.
MenC (BZ133)	>4096	>8192	>4096	<16	-	2048

Hybrids of ORF46.1 and 919 were also constructed. Best results (four-fold higher titre) were achieved with 919 at the N-terminus.

Hybrids 919-519His, ORF97-225His and 225-ORF97His were also tested. These gave moderate ELISA titres and bactericidal antibody responses.

5 Example 18 – the leader peptide from ORF4

As shown above, the leader peptide of ORF4 can be fused to the mature sequence of other proteins (e.g. proteins 287 and 919). It is able to direct lipidation in *E.coli*.

Example 19 – domains in 564

The protein '564' is very large (2073aa), and it is difficult to clone and express it in complete form. To facilitate expression, the protein has been divided into four domains, as shown in figure 8 (according to the MC58 sequence):

Domain	A	B	C	D
Amino Acids	79-360	361-731	732-2044	2045-2073

These domains show the following homologies:

• Domain A shows homology to other bacterial toxins:

- 15 gb|AAG03431.1|AE004443_9probable hemagglutinin [*Pseudomonas aeruginosa*] (38%)
 gb|AAC31981.1|(139897) HecA [*Pectobacterium chrysanthemi*] (45%)
 emb|CAA36409.1|(X52156) filamentous hemagglutinin [*Bordetella pertussis*] (31%)
 gb|AAC79757.1|(AF057695) large supernatant protein1 [*Haemophilus ducreyi*] (26%)
 gb|AAA25657.1|(M30186) HpmA precursor [*Proteus mirabilis*] (29%)

20 • Domain B shows no homology, and is specific to 564.

• Domain C shows homology to:

- 25 gb|AAF84995.1|AE004032 HA-like secreted protein [*Xylella fastidiosa*] (33%)
 gb|AAG05850.1|AE004673 hypothetical protein [*Pseudomonas aeruginosa*] (27%)
 gb|AAF68414.1|AF237928 putative FHA [*Pasteurella multocida*] (23%)
 gb|AAC79757.1|(AF057695) large supernatant protein1 [*Haemophilus ducreyi*] (23%)
 pir||S21010 FHA B precursor [*Bordetella pertussis*] (20%)

• Domain D shows homology to other bacterial toxins:

gb|AAF84995.1|AE004032_14 HA-like secreted protein [*Xylella fastidiosa*] (29%)

Using the MC58 strain sequence, good intracellular expression of 564ab was obtained in the form of GST-fusions (no purification) and his-tagged protein; this domain-pair was also expressed as a lipoprotein, which showed moderate expression in the outer membrane/supernatant fraction.

The b domain showed moderate intracellular expression when expressed as a his-tagged product (no purification), and good expression as a GST-fusion.

The c domain showed good intracellular expression as a GST-fusion, but was insoluble. The d domain showed moderate intracellular expression as a his-tagged product (no purification). The cd protein domain-pair showed moderate intracellular expression (no purification) as a GST-fusion.

Good bactericidal assay titres were observed using the c domain and the bc pair.

Example 20 – the 919 leader peptide

The 20mer leader peptide from 919 is discussed in example 1 above:

MKKYLFRAL YGIAAAILAA

As shown in example 1, deletion of this leader improves heterologous expression, as does substitution with the ORF4 leader peptide. The influence of the 919 leader on expression was investigated by fusing the coding sequence to the *PhoC* reporter gene from *Morganella morganii* [Thaller *et al.* (1994) *Microbiology* 140:1341-1350]. The construct was cloned in the pET21-b plasmid between the *NdeI* and *XhoI* sites (Figure 9):

```

1  MKKYLFRAL YGIAAAILAA AIPAGNDATT KPDLYYLNKNE QAIDSLKLLP
51  PPPEVGSIQF LNDQAMYKRG RMLRNTERGK QAQADADLAA GGVATAFSGA
101 FGYPITEKDS PELYKLLTNM IEDAGDLATR SAKEHYMRIR PFAFYGTETC
151 NTKDQKKLST NGSYPSGHTS IGWATALVLA EVNPNQDAI LERGYQLGQS
201 RVICGYHWQS DVDAARIVGS AAVATLHSDP AFQAQLAKAK QEFAQKSQK*
```

The level of expression of *PhoC* from this plasmid is >200-fold lower than that found for the same construct but containing the native *PhoC* signal peptide. The same result was obtained even after substitution of the T7 promoter with the *E. coli* *Plac* promoter. This means that the influence of the 919 leader sequence on expression does not depend on the promoter used.

In order to investigate if the results observed were due to some peculiarity of the 919 signal peptide nucleotide sequence (secondary structure formation, sensitivity to RNAases, *etc.*) or

to protein instability induced by the presence of this signal peptide, a number of mutants were generated. The approach used was a substitution of nucleotides of the 919 signal peptide sequence by cloning synthetic linkers containing degenerate codons. In this way, mutants were obtained with nucleotide and/or amino acid substitutions.

- 5 Two different linkers were used, designed to produce mutations in two different regions of the 919 signal peptide sequence, in the first 19 base pairs (L1) and between bases 20-36 (S1).

10 **L1:** 5' T ATG AAa/g TAc/t c/tTN TTt/c a/cGC GCC GCC CTG TAC GGC ATC GCC GCC
GCC ATC CTC GCC GCC GCG ATC CC 3'
S1: 5' T ATG AAA AAA TAC CTA TTC CGa/g GCN GCN c/tTa/g TAc/t GGc/g ATC GCC
GCC GCC ATC CTC GCC GCC GCG ATC CC 3'

The alignment of some of the mutants obtained is given below.

15 **L1 mutants:**
9L1-a ATGAAGAAGTACCTTTTCAGCGCCGCC~
9L1-e ATGAAAAAATACTTTTCCGCGCCGCC~
9L1-d ATGAAAAAATACTTTTCCGCGCCGCC~
9L1-f ATGAAAAAATATCTCTTAGCGCCGCCCTGTACGGCATCGCCGCCCATCCTCGCCGCC
919sp ATGAAAAAATACCTATTCGCGCCGCCCTGTACGGCATCGCCGCCCATCCTCGCCGCC

20 9L1a MKKYLFSAA~
9L1e MKKYFFRAA~
9L1d MKKYFFRAA~
9L1f MKKYLFSAAALYGIAAILAA
919sp MKKYLFRALYGIAAAILAA (i.e. native signal peptide)

25 **S1 mutants:**
9S1-e ATGAAAAAATACCTATTC.....ATCGCCGCCGCCATCCTCGCCGCC
9S1-c ATGAAAAAATACCTATTCGAGCTGCCCAATACGGCATCGCCGCCGCCATCCTCGCCGCC
9S1-b ATGAAAAAATACCTATTCGCGCGCCCAATACGGCATCGCCGCCGCCATCCTCGCCGCC
30 9S1-i ATGAAAAAATACCTATTCGCGCGGCTTTGTACGGGATCGCCGCCGCCATCCTCGCCGCC
919sp ATGAAAAAATACCTATTCGCGCGCCCTGTACGGCATCGCCGCCGCCATCCTCGCCGCC

35 9S1e MKKYL.....IAAILAA
9S1c MKKYLFRAAQYGIAAAILAA
9S1b MKKYLFRAAQYGIAAAILAA
9S1i MKKYLFRALYGIAAAILAA
919sp MKKYLFRALYGIAAAILAA

- 40 As shown in the sequences alignments, most of the mutants analysed contain in-frame deletions which were unexpectedly produced by the host cells.

Selection of the mutants was performed by transforming *E. coli* BL21(DE3) cells with DNA prepared from a mixture of L1 and S1 mutated clones. Single transformants were screened for high PhoC activity by streaking them onto LB plates containing 100 µg/ml ampicillin,
45 50µg/ml methyl green, 1 mg/ml PDP (phenolphthaleindiphosphate). On this medium PhoC-producing cells become green (Figure 10).

A quantitative analysis of PhoC produced by these mutants was carried out in liquid medium using pNPP as a substrate for PhoC activity. The specific activities measured in cell extracts and supernatants of mutants grown in liquid medium for 0, 30, 90, 180 min. were:

CELL EXTRACTS

	0	30	90	180
control	0,00	0,00	0,00	0,00
9phoC	1,11	1,11	3,33	4,44
9S1e	102,12	111,00	149,85	172,05
9L1a	206,46	111,00	94,35	83,25
9L1d	5,11	4,77	4,00	3,11
9L1f	27,75	94,35	82,14	36,63
9S1b	156,51	111,00	72,15	28,86
9S1c	72,15	33,30	21,09	14,43
9S1i	156,51	83,25	55,50	26,64
phoCwt	194,25	180,93	149,85	142,08

5

SUPERNATANTS

	0	30	90	180
control	0,00	0,00	0,00	0,00
9phoC	0,33	0,00	0,00	0,00
9S1e	0,11	0,22	0,44	0,89
9L1a	4,88	5,99	5,99	7,22
9L1d	0,11	0,11	0,11	0,11
9L1f	0,11	0,22	0,11	0,11
9S1b	1,44	1,44	1,44	1,67
9S1c	0,44	0,78	0,56	0,67
9S1i	0,22	0,44	0,22	0,78
phoCwt	34,41	43,29	87,69	177,60

Some of the mutants produce high amounts of PhoC and in particular, mutant 9L1a can secrete PhoC in the culture medium. This is noteworthy since the signal peptide sequence of this mutant is only 9 amino acids long. This is the shortest signal peptide described to date.

10

Example 21 – C-terminal deletions of Maf-related proteins

MafB-related proteins include 730, ORF46 and ORF29.

The 730 protein from MC58 has the following sequence:

15

20

```

1  VKPLRLRLTNL LAACAVAAAA LIQPALAADL AQDPFITDNA QRQHYEPGGK
51  YHLFGDPRGS VSDRTGKINV IQDYTHQMGN LLIQQANING TIGYHTRFSG
101 HGHEEHAPFD NHAADSASEE KGNVDEGFTV YRLNWEGHEH HPADAYDGPK
151 GGNYPKPTGA RDEYTYHVNG TARSIKLNPT DTRSIRQRIS DNYSNLGSGNF
201 SDRADEANRK MFEHNAKLDR WGNMSEFING VAAGALNPFI SAGEALGIGD
251 ILYGTRYAID KAAMRNIAPL PAEGKFAVIG GLGSVAGPEK NTREAVDRWI
301 QENPNAAETV EAVFNVAATA KVAKLAKAAK PGKAAVSGDF ADSYKKKLAL

```

-60-

351 SDSARQLYQN AKYREALDIH YEDLIRRKTD GSSKFINGRE IDAVTNDALI
 401 QAKRTISAID KPNFLNQKN RKQIKATIEA ANQQGKRAEF WFKYGVHSQV
 451 KSYIESKGGI VKTGLGD*

5 The leader peptide is underlined.

730 shows similar features to ORF46 (see example 8 above):

- as for Orf46, the conservation of the 730 sequence among MenB, MenA and gonococcus is high (>80%) only for the N-terminal portion. The C-terminus, from ~340, is highly divergent.
- 10 - its predicted secondary structure contains a hydrophobic segment spanning the central region of the molecule (aa. 227-247).
- expression of the full-length gene in *E. coli* gives very low yields of protein. Expression from tagged or untagged constructs where the signal peptide sequence has been omitted has a toxic effect on the host cells. In other words, the presence of the full-length mature protein in the cytoplasm is highly toxic for the host cell while its translocation to the periplasm (mediated by the signal peptide) has no detectable effect on cell viability. This "intracellular toxicity" of 730 is particularly high since clones for expression of the leaderless 730 can only be obtained at very low frequency using a *recA* genetic background (*E. coli* strains: HB101 for cloning; HMS174(DE3) for expression).
- 15
- 20 To overcome this toxicity, a similar approach was used for 730 as described in example 8 for ORF46. Four C-terminal truncated forms were obtained, each of which is well expressed. All were obtained from intracellular expression of His-tagged leaderless 730.

Form A consists of the N-terminal hydrophilic region of the mature protein (aa. 28-226). This was purified as a soluble His-tagged product, having a higher-than-expected MW.

- 25 Form B extends to the end of the region conserved between serogroups (aa. 28-340). This was purified as an insoluble His-tagged product.

The C-terminal truncated forms named C1 and C2 were obtained after screening for clones expressing high levels of 730-His clones in strain HMS174(DE3). Briefly, the pET21b plasmid containing the His-tagged sequence coding for the full-length mature 730 protein was used to transform the *recA* strain HMS174(DE3). Transformants were obtained at low frequency which showed two phenotypes: large colonies and very small colonies. Several large and small colonies were analysed for expression of the 730-His clone. Only cells from large colonies over-expressed a protein recognised by anti-730A antibodies. However the

30

protein over-expressed in different clones showed differences in molecular mass. Sequencing of two of the clones revealed that in both cases integration of an *E. coli* IS sequence had occurred within the sequence coding for the C terminal region of 730. The two integration events have produced in-frame fusion with 1 additional codon in the case of C1, and 12 additional codons in the case of C2 (Figure 11). The resulting "mutant" forms of 730 have the following sequences:

730-C1 (due to an IS1 insertion - figure 11A)

```

1  MADLAQDPFI TDNAQRQHYE PGGKYHLFGD PRGSVSDRTG KINVIQDYTH
51  QMGNLLIQQA NINGTIGYHT RFSGHGHEEH APFDNHAADS ASEKGNVDE
101 GFTVYRLNWE GHEHHPADAY DGPKGGNYPK PTGARDEYTY HVNGTARSIK
151 LNPTDTRSIR QRISDNYSNL GSNFSDRADE ANRKMFEHNA KLDRWGNSME
201 FINGVAAGAL NPFISAGEAL GIGDILYGTR YAIDKAAMRN IAPLPAEGKF
251 AVIGGLGSAV GFENKTREAV DRWIQENPNA AETVEAVFNV AAAAKVAKLA
301 KAAKPGKAAV SGDFADSYKK KLALSDSARQ LYQNAKYREA LDIHYEDLIR
15 351 RRTDGSSKFI NGREIDAVTN DALIQAR*
```

The additional amino acid produced by the insertion is underlined.

730-C2 (due to an IS5 insertion - Figure 11B)

```

1  MADLAQDPFI TDNAQRQHYE PGGKYHLFGD PRGSVSDRTG KINVIQDYTH
20 51  QMGNLLIQQA NINGTIGYHT RFSGHGHEEH APFDNHAADS ASEKGNVDE
101 GFTVYRLNWE GHEHHPADAY DGPKGGNYPK PTGARDEYTY HVNGTARSIK
151 LNPTDTRSIR QRISDNYSNL GSNFSDRADE ANRKMFEHNA KLDRWGNSME
201 FINGVAAGAL NPFISAGEAL GIGDILYGTR YAIDKAAMRN IAPLPAEGKF
251 AVIGGLGSAV GFENKTREAV DRWIQENPNA AETVEAVFNV AAAAKVAKLA
25 301 KAAKPGKAAV SGDFADSYKK KLALSDSARQ LYQNAKYREA LGKVRISGEI
351 LLG*
```

The additional amino acids produced by the insertion are underlined.

In conclusion, intracellular expression of the 730-C1 form gives very high level of protein and has no toxic effect on the host cells, whereas the presence of the native C-terminus is toxic. These data suggest that the "intracellular toxicity" of 730 is associated with the C-terminal 65 amino acids of the protein.

Equivalent truncation of ORF29 to the first 231 or 368 amino acids has been performed, using expression with or without the leader peptide (amino acids 1-26; deletion gives cytoplasmic expression) and with or without a His-tag.

Example 22 - domains in 961

As described in example 9 above, the GST-fusion of 961 was the best-expressed in *E. coli*. To improve expression, the protein was divided into domains (figure 12).

The domains of 961 were designed on the basis of YadA (an adhesin produced by *Yersinia* which has been demonstrated to be an adhesin localized on the bacterial surface that forms

oligomers that generate surface projection [Hoiczky *et al.* (2000) *EMBO J* 19:5989-99]) and are: leader peptide, head domain, coiled-coil region (stalk), and membrane anchor domain.

These domains were expressed with or without the leader peptide, and optionally fused either to C-terminal His-tag or to N-terminal GST. *E.coli* clones expressing different domains of 961 were analyzed by SDS-PAGE and western blot for the production and localization of the expressed protein, from over-night (o/n) culture or after 3 hours induction with IPTG. The results were:

	Total lysate (Western Blot)	Periplasm (Western Blot)	Supernatant (Western Blot)	OMV SDS-PAGE
961 (o/n)	-	-	-	
961 (IPTG)	+/-	-	-	
961-L (o/n)	+	-	-	+
961-L (IPTG)	+	-	-	+
961c-L (o/n)	-	-	-	
961c-L (IPTG)	+	+	+	
961 Δ_1 -L (o/n)	-	-	-	
961 Δ_1 -L (IPTG)	+	-	-	+

The results show that in *E.coli*:

- 961-L is highly expressed and localized on the outer membrane. By western blot analysis two specific bands have been detected: one at ~45kDa (the predicted molecular weight) and one at ~180kDa, indicating that 961-L can form oligomers. Additionally, these aggregates are more expressed in the over-night culture (without IPTG induction). OMV preparations of this clone were used to immunize mice and serum was obtained. Using overnight culture (predominantly by oligomeric form) the serum was bactericidal; the IPTG-induced culture (predominantly monomeric) was not bactericidal.
- 961 Δ_1 -L (with a partial deletion in the anchor region) is highly expressed and localized on the outer membrane, but does not form oligomers;
- the 961c-L (without the anchor region) is produced in soluble form and exported in the supernatant.

20 Titres in ELISA and in the serum bactericidal assay using His-fusions were as follows:

	ELISA	Bactericidal
961a (aa 24-268)	24397	4096

-63-

961b (aa 269-405)	7763	64
961c-L	29770	8192
961c (2996)	30774	>65536
961c (MC58)	33437	16384
961d	26069	>65536

E. coli clones expressing different forms of 961 (961, 961-L, 961 Δ ₁-L and 961c-L) were used to investigate if the 961 is an adhesin (*c.f.* YadA). An adhesion assay was performed using (a) the human epithelial cells and (b) *E. coli* clones after either over-night culture or three hours IPTG induction. 961-L grown over-night (961 Δ ₁-L) and IPTG-induced 961c-L (the clones expressing protein on surface) adhere to human epithelial cells.

961c was also used in hybrid proteins (see above). As 961 and its domain variants direct efficient expression, they are ideally suited as the N-terminal portion of a hybrid protein.

Example 23 – further hybrids

Further hybrid proteins of the invention are shown below (see also Figure 14). These are advantageous when compared to the individual proteins:

ORF46.1-741

```

1  ATGTCAGATT TGGCAAACGA TTCTTTTATC CGGCAGGTTC TCGACCGTCA
51  GCATTTTCGAA CCCGACGGGA AATACCACCT ATTCCGGCAGC AGGGGGGAAC
101 TTGCCGAGCG CAGCGGCCAT ATCGGATTGG GAAAAATACA AAGCCATCAG
15  151 TTGGGCAACC TGATGATTCA ACAGGCGGCC ATTAAGGAA ATATCGGCTA
201 CATGTCCGC TTTCCGATC ACGGCGACGA AGTCCATTCC CCCTTCGACA
251 ACCATGCCCTC ACATTCCGAT TCTGATGAAG CCGGTAGTCC CGTTGACGGA
301 TTTAGCCTTT ACCGCATCCA TTGGGACGGA TACGAACACC ATCCCGCCGA
351 CGGCTATGAC GGGCCACAGG GCGGCGGCTA TCCCGCTCCC AAAGGCGCGA
20  401 GGGATATATA CAGCTACGAC ATAAAAGGCG TTGCCAAAA TATCCGCCTC
451 AACCTGACCG ACAACCGCAG CACCGGACAA CGGCTTGCCG ACCGTTTCCA
501 CAATGCCGGT AGTATGCTGA CGCAAGGAGT AGGCGACGGA TTCAAACGCG
551 CCACCCGATA CAGCCCCGAG CTGGACAGAT CGGGCAATGC CGCCGAAGCC
601 TTCAACGGCA CTGCAGATAT CGTTAAAAAC ATCATCGGCG CGGCAGGAGA
25  651 AATTGTCGGC GCAGGCGATG CCGTGCAGGG CATAAGCGAA GGCTCAAACA
701 TTGCTGTCTG GCACGGCTTG GGTCTGCTTT CCACCGAAAA CAAGATGGCG
751 CGCATCAACG ATTTGGCAGA TATGGCGCAA CTCAAAGACT ATGCCGCGAG
801 AGCCATCCGC GATTGGGCAG TCCAAAACCC CAATGCCGCA CAAGGCATAG
851 AAGCCGTCAG CAATATCTTT ATGGCAGCCA TCCCCATCAA AGGGATTGGA
30  901 GCTGTTCGGG GAAATACGG CTTGGGCGGC ATCACGGCAC ATCCTATCAA
951 GCGGTCGCAG ATGGGCGCGA TCGCATTGCC GAAAGGGAAA TCCGCCGTCA
1001 GCGCAATTT TGCCGATGCG GCATACGCCA AATACCCGTC CCCTTACCAT
1051 TCCCGAAATA TCCGTTCAAA CTTGGAGCAG CGTTACGGCA AAGAAAACAT
1101 CACCTCCTCA ACCGTGCCGC CGTCAAACGG CAAAAATGTC AAAGTGGCAG
35  1151 ACCAACGCCA CCCGAAGACA GGCGTACCGT TTGACGGTAA AGGGTTTCCG
1201 AATTTTGAGA AGCACGTGAA ATATGATACG GGATCCGGAG GGGGTGGTGT
1251 CGCCGCCGAC ATCGGTGCGG GGCTTGCCGA TGCACTAACC GCACCGCTCG
1301 ACCATAAAGA CAAAGGTTTG CAGTCTTTGA CGCTGGATCA GTCCGTCAGG
1351 AAAAACGAGA AACTGAAGCT GGCGGCACAA GGTGCGGAAA AAAGTTATGG
40  1401 AAACGGTGAC AGCCTCAATA CGGGCAAATT GAAGAACGAC AAGGTCAGCC
1451 GTTTCGACTT TATCCGCCAA ATCGAAGTGG ACGGGCAGCT CATTACCTTG
1501 GAGAGTGGAG AGTTCCAAAGT ATACAAACAA AGCCATTCCG CCTTAACCGC
1551 CTTTCAGACC GAGCAAATAC AAGATTCCGGA GCATTCCGGG AAGATGGTTG
1601 CGAAACGCCA GTTCAGAATC GGCGACATAG CGGGCGAACA TACATCTTTT

```

-64-

5	1651	GACAAGCTTC	CCGAAGGCGG	CAGGCGGACA	TATCGCGGGA	CGGCGTTCGG
	1701	TTCAGACGAT	GCCGGCGGAA	AACTGACCTA	CACCATAGAT	TTCCGCCCCA
	1751	AGCAGGGA	CGGCAAAATC	GAACATTGTA	AATCGCCAGA	ACTCAATGTC
	1801	GACCTGGCCG	CCGCCGATAT	CAAGCCGGAT	GGAAAACGCC	ATGCCGTCAT
	1851	CAGCGGTTC	GTCCTTTTACA	ACCAAGCCGA	GAAAGGCAGT	TACTCCCTCG
	1901	GTATCTTTGG	CGGAAAAGCC	CAGGAAGTTG	CCGGCAGCGC	GGAAGTGA
	1951	ACCGTAAACG	GCATACGCCA	TATCGGCCTT	GCCGCCAAGC	AACTCGAGCA
	2001	CCACCACCAC	CACCACTGA			
10	1	MSDLANDSFI	RQVLDRQHFE	PDGKYHLFGS	RGELAERSGH	IGLGKIQSHQ
	51	LGNLMIQQA	IKGNIGYIVR	FSDHGHEVHS	PFDNHASHSD	SDEAGSPVDG
	101	FSLYRIHWDG	YEHHPADGYD	GPQGGGYPAP	KGARDIYSYD	IKGVAQNIRL
	151	NLTDRNSTGQ	RLADRFHNAG	SMLTQGVGDG	FKRATRYSP	LDRSGNAEA
	201	FNGTADIVKN	IIGAAGEIVG	AGDAVQGISE	GSNIIVMHGL	GLLSTENKMA
15	251	RINDLADMAQ	LKDYAAAAIR	DWAVQNPNA	QGIEAVSNIF	MAAIIPIKGIG
	301	AVRGKYGLGG	ITAHPIKRSQ	MGAIALPKGK	SAVSDNFADA	AYAKYPSPYH
	351	SRNIRSNLEQ	RYGKENITSS	TVPPSNGKNV	KLADQRHPKT	GVPPFDGKGF
	401	NFEKHVKYDT	GSGGGGVAAD	IGAGLADALT	APLDHKDKGL	QSLTLDQSVR
	451	KNEKLKLAQ	GAEKTYGNGD	SLNTGKLNND	KVSRFDFIRQ	IEVDGQLITL
20	501	ESGEFQVYKQ	SHSALTAFQT	EQIQDSEHSG	KMVAKRQFRI	GDIAGEHTSF
	551	DKLPEGGRAT	YRGTAFGSDD	AGGKLTYTID	FAAQONGNGKI	EHLKSPELNV
	601	DLAAADIKPD	GKRHAIVISG	VLYNQAEKGS	YSLGIFGGKA	QEVAGSAEVK
	651	TVNGIRHIGL	AAQLEHHHH	HH*		
25	ORF46.1-961					
	1	ATGTCAGATT	TGGCAAACGA	TTCTTTTATC	CGGCAGGTTC	TCGACCGTCA
	51	GCATTTCGAA	CCCGACGGGA	AATACCACCT	ATTTCGGCAGC	AGGGGGGAAC
	101	TTGCCGAGCG	CAGCGGCCAT	ATCGGATTGG	GAAAAATACA	AAGCCATCAG
30	151	TGGGCAACC	TGATGATTCA	ACAGGCGGCC	ATTAAAGGAA	ATATCGGCTA
	201	CATTGTCCGC	TTTTCGGATC	ACGGGCACGA	AGTCCATTCC	CCCTTCGACA
	251	ACCATGCCCTC	ACATTCCGAT	TCTGATGAAG	CCGGTAGTCC	CGTTGACGGA
	301	TTTAGCCTTT	ACCGCATCCA	TTGGGACGGA	TACGAACACC	ATCCCGCCGA
	351	CGGCTATGAC	GGGCCACAGG	GCGGCGGCTA	TCCCGCTCCC	AAAGGCGCGA
35	401	GGGATATATA	CAGCTACGAC	ATAAAAGGCG	TTGCCCAAAA	TATCCGCTTC
	451	AACCTGACCG	ACAACCGCAG	CACCGGACAA	CGGCTTGCCG	ACCGTTTCCA
	501	CAATGCCGGT	AGTATGCTGA	CGCAAGGAGT	AGGCGACGGA	TTCAAACGCG
	551	CCACCCGATA	CAGCCCCGAG	CTGGACAGAT	CGGGCAATGC	CGCCGAAGCC
	601	TTCAACGGCA	CTGCAGATAT	CGTTAAAAAC	ATCATCGGCG	CGGCAGGAGA
40	651	AATTGTCCGGC	GCAGGCGATG	CCGTGCAAGG	CATAAGCGAA	GGCTCAAACA
	701	TTGCTGTGTC	GCACGGCTTG	GGTCTGCTTT	CCACCGAAAA	CAAGATGGCG
	751	CGCATCAACG	ATTGTGGCAGA	TATGGCGCAA	CTCAAAGACT	ATGCCCGAGC
	801	AGCCATCCGC	GATTGGGCAG	TCCAAAACCC	CAATGCCGCA	CAAGGCATAG
	851	AAGCCGTCAG	CAATATCTTT	ATGGCAGCCA	TCCCCATCAA	AGGGATTGGA
45	901	GCTGTTCGGG	GAAAATACGG	CTTGGGCGGC	ATCACGGCAC	ATCCTATCAA
	951	GCGGTCGCG	ATGGGCGCGA	TGCGATTGCG	GAAAGGGAAA	TCCGCCGTCA
	1001	GCGACAATTT	TGCCGATGCG	GCATACGCCA	AATACCCGTC	CCCTTACCAT
	1051	TCCCGAAATA	TCCGTTCAAA	CTTGGAGCAG	CGTTACGGCA	AAGAAAACAT
	1101	CACCTCCTCA	ACCGTGCCGC	CGTCAAACGG	CAAAAATGTC	AAACTGGCAG
50	1151	ACCAACGCCA	CCCGAAGACA	GGCGTACCGT	TTGACGGTAA	AGGGTTTCCG
	1201	AATTTTGAGA	AGCACGTGAA	ATATGATACG	GGATCCGGAG	GAGGAGGAGC
	1251	CACAAACGAC	GACGATGTTA	AAAAAGCTGC	CACTGTGGCC	ATTGCTGCTG
	1301	CCTACAACAA	TGGCCAAAGAA	ATCAACGGTT	TCAAAGCTGG	AGAGACCATC
	1351	TACGACATTG	ATGAAGACGG	CACAATTACC	AAAAAAGACG	CAACTGCAGC
55	1401	CGATGTTGAA	GCCGACGACT	TTAAAGGTCT	GGGTCTGAAA	AAAGTCTGTA
	1451	CTAACCTGAC	CAAACCGTTC	AATGAAAACA	AACAAAACGT	CGATGCCAAA
	1501	GTAAAAGCTG	CAGAATCTGA	AATAGAAAAG	TTAACAACCA	AGTTAGCAGA
	1551	CAGTGATGCC	GCTTTAGCAG	ATACTGATGC	CGCTCTGGAT	GCAACCACCA
	1601	ACGCCTTGAA	TAAATTGGGA	GAAAATATAA	CGACATTTGC	TGAAGAGACT
60	1651	AAGACAAATA	TCGTAAAAAT	TGATGAAAAA	TTAGAAGCCG	TGGCTGATAC
	1701	CGTCGACAAG	CATGCCGAAG	CATTCAACGA	TATCGCCGAT	TCATTGGATG
	1751	AAACCAACAC	TAAGGCAGAC	GAAGCCGTCA	AAACCGCCAA	TGAAGCCAAA
	1801	CAGACGGCCG	AAGAAACCAA	ACAAAACGTC	GATGCCAAAG	TAAAAGCTGC
	1851	AGAAACTGCA	GCAGGCAAAAG	CCGAAGCTGC	CGCTGGCACA	GCTAATACTG
65	1901	CAGCCGACAA	GGCCGAAGCT	GTCGCTGCAA	AAGTTACCGA	CATCAAAGCT
	1951	GATATCGCTA	CGAACAAAGA	TAATATTGCT	AAAAAAGCAA	ACAGTGCCGA
	2001	CGTGATACAC	AGAGAAGAGT	CTGACAGCAA	ATTTGTGAGA	ATTGATGGTC

-65-

5	2051	TGAACGCTAC	TACCGAAAAA	TTGGACACAC	GCTTGGCTTC	TGCTGAAAAA
	2101	TCCATTGCCG	ATCACGATAC	TCGCCTGAAC	GGTTTGGATA	AAACAGTGTC
	2151	AGACCTGCGC	AAAGAAACCC	GCCAAGGCCT	TGCAGAACAA	GCCGCGCTCT
	2201	CCGTCTGTTC	CCAACCTTAC	AACGTGGGTC	GGTTCAATGT	AACGGCTGCA
	2251	GTCGGCGGCT	ACAAATCCGA	ATCGGCAGTC	GCCATCGGTA	CCGGCTTCCG
	2301	CTTTACCGAA	AACTTTGCCG	CCAAAGCAGG	CGTGGCAGTC	GGCACTTCGT
	2351	CCGTTCTTTC	CGCAGCCTAC	CATGTCGGCG	TCAATTACGA	GTGGCTCGAG
	2401	CACCACCACC	ACCACCCTG	A		
10	1	MSDLANDSFI	RQVLDRQHFE	PDGKYHLFGS	RGELAERSGH	IGLGKIQSHQ
	51	LGNLMIQQA	IKGNIGYIVR	FSDHGHEVHS	PFDNHASHSD	SDEAGSPVDG
	101	FSLYRIHWDG	YEHHPADGYD	GPQGGGYPAP	KGARDIYSYD	IKGVAQNIRL
	151	NLTDMNRSTGQ	RLADRFHNAG	SMLTQGVGDG	FKRATRYSP	LDRSGNAAEA
	201	FNGTADIVKN	IIGAAGEIVG	AGDAVQGISE	GSNIAMVHGL	GLLSTENKMA
	251	RINDLADMAQ	LKDYAAAAIR	DWAVQNPNA	QGIEAVSNIF	MAAIIKIGIG
	301	AVRGKYGLGG	ITAHPIKRSQ	MGAIALPKGK	SAVSDNFADA	AYAKYPSPYH
	351	SRNIRSNELEQ	RYGKENITSS	TVPPSNGKNV	KLADQRHPKT	GVPFDGKGF
15	401	NFEKHVKYDT	SGSGGGATND	DDVKKAATVA	IAAAYNNGQE	INGFKAGETI
	451	YDIDEDGTIT	KKDATAADVE	ADDFKGLGLK	KVVTNLTKTV	NENKQNVDAK
	501	VKAAESEIEK	LTTKLADTDA	ALADTDAALD	ATTNALNKL	ENITTFAEET
	551	KTNIVKIDEX	LEAVADTVDK	HAEAFNDIAD	SLDETNTKAD	EAVKTANEAK
	601	QTAEETKQNV	DAKVKAETA	AGKAEAAAGT	ANTAADKAEA	VAKVVTDIKA
	651	DIATNKDNIA	KKANSADVYT	REESDSKFVR	IDGLNATTEK	LDTRLASAER
	701	SIADHDTRLN	GLDKTVSDLR	KETRQGLAEQ	AALSGLFQPY	NVGRFNVTA
	751	VGGYKSESAY	AIGTGFRFTE	NFAAKAGVAV	GTSSGSSAAY	HVGVNVEWLE
20	801	HHHHHH*				
25						
30						
35						
40						
45						
50						
55						
60						
65						

ORF46.1-961c

-66-

5	1901	CAGCCGACAA	GGCCGAAGCT	GTCGCTGCAA	AAGTTACCGA	CATCAAAGCT
	1951	GATATCGCTA	CGAACAAAGA	TAATATTGCT	AAAAAAGCAA	ACAGTGCCGA
	2001	CGTGTACACC	AGAGAAGAGT	CTGACAGCAA	ATTTGTGAGA	ATTGATGGTC
	2051	TGAACGCTAC	TACCGAAAAA	TTGGACACAC	GCTTGGCTTC	TGCTGAAAAA
	2101	TCCATTGCCG	ATCACGATAC	TCGCCTGAAC	GGTTTGGATA	AAACAGTGTC
	2151	AGACCTGCGC	AAAGAAACCC	GCCAAGGCCT	TGCAGAACAA	GCCGCGCTCT
	2201	CCGGTCTGTT	CCAACCTTAC	AACGTGGGTC	TCGAGCACCA	CCACCACCAC
2251	CACTGA					
10	1	MSDLANDSFI	RQVLDRQHFE	PDGKYHLFGS	RGELAERSGH	IGLGKIQSHQ
	51	LGNLMIQQA	IKGNIGYIVR	FSDHGHEVHS	PFDNHASHSD	SDEAGSPVDG
	101	FSLYRIHWDG	YEHHPADGYD	GPQGGYPAP	KGARDIYSYD	IKGVAQNIRL
	151	NLTDNRSTGQ	RLADRFHNAG	SMLTQGVGDG	FKRATRYSPE	LDRSGNAAEA
	201	FNGTADIVKN	IIGAAGEIVG	AGDAVQGISE	GSNIAMVHGL	GLLSTENKMA
15	251	RINDLADMAQ	LKDYAAAAIR	DWAVQNPNA	QGIEAVSNIF	MAAIPKIGIG
	301	AVRGKYGLGG	ITAHPIKRSQ	MGAIALPKGK	SAVSDNFADA	AYAKYPSPYH
	351	SRNIRSNLEQ	RYGKENITSS	TVPPSNGKNV	KLADQRHPKT	GVPFDGKGFP
	401	NPEKHVKYDT	GSGGGGATND	DDVKAATVA	IAAAYNNGQE	INGFKAGETI
20	451	YDIDEDGTIT	KKDATAADVE	ADDFKGLGLK	KVVTNLTKTV	NENKQNVDAK
	501	VKAAESEIEK	LTTKLADTDA	ALADTDAALD	ATTNALNKLK	ENITTFAEET
	551	KTNIVKIDEX	LEAVADTVDK	HAEAFNDIAD	SLDETNTKAD	EAVKTANEAK
	601	QTAEETKQNV	DAKVKAETA	AGKAEAAAGT	ANTAADKAEA	VAAKVTDIKA
	651	DIATNKDNIA	KKANSADVYT	REESDSKFVR	IDGLNATTEK	LDTRLASAEK
25	701	SIADHDTRLN	GLDKTVSDLR	KETRQGLAEQ	AALSGLFPQY	NVGLEHHHHH
	751	H*				

961-ORF46.1

30	1	ATGGCCACAA	ACGACGACGA	TGTTAAAAAA	GCTGCCACTG	TGGCCATTGC
	51	TGCTGCCTAC	AACAATGGCC	AAGAAATCAA	CGGTTTCAAA	GCTGGAGAGA
	101	CCATCTACGA	CATTGATGAA	GACGGCACAA	TTACCAAAAA	AGACGCAACT
	151	GCAGCCGATG	TTGAAGCCGA	CGACTTTAAA	GGTCTGGGTC	TGAAAAAAGT
	201	CGTGACTAAC	CTGACCAAAA	CCGTCAATGA	AAACAAACAA	AACGTCGATG
	251	CCAAAGTAAA	AGCTGCGAAA	TCTGAAATAG	AAAAGTTAAC	AACCAAGTTA
35	301	GCAGACACTG	ATGCCCGTTT	AGCAGATACT	GATGCCGCTC	TGGATGCAAC
	351	CACCAACGCC	TTGAATAAAT	TGGGAGAAAA	TATAACGACA	TTTGCTGAAG
	401	AGACTAAGAC	AAATATCGTA	AAAATTGATG	AAAAATTAGA	AGCCGTGGCT
	451	GATACCGTCG	ACAAGCATGC	CGAAGCATTC	AACGATATCG	CCGATTCAAT
	501	GGATGAAACC	AACACTAAGG	CAGACGAAGC	CGTCAAAACC	GCCAAATGAAG
40	551	CCAAACAGAC	GGCCGAAGAA	ACCAAACAAA	ACGTCGATGC	CAAAGTAAAA
	601	GCTGCAGAAA	CTGCAGCAGG	CAAAGCCGAA	GCTGCCGCTG	GCACAGCTAA
	651	TACTGCAGCC	GACAAGGCCG	AAGCTGTGCG	TGCAAAAGTT	ACCGACATCA
	701	AAGCTGATAT	CGCTACGAAC	AAAGATAATA	TTGCTAAAAA	AGCAAACAGT
	751	GCCGACGTGT	ACACCAGAGA	AGAGTCTGAC	AGCAAATTTG	TCAGAAATTGA
45	801	TGGTCTGAAC	GCTACTACCG	AAAAATTGGA	CACACGCTTG	GCTTCTGCTG
	851	AAAAATCCAT	TGCCGATCAC	GATACTCGCC	TGAACGGTTT	GGATAAAACA
	901	GTCTCAGACC	TGCGCAAAGA	AACCCGCCAA	GGCCTTGCAG	AACAAGCCGC
	951	GCTCTCCGGT	CTGTTCCAAC	CTTACAACGT	GGGTCGGTTC	AATGTAACGG
	1001	CTGCAGTCGG	CGGCTACAAA	TCCGAATCGG	CAGTCGCCAT	CGGTACCGGC
50	1051	TTCCGCTTTA	CCGAAAACCT	TGCCGCCAAA	GCAGGCGTGG	CAGTCGGCAC
	1101	TTTCGTCGGT	TCTTCCGCAG	CCTACCATGT	CGGCGTCAAT	TACGAGTGGG
	1151	GATCCGGAGG	AGGAGGATCA	GATTTGGCAA	ACGATTCTTT	TATCCGGCAG
	1201	GTTCCTCGACC	GTCAAGCATTT	CGAACCAGAC	GGGAAATACC	ACCTATTTCGG
	1251	CAGCAGGGGG	GAACCTGCGG	AGCGCAGCGG	CCATATCGGA	TTGGGAAAAA
55	1301	TACAAAGCCA	TCAGTTGGGC	AACCTGATGA	TTCAACAGGC	GGCCATTAAA
	1351	GGAAATATCG	GCTACATTGT	CCGCTTTTCC	GATCACGGGC	ACGAAGTCCA
	1401	TTCCCCCTTC	GACAACCATG	CCTCACATTTC	CGATTCTGAT	GAAGCCGGTA
	1451	GTCCCGTTGA	CGGATTTAGC	CTTTACCGCA	TCCATTGGGA	CGGATACGAA
	1501	CACCATCCCG	CCGACGGGTA	TGACGGGCCA	CAGGGCGGCG	GCTATCCCGC
60	1551	TCCCAAAGGC	GCGAGGGATA	TATACAGCTA	CGACATAAAA	GGCGTTGCCC
	1601	AAAATATCCG	CCTCAACCTG	ACCGACAACC	GCAGCACCAG	ACAACGGCTT
	1651	GCCGACCGTT	TCCACAATGC	CGGTAGTATG	CTGACGCAAG	GAGTAGGCGA
	1701	CGGATTCAAA	CGCGCCACCC	GATACAGCCC	CGAGCTGGAC	AGATCGGGCA
	1751	ATGCCGCCGA	AGCCTTCAAC	GGCACTGCAG	ATATCGTTAA	AAACATCATC
65	1801	GGCCGCGCAG	GAGAAATTGT	CGGCGCAGGC	GATGCCGTGC	AGGGCATAAG
	1851	CGAAGGCTCA	AACATTGCTG	TCATGCACGG	CTTGGGTCTG	CTTTCCACCG
	1901	AAAACAAGAT	GGCGCGCATC	AACGATTGTTG	CAGATATGGC	GCAACTCAAA

1951	GACTATGCCG	CAGCAGCCAT	CCGCGATTGG	GCAGTCCAAA	ACCCCAATGC
2001	CGCACAAGGC	ATAGAAGCCG	TCAGCAATAT	CTTTATGGCA	GCCATCCCCA
2051	TCAAAGGGAT	TGGAGCTGTT	CGGGGAAAT	ACGGCTTGGG	CGGCATCACG
2101	GCACATCCTA	TCAAGCGGTC	GCAGATGGGC	CGCATCGCAT	TGCCGAAAGG
2151	GAAATCCGCC	GTCAGCGACA	ATTTTGCCGA	TGCGGCATAC	GCCAAATACC
2201	CGTCCCCTTA	CCATTCCCGA	AATATCCGTT	CAAACCTGGA	GCAGCGTTAC
2251	GGCAAAGAAA	ACATCACCTC	CTCAACCGTG	CCGCCGTCAA	ACGGCAAAAA
2301	TGTCAAAC TG	GCAGACCAAC	GCCACCCGAA	GACAGGCGTA	CCGTTTGACG
2351	GTAAAGGGTT	TCCGAATTTT	GAGAAGCACG	TGAAATATGA	TACGCTCGAG
2401	CACCACCACC	ACCACCCTG	A		
1	MATNDDDVKK	AATVAIAAAY	NNGQEINGFK	AGETIYDIDE	DGTITKKDAT
51	AADVEADDFK	GLGLKKVVTN	LTKTVNENKQ	NVDAKVKAAB	SEIEKLTTKL
101	ADTDALADT	DAALDATNA	LNKLGENITT	FAEETKTNIV	KIDEKLEAVA
151	DTVDKHAEAF	NDIADSLDET	NTKADEAVKT	ANEAKQTAE	TKQNVDAKVK
201	AAETAAGKAE	AAAGTANTAA	DKAEAVAAKV	TDIKADIATN	KDNIANKANS
251	ADVVTREESD	SKFVRIDGLN	ATTEKLDTRL	ASAEKSIADH	DTRLNGLDKT
301	VSDLRKETRQ	GLAEQAALSG	LFQPYNVGRF	NVTAAVGGYK	SESAVAIGTG
351	FRFTENFAAK	AGVAVGTSSG	SSAAHYHGVN	YEWGSGGGGS	DLANDSFIRQ
401	VLDROHFEPD	GKYHLFGSRG	ELAERSGHIG	LGKIQSHQLG	NLMIQQAIAK
451	GNIGYIVRFS	DHGHEVHSPF	DNHASHSDSD	EAGSPVDGFS	LYRIHWDGYE
501	HHPADGYDGP	QGGGYPAKPG	ARDIYSYDIK	GVAQNIRLNL	TDNRSTGQRL
551	ADRFHNAGSM	LTQGVGDGFK	RATRYSPELD	RSGNAAEAFN	GTADIVKNII
601	GAAGEIVGAG	DAVQGISSEGS	NIAMVHGLGL	LSTENKMARI	NDLADMAQLK
651	DYAAAAIRDW	AVQNPNAAQG	IEAVSNIFMA	APIKIGIGAV	RGKYGLGGIT
701	AHPIKRSQMG	AIALPKGKSA	VSDNFADAAY	AKYPSPYHSR	NIRSNEQRY
751	GKENITSSTV	PPSNGKNVKL	ADQRHPKTGV	PFDGKGFPNF	EKHVKYDTLE
801	HHHHHH*				
961-741					
1	ATGGCCACAA	ACGACGACGA	TGTTAAAAAA	GCTGCCACTG	TGGCCATTGC
51	TGCTGCCTAC	AACAATGGCC	AAGAAATCAA	CGGTTTCAA	GCTGGAGAGA
101	CCATCTACGA	CATTGATGAA	GACGGCACAA	TTACCAAAAA	AGACGCAACT
151	CGAGCCGATG	TTGAAGCCGA	CGACTTTAAA	GGTCTGGGTC	TGAAAAAAGT
201	CGTGACTAAC	CTGACCAAAA	CCGTCAATGA	AAACAAACAA	AACGTCGATG
251	CCAAAGTAAA	AGCTGCAGAA	TCTGAAATAG	AAAAGTTAAC	AACCAAGTTA
301	GCAGACACTG	ATGCCGCTTT	AGCAGATACT	GATGCCGCTC	TGGATGCAAC
351	CACCAACGCC	TTGAATAAAT	TGGGAGAAAA	TATAACGACA	TTTGCTGAAG
401	AGACTAAGAC	AAATATCGTA	AAAATTGATG	AAAAATTAGA	AGCCGTGGCT
451	GATACCGTCG	ACAAGCATGC	CGAAGCATTG	AACGATATCG	CCGATTTCAT
501	GGATGAAACC	AACACTAAGG	CAGACGAAGC	CGTCAAAACC	GCCAATGAAG
551	CCAAACAGAC	GGCCGAAGAA	ACCAACAAAA	ACGTCGATGC	CAAAGTAAAA
601	GCTGCAGAAA	CTGCAGCAGG	CAAAGCCGAA	GCTGCCGCTG	GCACAGCTAA
651	TACTGCAGCC	GACAAGGCCG	AAGCTGTGCG	TGCAAAAGTT	ACCGACATCA
701	AAGCTGATAT	CGCTACGAAC	AAAGATAATA	TTGCTAAAAA	AGCAAACAGT
751	CGCGACGTGT	ACACCAGAGA	AGAGTCTGAC	AGCAAATTTG	TCAGAAATTGA
801	TGGCTCTGAAC	GCTACTACCG	AAAAATTGGA	CACACGCTTG	GCTTCTGCTG
851	AAAAATCCAT	TGCCGATCAC	GATACTCGCC	TGAACGGTTT	GGATAAAACA
901	GTGTCAAGAC	TGCGCAAAGA	AACCCGCCAA	GGCCTTGCG	AACAAGCCGC
951	GCTCTCCGGT	CTGTTCCAAC	CTTACAACGT	GGGTCGGTTC	AATGTAACGG
1001	CTGCAGTCGG	CGGCTACAAA	TCCGAATCGG	CAGTCGCCAT	CGGTACCGGC
1051	TTCCGCTTTA	CCGAAAAC TT	TGCCGCCAAA	GCAGGCGTGG	CAGTCGCCAC
1101	TTCCGTCGGT	TCTTCCGCAG	CCTACCATGT	CGGCGTCAAT	TACGAGTGGG
1151	GATCCGGAGG	GGGTGGTGTC	GCCGCCGACA	TCGGTGCGGG	GCTTGCCGAT
1201	GCAC TAACCG	CACCGCTCGA	CCATAAAGAC	AAAGGTTTGC	AGTCTTTGAC
1251	GCTGGATCAG	TCCGTCAGGA	AAAACGAGAA	ACTGAAGCTG	GCGGCACAAG
1301	GTGCGGAAAA	AAC TTATGGA	AACGGTGACA	GCCTCAATAC	GGGCAAA TTG
1351	AAGAACGACA	AGGTCAGCCG	TTTCGACTTT	ATCCGCCAAA	TCGAAGTTGA
1401	CGGGCAGCTC	ATTACCTTGG	AGAGTGGAGA	GTTCCAAGTA	TACAAACAAA
1451	GCCATTCCGC	CTTAACCGCC	TTTCAGACCG	AGCAAATACA	AGATTCCGAG
1501	CATTCCGGGA	AGATGGTTGC	GAAACGCCAG	TTCAAGATCG	GCGACATAGC
1551	GGGCGAACAT	ACATCTTTTG	ACAAGCTTCC	CGAAGCGGGC	AGGGCGACAT
1601	ATCCGCGGAC	GGCGTTCCGT	TCAGACGATG	CCGGCGGAAA	ACTGACCTAC
1651	ACCATAGATT	TCGCCGCCAA	GCAGGGAAAC	GGCAAAATCG	AACATTTGAA
1701	ATCGCCAGAA	CTCAATGTCG	ACCTGGCCGC	CGCCGATATC	AAGCCGGATG
1751	GAAAACGCCA	TGCCGTCATC	AGCGGTTCCG	TCCTTTACAA	CCAAGCCGAG
1801	AAAGGCAGTT	ACTCCCTCGG	TATCTTTGGC	GGAAAAGCCC	AGGAAGTTGC

-68-

1851 CCGCAGCGCG GAAGTGAAAA CCGTAAACGG CATACGCCAT ATCGGCCTTG
 1901 CCGCCAAGCA ACTCGAGCAC CACCACCACC ACCACTGA

5 1 MATNDDDVKK AATVAIAAAY NNGQEINGFK AGETIYDIDE DGTITKKDAT
 51 AADVEADDFK GLGLKKVVTN LTKTVNENKQ NVDAKVKAAB SEIEKLTTKL
 101 ADTDAALADT DAALDATTNA LNKLGENTTT FAEETKTNIV KIDEKLEAVA
 151 DTVDKHAEAF NDIADSLDET NTKADEAVKT ANEAKQTAE TKQNVDAKVK
 201 AAETAAGKAE AAAGTANTAA DKAEAVAANKV TDIKADIATN KDNIACKANS
 251 ADVYTREESD SKFVRIDGLN ATTEKLDTRL ASAEKSIADH DTRLNGLDKT
 10 301 VSDLRKETRO GLAEQAALSG LFQPYNVGRF NVTAAVGGYK SESAVAIGTG
 351 FRFTENFAAK AGVAVGTSSG SSAAYHVGVN YEWGSGGGGV AADIGAGLAD
 401 ALTAPLDHKD KGLQSLTLDQ SVRKNEKLKL AAQGAERTYG NGDSLNTGKL
 451 KNDKVSRLFDF IRQIEVDGQL ITLESGEFQV YKQSHSALTA FQTEQIQDSE
 501 HSGKMVAKRQ FRIGDIAGEH TSFDKLPPEG RATYRGTAFG SDDAGGKLTy
 15 551 TIDFAAKQGN GKIEHLKSPE LNVDLAAADI KPDGKRHAVI SGSVLYNQAE
 601 KGSYSLGIFG GKAEVAGSA EVKTVNGIRH IGLAAKQLEH HHHHH*

961-983

20 1 ATGGCCACAA ACGACGACGA TGTAAAAA GCTGCCACTG TGGCCATTGC
 51 TGCTGCCTAC AACATGGGCC AAGAAATCAA CGGTTTCAAA GCTGGAGAGA
 101 CCATCTACGA CATTGATGAA GACGCACAAA TTACCAAAAA AGACGCAACT
 151 GCAGCCGATG TTGAAGCCGA CGACTTTAAA GGTCTGGGTC TGAAAAAGT
 201 CGTGACTAAC CTGACCAAAA CCGTCAATGA AAACAAACAA AACGTCGATG
 25 251 CCAAAGTAAA AGCTGCAGAA TCTGAAATAG AAAAGTTAAC AACCAAGTTA
 301 GCAGACACTG ATGCCGCTTT AGCAGATACT GATGCCGCTC TGGATGCAAC
 351 CACCAACGCC TTGAATAAAT TGGGAGAAAA TATAACGACA TTTGCTGAAG
 401 AGACTAAGAC AAATATCGTA AAAATGTATG AAAAATTAGA AGCCGTGGCT
 451 GATACCGTCG ACAAGCATGC CGAAGCATTG AACGATATCG CCGATTCAAT
 30 501 GGATGAAACC AACACTAAGG CAGACGAAGC CGTCAAAACC GCCAATGAAG
 551 CCAAACAGAC GGCCGAAGAA ACCAAACAAA ACGTCGATGC CAAAGTAAAA
 601 GCTGCAGAAA CTGCAGCAGG CAAAGCCGAA GCTGCCGCTG GCACAGCTAA
 651 TACTGCAGCC GACAAGCCG AAGCTGTTCG TGCAAAAGTT ACCGACATAC
 701 AAGCTGATAT CGCTACGAAC AAAGATAATA TTGCTAAAAA AGCAAAACAGT
 35 751 GCCGACGTGT ACACCAGAGA AGAGTCTGAC AGCAAATTTG TCAGAATTGA
 801 TGGTCTGAAC GCTACTACCG AAAAATTGGA CACACGCTTG GCTTCTGCTG
 851 AAAAATCCAT TGCCGATCAC GATACTCGCC TGAACGGTTT GGATAAAACA
 901 GTGTCAGACC TGCGCAAAGA AACC CGCCAA GGCTTTCAG AACAAAGCCG
 951 GCTCTCCGGT CTGTTCCAAC CTTACAACGT GGGTCGGTTC AATGTAACGG
 40 1001 CTGCAGTCGG CGGCTACAAA TCCGAATCGG CAGTCGCCAT CGGTACCGGC
 1051 TTCCGCTTTA CCGAAACTTT TGCCGCCAAA GCAGGCGTGG CAGTCGGCAC
 1101 TTCTCCGGT TCTTCCGCG CTTACCATGT CGGCGTCAAT TACGAGTGGG
 1151 GATCCGGCGG AGGCGGCACT TCTGCGCCCG ACTTCAATGC AGGCGGTACC
 45 1201 GTATTCGGCA GCAACAGACG AGCAACAACA GCGAAATCAG CAGCAGTATG
 1251 TTAGCCCGGT ATCAAGAACG AAATGTGCAA AGACAGAAGC ATGCTCTGTG
 1301 CCGGTTCGGA TGACGTTGCG GTTACAGACA GGGATGCCAA AATCAATGCC
 1351 CCCCCCGA ATCTGCATAC CGGAGACTTT CCAAACCCAA ATGACGCATA
 1401 CAAGAATTTG ATCAACCTCA AACCTGCAAT TGAAGCAGGC TATACAGGAC
 1451 GCGGGGTAGA GGTAGGTATC GTCGACACAG GCGAATCCGT CGGCAGCATA
 50 1501 TCCTTTCCCG AACTGTATGG CAGAAAAGAA CACGGCTATA ACGAAAATTA
 1551 CAAAAACTAT ACGGCGTATA TGCGGAAGGA AGCGCCTGAA GACGGAGGCG
 1601 GTAAAGACAT TGAAGCTTCT TTCGACGATG AGGCCGTTAT AGAGACTGAA
 1651 GCAAAGCCGA CGGATATCCG CCACGTAAAA GAAATCGGAC ACATCGATTT
 1701 GGTCTCCCAT ATTATTGGCG GGCCTTCCGT GGACGGCAGA CCTGCAAGCG
 55 1751 GTATTCGGCC CGATGCGACG CTACACATAA TGAATACGAA TGATGAAACC
 1801 AAGAACGAAA TGATGTTTGC AGCCATCCGC AATGCATGGG TCAAGCTGGG
 1851 CGAACGTGGC GTGCGCATCG TCAATAACAG TTTTGGAAAC ACATCGAGGG
 1901 CAGGCACTGC CGACCTTTTC CAAATAGCCA ATTCGGAGGA GCAGTACCGC
 1951 CAAGCGTTGC TCGACTATTG CGGCGGTGAT AAAACAGACG AGGGTATCCG
 60 2001 CCTGATGCAA CAGAGCGATT ACGGCAACCT GTCCCTACCAC ATCCGTAATA
 2051 AAAACATGCT TTTTCATCTT TCGACAGGCA ATGACGCACA AGCTCAGCCC
 2101 AACACATATG CCTATTGCC ATTTTATGAA AAAGACGCTC AAAAAGGCAT
 2151 TATCACAGTC GCAGGCGTAG ACCGCACTGG AGAAAAGTTC AAACGGGAAA
 2201 TGTATGGAGA ACCGGGTACA GAACCGCTTG AGTATGGCTC CAACCATTCG
 65 2251 GGAATTACTG CCATGTGTG CCTGTCCGCA CCTATGAAG CAAGCGTCCG
 2301 TTTACCCCGT ACAAACCCGA TTCAAATTGC CGGAACATCC TTTTCCGCAC
 2351 CCATCGTAAC CGGCACGGCG GCTCTGCTGC TGCAGAAATA CCCGTGGATG

	2401	AGCAACGACA	ACCTGCGTAC	CACGTTGCTG	ACGACGGCTC	AGGACATCGG
	2451	TGCAGTCGGC	GTGGACAGCA	AGTTCGGCTG	GGGACTGCTG	GATGCGGGTA
	2501	AGGCCATGAA	CGGACCCGCG	TCCTTTCCGT	TCGGCGACTT	TACCGCCGAT
5	2551	ACGAAAGGTA	CATCCGATAT	TGCTACTTCC	TTCCGTAACG	ACATTTACAG
	2601	CACGGGCGGC	CTGATCAAAA	AAGGCGGCAG	CCAACTGCAA	CTGCACGGCA
	2651	ACAACACCTA	TACGGGCAAA	ACCATTATCG	AAGGCGGTTT	GCTGGTGTG
	2701	TACGGCAACA	ACAAATCGGA	TATGCGCGTC	GAAACCAAAG	GTGCGCTGAT
	2751	TTATAACGGG	GCGGCATCCG	GCGGCAGCCT	GAACAGCGAC	GGCATGTGCT
10	2801	ATCTGGCAGA	TACCGACCAA	TCCGGCGCAA	ACGAAACCGT	ACACATCAAA
	2851	GGCAGTCTGC	AGCTGGACGG	CAAAGGTACG	CTGTACACAC	GTTTGGGCAA
	2901	ACTGCTGAAA	GTGGACGGTA	CGGCGATTAT	CGGCGGCAAG	CTGTACATGT
	2951	CGGCACGCGG	CAAGGGGGCA	GGCTATCTCA	ACAGTACCGG	ACGACGTGTT
	3001	CCCTTCCTGA	GTGCCGCCAA	AATCGGGCAG	GATTATTTCTT	TCTTCACAAA
	3051	CATCGAAACC	GACGGCGGCC	TGCTGGCTTC	CCTCGACAGC	GTGAAAAAAA
15	3101	CAGCGGGCAG	TGAAGGCGAC	ACGCTGTCCCT	ATTATGTCCG	TCGCGGCAAT
	3151	GCGGCACGGA	CTGCTTCGGC	AGCGGCACAT	TCCGCGCCCG	CCGGTCTGAA
	3201	ACACGCCGTA	GAACAGGGCG	GCAGCAATCT	GGAAAACCTG	ATGGTCGAAC
	3251	TGATGCGCTC	CGAATCATCC	GCAACACCCG	AGACGGTTGA	AACTGCGGCA
20	3301	GCCGACCGCA	CAGATATGCC	GGGCATCCGC	CCCTACGGCG	CAACTTTCCG
	3351	CGCAGCGGCA	GCCGTACAGC	ATGCGAATGC	CGCCGACGGT	GTACGCATCT
	3401	TCAACAGTCT	CGCCGCTACC	GTCTATGCCG	ACAGTACCGC	CGCCCATGCC
	3451	GATATGCAGG	GACGCCGCTT	GAAAGCCGTA	TCGGACGGGT	TGGACCACAA
	3501	CGGCACGGGT	CTGCGCGTCA	TCGCGCAAAAC	CCAACAGGAC	GGTGGAACTG
25	3551	GGGAACAGGG	CGGTGTTGAA	GGCAAAATGC	GCGGCAGTAC	CCAAACCGTC
	3601	GGCATTGCCG	CGAAAACCGG	CGAAAATACG	ACAGCAGCCG	CCACACTGGG
	3651	CATGGGACGC	AGCACATGGA	GCGAAAACAG	TGCAAATGCA	AAAACCGACA
	3701	GCATTAGTCT	GTTTGCAGGC	ATACGGCACG	ATGCGGGCGA	TATCGGCTAT
	3751	CTCAAAGGCC	TGTTCTCCTA	CGGACGCTAC	AAAAACAGCA	TCAGCCGCAG
30	3801	CACCGGTGCG	GACGAACATG	CGGAAGGCAG	CGTCAACCGC	ACGCTGATGC
	3851	AGCTGGGCGC	ACTGGGCGGT	GTCAACGTTT	CGTTTGCCGC	AACGGGAGAT
	3901	TTGACGGTCG	AAGGCGGTCT	GCGCTACGAC	CTGCTCAAAC	AGGATGCATT
	3951	CGCCGAAAAA	GGCAGTGCTT	TGGGCTGGAG	CGGCAACAGC	CTCACTGAAG
	4001	GCACGCTGGT	CGGACTCGCG	GGTCTGAAGC	TGTCGCAACC	CTTGAGCGAT
35	4051	AAAGCCGTCC	TGTTTGCAC	GGCGGGCGTG	GAACGCGACC	TGAACGGACG
	4101	CGACTACACG	GTAACGGCGG	GCTTTACCGG	CGCGACTGCA	GCAACCGGCA
	4151	AGACGGGGGC	ACGCAATATG	CCGCACACCC	GTCTGGTTGC	CGGCCTGGGC
	4201	GCGATGTTCG	AATTCGGCAA	CGGCTGGAAC	GGCTTGGCAC	GTTACAGCTA
	4251	CGCCGTTTCC	AAACAGTACG	GCAACCACAG	CGGACGAGTC	GGCGTAGGCT
40	4301	ACCGGTTTCT	CGAGCACCAC	CACCACCACC	ACTGA	
	1	MATNDDVVK	AATVAIAAAY	NNGQEINGFK	AGETIYDIDE	DGTITKKDAT
	51	AADVEADDFK	GLGLKKVVTN	LTKTVNENKQ	NVDAKVKAAB	SEIEKLTKL
	101	ADTDAALADT	DAALDATNA	LNKLGENTIT	FAEETKTNIV	KIDEKLEAVA
45	151	DTVDKHAEAF	NDIADSLDET	NTKADEAVKT	ANEAKQTABE	TKQNVDAKVK
	201	AAETAAGKAE	AAAGTANTAA	DKAEAVAAKV	TDIKADIATN	KDNIARKANS
	251	ADVTREESD	SKFVRIDLIN	ATTEKLDTRL	ASAEKSIADH	DTRLNLGDKT
	301	VSDLRKETRQ	GLAEQAALSG	LFQPVNVGRF	NVTAAVGGYK	SESAVAIGTG
	351	FRFTENFAAK	AGVAVGTSSG	SSAAYHGVVN	YEWGSGGGGT	SAPDFNAGGT
50	401	GIGSNSRATT	AKSAAVSYAG	IKNEMCKDRS	MLCAGRDDVA	VTDRDAKINA
	451	PPPNLHTGDF	PNPNDAYKNL	INLKPAIEAG	YTGRGVEVGI	VDTGESVSGI
	501	SFPELYGRKE	HGYNENYKNY	TAYMRKEAPE	DGGGKDIEAS	FDDEAVIETE
	551	AKPTDIRHVK	EIGHIDLVS	IIGGRSVDGR	PAGGIAPDAT	LHIMNTNDET
	601	KNEMMVAAIR	NAWVKLGERG	VRIVNNSFGT	TSRAGTADLF	QIANSEQYR
55	651	QALLDYSGGD	KTDEGIRLMQ	QSDYGNLSYH	IRNKNMLFIF	STGNDQAQOP
	701	NTYALLPFYE	KDAQKGITTV	AGVDRSGEKF	KREMYGEPGT	EPLEYGSNHC
	751	GITAMWCLSA	PYEASVRPTR	TNPIQIAGTS	FSAPIVTGTA	ALLLQKYPWM
	801	SNDNLRTTLL	TTAQDIGAVG	VDSKFGWGLL	DAGKAMNGPA	SFPFGDPTAD
	851	TKGTSDIAYS	FRNDISGTGG	LIKKGGSQLO	LHGNNYTYGK	TIIEGGSVLV
60	901	YGNKSDMRV	ETKGALIYNG	AASGGSLSND	GIVYLADTDQ	SGANETVHIK
	951	GSLQLDGKGT	LYTRLGKLLK	VDGTAIIGGK	LYMSARGKGA	GYLNSTGRRV
	1001	PFLSAAKIGQ	DYSFFTNIET	DGGLLASLDS	VEKTAGSEGD	TLSYVVRGN
	1051	AARTASAAAH	SAPAGLKHAV	EQGGSNLNL	MVELDASESS	ATPETVETAA
	1101	ADRTDMPGIR	PYGATFRAAA	AVQHANAADG	VRIFNSLAAT	VYADSTAHA
	1151	DMQGRRLKAV	SDGLDHNGTG	LRVIAQTQOD	GGTWEQGGVE	GKMRGSTQTV
65	1201	GIAKTGENT	TAAATLGMGR	STWSSENSANA	KTDSSISLFA	IRHDAGDIGY
	1251	LKGLFSYGRY	KNSISRSTGA	DEHAEBSVNG	TLMQLGALGG	VNVPFAATGD
	1301	LTVEGGLRYD	LLKQDAFAEK	GSALGWSGNS	LTEGTLVGLA	GLKLSQPLSD

1351 KAVLFATAGV ERDLNGRDYT VTGGFTGATA ATGKTGARNM PHTRLVAGLG
1401 ADVEFGNGWN GLARYSYAGS KQYGNHSGRV GVGYRFLEHH HHHH*

5

961c-ORF46.1

10

15

20

25

30

35

40

45

50

55

60

65

1 ATGGCCACAA ACCAGCACGA TGTTAAAAA GCTGCCACTG TGGCCATTGC
51 TGCTGCCTAC AACAAATGGCC AAGAAATCAA CGGTTTCAA GCTGGAGAGA
101 CCATCTACGA CATTGATGAA GACGGCACAA TTACCAAAAA AGACGCAACT
151 GCAGCCGATG TTGAAGCCGA CGACTTTAAA GGTCTGGGTC TGAAAAAAGT
201 CGTGACTAAC CTGACCAAAA CCGTCAATGA AAACAAACAA AACGTCGATG
251 CCAAAGTAAA AGCTGCAGAA TCTGAAATAG AAAAGTTAAC AACCAAGTTA
301 GCAGACACTG ATGCCGCTTT AGCAGATACT GATGCCGCTC TGGATGCAAC
351 CACCAACGCC TTGAATAAAT TGGGAGAAAA TATAACGACA TTTGCTGAAG
401 AGACTAAGAC AAATATCGTA AAAATTGATG AAAAATTAGA AGCCGTGGCT
451 GATACCGTCG ACAAGCATGC CGAAGCATTC AACGATATCG CCGATTTCATT
501 GGATGAAACC AACACTAAGG CAGACGAAGC CGTCAAAACC GCCAATGAAG
551 CCAAACAGAC GGCCGAAGAA ACCAAACAAA ACGTCGATGC CAAAGTAAAA
601 GCTGCAGAAA CTGCAGCAGG CAAAGCCGAA GCTGCCGCTG GCACAGCTAA
651 TACTGCAGCC GACAAGGCCG AAGCTGTGCG TGCAAAAGTT ACCGACATCA
701 AAGCTGATAT CGCTACGAAC AAAGATAATA TTGCTAAAAA AGCAAACAGT
751 GCCGACGTGT ACACCAGAGA AGAGTCTGAC AGCAAATTTG TCAGAAATGA
801 TGGTCTGAAC GCTACTACCG AAAAATTGGA CACACGCTTG GCTTCTGCTG
851 AAAAAATCCAT TGCCGATCAC GATACTCGCC TGAACGGTTT GGATAAAACA
901 GTGTCAGACC TGCGCAAAGA AACC CGCCAA GGCCTTGCG AGCAAGCCGC
951 GCTCTCCGGT CTGTTCCAAC CTTACAACGT GGGTGGATCC GGAGGAGGAG
1001 GATCAGATTT GGCAAACGAT TCTTTTATCC GGCAGGTTCT CGACCGTCAG
1051 CATTTGGAAC CCGACGGGAA ATACCACCTA TTCGGCAGCA GGGGGGAACT
1101 TGCCGAGCGC AGCGGCCATA TCGGATTGGG AAAAATACAA AGCCATCAGT
1151 TGGGCAACCT GATGATTCAA CAGGCGGCCA TTAAGGAAA TATCGGCTAC
1201 ATTGTCGCTT TTTCCGATCA CGGGCACGAA GTCCATTCCC CTTTCGACAA
1251 CCATGCCTCA CATTCGGATT CTGATGAAGC CGGTAGTCCC GTTGACCGAT
1301 TTAGCCTTTA CCGCATCCAT TGGGACGGAT ACGAACACCA TCCCGCCGAC
1351 GGCTATGACG GGCCACAGGG CGGCGGCTAT CCCGCTCCCA AAGGCGCGAG
1401 GGATATATAC AGCTACGACA TAAAAGGCGT TGCCCAAAAT ATCCGCTCA
1451 ACCTGACCGA CAACCGCAGC ACCGGACAAC GGCTTGCCGA CCGTTTCCAC
1501 AATGCCGGTA GTATGCTGAC GCAAGGAGTA GCGACGGAT TCAAACGGCG
1551 CACCCGATAC AGCCCCGAGC TGGACAGATC GGGCAATGCC GCCGAAGCCT
1601 TCAACGGCAC TGCAGATATC GTTAAAAACA TCATCGGCGC GGCAGGAGAA
1651 ATGTGCGCGC CAGGCGATGC CGTGCAGGCG ATAAGCGAAG GCTCAAACAT
1701 TGCTGTCATG CACGGCTTGG GTCTGCTTTC CACCGAAAAC AAGATGGCGC
1751 GCATCAACGA TTTGGCAGAT ATGGCGCAAC TCAAAGACTA TGCCGAGCA
1801 GCCATCCGCG ATTGGGCAGT CCAAAACCCC AATGCCGCAC AAGGCATAGA
1851 AGCCGTCAGC AATATCTTTA TGGCAGCCAT CCCCATCAA GGGATTGGAG
1901 CTGTTCCGGG AAAATACGGC TTGGGCGGCA TCACGGCACA TCCTATCAAG
1951 CCGTCGAGA TGGGCGCGAT CGCATTGCCG AAAGGGAAAT CCGCCGTCAG
2001 CGACAATTTT GCCGATGCGG CATACGCCAA ATACCCGTCC CCTTACCATT
2051 CCCGAAATAT CCGTTCAAAC TTGGAGCAGC GTTACGGCAA AGAAAACATC
2101 ACCTCCTCAA CCGTGCCGCC GTCAAACGGC AAAAATGTCA AACTGGCAGA
2151 CCAACGCCAC CCGAAGACAG GCGTACCGTT TGACGGTAAA GGGTTTCCGA
2201 ATTTTGAGAA GCACGTGAAA TATGATACGC TCGAGCACCA CCACCACCAC
2251 CACTGA

1 MATNDDVVK AATVAIAAAY NNGQEBINGFK AGETIYDIDE DGTITKKDAT
51 AADVEADDFK GLGLKVVVN LTKTVNENKQ NVDKVKAAE SEIEKLPTKL
101 ADTDAALADT DAALDATNA LNKLGENTIT FAETKTNTIV KIDEKLEAVA
151 DTVDKHAFAF NDIADSLDET NTKADEAVKT ANEAKQTAEE TKQNVDAKVK
201 AAETAAGKAE AAAGTANTAA DKAEVAVAKV TDIKADIATN KDNIKKANS
251 ADVYTREESD SKFVRIDGLN ATTEKLDTRL ASAEKSIADH DTRLNGLDKT
301 VSDLRKETRQ GLAEQAALSG LFQPYNVGGS GGGGSDLAND SFIRQVLDRO
351 HFEPDGKYHL FGSRGELAER SHIGLGKIQ SHQLGNLMIQ QAAIKGNIGY
401 IYRFSHDGHE VHSPFDNHAS HSDSDEAGSP VDGFSLYRIH WDGYEHHPAD
451 GVDLPQGGYV PAPKGARDIY SYDIKGVAQN IRLNLTNRS TGQRLADRFH
501 NAGSMLTQGV GDGPKRATRY SPELDRSGNA AEAFNGTADI VKNIIGAAGE
551 IVGAGDAVQG ISEGSNIAMV HGLGLLSTEN KMARINDLAD MAQLKDYAAA
601 AIRDWAVQNP NAAQIEAVS NIFMAAPIK GIGAVRGKYG LGGITAHPIK
651 RSQMGALALP KGKSAVSDNF ADAAYAKYPS PYHSRNIRSN LBQRYGKENI
701 TSSTVPPSNG KNVKLADQRH PKTGVFPDGK GFPNFEKHVK YDTLEHHHHH

-71-

751 H*

961c-741

5 1 ATGGCCACAA ACGACGACGA TGT TAAAAA GCTGCCACTG TGGCCATTGC
51 TGCTGCCTAC AACAAATGGCC AAGAAATCAA CGGTTTCAA GCTGGAGAGA
101 CCATCTACGA CATTGATGAA GACGGCACAA TTACCAAAAA AGACGCAACT
151 GCAGCCGATG TTGAAGCCGA CGACTTTAAA GGTCTGGGTC TGAAAAAAGT
201 CGTGACTAAC CTGACCAAAA CCGTCAATGA AAACAAACAA AACGTCGATG
10 251 CCAAAGTAAA AGCTGCAGAA TCTGAAATAG AAAAGTTAAC AACCAAGTTA
301 GCAGACACTG ATGCCGCTTT AGCAGATACT GATGCCGCTC TGGATGCAAC
351 CACCAACGCC TTGAATAAAT TGGGAGAAAA TATAACGACA TTTGCTGAAG
401 AGACTAAGAC AAATATCGTA AAAATTGATG AAAAATTAGA AGCCGTGGCT
451 GATACCGTCG ACAAGCATGC CGAAGCATTC AACGATATCG CCGATTCAAT
15 501 GGATGAAACC AACACTAAGG CAGACGAAGC CGTCAAAACC GCCAATGAAG
551 CCAAACAGAC GGCCGAAGAA ACCAAACAAA ACGTCGATGC CAAAGTAAAA
601 GCTGCAGAAA CTGCAGCAGG CAAAGCCGAA GCTGCCGCTG GCACAGCTAA
651 TACTGCAGCC GACAAGGCCG AAGCTGTCGC TGC AAAAGTT ACCGACATCA
701 AAGCTGATAT CGCTACGAAC AAAGATAATA TTGCTAAAA AGCAAACAGT
20 751 GCCGACGTGT ACACCAGAGA AGAGTCTGAC AGCAAATTTG TCAGAATTGA
801 TGGTCTGAAC GCTACTACCG AAAAATTGGA CACACGCTTG GCTTCTGCTG
851 AAAAATCCAT TGCCGATCAC GATACTCGCC TGAACGGTTT GGATAAAACA
901 GTGTCAGACC TGCGCAAAGA AACCCGCCAA GGCTTGCAG AACAGCCGC
951 GCTCTCCGCT CTGTTCCAAC CTTACAACGT GGGTGGATCC GGAGGGGGTG
25 1001 GTGTCGCCGC CGACATCGGT GCGGGGCTTG CCGATGCACT AACCGCACCG
1051 CTCGACCATA AAGACAAAGG TTTGCAGTCT TTGACGCTGG ATCAGTCCGT
1101 CAGGAAAAAC GAGAACTGA AGCTGGCGGC ACAAGGTGCG GAAAAAATTT
1151 ATGGAAACGG TGACAGCCTC AATACGGGCA AATTGAAGAA CGACAAGGTC
1201 AGCCGTTTCG ACTTTATCCG CCAATTCGAA GTGGACGGGC AGCTCATTA
30 1251 CTTGGAGAGT GGAGAGTTCC AAGTATACAA ACAAGCCAT TCCGCCTTAA
1301 CCGCCTTTCA GACCGAGCAA ATACAAGATT CCGAGCATTC CCGGAAGATG
1351 GTTGCGAAC GCCAGTTCAG AATCGGCGAC ATAGCGGGCG AACATACATC
1401 TTTTGACAAG CTTCCCGAAG GCGGCAGGGC GACATATCGC GGGACGGCGT
1451 TCGGTTTCTAGA CGATGCCGGC GGAAACTGA CCTACACCAT AGATTTTCGCC
35 1501 GCCAAGCAGG GAAACGGCAA AATCGAACAT TTGAAATCGC CAGAACTCAA
1551 TGTCGACCTG GCCGCCCGC ATATCAAGCC GGATGGAAA CGCCATGCCG
1601 TCATCAGCGG TTCCGTCTTT TACAACCAAG CCGAGAAAGG CAGTTACTCC
1651 CTCGGTATCT TTGGCGGAAA AGCCCAGGAA GTTGCCGGCA GCGCGGAAGT
1701 GAAAACCGTA AACGGCATAC GCCATATCGG CCTTGCCGCC AAGCAACTCG
40 1751 AGCACCACCA CCACCACCAC TGA

1 MATNDDVKK AATVAIAAAY NNGQEINGFK AGETIYDIDE DGTITKKDAT
51 AADVEADDFK GLGLKKVVTN LTKTVNENKQ NVDAKVAAE SEIEKLTTKL
101 ADTDAALADT DAALDATNA LNKLGENTIT FAETKTNIV KIDEKLEAVA
45 151 DTVDKHAFAF NDIADSLDET NTKADEAVKT ANEAKQTAE TRQNVDAKVK
201 AAETAAGKAE AAAGTANTAA DKAEVAIAKV TDIKADIATN KDNIAKKANS
251 ADVYTREESD SKFVRIDGLN ATTEKLDTRL ASAEKSIADH DTRLNGLDKT
301 VSDLRKETRQ GLAEQAALSG LFQPNVGGG GGGGVAADIG AGLADALTAP
50 351 LDHKDKGLQS LTLDQSVRKN EKLKLAQGA EPTYGNGLSL NTGKLKNDKV
401 SRFDFIRQIE VDGQLITLES GEFQVYKQSH SALTAFTQTE IQDSEHSGKM
451 VAKRQFRIGD IAGEHTSFDK LPEGGRATYR GTAFGSDDAG GKLTYTIDFA
501 AKQNGKIEH LKSPELNVDL AAADIKPDGK RHAVISGSVL YNQAERKSYS
551 LGIFGGKAQE VAGSAEVRTV NGIRHIGLAA KQLEHHHHHH *

55

961c-983

1 ATGGCCACAA ACGACGACGA TGT TAAAAA GCTGCCACTG TGGCCATTGC
51 TGCTGCCTAC AACAAATGGCC AAGAAATCAA CGGTTTCAA GCTGGAGAGA
60 101 CCATCTACGA CATTGATGAA GACGGCACAA TTACCAAAAA AGACGCAACT
151 GCAGCCGATG TTGAAGCCGA CGACTTTAAA GGTCTGGGTC TGAAAAAAGT
201 CGTGACTAAC CTGACCAAAA CCGTCAATGA AAACAAACAA AACGTCGATG
251 CCAAAGTAAA AGCTGCAGAA TCTGAAATAG AAAAGTTAAC AACCAAGTTA
301 GCAGACACTG ATGCCGCTTT AGCAGATACT GATGCCGCTC TGGATGCAAC
351 CACCAACGCC TTGAATAAAT TGGGAGAAAA TATAACGACA TTTGCTGAAG
65 401 AGACTAAGAC AAATATCGTA AAAATTGATG AAAAATTAGA AGCCGTGGCT
451 GATACCGTCG ACAAGCATGC CGAAGCATTC AACGATATCG CCGATTCAAT
501 GGATGAAACC AACACTAAGG CAGACGAAGC CGTCAAAACC GCCAATGAAG

551 CCAAACAGAC GGCCGAAGAA ACCAAACAAA ACGTCGATGC CAAAGTAAAA
 601 GCTGCAGAAA CTGCAGCAGG CAAAGCCGAA GCTGCCGCTG GCACAGCTAA
 651 TACTGCAGCC GACAAGGCCG AAGCTGTCTG TGCAAAAGTT ACCGACATCA
 701 AAGCTGATAT CGCTACGAAC AAAGATAATA TTGCTAAAAA AGCAAACAGT
 751 GCCGACGTGT ACACCAGAGA AGAGTCTGAC AGCAAAATTG TCAGAATTGA
 801 TGGTCTGAAC GCTACTACCG AAAAATTGGA CACACGCTTG GCTTCTGCTG
 851 AAAAATCCAT TGCCGATCAC GATACTCGCC TGAACGGTTT GGATAAAACA
 901 GTGTCAGACC TGCACAAAGA AACC CGCCAA GGCCTTGAG AACAGCCGC
 951 GCTCTCCGGT CTGTTCCAAC CTTACAACGT GGGTGGATCC GGCGGAGGCG
 1001 GCACTTCTGC GCCCCACTTC AATGCAGGCG GTACCGGTAT CGGCAGCAAC
 1051 AGCAGAGCAA CAACAGCGAA ATCAGCAGCA GTATCTTACG CCGGTATCAA
 1101 GAACGAAATG TGCAAAGACA GAAGCATGCT CTGTGCCGGT CGGGATGACG
 1151 TTGCCGTTAC AGACAGGGAT GCCAAATCA ATGCCCCCCC CCCGAATCTG
 1201 CATACCGGAG ACTTTCCAAA CCCAAATGAC GCATACAAGA ATTTGATCAA
 1251 CCTCAAACCT GCAATTGAAG CAGGTATAC AGGACCGCGG GTAGAGGTAG
 1301 GTATCGTCGA CACAGGCGAA TCCGTCCGCA GCATATCCTT TCCCGAAGT
 1351 TATGGCAGAA AAGAACACGG CTATAACGAA AATTACAAA ACTATACGGC
 1401 GTATATGCGG AAGGAAGCGC CTGAAGACGG AGGCGGTAAA GACATTGAAG
 1451 CTTCTTTTGA CGATGAGGCC GTTATAGAGA CTGAAGCAA GCCGACGGAT
 1501 ATCCGCCACG TAAAGAAAT CGGACACATC GATTTGGTCT CCCATATTAT
 1551 TGGCGGGCGT TCCGTGGACG GCAGACCTGC AGGCGGTATT GCGCCCGATG
 1601 CGACGCTACA CATAATGAAT ACGAATGATG AAACCAAGAA CGAAATGATG
 1651 GTTGCAGCCA TCCGCAATGC ATGGGTCAAG CTGGGCGAAC GTGGCGTGCG
 1701 CATTGCTCAAT AACAGTTTGT GAACAACATC GAGGGCAGGC ACTGCCGACC
 1751 TTTTCCAAAT AGCCAATTCT GAGGAGCAGT ACCGCCAAGC GTTGCTCGAC
 1801 TATTCCGGCG GTGATAAAAC AGACGAGGGT ATCCGCCTGA TGCAACAGAG
 1851 CGATTACGGC AACCTGTCTT ACCACATCCG TAATAAAAAC ATGCTTTTCA
 1901 TCTTTTTCGAC AGGCAATGAC GCACAAGCTC AGCCCAACAC ATATGCCCTA
 1951 TTGCCATTTT ATGAAAAGA CGTCAAAAA GGCAATTATCA CAGTCGCGAG
 2001 CGTAGACCGC AGTGGAGAAA AGTTCAAACG GGAAATGTAT GGAGAACCGG
 2051 GTACAGAACC GCTTGAGTAT GGCTCCAACC ATTGCGGAAT TACTGCCATG
 2101 TGGTGCCTGT CGGCACCCTA TGAAGCAAGC GTCCGTTTCA CCCGTACAAA
 2151 CCCGATTCAA ATTGCCGGA CATCCTTTTC CGCACCCATC GTAACCGGCA
 2201 CGGCGGCTCT GCTGCTGCAG AAATACCCGT GGATGAGCAA CGACAACCTG
 2251 CGTACCACGT TGCTGACGAC GGCTCAGGAC ATCGGTGCAG TCGGCGTGGA
 2301 CAGCAAGTTC GGCTGGGGAC TGCTGGATGC GGGTAAGGCC ATGAACGGAC
 2351 CCGCGTCTTT TCCGTTCGGC GACTTTACCG CCGATACGAA AGGTACATCC
 2401 GATATTGCCT ACTCCTTCCG TAACGACATT TCAGGACCGG GCGGCCTGAT
 2451 CAAAAAAGGC GGCAGCCAAC TGCAACTGCA CGGCAACAAC ACCTATACGG
 2501 GCAAAACCAT TATCGAAGGC GGTTCGTGCG GTTTGTACGG CAACAACAAA
 2551 TCGGATATGC GCGTCGAAAC CAAAGGTGCG CTGATTTATA ACGGGGCGGC
 2601 ATCCGGCGGC AGCCTGAACA GCGACGGCAT TGTCTATCTG GCAGATACCG
 2651 ACCAATCCGG CGCAAACGAA ACCGTACACA TCAAAGGCAG TCTGCAGCTG
 2701 GACGGCAAAG GTACGCTGTA CACACGTTTG GGCAAACTGC TGAAAGTGGA
 2751 CGGTACGGCG ATTATCGGCG GCAAGCTGTA CATGTCGGCA CGCGGCAAGG
 2801 GGCAGGCTA TCTCAACAGT ACCGGACGAC GTGTTCCCTT CTTGAGTGCC
 2851 GCCAAAATCG GGCAGGATTA TTCTTTCTTC ACAAACATCG AAACCGACGG
 2901 CGGCCTGCTG GCTTCCCTCG ACAGCGTCGA AAAACAGCG GGCAGTGAAG
 2951 GCACACGCT GTCTTATTAT GTCCGTGCGG GCAATGCGGC ACGGACTGCT
 3001 TCGGACGCGG CACATTCCGC GCCC GCCGGT CTGAAACAGC CCGTAGAACA
 3051 GGGCGGCAGC AATCTGGAAC ACCTGATGGT CGAAGTGGAT GCCTCCGAAT
 3101 CATCCGCAAC ACCCGAGACG GTTGAAACTG CGGCAGCCGA CCGCACAGAT
 3151 ATGCCGGGCA TCCGCCCTTA CGGCGCAACT TTCCGCGCAG CCGCAGCCGT
 3201 ACAGCATGCG AATGCCGCGG ACGGTGTACG CATCTTCAAC AGTCTCGCCG
 3251 CTACCGTCTA TGCCGACAGT ACCGCCGCCG ATGCCGATAT GCAGGGACCG
 3301 CGCCTGAAAG CCGTATCGGA CGGGTTGGAC CACAACGGCA CCGGTCTGCG
 3351 CGTCATCGCG CAAACCCAAC AGGACGGTGG AACGTGGGAA CAGGGCGGTG
 3401 TTGAAGGCAA AATGCGCGGC AGTACCCAAA CCGTCGGCAT TGCCGCGAAA
 3451 ACCGGCGAAA ATACGACAGC AGCCGCCACA CTGGGCATGG GACGACGAC
 3501 ATGGAGCGAA AACAGTGCAA ATGCAAAAAC CGACAGCATT AGTCTGTTTG
 3551 CAGGCATACG GCACGATGCG GCGGATATCG GCTATCTCAA AGGCCTGTTC
 3601 TCCTACGGAC GCTACAAAAA CAGCATCAGC CGCAGCACCG GTGCGGACGA
 3651 ACATGCGGAA GGCAGCGTCA ACGGCACGCT GATGCAGCTG GCGCACTGG
 3701 GCGGTGTCAA CGTTCCGTTT GCCGCAACGG GAGATTTGAC GGTGGAAGGC
 3751 GGTCTGCGCT ACGACCTGCT CAAACAGGAT GCATTGCGCG AAAAAGGCAG
 3801 TGCTTTGGGC TGGAGCGGCA ACAGCCTCAC TGAAGGCAGC CTGGTCCGAC
 3851 TCGCGGTCTT GAAGCTGTGC CAACCTTGA GCGATAAAGC CGTCTGTTT

-73-

3901	GCAACGGCGG	GCGTGGAACG	CGACCTGAAC	GGACGCGACT	ACACGGTAAC
3951	GGGGGGCTTT	ACCGGCGCGA	CTGCAGCAAC	CGGCAAGACG	GGGGCACGCA
4001	ATATGCCGCA	CACCCGTCTG	GTTGCCGGCC	TGGGCGCGGA	TGTCGAATTC
4051	GGCAACGGCT	GGAACGGCTT	GGCACGTTAC	AGCTACGCCG	GTTCCAAACA
4101	GTACGGCAAC	CACAGCGGAC	GAGTCGGCGT	AGGCTACCGG	TTCTTCGAGC
4151	ACCACCACCA	CCACCCTGA			
1	MATNDDDVKK	AATVAIAAAY	NNGQEINGFK	AGETIYDIDE	DGTITKKDAT
51	AADVEADDFK	GLGLKKVVTN	LTKTVNENKQ	NVDAKVKAAB	SEIEKLTTKL
101	ADTDAALADT	DAALDATTNA	LNLKGENITT	FAEETKTNIV	KIDEKLEAVA
151	DTVDKHAEAF	NDIADSLDET	NTKADEAVKT	ANEAKQTAE	TKQNVDAKVK
201	AAETAAGKAE	AAAGTANTAA	DKAEAVAANKV	TDIKADIATN	KDNIARKANS
251	ADVVTREESD	SKFVRIDGLN	ATTEKLDTRL	ASAEKSIADH	DTRLNGLDKT
301	VSDLRKETRQ	GLAEQAALSG	LFQPYNVGGS	GGGGTSAPDF	NAGGTGIGSN
351	SRATTAKSAA	VSYAGIKNEM	CKDRSMLCAG	RDDVAVTDRD	AKINAPPPNL
401	HTGDFPNPND	AYKNLINLKP	AIEAGYTGRG	VEVGIVDTGE	SVGSISFPEL
451	YGRKEHGYNE	NYKNYTAYMR	KEAPEDGGGK	DIEASFDEA	VIEAEKPTD
501	IRHVKEIGHI	DLVSHIIGGR	SVDGRPAGGI	APDATLHIMN	TNDETKNEMM
551	VAAIRNAWVK	LGERGVRIVN	NSFGTTSRAG	TADLFQIANS	EEQYRQALLD
601	YSGGDKTDEG	IRLMQSQSYG	NLSYHIRNKN	MLFIFSTGND	AQAQPNITYAL
651	LPFYEKDAQK	GIITVAGVDR	SGEKFKREMY	GEPGTEPLEY	GSNHCGITAM
701	WCLSAPEYAS	VRFTRTNPIQ	IAGTSFSAPI	VTGTAALLLQ	KYPWMSNDNL
751	RTTLLTTAQD	IGAVGVDSKF	GWGLLDAGKA	MNGPASFPFG	DFTADTKGTS
801	DIAYSFRNDI	SGTGGLIKKG	GSQQLQHGNN	TYTGKTIIEG	GSLVLYGNK
851	SDMRVETKGA	LIYNGAASGG	SLNSDGIYVL	ADTDQSGANE	TVHIKGSLOL
901	DGKGTLYTRL	GKLLKVDGTA	IIGGKLYMSA	RGKGAGYLNS	TGRRVPFLSA
951	AKIGQDYSFF	TNIETDGGLL	ASLDSVEKTA	GSEGDLSYY	VRRGNAARTA
1001	SAAHSAPAG	LKHAVEQGGG	NLENLMVELD	ASESSATPET	VETAAADRTD
1051	MPGIRPYGAT	FRAAAAYQHA	NAADGVRIFN	SLAATVYADS	TAAHADMQGR
1101	RLKAVSDGLD	HNGTGLRVIA	QTQQDGGTWE	QGGVEGKMRG	STQTVGIAAK
1151	TGENTTAAAT	LGMGRSTWSE	NSANAKTDSI	SLFAGIRHDA	GDIGYLKGLF
1201	SYGRYKNSIS	RSTGADEHAE	GSVNGTLMQL	GALGGVNVVF	AATGDLTVEG
1251	GLRYDLLKQD	AFAEKGSALG	WSGNSLTGEG	LVGLAGLKLS	QPLSDRAVLV
1301	ATGATVERDLN	GRDYTVTGGF	TGATAATGKT	GARNMPHTRL	VAGLGADVEF
1351	GNGWNLARY	SYAGSKQYGN	HSGRVGVGYR	FLEHHHHHH*	

961cL-ORF46.1

1	ATGAAACACT	TTCCATCCAA	AGTACTGACC	ACAGCCATCC	TTGCCACTTT
51	CTGTAGCGGC	GCACTGGCAG	CCACAAACGA	CGACGATGTT	AAAAAAGCTG
101	CCACTGTGGC	CATTGCTGCT	GCCTACAACA	ATGGCCAAGA	AATCAACGGT
151	TTCAAAGCTG	GAGAGACCAT	CTACGACATT	GATGAAGACG	GCACAATTAC
201	CAAAAAGAC	GCAACTGCAG	CCGATGTTGA	AGCCGACGAC	TTTAAAGGTC
251	TGGGTCTGAA	AAAAGTCGTG	ACTAACCTGA	CCAAAACCGT	CAATGAAAAA
301	AAACAAAACG	TCGATGCCAA	AGTAAAAGCT	GCAGAATCTG	AAATAGAAAA
351	GTAAACAACC	AAGTTAGCAG	ACACTGATGC	CGCTTTAGCA	GATACTGATG
401	CCGCTCTGGA	TGCAACCACC	AACGCCTTGA	ATAAATTGGG	AGAAAAATATA
451	ACGACATTTG	CTGAAGAGAC	TAAGACAAAT	ATCGTAAAAA	TTGATGAAAA
501	ATTAGAAGCC	GTGGCTGATA	CCGTGCAACA	GCATGCCGAA	GCATTCAACG
551	ATATCGCCGA	TTCATTGGAT	GAAACCAACA	CTAAGGCAGA	CGAAGCCGTC
601	AAAACCGCCA	ATGAAGCCAA	ACAGACGGCC	GAAGAAACCA	AACAAAACGT
651	CGATGCCAAA	GTAAGAGCTG	CAGAACTGTC	AGCAGGCAAA	GCCGAAGCTG
701	CCGCTGGCAC	AGCTAATACT	GCAGCCGACA	AGGCCGAAGC	TGTCGCTGCA
751	AAAGTTACCG	ACATCAAAGC	TGATATCGCT	ACGAACAAAG	ATAATATTGC
801	TAAAAAGCA	AACAGTGCCG	ACGTGTACAC	CAGAGAAGAG	TCTGACAGCA
851	AATTGTCTAG	AATTGATGGT	CTGAACGCTA	CTACCGAAAA	ATTGGACACA
901	CGCTTGGCTT	CTGCTGAAAA	ATCCATTGCC	GATCACGATA	CTCGCCTGAA
951	CGGTTTGGAT	AAAACAGTGT	CAGACCTGCG	CAAAGAAACC	CGCCAAGGCC
1001	TTGCAGAACA	AGCCGCGCTC	TCCGGTCTGT	TCCAACCTTA	CAACGTGGGT
1051	GGATCCGGAG	GAGGAGGATC	AGATTGGGCA	AACGATTCTT	TTATCCGGCA
1101	GGTTCTCGAC	CGTCAGCATT	TGGAACCCGA	CGGGAAATAC	CACCTATTCTG
1151	CGACGAGGGG	GGAACCTGCC	GAGCGCAGCG	GCCATATCGG	ATTGGGAAAA
1201	ATACAAAGCC	ATCAGTTGGG	CAACCTGATG	ATTCAACAGG	CGGCCATTAA
1251	AGGAAATATC	GGCTACATTG	TCCGCTTTTC	CGATCACGGG	CACGAAGTCC
1301	ATTCCCCCTT	CGACAACCAT	GCCTCACATT	CCGATTCTGA	TGAAGCCGGT
1351	AGTCCCGTTG	ACGGATTTAG	CCTTTACCGC	ATCCATTGGG	ACGGATACGA
1401	ACACCATCCC	GCCGACGGCT	ATGACGGGCC	ACAGGGCGGC	GGCTATCCCG

-74-

5	1451	CTCCCAAAGG	CGCGAGGGAT	ATATACAGCT	ACGACATAAA	AGGCGTTGCC
	1501	CAAAATATCC	GCCTCAACCT	GACCGACAAC	CGCAGCACCG	GACAACGGCT
	1551	TGCCGACCGT	TTCCACAATG	CCGGTAGTAT	GCTGACGCAA	GGAGTAGGCG
	1601	ACGGATTCAA	ACGCGCCACC	CGATACAGCC	CCGAGCTGGA	CAGATCGGGC
	1651	AATGCCGCGG	AAGCCTTCAA	CGGCACTGCA	GATATCGTTA	AAAACATCAT
	1701	CGGCGCGGCA	GGAGAAATTG	TCGGCGCAGG	CGATGCCGTG	CAGGGCATAA
	1751	GCGAAGGCTC	AAACATTGCT	GTCATGCACG	GCTTGGGTCT	GCTTTCCACC
10	1801	GAAAACAAGA	TGGCGCGCAT	CAACGATTTG	GCAGATATGG	CGCAACTCAA
	1851	AGACTATGCC	GCAGCAGCCA	TCCGCGATTG	GGCAGTCCAA	AACCCCAATG
	1901	CCGCACAAGG	CATAGAAGCC	GTCAGCAATA	TCTTTATGGC	AGCCATCCCC
	1951	ATCAAAGGGA	TTGGAGCTGT	TCGGGGAAAA	TACGGCTTGG	GCGGCATCAC
15	2001	GGCACATCCT	ATCAAGCGGT	CGCAGATGGG	CGCGATCGCA	TTGCCGAAAG
	2051	GGAAATCCGC	CGTCAGCGAC	AATTTTGCCG	ATGCGGCATA	CGCCAAATAC
	2101	CCGTCCCCTT	ACCATTCCCG	AAATATCCGT	TCAAAC TTGG	AGCAGCGTTA
	2151	CGGCAAAGAA	AACATCACCT	CCTCAACCGT	GCCGCCGTCA	AACGGCAAAA
	2201	ATGTCAAACT	GGCAGACCAA	CGCCACCCGA	AGACAGGCGT	ACCGTTTGAC
	2251	GGTAAAGGGT	TTCCGAATTT	TGAGAAGCAC	GTGAAATATG	ATACGTAAC T
	2301	CGAG				
20	1	MKHFP SKVLT	TAILATFCSG	ALAATNDDDV	KKAATVAIAA	AYNNGQEING
	51	FKAGETIYDI	DEDGTITKDD	ATAADVEADD	FKGLGLKKVV	TNLTKTVNEN
	101	KQNVDAKVK	AESEIEKLTT	KLADTDAAALA	DTDAALDAT T	NALNKLGENI
	151	TTFAEETKTN	IVKIDEXLEA	VADTVDKHAE	AFNDIADSLD	ETNTKADEAV
25	201	KTANEAKQTA	EETKQNVDAK	VKAAETAAGK	AEAAAGTANT	AADKAEAVAA
	251	KVTDIKADIA	TNKDNIAKKA	NSADVYTREE	SDSKFVRIDG	LNATTEKLDT
	301	RLASAEKSIA	DHDTRLNGLD	KTVSDLRKET	RQGLAEQAAL	SGLFQPYNVG
	351	SGSGGSDLA	NDSFIRQVLD	RQHFEPDGKY	HLFGSRGELA	ERSGHIGLGK
30	401	IQSHQLGNLM	IQQAAIKGNI	GYIVRFSDHG	HEVHSPFDNH	ASHSDSDEAG
	451	SPVDGFSLYR	IHWDDGYEHP	ADGYDGPQGG	GYPAPKGARD	IYSYDIKVA
	501	QNIRLNLTDN	RSTGQRLADR	FHNAGSMLTQ	GVGDGFKRAT	RYSPELDRSG
	551	NAAEAFNGTA	DIVKNIIGAA	GEIVGAGDAV	QGISEGSNIA	VMHGLGLLST
	601	ENKMARINDL	ADMAQLKDYA	AAAIRDWAVQ	NPNAAQGIEA	VSNIFMAAIP
	651	IKGIGAVRGK	YGLGGITAHF	IKRSQMGALA	LPGKSAVSD	NFADAAYAKY
	701	PSPYHSRNIR	SNLEQRYGKE	NITSSTVPPS	NGKNVKLADQ	RHPKTGVPFD
35	751	GKGFNFKEKH	VKYDT*			

961cL-741

40	1	ATGAAACACT	TTCCATCCAA	AGTACTGACC	ACAGCCATCC	TTGCCACTTT
	51	CTGTAGCGGC	GCACTGGCAG	CCACAAACGA	CGACGATGTT	AAAAAAGCTG
	101	CCACTGTGGC	CATTGCTGCT	GCCTACAACA	ATGGCCAAGA	AATCAACGGT
	151	TTCAAAGCTG	GAGAGACCAT	CTACGACATT	GATGAAGACG	GCACAATTAC
	201	CAAAAAAGAC	GCAACTGCAG	CCGATGTTGA	AGCCGACGAC	TTTAAAGGTC
45	251	TGGGTCTGAA	AAAAGTCGTG	ACTAACCTGA	CCAAAACCGT	CAATGAAAAC
	301	AAACAAAACG	TCGATGCCAA	AGTAAAAGCT	GCAGAATCTG	AAATAGAAAA
	351	GTTAACAACC	AAGTTAGCAG	ACACTGATGC	CGCTTTAGCA	GATACTGATG
	401	CCGCTCTGGA	TGCAACCACC	AACGCCTTGA	ATAAATTGGG	AGAAAATATA
	451	ACGACATT TG	CTGAAGAGAC	TAAGACAAAT	ATCGTAAAAA	TTGATGAAAA
50	501	ATTAGAAGCC	GTGGCTGATA	CCGTCGACAA	GCATGCCGAA	GCATTCAACG
	551	ATATCGCCGA	TTCAATTGGAT	GAAACCAACA	CTAAGGCAGA	CGAAGCCGTC
	601	AAAACCGCCA	ATGAAGCCAA	ACAGACGGCC	GAAGAAACCA	AACAAAACGT
	651	CGATGCCAAA	GTAAAAGCTG	CAGAACTGAC	AGCAGGCAAA	GCCGAAGCTG
	701	CCGCTGGCAC	AGCTAATACT	GCAGCCGACA	AGGCCGAAGC	TGTCGCTGCA
55	751	AAAGTTACCG	ACATCAAAGC	TGATATCGCT	ACGAACAAAG	ATAATATTGC
	801	TAAAAAAGCA	AACAGTGCCG	ACGTGTACAC	CAGAGAAGAG	TCTGACAGCA
	851	AATTTGTCAG	AATTGATGGT	CTGAACGCTA	CTACCGAAAA	ATTGGACACA
	901	CGCTTGGCTT	CTGCTGAAAA	ATCCATTGCC	GATCACGATA	CTCGCCTGAA
	951	CGGTTTGGAT	AAAACAGTGT	CAGACCTGCG	CAAAGAAACC	CGCCAAGGCC
60	1001	TTGCAGAAC	AGCCGCGCTC	TCCGCTCTGT	TCCAACCTTA	CAACGTGGGT
	1051	GGATCCGGAG	GGGGTGGTGT	CGCCGCCGAC	ATCGGTGCGG	GGCTTGCCGA
	1101	TGCACTAACC	GCACCGCTCG	ACCATAAAGA	CAAAGGTTTG	CAGTCTTTGA
	1151	CGCTGGATCA	GTCCGTCAGG	AAAAACGAGA	AACTGAAGCT	GGCGGCACAA
	1201	GGTCCGAAAA	AACTTTATGG	AAACGGTGAC	AGCCTCAATA	CGGGCAAAAT
	1251	AAGAACGAC	AAGGTCAAGC	GTTTCGACTT	TATCCGCCAA	ATCGAAGTGG
65	1301	ACGGGCAGCT	CATTACCTTG	GAGAGTGGAG	AGTTCCAAGT	ATACAAACAA
	1351	AGCCATTCCG	CCTTAACCGC	CTTTCAGACC	GAGCAAATAC	AAGATTCCGA
	1401	GCATTCCGGG	AAGATGGTTG	CGAAACGCCA	GTTTCAGAATC	GGCGACATAG

-75-

5	1451	CGGGCGAACA	TACATCTTTT	GACAAGCTTC	CCGAAGGCGG	CAGGGCGACA
	1501	TATCGCGGGA	CGGCGTTCGG	TTCAGACGAT	GCCGGCGGAA	AACTGACCTA
	1551	CACCATAGAT	TTCGCCGCCA	AGCAGGGAAA	CGGCAAAATC	GAACATTTGA
	1601	AATCGCCAGA	ACTCAATGTC	GACCTGGCCG	CCGCCGATAT	CAAGCCGGAT
	1651	GGAAAACGCC	ATGCCGTCAT	CAGCGGTTCC	GTCTTTTACA	ACCAAGCCGA
	1701	GAAAGGCAGT	TACTCCTCG	GTATCTTTGG	CGGAAAAGCC	CAGGAAGTTG
	1751	CCGCGAGCGC	GGAAAGTAAA	ACCGTAAACG	GCATACGCCA	TATCGGCCTT
	1801	GCCGCCAAGC	AACTCGAGCA	CCACCACCAC	CACCAC'TGA	
10	1	MKHFP SKVLT	TAILATFCSG	ALAATNDDDV	KKAATVAIAA	AYNNGQEING
	51	FKAGETIYDI	DEDGTITKID	ATAADVEADD	FKGLGLKKV	TNLTKT V NEN
	101	KQNVDAKVA	AESEIEKLTT	KLADTDALA	DTDAALDAT	NALNKLGENI
	151	TTFAEETKTN	IVKIDEKLEA	VADTVDKHAE	AFNDIADSLD	ETNTKADEAV
	201	KTANEAKQTA	EETKQNVDAK	VKAAETAAGK	AEAAAGTANT	AADKAEAVAA
15	251	KVTDIKADIA	TNKDNIARKA	NSADVYTREE	SDSKFVRIDG	LNATTEKLD
	301	RLASAEKSIA	DHDTRLNGLD	KTVSDLRKET	RQGLAEQAAL	SGLFQPYNVG
	351	GSGGGGVAAD	IGAGLADALT	APLDHKDKGL	QSLTLDQSVR	KNEKLKLAQ
	401	GAEKTYGNGD	SLNTGKLNKD	KVSRFD FIRQ	IEVDGQLITL	ESGEFQVYKQ
	451	SHSALTAFQT	EQIQDSEHSG	KMVAKRQFRI	GDIAGEHTSF	DKLPEGGRAT
20	501	YRGTAFGSDD	AGGKLT Y TID	FAAKQGNNGKI	EHLKSPELNV	DLAAADIKPD
	551	GKRHAVISGS	VLYNQAEKGS	YSLGIFGGKA	QEVAGSAEVK	TVNGIRHIGL
	601	AAKQLEHHHH	HH*			
25	961cL-983					
	1	ATGAAACACT	TTCCATCCAA	AGTACTGACC	ACAGCCATCC	TTGCCACTTT
	51	CTGTAGCGGC	GCACTGGCAG	CCACAAACGA	CGACGATGTT	AAAAAAGCTG
	101	CCACTGTGGC	CATTGCTGCT	GCCTACAACA	ATGGCCAAGA	AATCAACGGT
30	151	TTCAAAGCTG	GAGAGACCAT	CTACGACATT	GATGAAGACG	GCACAATTAC
	201	CAAAAAAGAC	GCAACTGCAG	CCGATGTTGA	AGCCGACGAC	TTTAAAGGTC
	251	TGGGTCTGAA	AAAAGTCGTG	ACTAACCTGA	CCAAAACCGT	CAATGAAAAC
	301	AAACAAAACG	TCGATGCCAA	AGTAAAAGCT	GCAGAATCTG	AAATAGAAAA
	351	GTTAACAACC	AAGTTAGCAG	ACACTGATGC	CGCTTTAGCA	GATACTGATG
	401	CCGCTCTGGA	TGCAACCACC	AACGCCTTGA	ATAAATTTGG	AGAAAATATA
35	451	ACGACATTTG	CTGAAGAGAC	TAAGACAAAT	ATCGTAAAAA	TTGATGAAAA
	501	ATTAGAAGCC	GTGGCTGATA	CCGTCGACAA	GCATGCCGAA	GCATTCAACG
	551	ATATCGCCGA	TTCATTGGAT	GAAACCAACA	CTAAGGCAGA	CGAAGCCGTC
	601	AAAACCGCCA	ATGAAGCCAA	ACAGACGGCC	GAAGAAACCA	AACAAAACGT
	651	CGATGCCAAA	GTAAAAGCTG	CAGAAACTGC	AGCAGGCAAA	GCCGAAGCTG
40	701	CCGCTGGCAC	AGCTAATACT	GCAGCCGACA	AGGCCGAAGC	TGTCGCTGCA
	751	AAAGTTACCG	ACATCAAAGC	TGATATCGCT	ACGAACAAAG	ATAATATTGC
	801	TAAAAAAGCA	AACAGTGCCG	ACGTGTACAC	CAGAGAAGAG	TCTGACAGCA
	851	AATTTGTGAG	AATTGATGGT	CTGAACGCTA	CTACCGAAAA	ATTGGACACA
	901	CGCTTTGGCT	CTGCTGAAAA	ATCCATTGCC	GATCACGATA	CTCGCCTGAA
45	951	CGGTTTGGAT	AAAACAGTGT	CAGACCTGCG	CAAAGAAACC	CGCCAAGGCC
	1001	TTGCAGAACA	AGCCGCGCTC	TCCGGTCTGT	TCCAACCTTA	CAACGTGGGT
	1051	GGATCCGGCG	GAGGCGGCAC	TTCTGCGCCC	GACTTCAATG	CAGGCGGTAC
	1101	CGGTATCGGC	AGCAACAGCA	GAGCAACAAC	AGCGAAATCA	GCAGCAGTAT
	1151	CTTACGCCGG	TATCAAGAAC	GAAATGTGCA	AAGACAGAAG	CATGCTCTGT
50	1201	GCCGGTCCGG	ATGACGTTGC	GGTTACAGAC	AGGGATGCCA	AAATCAATGC
	1251	CCCCCCCCCG	AATCTGCATA	CCGGAGACTT	TCCAAACCCA	AATGACGCAT
	1301	ACAAGAATTT	GATCAACCTC	AAACCTGCAA	TTGAAGCAGG	CTATACAGGA
	1351	CGCGGGGTAG	AGGTAGGTAT	CGTCGACACA	GGCGAATCCG	TCCGGCAGCAT
	1401	ATCCTTTCCC	GAAGTGTATG	GCAGAAAAGA	ACACGGCTAT	AACGAAAATT
55	1451	ACAAAAACTA	TACGGCGTAT	ATGCGGAAGG	AAGCGCCTGA	AGACGGAGGC
	1501	GGTAAAGACA	TTGAAGCTTC	TTTCGACGAT	GAGGCCGTTA	TAGAGACTGA
	1551	AGCAAAGCCG	ACGGATATCC	GCCACGTAAA	AGAAATCGGA	CACATCGATT
	1601	TGCTCTCCCA	TATTATTGGC	GGGCGTTCCG	TGGACGGCAG	ACCTGCAGGC
	1651	GGTATTGCGC	CCGATGCGAC	GCTACACATA	ATGAATACGA	ATGATGAAAC
60	1701	CAAGAACGAA	ATGATGGTTG	CAGCCATCCG	CAATGCATGG	GTCAAGCTGG
	1751	GCGAACGTGG	CGTGCGCATC	GTCAAATAACA	GTTTGTGAAC	AACATCGAGG
	1801	GCAGGCACTG	CCGACCTTTT	CCAAATAGCC	AATTCGGAGG	AGCAGTACCG
	1851	CCAAGCGTTG	CTCGACTATT	CCGGCGGTGA	TAAAACAGAC	GAGGGTATCC
	1901	GCTTGATGCA	ACAGAGCAAC	TACGGCAACC	TGTCCTACCA	CATCCGTAAT
65	1951	AAAAACATGC	TTTTCATCTT	TTTCGACAGG	AATGACGCAC	AAGCTCAGCC
	2001	CAACACATAT	GCCCTATTGC	CATTTTATGA	AAAAGACGCT	CAAAAAGGCA
	2051	TTATCACAGT	CGCAGGCGTA	GACCGCAGTG	GAGAAAAGTT	CAACGGGAA

-76-

5	2101	ATGTATGGAG	AACCGGGTAC	AGAACCCTTT	GAGTATGGCT	CCAACCATTG	
	2151	CGGAATTACT	GCCATGTGGT	GCCTGTCCGC	ACCCTATGAA	GCAAGCGTCC	
	2201	GTTTCACCCG	TACAAACCCG	ATTCAAATTG	CCGGAACATC	CTTTTCCGCA	
	2251	CCCATCGTAA	CCGGCACGGC	GGCTCTGCTG	CTGCAGAAAT	ACCCGTGGAT	
	2301	GAGCAACGAC	AACCTGCGTA	CCACGTTGCT	GACGACGGCT	CAGGACATCG	
10	2351	GTGCAGTCGG	CGTGGACAGC	AAGTTCGGCT	GGGACTGCT	GGATGCGGGT	
	2401	AAGGCCATGA	ACGGACCCGC	GTCCCTTTCCG	TTCGGCGACT	TTACCGCCGA	
	2451	TACGAAAGGT	ACATCCGATA	TTGCCTACTC	CTTCCGTAAC	GACATTTTCAG	
	2501	GCACGGGCGG	CCTGATCAAA	AAAGGCGGCA	GCCAACTGCA	ACTGCACGGC	
	2551	AACAACACCT	ATACGGGCAA	AACCATTATC	GAAGGCGGTT	CGCTGGTGTT	
15	2601	GTACGGCAAC	AACAAATCGG	ATATGCGCGT	CGAAACCAAA	GGTGCGCTGA	
	2651	TTTATAACCG	GGCGGCATCC	GGCGGCAGCC	TGAACAGCGA	CGGCATTGTC	
	2701	TATCTGGCAG	ATACCGACCA	ATCCGGCGCA	AACGAAACCG	TACACATCAA	
	2751	AGGCAGTCTG	CAGCTGGACG	GCAAAGGTAC	GCTGTACACA	CGTTTGGGCA	
	2801	AACTGCTGAA	AGTGGACGGT	ACGGCGATTA	TCGGCGGCAA	GCTGTACATG	
20	2851	TCGGCACCGC	GCAAGGGGGC	AGGCTATCTC	AACAGTACCG	GACGACGTGT	
	2901	TCCCTTCCTG	AGTCCGCCA	AAATCGGGCA	GGATTATTCT	TTCTTCACAA	
	2951	ACATCGAAAC	CGACGGCGGC	CTGCTGGCTT	CCCTCGACAG	CGTCGAAAAA	
	3001	ACAGCGGGCA	GTGAAGGCGA	CACGCTGTCC	TATTATGTCC	GTCGCGGCAA	
	3051	TGCGGCACGG	ACTGCTTCGG	CAGCGGCACA	TTCCGCGCCC	GCCGGTCTGA	
25	3101	AACACGCCGT	AGAACAGGGC	GGCAGCAATC	TGGAAAACCT	GATGGTCGAA	
	3151	CTGGATGCCT	CCGAATCATC	CGCAACACCC	GAGACGGTTG	AAACTGCGGC	
	3201	AGCCGACCGC	ACAGATATGC	CGGGCATCCG	CCCCTACGGC	GCAACTTTCC	
	3251	GCGCAGCGGC	AGCCGTACAG	CATGCCAATG	CCGCCGACGG	TGTACGCATC	
	3301	TTCAACAGTC	TCGCCGCTAC	CGTCTATGCC	GACAGTACCG	CCGCCCATGC	
30	3351	CGATATGCAG	GGACGCCGCC	TGAAAGCCGT	ATCGGACGGG	TTTGACCACA	
	3401	ACGGCACGGG	TCTGCGCGTC	ATCGCGCAAA	CCCAACAGGA	CGGTGGAACG	
	3451	TGGGAACAGG	GCGGTGTTGA	AGGCAAAATG	CGCGGCAGTA	CCCAAACCGT	
	3501	CGGCATTGCC	GCGAAAACCG	GCGAAAATAC	GACAGCAGCC	GCCACACTGG	
	3551	GCATGGGACG	CAGCACATGG	AGCGAAAACA	GTGCAAATGC	AAAAACCGAC	
35	3601	AGCATTAGTC	TGTTTGCAGG	CATACGGCAC	GATGCGGGCG	ATATCGGCTA	
	3651	TCTCAAAGGC	CTGTTCTCCT	ACGGACGCTA	CAAAAACAGC	ATCAGCCGCA	
	3701	GCACCGGTGC	GGACGAACAT	GCGGAAGGCA	GCGTCAACGG	CACGCTGATG	
	3751	CAGCTGGGCG	CAGTGGCGGG	TGTCAACGTT	CCGTTTGCCG	CAACGGGAGA	
	3801	TTTGACGGTC	GAAGGCGGTC	TGCGCTACGA	CCTGCTCAAA	CAGGATGCAT	
40	3851	TCGCCGAAAA	AGGCAGTGCT	TTGGGCTGGA	GCGGCAACAG	CCTCACTGAA	
	3901	GGCACGCTGG	TCGGACTCGC	GGGTCTGAAG	CTGTGCGAAC	CCTTGAGCGA	
	3951	TAAAGCCGTC	CTGTTTGCAA	CGGCGGGCGT	GGAACGCGAC	CTGAACGGCA	
	4001	GCGACTACAC	GGTAACGGGC	GCGTTTACCG	GCGCGACTGC	AGCAACCGGC	
	4051	AAGACGGGGG	CACGCAATAT	GCCGCACACC	CGTCTGGTTG	CCGGCCTGGG	
45	4101	CGCGGATGTC	GAATTCGGCA	ACGGCTGGAA	CGGCTTGGCA	CGTTACAGCT	
	4151	ACGCCGGTTC	CAAACAGTAC	GGCAACCACA	GCGGACGAGT	CGGCGTAGGC	
	4201	TACCGGTTCT	GACTCGAG				
	45	1	MKHFPKSVLT	TAILATFCSG	ALAATNDDDV	KKAATVAIAA	AYNNGQEING
	51	FKAGETIYDI	DEDGTITKDD	ATAADVEADD	FKGLGLKKVV	TNLTKTVNEN	
50	101	KQNVDAKVA	AESEIEKLTT	KLADTDAAALA	DTDAALDATT	NALNKLGENI	
	151	TTFAEETKTN	IVKIDEKLEA	VADTVDKHAE	AFNDIADSLD	ETNTKADRAV	
	201	KTANEAKQTA	BETKQNVDAK	VKAAETAAGK	AEAAAGTANT	AADKAEAVAA	
	251	KVTDIKADIA	TNKNIDAKKA	NSADVYTRRE	SDSKFVRIDG	LNATTEKLDI	
	301	RLASAEKSIA	DHDTRLNGLD	KTVSDLRKET	RQGLAEQAAL	SGLFQPYNVG	
55	351	SGGGGTSAP	DFNAGGTGIG	SNSRATTAKS	AAVSYAGIKN	EMCKDRSMLC	
	401	AGRDDVAVTD	RDakinAPPP	NLHTGDFPNP	NDAYKNLINL	KPAIEAGYTG	
	451	RGVEVGIVDT	GESVGSISFP	ELYGRKEBGY	NENYKNYTAY	MRKEAPEDGG	
	501	GKDIEASFDD	EAVIETRAKP	TDIRHVKEIG	HIDLVSHIIG	GRSVDGRPAG	
	551	GIAPDATLHI	MNTNDETKNE	MMVAAIRNAW	VKLGERGVRI	VNNSFGTTTSR	
60	601	AGTADLFQIA	NSBEQYRQAL	LDYSGGDKTD	EGIRLMQOSD	YGNLSYHIRN	
	651	KNMLFIFSTG	NDAQAQPNTY	ALLPFYKEDA	QKGIITVAGV	DRSGEKFKRE	
	701	MYGEPGTEPL	EYGSNHCCGT	AMWCLAPYE	ASVRFTRTNP	IQIAGTSFSA	
	751	PIVTGTALL	LQKYPWMSND	NLRTTLLTTA	QDIGAVGVDS	KFGWGLLDAG	
	801	KAMNGPASFP	FGDFTADTKG	TSDIAYSFRN	DISGTGGLIK	KGGSQQLQHG	
65	851	NNTYTGKTI	EGGSLVLYGN	NKSDMRVETK	GALIYNGAAS	GGSLNSDGIV	
	901	YLADTDQSGA	NETVHIKGLS	QLDGKGTLYT	RLGKLLKVDG	TAIIGKLYM	
	951	SARGKGAGYL	NSTGRRVPFL	SAAKIGQDYS	FFTNIETDGG	LLASLDSVEK	
	1001	TAGSEGDTLS	YYVRRGNAAR	TASAAHSAP	AGLKHAVEQG	GSNLENLMVE	
	1051	LDASESATP	ETVETAAADR	TDMPGIRPYG	ATFRAAAVQ	HANAADGVRI	
	1101	FNSLAATVYA	DSTAAHADMO	GRRLKAVSDG	LDHNGTGLRV	IAOTODDGGT	

-77-

5

1151 WEQGGVEGKM RGSTQTVGIA AKTGENTTAA ATLMGRSTW SENSANAKTD
 1201 SISLFAGIRH DAGDIGYLKG LFSYGRYKNS ISRSTGADEH AEGSVNGTLM
 1251 QLGA LGGVNV PFAATGDLTV EGGLRYDLLK QDAFAEKGSA LGWSGNSLTE
 1301 GTLVGLAGLK LSQPLSDKAV LFATAGVERD LNGRDYTVTG GFTGATAATG
 1351 KTGARNMPHT RLVAGLGADV EFGNGWNGLA RYSYAGSKQY GNHSGRVGVG
 1401 YRF*

It will be understood that the invention has been described by way of example only and modifications may be made whilst remaining within the scope and spirit of the invention. For instance, the use of proteins from other strains is envisaged [e.g. see WO00/66741 for polymorphic sequences for ORF4, ORF40, ORF46, 225, 235, 287, 519, 726, 919 and 953].

EXPERIMENTAL DETAILS

FPLC protein purification

15 The following table summarises the FPLC protein purification that was used:

Protein	PI	Column	Buffer	pH	Protocol
121.1 ^{untagged}	6.23	Mono Q	Tris	8.0	A
128.1 ^{untagged}	5.04	Mono Q	Bis-Tris propane	6.5	A
406.1L	7.75	Mono Q	Diethanolamine	9.0	B
576.1L	5.63	Mono Q	Tris	7.5	B
593 ^{untagged}	8.79	Mono S	Hepes	7.4	A
726 ^{untagged}	4.95	Hi-trap S	Bis-Tris	6.0	A
919 ^{untagged}	10.5(-leader)	Mono S	Bicine	8.5	C
919Lorf4	10.4(-leader)	Mono S	Tris	8.0	B
920L	6.92(-leader)	Mono Q	Diethanolamine	8.5	A
953L	7.56(-leader)	Mono S	MES	6.6	D
982 ^{untagged}	4.73	Mono Q	Bis-Tris propane	6.5	A
919-287	6.58	Hi-trap Q	Tris	8.0	A
953-287	4.92	Mono Q	Bis-Tris propane	6.2	A

Buffer solutions included 20-120 mM NaCl, 5.0 mg/ml CHAPS and 10% v/v glycerol. The dialysate was centrifuged at 13000g for 20 min and applied to either a mono Q or mono S FPLC ion-exchange resin. Buffer and ion exchange resins were chosen according to the pI of the protein of interest and the recommendations of the FPLC protocol manual [Pharmacia: FPLC Ion Exchange and Chromatofocussing; Principles and Methods. Pharmacia

Publication]. Proteins were eluted using a step-wise NaCl gradient. Purification was analysed by SDS-PAGE and protein concentration determined by the Bradford method.

The letter in the 'protocol' column refers to the following:

5 FPLC-A: Clones 121.1, 128.1, 593, 726, 982, periplasmic protein 920L and hybrid proteins 919-287, 953-287 were purified from the soluble fraction of *E.coli* obtained after disruption of the cells. Single colonies harbouring the plasmid of interest were grown overnight at 37°C in 20 ml of LB/Amp (100 µg/ml) liquid culture. Bacteria were diluted 1:30 in 1.0 L of fresh medium and grown at either 30°C or 37°C until the OD₅₅₀ reached 0.6-0.8. Expression of recombinant protein was induced with IPTG at a final concentration of 1.0 mM. After
10 incubation for 3 hours, bacteria were harvested by centrifugation at 8000g for 15 minutes at 4°C. When necessary cells were stored at -20°C. All subsequent procedures were performed on ice or at 4°C. For cytosolic proteins (121.1, 128.1, 593, 726 and 982) and periplasmic protein 920L, bacteria were resuspended in 25 ml of PBS containing complete protease inhibitor (Boehringer-Mannheim). Cells were lysed by sonication using a Branson
15 Sonifier 450. Disrupted cells were centrifuged at 8000g for 30 min to sediment unbroken cells and inclusion bodies and the supernatant taken to 35% v/v saturation by the addition of 3.9 M (NH₄)₂SO₄. The precipitate was sedimented at 8000g for 30 minutes. The supernatant was taken to 70% v/v saturation by the addition of 3.9 M (NH₄)₂SO₄ and the precipitate collected as above. Pellets containing the protein of interest were identified by SDS-PAGE
20 and dialysed against the appropriate ion-exchange buffer (see below) for 6 hours or overnight. The periplasmic fraction from *E.coli* expressing 953L was prepared according to the protocol of Evans *et. al.* [*Infect.Immun.* (1974) 10:1010-1017] and dialysed against the appropriate ion-exchange buffer. Buffer and ion exchange resin were chosen according to the pI of the protein of interest and the recommendations of the FPLC protocol manual (Pharmacia). Buffer solutions included 20 mM NaCl, and 10% (v/v) glycerol. The dialysate
25 was centrifuged at 13000g for 20 min and applied to either a mono Q or mono S FPLC ion-exchange resin. Buffer and ion exchange resin were chosen according to the pI of the protein of interest and the recommendations of the FPLC protocol manual (Pharmacia). Proteins were eluted from the ion-exchange resin using either step-wise or continuous NaCl
30 gradients. Purification was analysed by SDS-PAGE and protein concentration determined by Bradford method. Cleavage of the leader peptide of periplasmic proteins was demonstrated by sequencing the NH₂-terminus (see below).

FPLC-B: These proteins were purified from the membrane fraction of *E.coli*. Single colonies harbouring the plasmid of interest were grown overnight at 37°C in 20 ml of LB/Amp (100 µg/ml) liquid culture. Bacteria were diluted 1:30 in 1.0 L of fresh medium. Clones 406.1L and 919Lorf4 were grown at 30°C and Orf25L and 576.1L at 37°C until the OD₅₅₀ reached 0.6-0.8. In the case of 919Lorf4, growth at 30°C was essential since expression of recombinant protein at 37°C resulted in lysis of the cells. Expression of recombinant protein was induced with IPTG at a final concentration of 1.0 mM. After incubation for 3 hours, bacteria were harvested by centrifugation at 8000g for 15 minutes at 4°C. When necessary cells were stored at -20 °C. All subsequent procedures were performed at 4°C. Bacteria were resuspended in 25 ml of PBS containing complete protease inhibitor (Boehringer-Mannheim) and lysed by osmotic shock with 2-3 passages through a French Press. Unbroken cells were removed by centrifugation at 5000g for 15 min and membranes precipitated by centrifugation at 100000g (Beckman Ti50, 38000rpm) for 45 minutes. A Dounce homogenizer was used to re-suspend the membrane pellet in 7.5 ml of 20 mM Tris-HCl (pH 8.0), 1.0 M NaCl and complete protease inhibitor. The suspension was mixed for 2-4 hours, centrifuged at 100000g for 45 min and the pellet resuspended in 7.5 ml of 20mM Tris-HCl (pH 8.0), 1.0M NaCl, 5.0mg/ml CHAPS, 10% (v/v) glycerol and complete protease inhibitor. The solution was mixed overnight, centrifuged at 100000g for 45 minutes and the supernatant dialysed for 6 hours against an appropriately selected buffer. In the case of Orf25.L, the pellet obtained after CHAPS extraction was found to contain the recombinant protein. This fraction, without further purification, was used to immunise mice.

FPLC-C: Identical to FPLC-A, but purification was from the soluble fraction obtained after permeabilising *E.coli* with polymyxin B, rather than after cell disruption.

FPLC-D: A single colony harbouring the plasmid of interest was grown overnight at 37°C in 20 ml of LB/Amp (100 µg/ml) liquid culture. Bacteria were diluted 1:30 in 1.0 L of fresh medium and grown at 30°C until the OD₅₅₀ reached 0.6-0.8. Expression of recombinant protein was induced with IPTG at a final concentration of 1.0mM. After incubation for 3 hours, bacteria were harvested by centrifugation at 8000g for 15 minutes at 4°C. When necessary cells were stored at -20 °C. All subsequent procedures were performed on ice or at 4°C. Cells were resuspended in 20mM Bicine (pH 8.5), 20mM NaCl, 10% (v/v) glycerol, complete protease inhibitor (Boehringer-Mannheim) and disrupted using a Branson Sonifier 450. The sonicate was centrifuged at 8000g for 30 min to sediment unbroken cells and

inclusion bodies. The recombinant protein was precipitated from solution between 35% v/v and 70% v/v saturation by the addition of 3.9M (NH₄)₂SO₄. The precipitate was sedimented at 8000g for 30 minutes, resuspended in 20 mM Bicine (pH 8.5), 20 mM NaCl, 10% (v/v) glycerol and dialysed against this buffer for 6 hours or overnight. The dialysate was
5 centrifuged at 13000g for 20 min and applied to the FPLC resin. The protein was eluted from the column using a step-wise NaCl gradients. Purification was analysed by SDS-PAGE and protein concentration determined by Bradford method.

Cloning strategy and oligonucleotide design

Genes coding for antigens of interest were amplified by PCR, using oligonucleotides
10 designed on the basis of the genomic sequence of *N. meningitidis* B MC58. Genomic DNA from strain 2996 was always used as a template in PCR reactions, unless otherwise specified, and the amplified fragments were cloned in the expression vector pET21b+ (Novagen) to express the protein as C-terminal His-tagged product, or in pET-24b+(Novagen) to express the protein in 'untagged' form (*e.g.* ΔG 287K).

15 Where a protein was expressed without a fusion partner and with its own leader peptide (if present), amplification of the open reading frame (ATG to STOP codons) was performed.

Where a protein was expressed in 'untagged' form, the leader peptide was omitted by designing the 5'-end amplification primer downstream from the predicted leader sequence.

The melting temperature of the primers used in PCR depended on the number and type of
20 hybridising nucleotides in the whole primer, and was determined using the formulae:

$$T_{m1} = 4 (G+C) + 2 (A+T) \quad \text{(tail excluded)}$$

$$T_{m2} = 64.9 + 0.41 (\% \text{ GC}) - 600/N \quad \text{(whole primer)}$$

The melting temperatures of the selected oligonucleotides were usually 65-70°C for the whole oligo and 50-60°C for the hybridising region alone.

25 Oligonucleotides were synthesised using a Perkin Elmer 394 DNA/RNA Synthesizer, eluted from the columns in 2.0ml NH₄OH, and deprotected by 5 hours incubation at 56°C. The oligos were precipitated by addition of 0.3M Na-Acetate and 2 volumes ethanol. The samples were centrifuged and the pellets resuspended in water.

		Sequences	Restriction site
Orf1L	Fwd	CGCGGATCCGCTAGC-AAAACAACCGACAAACGG	NheI
	Rev	CCCGCTCGAG-TTACCAGCGGTAGCCTA	XhoI
Orf1	Fwd	CTAGCTAGC-GGACACACTTATTTCCGGCATC	NheI
	Rev	CCCGCTCGAG-TTACCAGCGGTAGCCTAATTTG	XhoI
Orf1LOmpA	Fwd		NdeI-(NheI)
	Rev	CCCGCTCGAG-	XhoI
Orf4L	Fwd	CGCGGATCCCATATG-AAAACCTTCTTCAAAACC	NdeI
	Rev	CCCGCTCGAG-TTATTTGGCTGCGCCTTC	XhoI
Orf7-1L	Fwd	GCGGCATTAAT-ATGTTGAGAAAATTGTTGAAATGG	AseI
	Rev	GCGGCCTCGAG-TTATTTTTTCAAAATATATTTGC	XhoI
Orf9-1L	Fwd	GCGGCCATATG-TTACCTAACC GTTTC AAAATGT	NdeI
	Rev	GCGGCCTCGAG-TTATTTCCGAGGTTTTCGGG	XhoI
Orf23L	Fwd	CGCGGATCCCATATG-ACACGCTTCAAATATTC	NdeI
	Rev	CCCGCTCGAG-TTATTTAAACCGATAGGTAAA	XhoI
Orf25-1 His	Fwd	CGCGGATCCCATATG-GGCAGGGAAGAACCGC	NdeI
	Rev	GCCCAAGCTT-ATCGATGGAATAGCCGCG	HindIII
Orf29-1 b-His (MC58)	Fwd	CGCGGATCCGCTAGC-AACGGTTTGGATGCCCCG	NheI
	Rev	CCCGCTCGAG-TTTGTCTAAGTTCCTGATAT CCCGCTCGAG-ATTCCCACCTGCCATC	XhoI
Orf29-1 b-L (MC58)	Fwd	CGCGGATCCGCTAGC-ATGAATTTGCCTATTCAAAAAT	NheI
	Rev	CCCGCTCGAG-TTAATTTCCACCTGCCATC	XhoI
Orf29-1 c-His (MC58)	Fwd	CGCGGATCCGCTAGC-ATGAATTTGCCTATTCAAAAAT	NheI
	Rev	CCCGCTCGAG-TTGGACGATGCCCGCA	XhoI
Orf29-1 c-L (MC58)	Fwd	CGCGGATCCGCTAGC-ATGAATTTGCCTATTCAAAAAT	NheI
	Rev	CCCGCTCGAG-TTATTGGACGATGCCCGC	XhoI
Orf25L	Fwd	CGCGGATCCCATATG-TATCGCAAACGATTGC	NdeI
	Rev	CCCGCTCGAG-CTAATCGATGGAATAGCC	XhoI
Orf37L	Fwd	CGCGGATCCCATATG-AAACAGACAGTCAAATG	NdeI
	Rev	CCCGCTCGAG-TCAATAACCCGCCTTCAG	XhoI
Orf38L	Fwd	CGCGGATCCCATATG-TTACGTTTGACTGCTTTAGCCGTATGCACC	NdeI
	Rev	CCCGCTCGAG-TTATTTGCCGCGTTAAAAGCGTCGGCAAC	XhoI
Orf40L	Fwd	CGCGGATCCCATATG-AACAAAATATACCGCAT	NdeI
	Rev	CCCGCTCGAG-TTACCACTGATAACCGAC	XhoI
Orf40.2-His	Fwd	CGCGGATCCCATATG-ACCGATGACGACGATTTAT	NdeI
	Rev	GCCCAAGCTT-CCACTGATAACCGACAGA	HindIII
Orf40.2L	Fwd	CGCGGATCCCATATG-AACAAAATATACCGCAT	NdeI
	Rev	GCCCAAGCTT-TTACCACTGATAACCGAC	HindIII
Orf46-2L	Fwd	GGGAATTCCATATG-GGCATTTCCCGCAAAATATC	NdeI
	Rev	CCCGCTCGAG-TTATTTACTCCTATAACGAGGTCTCTTAAC	XhoI
Orf46-2	Fwd	GGGAATTCCATATG-TCAGATTTGGCAAACGATTCTT	NdeI
	Rev	CCCGCTCGAG-TTATTTACTCCTATAACGAGGTCTCTTAAC	XhoI
Orf46.1L	Fwd	GGGAATTCCATATG-GGCATTTCCCGCAAAATATC	NdeI

	Rev	CCCGCTCGAG-TTACGTATCATATTTACGTGC	XhoI
orf46. (His-GST)	Fwd	GGGAATTCCATATGCACGTGAAATATGATACGAAG	BamHI-NdeI
	Rev	CCCGCTCGAGTTTACTCCTATAACGAGGTCTCTTAAC	XhoI
orf46.1-His	Fwd	GGGAATTCCATATGTCAGATTTGGCAAACGATTCTT	NdeI
	Rev	CCCGCTCGAGCGTATCATATTTACGTGC	XhoI
orf46.2-His	Fwd	GGGAATTCCATATGTCAGATTTGGCAAACGATTCTT	NdeI
	Rev	CCCGCTCGAGTTTACTCCTATAACGAGGTCTCTTAAC	XhoI
Orf65-1-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG-CAAAATGCGTTCAAAATCCC	BamHI-NdeI
	Rev	CGCGGATCCCATATG-AACAAAATATACCGCAT CCCGCTCGAG-TTTGCTTTTCGATAGAACGG	XhoI
Orf72-1L	Fwd	GCGGCCATATG-GTCATAAAATATACAAATTTGAA	NdeI
	Rev	GCGGCCTCGAG-TTAGCCTGAGACCTTTGCAAATT	XhoI
Orf76-1L	Fwd	GCGGCCATATG-AAACAGAAAAAACCGCTG	NdeI
	Rev	GCGGCCTCGAG-TTACGGTTTGACACCGTTTTTC	XhoI
Orf83.1L	Fwd	CGCGGATCCCATATG-AAAACCCTGCTCCTC	NdeI
	Rev	CCCGCTCGAG-TTATCCTCCTTTGCGGC	XhoI
Orf85-2L	Fwd	GCGGCCATATG-GCAAAAATGATGAAATGGG	NdeI
	Rev	GCGGCCTCGAG-TTATCGGCGCGGCGGGCC	XhoI
Orf91L (MC58)	Fwd	GCGGCCATATGAAAAAATCCTCCCTCATCA	NdeI
	Rev	GCGGCCTCGAGTTATTTGCCGCCGTTTTTGGC	XhoI
Orf91-His(MC58)	Fwd	GCGGCCATATGGCCCCTGCCGACGCGGTAAG	NdeI
	Rev	GCGGCCTCGAGTTTGCCGCCGTTTTTGGCTTTC	XhoI
Orf97-1L	Fwd	GCGGCCATATG-AAACACATACTCCCCCTGA	NdeI
	Rev	GCGGCCTCGAG-TTATTCGCTACGGTTTTTTTG	XhoI
Orf119L (MC58)	Fwd	GCGGCCATATGATTTACATCGTACTGTTTC	NdeI
	Rev	GCGGCCTCGAGTTAGGAGAACAGGCGCAATGC	XhoI
Orf119-His(MC58)	Fwd	GCGGCCATATGTACAACATGTATCAGGAAAAC	NdeI
	Rev	GCGGCCTCGAGGGAGAACAGGCGCAATGCGG	XhoI
Orf137.1 (His-GST) (MC58)	Fwd	CGCGGATCCGCTAGCTGCGGCACGGCGGG	BamHI-NheI
	Rev	CCCGCTCGAGATAACGGTATGCCGCCAG	XhoI
Orf143-1L	Fwd	CGCGGATCCCATATG-GAATCAACACTTTTAC	NdeI
	Rev	CCCGCTCGAG-TTACACGCGGTTGCTGT	XhoI
008	Fwd	CGCGGATCCCATATG-AACAACAGACATTTTG	NdeI
	Rev	CCCGCTCGAG-TTACCTGTCCGGTAAAAG	XhoI
050-1(48)	Fwd	CGCGGATCCGCTAGC-ACCGTCATCAAACAGGAA	NheI
	Rev	CCCGCTCGAG-TCAAGATTCGACGGGGA	XhoI
105	Fwd	CGCGGATCCCATATG-TCCGCAAACGAATACG	NdeI
	Rev	CCCGCTCGAG-TCAGTGTCTGCCAGTTT	XhoI
111L	Fwd	CGCGGATCCCATATG-CCGTCTGAAACACG	NdeI
	Rev	CCCGCTCGAG-TTAGCGGAGCAGTTTTTC	XhoI
117-1	Fwd	CGCGGATCCCATATG-ACCGCCATCAGCC	NdeI
	Rev	CCCGCTCGAG-TTAAAGCCGGGTAACGC	XhoI
121-1	Fwd	GCGGCCATATG-GAAACACAGCTTTACATCGG	NdeI
	Rev	GCGGCCTCGAG-TCAATAATAATATCCCGCG	XhoI

122-1	Fwd	GCGGCCATATG-ATTAAATCCGCAATATCC	NdeI
	Rev	GCGGCCTCGAG-TTAAATCTTGGTAGATTGGATTGG	XhoI
128-1	Fwd	GCGGCCATATG-ACTGACAACGCACTGCTCC	NdeI
	Rev	GCGGCCTCGAG-TCAGACCGCGTTGTCGAAAC	XhoI
148	Fwd	CGCGGATCCCATATG-GCGTTAAAAACATCAAA	NdeI
	Rev	CCCGCTCGAG-TCAGCCCTTCATACAGC	XhoI
149.1L (MC58)	Fwd	GCGGCATTAATGGCACAACACTCAAAACC	AseI
	Rev	GCGGCCTCGAGTTAAACTTCACGTTACGCCG	XhoI
149.1-His(MC58)	Fwd	GCGGCATTAATGCATGAACTGAGCAATCGGTGG	AseI
	Rev	GCGGCCTCGAGAACTTCACGTTACGCCGCCGGTAAA	XhoI
205 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGGGCAAATCCGAAAATACG	BamHI-NdeI
	Rev	CCCGCTCGAGATAATGGCGGCGGCGG	XhoI
206L	Fwd	CGCGGATCCCATATG-TTCCCCCGACAA	NdeI
	Rev	CCCGCTCGAG-TCATTCTGTAAAAAAGTATG	XhoI
214 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGCTTCAAAGCGACAGCAG	BamHI-NdeI
	Rev	CCCGCTCGAGTTCGGATTTTTGCGTACTC	XhoI
216	Fwd	CGCGGATCCCATATG-GCAATGGCAGAAAACG	NdeI
	Rev	CCCGCTCGAG-CTATACAATCCGTGCCG	XhoI
225-1L	Fwd	CGCGGATCCCATATG-GATTCTTTTTCAAACC	NdeI
	Rev	CCCGCTCGAG-TCAGTTCAGAAAGCGGG	XhoI
235L	Fwd	CGCGGATCCCATATG-AAACCTTTGATTTTAGG	NdeI
	Rev	CCCGCTCGAG-TTATTTGGGCTGCTCTC	XhoI
243	Fwd	CGCGGATCCCATATG-GTAATCGTCTGGTTG	NdeI
	Rev	CCCGCTCGAG-CTACGACTTGGTTACCG	XhoI
247-1L	Fwd	GCGGCCATATG-AGACGTAAAATGCTAAAGCTAC	NdeI
	Rev	GCGGCCTCGAG-TCAAAGTGTCTGTTTGCGC	XhoI
264-His	Fwd	GCCGCCATATG-TTGACTTTAACCCGAAAAA	NdeI
	Rev	GCCGCTCGAG-GCCGCGGTCAATACGCCCGAA	XhoI
270 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGGCGCAATGCGATTTGAC	BamHI-NdeI
	Rev	CCCGCTCGAGTTCGGCGGTAAATGCCG	XhoI
274L	Fwd	GCGGCCATATG-GCGGGGCCGATTTTTGT	NdeI
	Rev	GCGGCCTCGAG-TTATTTGCTTTCAGTATTATTG	XhoI
283L	Fwd	GCGGCCATATG-AACTTTGCTTTATCCGTCA	NdeI
	Rev	GCGGCCTCGAG-TTAACGGCAGTATTTGTTTAC	XhoI
285-His	Fwd	CGCGGATCCCATATGGGTTTTCGCTTCGGGC	BamHI
	Rev	GCCCAAGCTTTTTTCTTTGCCGTTTCCG	HindIII
286-His (MC58)	Fwd	CGCGGATCCCATATG-GCCGACCTTTCGAAAAA	NdeI
	Rev	CCCGCTCGAG-GAAGCGCGTTCCCAAGC	XhoI
286L (MC58)	Fwd	CGCGGATCCCATATG-CACGACACCCGTAC	NdeI
	Rev	CCCGCTCGAG-TTAGAAGCGCGTTCCCAA	XhoI
287L	Fwd	CTAGCTAGC-TTAAACGCAGCGTAATCGCAATGG	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI

287	Fwd	CTAGCTAGC-GGGGGCGGCGGTGGCG	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
287Lorf4	Fwd	CTAGCTAGCGCTCATCTCGCCGCC-TGCGGGGGCGGCGGT	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
287-fu	Fwd	CGGGGATCC-GGGGGCGGCGGTGGCG	BamHI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
287-His	Fwd	CTAGCTAGC-GGGGGCGGCGGTGGCG	NheI
	Rev	CCCGCTCGAG-ATCCTGCTCTTTTTTGCC *	XhoI
287-His(2996)	Fwd	CTAGCTAGC-TGCGGGGGCGGCGGTGGCG	NheI
	Rev	CCCGCTCGAG-ATCCTGCTCTTTTTTGCC	XhoI
Δ 1 287-His	Fwd	CGCGGATCCGCTAGC-CCCAGTGTTAAATCGGC [§]	NheI
Δ 2 287-His	Fwd	CGCGGATCCGCTAGC-CAAGATATGGCGGCAGT [§]	NheI
Δ 3 287-His	Fwd	CGCGGATCCGCTAGC-GCCGAATCCGCAAAATCA [§]	NheI
Δ 4 287-His	Fwd	CGCGCTAGC-GGAAGGGTTGATTGGCTAATGG [§]	NheI
Δ 4 287MC58-His	Fwd	CGCGCTAGC-GGAAGGGTTGATTGGCTAATGG [§]	NheI
287a-His	Fwd	CGCCATATG-TTAAACGCAGCGTAATCGC	NdeI
	Rev	CCCGCTCGAG-AAAATTGCTACCGCCATTTCGAGG	XhoI
287b-His	Fwd	CGCCATATG-GGAAGGGTTGATTGGCTAATGG	NdeI
287b-2996-His	Rev	CCCGCTCGAG-CTTGCTTTTATAAATGATGACATATTTG	XhoI
287b-MC58-His	Rev	CCCGCTCGAG-TTTATAAAAGATAATATATTGATTGATTCC	XhoI
287c-2996-His	Fwd	CGCGCTAGC-ATGCCGCTGATTCGCGTCAATC [§]	NheI
'287 ^{untagged} ' (2996)	Fwd	CTAGCTAGC-GGGGGCGGCGGTGGCG	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
Δ G287-His *	Fwd	CGCGGATCCGCTAGC-CCCAGTGTTAAATCGGC	NheI
	Rev	CCCGCTCGAG-ATCCTGCTCTTTTTTGCC	XhoI
Δ G287K(2996)	Fwd	CGCGGATCCGCTAGC-CCCAGTGTTAAATCGGC	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
Δ G 287-L	Fwd	CGCGGATCCGCTAGC-TTTGAACGCAGTGTGATTGCAATGGCTTGTATTTTTTGCC CTTTCAGCCTGT TCGCCCGATGTTAAATCGGCG	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
Δ G 287-Orf4L	Fwd	CGCGGATCCGCTAGC-AAAACCTTCTTCAAAACCCCTTCCGCCGCCGCACTCGCG CTCATCCTCGCCGCTGC TCGCCCGATGTTAAATCG	NheI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
292L	Fwd	CGCGGATCCCATATG-AAAACCAAGTTAATCAAA	NdeI
	Rev	CCCGCTCGAG-TTATTGATTTTTGCGGATGA	XhoI
308-1	Fwd	CGCGGATCCCATATG-TTAAATCGGGTATTTTATC	NdeI
	Rev	CCCGCTCGAG-TTAATCCGCCATTCCCTG	XhoI
401L	Fwd	GCGGCCATATG-AAATTACAACAATTGGCTG	NdeI
	Rev	GCGGCCTCGAG-TTACCTTACGTTTTTCAAAG	XhoI
406L	Fwd	CGCGGATCCCATATG-CAAGCACGGCTGCT	NdeI
	Rev	CCCGCTCGAG-TCAAGGTTGTCTTGTCTA	XhoI
502-1L	Fwd	CGCGGATCCCATATG-ATGAAACCGCACAAAC	NdeI
	Rev	CCCGCTCGAG-TCAGTTGCTCAACACGTC	XhoI

502-A (His-GST)	Fwd	CGCGGATCCCATATGGTAGACGCGCTTAAGCA	BamHI-NdeI
	Rev	CCCGCTCGAGAGCTGCATGGCGGCG	XhoI
503-1L	Fwd	CGCGGATCCCATATG-GCACGGTCGTTATAC	NdeI
	Rev	CCCGCTCGAG-CTACCGCGCATTCCTG	XhoI
519-1L	Fwd	GCGGCCATATG-GAATTTTTCATTATCTTGTT	NdeI
	Rev	GCGGCCTCGAG-TTATTTGGCGGTTTTGCTGC	XhoI
525-1L	Fwd	GCGGCCATATG-AAGTATGTCCGGTTATTTTC	NdeI
	Rev	GCGGCCTCGAG-TTATCGGCTTGTCACCGG	XhoI
529-(His/GST) (MC58)	Fwd	CGCGGATCCGCTAGC-TCCGGCAGCAAAACCGA	Bam HI-NheI
	Rev	GCCCAAGCTT-ACGCAGTTCGGAATGGAG	HindIII
552L	Fwd	GCCGCCATATGTTGAATATTAAGTAAACCTTG	NdeI
	Rev	GCCGCCTCGAGTTATTTCTGATGCCTTTTCCC	XhoI
556L	Fwd	GCCGCCATATGGACAATAAGACCAAACCTG	NdeI
	Rev	GCCGCCTCGAGTTAACGGTGCAGGACGTTTC	XhoI
557L	Fwd	CGCGGATCCCATATG-AACAACTGTTTCTTAC	NdeI
	Rev	CCCGCTCGAG-TCATTCCGCCTTCAGAAA	XhoI
564ab-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG- CAAGGTATCGTTGCCGACAAATCCGCACCT	BamHI-NdeI
	Rev	CCCGCTCGAG- AGCTAATTGTGCTTGGTTTGCAGATAGGAGTT	XhoI
564abL (MC58)	Fwd	CGCGGATCCCATATG- AACCGCACCTGTACAAAGTTGTATTTAACAAACATC	NdeI
	Rev	CCCGCTCGAG- TTAAGCTAATTGTGCTTGGTTTGCAGATAGGAGTT	XhoI
564b- (His/GST)(MC58)	Fwd	CGCGGATCCCATATG- ACGGGAGAAAATCATGCGGTTTCACTTCATG	BamHI-NdeI
	Rev	CCCGCTCGAG- AGCTAATTGTGCTTGGTTTGCAGATAGGAGTT	XhoI
564c- (His/GST)(MC58)	Fwd	CGCGGATCCCATATG- GTTTCAGACGGCCTATACAACCAACATGGTGAAATT	BamHI-NdeI
	Rev	CCCGCTCGAG- GCGGTAAGTCCGCTTGCACTGAATCCGTAA	XhoI
564bc- (His/GST)(MC58)	Fwd	CGCGGATCCCATATG- ACGGGAGAAAATCATGCGGTTTCACTTCATG	BamHI-NdeI
	Rev	CCCGCTCGAG- GCGGTAAGTCCGCTTGCACTGAATCCGTAA	XhoI
564d- (His/GST)(MC58)	Fwd	CGCGGATCCCATATG- CAAAGCAAAGTCAAAGCAGACCATGCCTCCGTAA	BamHI-NdeI
	Rev	CCCGCTCGAG- TCTTTTCCTTTCAATTATAACTTTAGTAGGTTCAATTTTG GTCCCC	XhoI
564cd- (His/GST)(MC58)	Fwd	CGCGGATCCCATATG- GTTTCAGACGGCCTATACAACCAACATGGTGAAATT	BamHI-NdeI
	Rev	CCCGCTCGAG- TCTTTTCCTTTCAATTATAACTTTAGTAGGTTCAATTTTG GTCCCC	XhoI
570L	Fwd	GCGGCCATATG-ACCCGTTTGACCCGCG	NdeI
	Rev	GCGGCCTCGAG-TCAGCGGGCGTTTCAATTTCTT	XhoI
576-1L	Fwd	CGCGGATCCCATATG-AACACCATTTTCAAATC	NdeI
	Rev	CCCGCTCGAG-TTAATTTACTTTTTTGATGTGCG	XhoI

580L	Fwd	GCGGCCATATG-GATTCGCCCAAGGTCGG	NdeI
	Rev	GCGGCCTCGAG-CTACACTTCCCCGAAGTGG	XhoI
583L	Fwd	CGCGGATCCCATATG-ATAGTTGACCAAAGCC	NdeI
	Rev	CCCGCTCGAG-TTATTTTCCGATTTTCGG	XhoI
593	Fwd	GCGGCCATATG-CTTGAACGAACGGACT	NdeI
	Rev	GCGGCCTCGAG-TCAGCGGAAGCGGACGATT	XhoI
650 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGTCCAAACTCAAACCATCG	BamHI-NdeI
	Rev	CCCGCTCGAGGCTTCCAATCAGTTTGACC	XhoI
652	Fwd	GCGGCCATATG-AGCGCAATCGTTGATATTTTC	NdeI
	Rev	GCGGCCTCGAG-TTATTTGCCAGTTGGTAGAATG	XhoI
664L	Fwd	GCGGCCATATG-GTGATACATCCGCACTACTTC	NdeI
	Rev	GCGGCCTCGAG-TCAAAATCGAGTTTACACCA	XhoI
726	Fwd	GCGGCCATATG-ACCATCTATTTCAAAAACGG	NdeI
	Rev	GCGGCCTCGAG-TCAGCCGATGTTTAGCGTCCATT	XhoI
741-His(MC58)	Fwd	CGCGGATCCCATATG-AGCAGCGGAGGGGGTG	NdeI
	Rev	CCCGCTCGAG-TTGCTTGCGGCAAGGC	XhoI
ΔG741-His(MC58)	Fwd	CGCGGATCCCATATG-GTCGCCGCCGACATCG	NdeI
	Rev	CCCGCTCGAG-TTGCTTGCGGCAAGGC	XhoI
686-2-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GGCGGTTCCGAAGGCG	BamHI-NdeI
	Rev	CCCGCTCGAG-TTGAACACTGATGTCTTTCCGA	XhoI
719-(His/GST) (MC58)	Fwd	CGCGGATCCGCTAGC-AAACTGTCGTTGGTGTTAAC	BamHI-NheI
	Rev	CCCGCTCGAG-TTGACCCGCTCCACGG	XhoI
730-His (MC58)	Fwd	GCCGCCATATGGCGGACTTGCGCAAGACCC	NdeI
	Rev	GCCGCCTCGAGATCTCCTAAACCTGTTTAACAATGCCG	XhoI
730A-His (MC58)	Fwd	GCCGCCATATGGCGGACTTGCGCAAGACCC	NdeI
	Rev	GCGGCCTCGAGCTCCATGCTGTTGCCCCAGC	XhoI
730B-His (MC58)	Fwd	GCCGCCATATGGCGGACTTGCGCAAGACCC	NdeI
	Rev	GCGGCCTCGAGAAAATCCCCGCTAACCGCAG	XhoI
741-His (MC58)	Fwd	CGCGGATCCCATATG-AGCAGCGGAGGGGGTG	NdeI
	Rev	CCCGCTCGAG-TTGCTTGCGGCAAGGC	XhoI
ΔG741-His (MC58)	Fwd	CGCGGATCCCATATG-GTCGCCGCCGACATCG	NdeI
	Rev	CCCGCTCGAG-TTGCTTGCGGCAAGGC	XhoI
743 (His-GST)	Fwd	CGCGGATCCCATATGGACGGTGTGTGCCTGTT	BamHI-NdeI
	Rev	CCCGCTCGAGCTTACGGATCAAATTGACG	XhoI
757 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGGGCAGCCAATCTGAAGAA	BamHI-NdeI
	Rev	CCCGCTCGAGCTCAGCTTTTGCCGTCAA	XhoI
759-His/GST (MC58)	Fwd	CGCGGATCCGCTAGC-TACTCATCCATTGTCCGC	BamHI-NheI
	Rev	CCCGCTCGAG-CCAGTTGTAGCCTATTTTG	XhoI
759L (MC58)	Fwd	CGCGGATCCGCTAGC-ATGCGCTTCACACACAC	NheI
	Rev	CCCGCTCGAG-TTACCAGTTGTAGCCTATTT	XhoI
760-His	Fwd	GCCGCCATATGGCACAACGGAAGGTTTGGA	NdeI
	Rev	GCCGCCTCGAGAAAACGTAAACGCAGGTTTGCCGTC	XhoI
769-His (MC58)	Fwd	GCGGCCATATGGAAGAAACACCGCGCAACCG	NdeI

	Rev	GCGGCCTCGAGGAACGTTTTATTAAACTCGAC	XhoI
907L	Fwd	GCGGCCATATG-AGAAAACCGACCGATACCCTA	NdeI
	Rev	GCGGCCTCGAG-TCAACGCCACTGCCAGCGGTTG	XhoI
911L	Fwd	CGCGGATCCCATATG-AAGAAGAACATATTGGAATTTGGGTCGGA CTG	NdeI
	Rev	CCCGCTCGAG-TTATTCGGCGGCTTTTCCGCATTGCCG	XhoI
911LOmpA	Fwd	GGGAATTCCATATGAAAAAGACAGCTATCGCGATTGCA GTGGCACTGGCTGGTTTCGCTACCGTAGCGCAGGCCG TAGC-GCTTTCCGCGTGGCCGGCGGTGC	NdeI-(NheI)
	Rev	CCCGCTCGAG-TTATTCGGCGGCTTTTCCGCATTGCCG	XhoI
911LPelB	Fwd	CATGCCATGG-CTTCCGCGTGGCCGGCGGTGC	NcoI
	Rev	CCCGCTCGAG-TTATTCGGCGGCTTTTCCGCATTGCCG	XhoI
913-His/GST (MC58)	Fwd	CGCGGATCCCATATG-TTGCCGAAACCCGCC	BamHI-NdeI
	Rev	CCCGCTCGAG-AGGTTGTGTTCAGGTTG	XhoI
913L (MC58)	Fwd	CGCGGATCCCATATG-AAAAAAACCGCCTATG	NdeI
	Rev	CCCGCTCGAG-TTAAGGTTGTGTTCAGG	XhoI
919L	Fwd	CGCGGATCCCATATG-AAAAAATACCTATTCCGC	NdeI
	Rev	CCCGCTCGAG-TTACGGGCGGTATTCCG	XhoI
919	Fwd	CGCGGATCCCATATG-CAAAGCAAGAGCATCCAAA	NdeI
	Rev	CCCGCTCGAG-TTACGGGCGGTATTCCG	XhoI
919L Orf4	Fwd	GGGAATTCCATATGAAAACCTTCTTCAAAACCTTTCCG CCGCCGCTAGCGCTCATCCTCGCCGCC- TGCCAAAGCAAGAGCATC	NdeI-(NheI)
	Rev	CCCGCTCGAG-TTACGGGCGGTATTCCGGCTTCATACCG	XhoI
(919)-287fusion	Fwd	CGCGGATCCGTCGAC-TGTGGGGGCGGCGGTGGC	SalI
	Rev	CCCGCTCGAG-TCAATCCTGCTCTTTTTTGCC	XhoI
920-1L	Fwd	GCGGCCATATG-AAGAAAACATTGACACTGC	NdeI
	Rev	GCGGCCTCGAG-TTAATGGTGCGAATGACCGAT	XhoI
925-His/GST (MC58) ^{GATE}	Fwd	ggggacaagttgtacaaaaagcaggctTGCGGCAAGGATGCCGG	attB1
	Rev	ggggaccactttgtacaagaagctgggtCTAAAGCAACAATGCCGG	attB2
926L	Fwd	CGCGGATCCCATATG-AAACACACCGTATCC	NdeI
	Rev	CCCGCTCGAG-TTATCTCGTGCGCGCC	XhoI
927-2-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG-AGCCCCGCGCCGATT	BamHI-NdeI
	Rev	CCCGCTCGAG-TTTTTGTGCGGTCAGGCG	XhoI
932-His/GST (MC58) ^{GATE}	Fwd	ggggacaagttgtacaaaaagcaggctTGTTCTGTTTGGGGGATTTAA ACCAAACCAAATC	attB1
935 (His-GST) (MC58)	For	CGCGGATCCCATATGGCGGATGCGCCCGCG	BamHI-NdeI
	Rev	CCCGCTCGAGAAACCGCCAATCCGCC	XhoI
936-1L	Rev	ggggaccactttgtacaagaagctgggtTCATTTGTTTTTCCTTCTTCT CGAGGCCATT	attB2
	Fwd	CGCGGATCCCATATG-AAACCCAAACCGCAC	NdeI
	Rev	CCCGCTCGAG-TCAGCGTTGACGTAGT	XhoI
953L	Fwd	GGGAATTCCATATG-AAAAAATCATCTTCGCCG	NdeI
	Rev	CCCGCTCGAG-TTATTGTTTGGCTGCCTCGAT	XhoI
953-fu	Fwd	GGGAATTCCATATG-GCCACCTACAAAGTGGACG	NdeI
	Rev	CGGGGATCC-TTGTTTGGCTGCCTCGATTTG	BamHI

954 (His-GST) (MC58)	Fwd	CGCGGATCCCATATGCAAGAACAAATCGCAGAAAG	BamHI-NdeI
	Rev	CCCGCTCGAGTTTTTTCGGCAAATTGGCTT	XhoI
958-His/GST (MC58) ^{GATE}	Fwd	ggggacaagttgtacaaaaagcaggctGCCGATGCCGTTGCGG	<i>attB1</i>
	Rev	ggggaccactttgtacaagaagctgggtTCAGGGTCGTTTGTGCG	<i>attB2</i>
961L	Fwd	CGCGGATCCCATATG-AAACACTTTCCATCC	NdeI
	Rev	CCCGCTCGAG-TTACCACTCGTAATTGAC	XhoI
961	Fwd	CGCGGATCCCATATG-GCCACAAGCGACGAC	NdeI
	Rev	CCCGCTCGAG-TTACCACTCGTAATTGAC	XhoI
961 c (His/GST)	Fwd	CGCGGATCCCATATG-GCCACAAACGACG	BamHI-NdeI
	Rev	CCCGCTCGAG-ACCCACGTTGTAAGGTTG	XhoI
961 c-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GCCACAAGCGACGACGA	BamHI-NdeI
	Rev	CCCGCTCGAG-ACCCACGTTGTAAGGTTG	XhoI
961 c-L	Fwd	CGCGGATCCCATATG-ATGAAACACTTTCCATCC	NdeI
	Rev	CCCGCTCGAG-TTAACCCACGTTGTAAGGT	XhoI
961 c-L (MC58)	Fwd	CGCGGATCCCATATG-ATGAAACACTTTCCATCC	NdeI
	Rev	CCCGCTCGAG-TTAACCCACGTTGTAAGGT	XhoI
961 d (His/GST)	Fwd	CGCGGATCCCATATG-GCCACAAACGACG	BamHI-NdeI
	Rev	CCCGCTCGAG-GTCTGACACTGTTTTATCC	XhoI
961 Δ1-L	Fwd	CGCGGATCCCATATG-ATGAAACACTTTCCATCC	NdeI
	Rev	CCCGCTCGAG-TTATGCTTTGGCGGCAAAG	XhoI
fu 961-...	Fwd	CGCGGATCCCATATG- GCCACAAACGACGAC	NdeI
	Rev	CGCGGATCC-CCACTCGTAATTGACGCC	BamHI
fu 961-... (MC58)	Fwd	CGCGGATCCCATATG-GCCACAAGCGACGAC	NdeI
	Rev	CGCGGATCC-CCACTCGTAATTGACGCC	BamHI
fu 961 c -...	Fwd	CGCGGATCCCATATG-GCCACAAACGACGAC	NdeI
	Rev	CGCGGATCC -ACCCACGTTGTAAGGTTG	BamHI
fu 961 c-L-...	Fwd	CGCGGATCCCATATG- ATGAAACACTTTCCATCC	NdeI
	Rev	CGCGGATCC -ACCCACGTTGTAAGGTTG	BamHI
fu (961)- 741(MC58)-His	Fwd	CGCGGATCC -GGAGGGGGTGGTGTCC	BamHI
	Rev	CCCGCTCGAG-TTGCTTGGCGGCAAGGC	XhoI
fu (961)-983-His	Fwd	CGCGGATCC - GGCGGAGGCGGCACTT	BamHI
	Rev	CCCGCTCGAG-GAACC GG TAGCCTACG	XhoI
fu (961)- Orf46.1- His	Fwd	CGCGGATCCGGTGGTGGTGGT- TCAGATTTGGCAAACGATTC	BamHI
	Rev	CCCGCTCGAG-CGTATCATATTTACGTGC	XhoI
fu (961 c-L)- 741(MC58)	Fwd	CGCGGATCC -GGAGGGGGTGGTGTCC	BamHI
	Rev	CCCGCTCGAG-TTATTGCTTGGCGGCAAG	XhoI
fu (961c-L)-983	Fwd	CGCGGATCC - GGCGGAGGCGGCACTT	BamHI
	Rev	CCCGCTCGAG-TCAGAACCGGTAGCCTAC	XhoI
fu (961c-L)- Orf46.1	Fwd	CGCGGATCCGGTGGTGGTGGT- TCAGATTTGGCAAACGATTC	BamHI
	Rev	CCCGCTCGAG-TTACGTATCATATTTACGTGC	XhoI
961-(His/GST)	Fwd	CGCGGATCCCATATG-GCCACAAGCGACGACG	BamHI-NdeI

(MC58)	Rev	CCCGCTCGAG-CCACTCGTAATTGACGCC	XhoI
961 Δ1-His	Fwd	CGCGGATCCCATATG-GCCACAAACGACGAC	NdeI
	Rev	CCCGCTCGAG-TGCTTTGGCGGCAAAGTT	XhoI
961a-(His/GST)	Fwd	CGCGGATCCCATATG-GCCACAAACGACGAC	BamHI-NdeI
	Rev	CCCGCTCGAG-TTTAGCAATATTATCTTTGTTCTGTAGC	XhoI
961b-(His/GST)	Fwd	CGCGGATCCCATATG-AAAGCAAACCGTGCCGA	BamHI-NdeI
	Rev	CCCGCTCGAG-CCACTCGTAATTGACGCC	XhoI
961-His/GST ^{GATE}	Fwd	ggggacaagtttgtacaaaaaagcaggctGCAGCCACAAACGACGACG ATGTTAAAAAAGC	attB1
	Rev	ggggaccacttgtacaagaagctgggtTTACCACTCGTAATTGACGC CGACATGGTAGG	attB2
982	Fwd	GCGGCCATATG-GCAGCAAAAGACGTACAGTT	NdeI
	Rev	GCGGCCTCGAG-TTACATCATGCCGCCCATACCA	XhoI
983-His (2996)	Fwd	CGCGGATCCGCTAGC-TTAGGCGGGCGGCGGAG	NheI
	Rev	CCCGCTCGAG-GAACCGGTAGCCTACG	XhoI
ΔG983-His (2996)	Fwd	CCCCTAGCTAGC-ACTTCTGCGCCCGACTT	NheI
	Rev	CCCGCTCGAG-GAACCGGTAGCCTACG	XhoI
983-His	Fwd	CGCGGATCCGCTAGC-TTAGGCGGGCGGCGGAG	NheI
	Rev	CCCGCTCGAG-GAACCGGTAGCCTACG	XhoI
ΔG983-His	Fwd	CGCGGATCCGCTAGC-ACTTCTGCGCCCGACTT	NheI
	Rev	CCCGCTCGAG-GAACCGGTAGCCTACG	XhoI
983L	Fwd	CGCGGATCCGCTAGC- CGAACGACCCCAACCTTCCCTACAAAACTTTCAA	NheI
	Rev	CCCGCTCGAG-TCAGAACCGACGTGCCAAGCCGTTC	XhoI
987-His (MC58)	Fwd	GCCGCCATATGCCCCCACTGGAAGAACGGACG	NdeI
	Rev	GCCGCCTCGAGTAATAAACCTTCTATGGGCAGCAG	XhoI
989-(His/GST) (MC58)	Fwd	CGCGGATCCCATATG-TCCGTCCACGCATCCG	BamHI-NdeI
	Rev	CCCGCTCGAG-TTTGAATTTGTAGGTGTATTG	XhoI
989L (MC58)	Fwd	CGCGGATCCCATATG-ACCCCTTCCGCACT	NdeI
	Rev	CCCGCTCGAG-TTATTTGAATTTGTAGGTGTAT	XhoI
CrgA-His (MC58)	Fwd	CGCGGATCCCATATG-AAAACCAATTCAGAAGAA	NdeI
	Rev	CCCGCTCGAG-TCCACAGAGATTGTTTCC	XhoI
PilC1-ES (MC58)	Fwd	GATGCCCGAAGGGCGGG	
	Rev	GCCCAAGCTT-TCAGAAGAAGACTTCACGC	
PilC1-His (MC58)	Fwd	CGCGGATCCCATATG-CAAACCCATAAATACGCTATT	NdeI
	Rev	GCCCAAGCTT-GAAGAAGACTTCACGCCAG	HindIII
Δ1PilC1-His (MC58)	Fwd	CGCGGATCCCATATG-GTCTTTTTCGACAATACCGA	NdeI
	Rev	GCCCAAGCTT-	HindIII
PilC1L (MC58)	Fwd	CGCGGATCCCATATG-AATAAACTTTAAAAAGGCGG	NdeI
	Rev	GCCCAAGCTT-TCAGAAGAAGACTTCACGC	HindIII
ΔGTbp2-His (MC58)	Fwd	CGCGAATCCCATATG-TTCGATCTTGATTCTGTCGA	NdeI
	Rev	CCCGCTCGAG-TCGCACAGGCTGTTGGCG	XhoI
Tbp2-His (MC58)	Fwd	CGCGAATCCCATATG-TTGGGCGGAGGCGGCAG	NdeI
	Rev	CCCGCTCGAG-TCGCACAGGCTGTTGGCG	XhoI
Tbp2-His(MC58)	Fwd	CGCGAATCCCATATG-TTGGGCGGAGGCGGCAG	NdeI
	Rev	CCCGCTCGAG-TCGCACAGGCTGTTGGCG	XhoI

NMB0109- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GCAAATTTGGAGGTGCGC	BamHI-NdeI
	Rev	CCCGCTCGAG-TTCGGAGCGGTTGAAGC	XhoI
NMB0109L (MC58)	Fwd	CGCGGATCCCATATG-CAACGTCGTATTATAACCC	NdeI
	Rev	CCCGCTCGAG-TTATTCGGAGCGGTTGAAG	XhoI
NMB0207- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GGCATCAAAGTCGCCATCAACGGCTAC	BamHI-NdeI
	Rev	CCCGCTCGAG-TTTGAGCGGGCGCACTTCAAGTCCG	XhoI
NMB0462- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GGCGGCAGCGAAAAAAC	BamHI-NdeI
	Rev	CCCGCTCGAG-GTTGGTGCCGACTTTGAT	XhoI
NMB0623- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GGCGGCGGAAGCGATA	BamHI-NdeI
	Rev	CCCGCTCGAG-TTTGCCCGCTTTGAGCC	XhoI
NMB0625 (His- GST)(MC58)	Fwd	CGCGGATCCCATATGGGCAAATCCGAAAATACG	BamHI-NdeI
	Rev	CCCGCTCGAGCATCCCGTACTGTTTCG	XhoI
NMB0634 (His/GST)(MC58)	Fwd	ggggacaagttgtacaaaaagcaggctCCGACATTACCGTGTACAAC GGCCAACAAAGAA	<i>attB1</i>
	Rev	ggggaccactttgtacaagaaagctgggtCTTATTCATACCGGCTTGCT CAAGCAGCCGG	<i>attB2</i>
NMB0776- His/GST (MC58) GATE	Fwd	ggggacaagttgtacaaaaagcaggctGATACGGTGTTTTCTGTAA AACGGACAACAA	<i>attB1</i>
	Rev	ggggaccactttgtacaagaaagctgggtCTAGGAAAAATCGTCATCGT TGAAATTCGCC	<i>attB2</i>
NMB1115- His/GST (MC58) GATE	Fwd	ggggacaagttgtacaaaaagcaggctATGCACCCCATCGAAACC	<i>attB1</i>
	Rev	ggggaccactttgtacaagaaagctgggtCTAGTCTTGCAGTGCCTC	<i>attB2</i>
NMB1343- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-GGAAATTTCTTATATAGAGGCATTAG	BamHI-NdeI
	Rev	CCCGCTCGAG-GTTAATTTCTATCAACTCTTTAGCAATAAT	XhoI
NMB1369 (His- GST) (MC58)	Fwd	CGCGGATCCCATATGGCCTGCCAAGACGACA	BamHI-NdeI
	Rev	CCCGCTCGAGCCGCCTCTGCCGAAA	XhoI
NMB1551 (His- GST)(MC58)	Fwd	CGCGGATCCCATATGGCAGAGATCTGTTTGATAA	BamHI-NdeI
	Rev	CCCGCTCGAGCGGTTTTCCGCCCAATG	XhoI
NMB1899 (His- GST) (MC58)	Fwd	CGCGGATCCCATATGCAGCCGGATACGGTC	BamHI-NdeI
	Rev	CCCGCTCGAGAATCACTTCCAACACAAAAT	XhoI
NMB2050- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-TGTTTGCTGATGAAGGGC	BamHI-NdeI
	Rev	CCCGCTCGAG-GACTGCTTCATCTTCTGC	XhoI
NMB2050L (MC58)	Fwd	CGCGGATCCCATATG-GAACTGATGACTGTTTTGC	NdeI
	Rev	CCCGCTCGAG-TCAGACTGCTTCATCTTCT	XhoI
NMB2159- (His/GST) (MC58)	Fwd	CGCGGATCCCATATG-AGCATTAAGTAGCGATTAACGGTTTCGGC	BamHI-NdeI
	Rev	CCCGCTCGAG-GATTTTGCCTGCGAAGTATTCCAAAGTGCG	XhoI
fu-ΔG287...-His	Fwd	CGCGGATCCGCTAGC-CCCGATGTAAATCGGC	NheI

	Rev	CGGGGATCC-ATCCTGCTCTTTTTTGCCGG	BamHI
fu-(ΔG287)-919-His	Fwd	CGCGGATCCGGTGGTGGTGGT-CAAAGCAAGAGCATCCAAACC	BamHI
	Rev	CCCAAGCTT-TTCGGGCGGTATTCGGGGCTTC	HindIII
fu-(ΔG287)-953-His	Fwd	CGCGGATCCGGTGGTGGTGGT-GCCACCTACAAAGTGGAC	BamHI
	Rev	GCCCAAGCTT-TTGTTTGGCTGCCTCGAT	HindIII
fu-(ΔG287)-961-His	Fwd	CGCGGATCCGGTGGTGGTGGT-ACAAGCGACGACG	BamHI
	Rev	GCCCAAGCTT-CCACTCGTAATTGACGCC	HindIII
fu-(ΔG287)-Orf46.1-His	Fwd	CGCGGATCCGGTGGTGGTGGT-TCAGATTGGCAAACGATTC	BamHI
	Rev	CCCAAGCTT-CGTATCATATTTACGTGC	HindIII
fu-(ΔG287-919)-Orf46.1-His	Fwd	CCCAAGCTTGGTGGTGGTGGTGGT-TCAGATTGGCAAACGATTC	HindIII
	Rev	CCCGCTCGAG-CGTATCATATTTACGTGC	XhoI
fu-(ΔG287-Orf46.1)-919-His	Fwd	CCCAAGCTTGGTGGTGGTGGTGGT-CAAAGCAAGAGCATCCAAACC	HindIII
	Rev	CCCGCTCGAG-CGGGCGGTATTCGGGGCTT	XhoI
fu ΔG287(394.98)-...	Fwd	CGCGGATCCGCTAGC-CCCAGTGTTAAATCGGC	NheI
	Rev	CGGGGATCC-ATCCTGCTCTTTTTTGCCGG	BamHI
fu Orf1-(Orf46.1)-His	Fwd	CGCGGATCCGCTAGC-GGACACACTTATTTCGGCATC	NheI
	Rev	CGCGGATCC-CCAGCGGTAGCCTAATTTGAT	
fu (Orf1)-Orf46.1-His	Fwd	CGCGGATCCGGTGGTGGTGGT-TCAGATTGGCAAACGATTC	BamHI
	Rev	CCCAAGCTT-CGTATCATATTTACGTGC	HindIII
fu (919)-Orf46.1-His	Fwd1	GCGGCGTCGACGGTGGCGGAGGCACTGGATCCTCAG	SalI
	Fwd2	GGAGGCACTGGATCCTCAGATTTGGCAAACGATTC	
	Rev	CCCGCTCGAG-CGTATCATATTTACGTGC	XhoI
Fu orf46-....	Fwd	GGAATTCCATATGTCAGATTTGGCAAACGATTC	NdeI
	Rev	CGCGGATCCCGTATCATATTTACGTGC	BamHI
Fu (orf46)-287-His	Fwd	CGGGGATCCGGGGGCGGCGGTGGCG	BamHI
	Rev	CCCAAGCTTATCCTGCTCTTTTTTGCCGGC	HindIII
Fu (orf46)-919-His	Fwd	CGCGGATCCGGTGGTGGTGGTCAAAGCAAGAGCATCCA AACC	BamHI
	Rev	CCCAAGCTTCGGGCGGTATTCGGGGCTTC	HindIII
Fu (orf46-919)-287-His	Fwd	CCCAAGCTTGGGGGCGGCGGTGGCG	HindIII
	Rev	CCCGCTCGAGATCCTGCTCTTTTTTGCCGGC	XhoI
Fu (orf46-287)-919-His	Fwd	CCCAAGCTTGGTGGTGGTGGTGGTCAAAGCAAGAGCATCCAAACC	HindIII
	Rev	CCCGCTCGAGCGGGCGGTATTCGGGGCTT	XhoI
(ΔG741)-961c-His	Fwd1	GGAGGCACTGGATCCGAGCCACAAACGACGACGA	XhoI
	Fwd2	GCGGCCTCGAG-GGTGGCGGAGGCACTGGATCCGAG	
	Rev	CCCGCTCGAG-ACCCAGCTTGTAAGGTTG	XhoI
(ΔG741)-961-His	Fwd1	GGAGGCACTGGATCCGAGCCACAAACGACGACGA	XhoI
	Fwd2	GCGGCCTCGAG-GGTGGCGGAGGCACTGGATCCGAG	
	Rev	CCCGCTCGAG-CCACTCGTAATTGACGCC	XhoI

(ΔG741)-983-His	Fwd	GCGGCCTCGAG-GGATCCGGCGGAGGCGGCACTTCTGCG	XhoI
	Rev	CCCGCTCGAG-GAACCGGTAGCCTACG	XhoI
(ΔG741)-orf46.1-His	Fwd1	GGAGGCACTGGATCCTCAGATTTGGCAAACGATTTC	Sall
	Fwd2	GCGGCGTCGACGGTGGCGGAGGCACTGGATCCTCAGA	
	Rev	CCCGCTCGAG-CGTATCATATTTACGTGC	XhoI
(ΔG983)-741(MC58) -His	Fwd	GCGGCCTCGAG-GGATCCGGAGGGGGTGGTGTGCGCC	XhoI
	Rev	CCCGCTCGAG-TTGCTTGGCGGCAAG	XhoI
(ΔG983)-961c-His	Fwd1	GGAGGCACTGGATCCGCAGCCACAAACGACGACGA	XhoI
	Fwd2	GCGGCCTCGAG-GGTGGCGGAGGCACTGGATCCGCAG	
	Rev	CCCGCTCGAG-ACCCAGCTTGTAAGGTTG	XhoI
(ΔG983)-961-His	Fwd1	GGAGGCACTGGATCCGCAGCCACAAACGACGACGA	XhoI
	Fwd2	GCGGCCTCGAG-GGTGGCGGAGGCACTGGATCCGCAG	
	Rev	CCCGCTCGAG-CCACTCGTAATTGACGCC	XhoI
(ΔG983)- Orf46.1-His	Fwd1	GGAGGCACTGGATCCTCAGATTTGGCAAACGATTTC	Sall
	Fwd2	GCGGCGTCGACGGTGGCGGAGGCACTGGATCCTCAGA	
	Rev	CCCGCTCGAG-CGTATCATATTTACGTGC	XhoI

* This primer was used as a Reverse primer for all the C terminal fusions of 287 to the His-tag.

§ Forward primers used in combination with the 287-His Reverse primer.

NB – All PCR reactions use strain 2996 unless otherwise specified (e.g. strain MC58)

In all constructs starting with an ATG not followed by a unique *NheI* site, the ATG codon is part of the *NdeI* site used for cloning. The constructs made using *NheI* as a cloning site at the 5' end (e.g. all those containing 287 at the N-terminus) have two additional codons (GCT AGC) fused to the coding sequence of the antigen.

Preparation of chromosomal DNA templates

N.meningitidis strains 2996, MC58, 394.98, 1000 and BZ232 (and others) were grown to exponential phase in 100ml of GC medium, harvested by centrifugation, and resuspended in 5ml buffer (20% w/v sucrose, 50mM Tris-HCl, 50mM EDTA, pH8). After 10 minutes incubation on ice, the bacteria were lysed by adding 10ml of lysis solution (50mM NaCl, 1% Na-Sarkosyl, 50μg/ml Proteinase K), and the suspension incubated at 37°C for 2 hours. Two phenol extractions (equilibrated to pH 8) and one CHCl₃/isoamylalcohol (24:1) extraction were performed. DNA was precipitated by addition of 0.3M sodium acetate and 2 volumes of ethanol, and collected by centrifugation. The pellet was washed once with 70%(v/v) ethanol and redissolved in 4.0ml TE buffer (10mM Tris-HCl, 1mM EDTA, pH 8.0). The DNA concentration was measured by reading OD₂₆₀.

PCR Amplification

The standard PCR protocol was as follows: 200ng of genomic DNA from 2996, MC581000, or BZ232 strains or 10ng of plasmid DNA preparation of recombinant clones were used as template in the presence of 40µM of each oligonucleotide primer, 400-800 µM dNTPs solution, 1x PCR buffer (including 1.5mM MgCl₂), 2.5 units *TaqI* DNA polymerase (using
5 Perkin-Elmer AmpliTaq, Boehringer Mannheim Expand™ Long Template).

After a preliminary 3 minute incubation of the whole mix at 95°C, each sample underwent a two-step amplification: the first 5 cycles were performed using the hybridisation temperature that excluded the restriction enzyme tail of the primer (T_{m1}). This was followed by 30 cycles
10 according to the hybridisation temperature calculated for the whole length oligos (T_{m2}). Elongation times, performed at 68°C or 72°C, varied according to the length of the Orf to be amplified. In the case of Orf1 the elongation time, starting from 3 minutes, was increased by 15 seconds each cycle. The cycles were completed with a 10 minute extension step at 72°C.

The amplified DNA was either loaded directly on a 1% agarose gel. The DNA fragment
15 corresponding to the band of correct size was purified from the gel using the Qiagen Gel Extraction Kit, following the manufacturer's protocol.

Digestion of PCR fragments and of the cloning vectors

The purified DNA corresponding to the amplified fragment was digested with the appropriate restriction enzymes for cloning into pET-21b+, pET22b+ or pET-24b+. Digested
20 fragments were purified using the QIAquick PCR purification kit (following the manufacturer's instructions) and eluted with either H₂O or 10mM Tris, pH 8.5. Plasmid vectors were digested with the appropriate restriction enzymes, loaded onto a 1.0% agarose gel and the band corresponding to the digested vector purified using the Qiagen QIAquick Gel Extraction Kit.

Cloning

The fragments corresponding to each gene, previously digested and purified, were ligated into pET21b+, pET22b+ or pET-24b+. A molar ratio of 3:1 fragment/vector was used with T4 DNA ligase in the ligation buffer supplied by the manufacturer.

Recombinant plasmid was transformed into competent *E.coli* DH5 or HB101 by incubating
30 the ligase reaction solution and bacteria for 40 minutes on ice, then at 37°C for 3 minutes.

This was followed by the addition of 800µl LB broth and incubation at 37°C for 20 minutes. The cells were centrifuged at maximum speed in an Eppendorf microfuge, resuspended in approximately 200µl of the supernatant and plated onto LB ampicillin (100mg/ml) agar.

Screening for recombinant clones was performed by growing randomly selected colonies overnight at 37°C in 4.0ml of LB broth + 100µg/ml ampicillin. Cells were pelleted and plasmid DNA extracted using the Qiagen QIAprep Spin Miniprep Kit, following the manufacturer's instructions. Approximately 1µg of each individual miniprep was digested with the appropriate restriction enzymes and the digest loaded onto a 1-1.5% agarose gel (depending on the expected insert size), in parallel with the molecular weight marker (1kb DNA Ladder, GIBCO). Positive clones were selected on the basis of the size of insert.

Expression

After cloning each gene into the expression vector, recombinant plasmids were transformed into *E.coli* strains suitable for expression of the recombinant protein. 1µl of each construct was used to transform *E.coli* BL21-DE3 as described above. Single recombinant colonies were inoculated into 2ml LB+Amp (100µg/ml), incubated at 37°C overnight, then diluted 1:30 in 20ml of LB+Amp (100µg/ml) in 100ml flasks, to give an OD₆₀₀ between 0.1 and 0.2. The flasks were incubated at 30°C or at 37°C in a gyratory water bath shaker until OD₆₀₀ indicated exponential growth suitable for induction of expression (0.4-0.8 OD). Protein expression was induced by addition of 1.0mM IPTG. After 3 hours incubation at 30°C or 37°C the OD₆₀₀ was measured and expression examined. 1.0ml of each sample was centrifuged in a microfuge, the pellet resuspended in PBS and analysed by SDS-PAGE and Coomassie Blue staining.

Gateway cloning and expression

Sequences labelled GATE were cloned and expressed using the GATEWAY Cloning Technology (GIBCO-BRL). Recombinational cloning (RC) is based on the recombination reactions that mediate the integration and excision of phage into and from the *E.coli* genome, respectively. The integration involves recombination of the *attP* site of the phage DNA within the *attB* site located in the bacterial genome (BP reaction) and generates an integrated phage genome flanked by *attL* and *attR* sites. The excision recombines *attL* and *attR* sites back to *attP* and *attB* sites (LR reaction). The integration reaction requires two enzymes [the phage protein Integrase (Int) and the bacterial protein integration host factor (IHF)] (BP clonase). The

- excision reaction requires Int, IHF, and an additional phage enzyme, Excisionase (Xis) (LR clonase). Artificial derivatives of the 25-bp bacterial *attB* recombination site, referred to as B1 and B2, were added to the 5' end of the primers used in PCR reactions to amplify Neisserial ORFs. The resulting products were BP cloned into a "Donor vector" containing complementary derivatives of the phage *attP* recombination site (P1 and P2) using BP clonase. The resulting "Entry clones" contain ORFs flanked by derivatives of the *attL* site (L1 and L2) and were subcloned into expression "destination vectors" which contain derivatives of the *attL*-compatible *attR* sites (R1 and R2) using LR clonase. This resulted in "expression clones" in which ORFs are flanked by B1 and B2 and fused in frame to the GST or His N terminal tags.
- 10 The *E. coli* strain used for GATEWAY expression is BL21-SI. Cells of this strain are induced for expression of the T7 RNA polymerase by growth in medium containing salt (0.3 M NaCl).

Note that this system gives N-terminus His tags.

Preparation of membrane proteins.

- Fractions composed principally of either inner, outer or total membrane were isolated in order to obtain recombinant proteins expressed with membrane-localisation leader sequences. The method for preparation of membrane fractions, enriched for recombinant proteins, was adapted from Filip *et. al.* [*J.Bact.* (1973) 115:717-722] and Davies *et. al.* [*J.Immunol.Meth.* (1990) 143:215-225]. Single colonies harbouring the plasmid of interest were grown overnight at 37°C in 20 ml of LB/Amp (100 µg/ml) liquid culture. Bacteria were diluted 1:30 in 1.0 L of fresh medium and grown at either 30°C or 37°C until the OD₅₅₀ reached 0.6-0.8. Expression of recombinant protein was induced with IPTG at a final concentration of 1.0 mM. After incubation for 3 hours, bacteria were harvested by centrifugation at 8000g for 15 minutes at 4°C and resuspended in 20 ml of 20 mM Tris-HCl (pH 7.5) and complete protease inhibitors (Boehringer-Mannheim). All subsequent procedures were performed at 4°C or on ice.

- Cells were disrupted by sonication using a Branson Sonifier 450 and centrifuged at 5000g for 20 min to sediment unbroken cells and inclusion bodies. The supernatant, containing membranes and cellular debris, was centrifuged at 50000g (Beckman Ti50, 29000rpm) for 75 min, washed with 20 mM Bis-tris propane (pH 6.5), 1.0 M NaCl, 10% (v/v) glycerol and sedimented again at 50000g for 75 minutes. The pellet was resuspended in 20mM Tris-HCl (pH 7.5), 2.0% (v/v) Sarkosyl, complete protease inhibitor (1.0 mM EDTA, final

concentration) and incubated for 20 minutes to dissolve inner membrane. Cellular debris was pelleted by centrifugation at 5000g for 10 min and the supernatant centrifuged at 75000g for 75 minutes (Beckman Ti50, 33000rpm). Proteins 008L and 519L were found in the supernatant suggesting inner membrane localisation. For these proteins both inner and total
5 membrane fractions (washed with NaCl as above) were used to immunise mice. Outer membrane vesicles obtained from the 75000g pellet were washed with 20 mM Tris-HCl (pH 7.5) and centrifuged at 75000g for 75 minutes or overnight. The OMV was finally resuspended in 500 µl of 20 mM Tris-HCl (pH 7.5), 10% v/v glycerol. Orf1L and Orf40L were both localised and enriched in the outer membrane fraction which was used to
10 immunise mice. Protein concentration was estimated by standard Bradford Assay (Bio-Rad), while protein concentration of inner membrane fraction was determined with the DC protein assay (Bio-Rad). Various fractions from the isolation procedure were assayed by SDS-PAGE.

Purification of His-tagged proteins

Various forms of 287 were cloned from strains 2996 and MC58. They were constructed with
15 a C-terminus His-tagged fusion and included a mature form (aa 18-427), constructs with deletions ($\Delta 1$, $\Delta 2$, $\Delta 3$ and $\Delta 4$) and clones composed of either B or C domains. For each clone purified as a His-fusion, a single colony was streaked and grown overnight at 37°C on a LB/Amp (100 µg/ml) agar plate. An isolated colony from this plate was inoculated into 20ml of LB/Amp (100 µg/ml) liquid medium and grown overnight at 37°C with shaking.
20 The overnight culture was diluted 1:30 into 1.0 L LB/Amp (100 µg/ml) liquid medium and allowed to grow at the optimal temperature (30 or 37°C) until the OD₅₅₀ reached 0.6-0.8. Expression of recombinant protein was induced by addition of IPTG (final concentration 1.0mM) and the culture incubated for a further 3 hours. Bacteria were harvested by centrifugation at 8000g for 15 min at 4°C. The bacterial pellet was resuspended in 7.5 ml of
25 either (i) cold buffer A (300 mM NaCl, 50 mM phosphate buffer, 10 mM imidazole, pH 8.0) for soluble proteins or (ii) buffer B (10mM Tris-HCl, 100 mM phosphate buffer, pH 8.8 and, optionally, 8M urea) for insoluble proteins. Proteins purified in a soluble form included 287-His, $\Delta 1$, $\Delta 2$, $\Delta 3$ and $\Delta 4$ 287-His, $\Delta 4$ 287MC58-His, 287c-His and 287cMC58-His. Protein 287bMC58-His was insoluble and purified accordingly. Cells were disrupted by
30 sonication on ice four times for 30 sec at 40W using a Branson sonifier 450 and centrifuged at 13000xg for 30 min at 4°C. For insoluble proteins, pellets were resuspended in 2.0 ml buffer C (6 M guanidine hydrochloride, 100 mM phosphate buffer, 10 mM Tris- HCl, pH 7.5

and treated with 10 passes of a Dounce homogenizer. The homogenate was centrifuged at 13000g for 30 min and the supernatant retained. Supernatants for both soluble and insoluble preparations were mixed with 150µl Ni²⁺-resin (previously equilibrated with either buffer A or buffer B, as appropriate) and incubated at room temperature with gentle agitation for 30 min. The resin was Chelating Sepharose Fast Flow (Pharmacia), prepared according to the manufacturer's protocol. The batch-wise preparation was centrifuged at 700g for 5 min at 4°C and the supernatant discarded. The resin was washed twice (batch-wise) with 10ml buffer A or B for 10 min, resuspended in 1.0 ml buffer A or B and loaded onto a disposable column. The resin continued to be washed with either (i) buffer A at 4°C or (ii) buffer B at room temperature, until the OD₂₈₀ of the flow-through reached 0.02-0.01. The resin was further washed with either (i) cold buffer C (300mM NaCl, 50mM phosphate buffer, 20mM imidazole, pH 8.0) or (ii) buffer D (10mM Tris-HCl, 100mM phosphate buffer, pH 6.3 and, optionally, 8M urea) until OD₂₈₀ of the flow-through reached 0.02-0.01. The His-fusion protein was eluted by addition of 700µl of either (i) cold elution buffer A (300 mM NaCl, 50mM phosphate buffer, 250 mM imidazole, pH 8.0) or (ii) elution buffer B (10 mM Tris-HCl, 100 mM phosphate buffer, pH 4.5 and, optionally, 8M urea) and fractions collected until the OD₂₈₀ indicated all the recombinant protein was obtained. 20µl aliquots of each elution fraction were analysed by SDS-PAGE. Protein concentrations were estimated using the Bradford assay.

20 *Renaturation of denatured His-fusion proteins.*

Denaturation was required to solubilize 287bMC8, so a renaturation step was employed prior to immunisation. Glycerol was added to the denatured fractions obtained above to give a final concentration of 10% v/v. The proteins were diluted to 200 µg/ml using dialysis buffer I (10% v/v glycerol, 0.5M arginine, 50 mM phosphate buffer, 5.0 mM reduced glutathione, 0.5 mM oxidised glutathione, 2.0M urea, pH 8.8) and dialysed against the same buffer for 12-14 hours at 4°C. Further dialysis was performed with buffer II (10% v/v glycerol, 0.5M arginine, 50mM phosphate buffer, 5.0mM reduced glutathione, 0.5mM oxidised glutathione, pH 8.8) for 12-14 hours at 4°C. Protein concentration was estimated using the formula:

$$\text{Protein (mg/ml)} = (1.55 \times OD_{280}) - (0.76 \times OD_{260})$$

Amino acid sequence analysis.

Automated sequence analysis of the NH₂-terminus of proteins was performed on a Beckman sequencer (LF 3000) equipped with an on-line phenylthiohydantoin-amino acid analyser (System Gold) according to the manufacturer's recommendations.

5 *Immunization*

Balb/C mice were immunized with antigens on days 0, 21 and 35 and sera analyzed at day 49.

Sera analysis – ELISA

The acapsulated MenB M7 and the capsulated strains were plated on chocolate agar plates and incubated overnight at 37°C with 5% CO₂. Bacterial colonies were collected from the
10 agar plates using a sterile dracon swab and inoculated into Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD₆₂₀. The bacteria were let to grow until the OD reached the value of 0.4-0.5. The culture was centrifuged for 10 minutes at 4000rpm. The supernatant was discarded and bacteria were washed twice with PBS, resuspended in PBS containing 0.025% formaldehyde, and
15 incubated for 1 hour at 37°C and then overnight at 4°C with stirring. 100µl bacterial cells were added to each well of a 96 well Greiner plate and incubated overnight at 4°C. The wells were then washed three times with PBT washing buffer (0.1% Tween-20 in PBS). 200µl of saturation buffer (2.7% polyvinylpyrrolidone 10 in water) was added to each well and the plates incubated for 2 hours at 37°C. Wells were washed three times with PBT. 200µl of
20 diluted sera (Dilution buffer: 1% BSA, 0.1% Tween-20, 0.1% NaN₃ in PBS) were added to each well and the plates incubated for 2 hours at 37°C. Wells were washed three times with PBT. 100µl of HRP-conjugated rabbit anti-mouse (Dako) serum diluted 1:2000 in dilution buffer were added to each well and the plates were incubated for 90 minutes at 37°C. Wells were washed three times with PBT buffer. 100µl of substrate buffer for HRP (25ml of citrate
25 buffer pH5, 10mg of O-phenildiamine and 10µl of H₂O₂) were added to each well and the plates were left at room temperature for 20 minutes. 100µl 12.5% H₂SO₄ was added to each well and OD₄₉₀ was followed. The ELISA titers were calculated arbitrarily as the dilution of sera which gave an OD₄₉₀ value of 0.4 above the level of preimmune sera. The ELISA was considered positive when the dilution of sera with OD₄₉₀ of 0.4 was higher than 1:400.

30 *Sera analysis – FACS Scan bacteria binding assay*

The acapsulated MenB M7 strain was plated on chocolate agar plates and incubated overnight at 37°C with 5% CO₂. Bacterial colonies were collected from the agar plates using

a sterile dracon swab and inoculated into 4 tubes containing 8ml each Mueller-Hinton Broth (Difco) containing 0.25% glucose. Bacterial growth was monitored every 30 minutes by following OD₆₂₀. The bacteria were let to grow until the OD reached the value of 0.35-0.5. The culture was centrifuged for 10 minutes at 4000rpm. The supernatant was discarded and the pellet was resuspended in blocking buffer (1% BSA in PBS, 0.4% NaN₃) and centrifuged for 5 minutes at 4000rpm. Cells were resuspended in blocking buffer to reach OD₆₂₀ of 0.05. 100µl bacterial cells were added to each well of a Costar 96 well plate. 100µl of diluted (1:100, 1:200, 1:400) sera (in blocking buffer) were added to each well and plates incubated for 2 hours at 4°C. Cells were centrifuged for 5 minutes at 4000rpm, the supernatant aspirated and cells washed by addition of 200µl/well of blocking buffer in each well. 100µl of R-Phicoerytrin conjugated F(ab)₂ goat anti-mouse, diluted 1:100, was added to each well and plates incubated for 1 hour at 4°C. Cells were spun down by centrifugation at 4000rpm for 5 minutes and washed by addition of 200µl/well of blocking buffer. The supernatant was aspirated and cells resuspended in 200µl/well of PBS, 0.25% formaldehyde. Samples were transferred to FACScan tubes and read. The condition for FACScan (Laser Power 15mW) setting were: FL2 on; FSC-H threshold:92; FSC PMT Voltage: E 01; SSC PMT: 474; Amp. Gains 6.1; FL-2 PMT: 586; compensation values: 0.

Sera analysis – bactericidal assay

N. meningitidis strain 2996 was grown overnight at 37°C on chocolate agar plates (starting from a frozen stock) with 5% CO₂. Colonies were collected and used to inoculate 7ml Mueller-Hinton broth, containing 0.25% glucose to reach an OD₆₂₀ of 0.05-0.08. The culture was incubated for approximately 1.5 hours at 37 degrees with shaking until the OD₆₂₀ reached the value of 0.23-0.24. Bacteria were diluted in 50mM Phosphate buffer pH 7.2 containing 10mM MgCl₂, 10mM CaCl₂ and 0.5% (w/v) BSA (assay buffer) at the working dilution of 10⁵ CFU/ml. The total volume of the final reaction mixture was 50 µl with 25 µl of serial two fold dilution of test serum, 12.5 µl of bacteria at the working dilution, 12.5 µl of baby rabbit complement (final concentration 25%).

Controls included bacteria incubated with complement serum, immune sera incubated with bacteria and with complement inactivated by heating at 56°C for 30'. Immediately after the addition of the baby rabbit complement, 10µl of the controls were plated on Mueller-Hinton agar plates using the tilt method (time 0). The 96-wells plate was incubated for 1 hour at 37°C with rotation. 7µl of each sample were plated on Mueller-Hinton agar plates as spots, whereas 10µl of the controls were plated on Mueller-Hinton agar plates using the tilt method

(time 1). Agar plates were incubated for 18 hours at 37 degrees and the colonies corresponding to time 0 and time 1 were counted.

Sera analysis – western blots

Purified proteins (500ng/lane), outer membrane vesicles (5µg) and total cell extracts (25µg)
5 derived from MenB strain 2996 were loaded onto a 12% SDS-polyacrylamide gel and transferred to a nitrocellulose membrane. The transfer was performed for 2 hours at 150mA at 4°C, using transfer buffer (0.3% Tris base, 1.44% glycine, 20% (v/v) methanol). The membrane was saturated by overnight incubation at 4°C in saturation buffer (10% skimmed milk, 0.1% Triton X100 in PBS). The membrane was washed twice with washing buffer (3%
10 skimmed milk, 0.1% Triton X100 in PBS) and incubated for 2 hours at 37°C with mice sera diluted 1:200 in washing buffer. The membrane was washed twice and incubated for 90 minutes with a 1:2000 dilution of horseradish peroxidase labelled anti-mouse Ig. The membrane was washed twice with 0.1% Triton X100 in PBS and developed with the Opti-4CN Substrate Kit (Bio-Rad). The reaction was stopped by adding water.

15 The OMVs were prepared as follows: *N. meningitidis* strain 2996 was grown overnight at 37 degrees with 5% CO₂ on 5 GC plates, harvested with a loop and resuspended in 10 ml of 20mM Tris-HCl pH 7.5, 2 mM EDTA. Heat inactivation was performed at 56°C for 45 minutes and the bacteria disrupted by sonication for 5 minutes on ice (50% duty cycle, 50% output, Branson sonifier 3 mm microtip). Unbroken cells were removed by centrifugation at
20 5000g for 10 minutes, the supernatant containing the total cell envelope fraction recovered and further centrifuged overnight at 50000g at the temperature of 4°C. The pellet containing the membranes was resuspended in 2% sarkosyl, 20mM Tris-HCl pH 7.5, 2 mM EDTA and incubated at room temperature for 20 minutes to solubilise the inner membranes. The suspension was centrifuged at 10000g for 10 minutes to remove aggregates, the supernatant
25 was further centrifuged at 50000g for 3 hours. The pellet, containing the outer membranes was washed in PBS and resuspended in the same buffer. Protein concentration was measured by the D.C. Bio-Rad Protein assay (Modified Lowry method), using BSA as a standard.

Total cell extracts were prepared as follows: *N. meningitidis* strain 2996 was grown overnight on a GC plate, harvested with a loop and resuspended in 1ml of 20mM Tris-HCl.
30 Heat inactivation was performed at 56°C for 30 minutes.

961 domain studies

Cellular fractions preparation Total lysate, periplasm, supernatant and OMV of *E.coli* clones expressing different domains of 961 were prepared using bacteria from over-night cultures or

-101-

after 3 hours induction with IPTG. Briefly, the periplasm were obtained suspending bacteria in saccarose 25% and Tris 50mM (pH 8) with polymyxine 100µg/ml. After 1hr at room temperature bacteria were centrifuged at 13000rpm for 15 min and the supernatant were collected. The culture supernatant were filtered with 0.2µm and precipitated with TCA 50% in ice for two hours. After centrifugation (30 min at 13000 rp) pellets were rinsed twice with ethanol 70% and suspended in PBS. The OMV preparation was performed as previously described. Each cellular fraction were analyzed in SDS-PAGE or in Western Blot using the polyclonal anti-serum raised against GST-961.

Adhesion assay Chang epithelial cells (Wong-Kilbourne derivative, clone 1-5c-4, human conjunctiva) were maintained in DMEM (Gibco) supplemented with 10% heat-inactivated FCS, 15mM L-glutamine and antibiotics.

For the adherence assay, sub-confluent culture of Chang epithelial cells were rinsed with PBS and treated with trypsin-EDTA (Gibco), to release them from the plastic support. The cells were then suspended in PBS, counted and dilute in PBS to 5×10^5 cells/ml.

Bacteria from over-night cultures or after induction with IPTG, were pelleted and washed twice with PBS by centrifuging at 13000 for 5 min. Approximately $2-3 \times 10^8$ (cfu) were incubated with 0.5 mg/ml FITC (Sigma) in 1ml buffer containing 50mM NaHCO_3 and 100mM NaCl pH 8, for 30 min at room temperature in the dark. FITC-labeled bacteria were wash 2-3 times and suspended in PBS at $1-1.5 \times 10^9$ /ml. 200µl of this suspension ($2-3 \times 10^8$) were incubated with 200µl (1×10^5) epithelial cells for 30min a 37°C. Cells were than centrifuged at 2000rpm for 5 min to remove non-adherent bacteria, suspended in 200µl of PBS, transferred to FACScan tubes and read

CLAIMS



1. A method for the heterologous expression of a protein of the invention, in which (a) at least one domain in the protein is deleted and, optionally, (b) no fusion partner is used.
2. The method of claim 1, in which the protein of the invention is ORF46.
- 5 3. The method of claim 2, in which ORF46 is divided into a first domain (amino acids 1-433) and a second domain (amino acids 433-608).
4. The method of claim 2, in which the protein of the invention is 564.
5. The method of claim 4, in which protein 564 is divided into domains as shown in Figure 8.
- 10 6. The method of claim 1 in which the protein of the invention is 961.
7. The method of claim 6, in which protein 961 is divided into domains as shown in Figure 12.
8. The method of claim 1, in which the protein of the invention is 502 and the domain is amino acids 28 to 167 (numbered according to the MC58 sequence).
- 15 9. The method of claim 1, in which the protein of the invention is 287.
10. A method for the heterologous expression of a protein of the invention, in which (a) a portion of the N-terminal domain of the protein is deleted.
11. The method of claim 9 or claim 10, in which protein 287 is divided into domains A B & C shown in Figure 5.
- 20 12. The method of claim 11, in which (i) domain A, (ii) domains A and B, or (iii) domains A and C are deleted.
13. The method of claim 11, wherein (i) amino acids 1-17, (ii) amino acids 1-25, (iii) amino acids 1-69, or (iv) amino acids 1-106, of domain A are deleted.
14. A method for the heterologous expression of a protein of the invention, in which (a) no
25 fusion partner is used, and (b) the protein's native leader peptide (if present) is used.

15. The method of claim 14, in which the protein of the invention is selected from the group consisting of: 111, 149, 206, 225-1, 235, 247-1, 274, 283, 286, 292, 401, 406, 502-1, 503, 519-1, 525-1, 552, 556, 557, 570, 576-1, 580, 583, 664, 759, 907, 913, 920-1, 936-1, 953, 961, 983, 989, Orf4, Orf7-1, Orf9-1, Orf23, Orf25, Orf37, Orf38, Orf40, Orf40.1, Orf40.2, Orf72-1, Orf76-1, Orf85-2, Orf91, Orf97-1, Orf119, Orf143.1, NMB0109, NMB2050, 008, 105, 117-1, 121-1, 122-1, 128-1, 148, 216, 243, 308, 593, 652, 726, 926, 982, Orf83-1 and Orf143-1.
16. A method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is replaced by the leader peptide from a different protein and, optionally, (b) no fusion partner is used.
17. The method of claim 16, in which the different protein is 961, ORF4, *E.coli* OmpA, or *E.carotovora* PelB, or in which the leader peptide is MKKYLFSAA.
18. The method of claim 17, in which the different protein is *E.coli* OmpA and the protein of the invention is ORF1.
19. The method of claim 17, in which the protein of the invention is 911 and the different protein is *E.carotovora* PelB or *E.coli* OmpA.
20. The method of claim 17, in which the different protein is ORF4 and the protein of the invention is 287.
21. A method for the heterologous expression of a protein of the invention, in which (a) the protein's leader peptide is deleted and, optionally, (b) no fusion partner is used.
22. The method of claim 21, in which the protein of the invention is 919.
23. A method for the heterologous expression of a protein of the invention, in which expression of a protein of the invention is carried out at a temperature at which a toxic activity of the protein is not manifested.
24. The method of claim 23, in which protein 919 is expressed at 30°C.
25. A method for the heterologous expression of a protein of the invention, in which protein is mutated to reduce or eliminate toxic activity.


26. The method of claim 25, in which the protein of the invention is 907, 919 or 922.
27. The method of claim 26, in which 907 is mutated at Glu-117 (*e.g.* Glu→Gly).
28. The method of claim 26, in which 919 is mutated at Glu-255 (*e.g.* Glu→Gly) and/or Glu-323 (*e.g.* Glu→Gly).
- 5 29. The method of claim 26, in which 922 is mutated at Glu-164 (*e.g.* Glu→Gly), Ser-213 (*e.g.* Ser→Gly) and/or Asn-348 (*e.g.* Asn→Gly).
30. A method for the heterologous expression of a protein of the invention, in which vector pSM214 is used or vector pET-24b is used.
- 10 31. The method of claim 30, in which the protein of the invention is 953 and the vector is pSM214.
32. A method for the heterologous expression of a protein of the invention, in which a protein is expressed or purified such that it adopts a particular multimeric form.
33. The method of claim 32, in which protein 953 is expressed and/or purified in monomeric form.
- 15 34. The method of claim 32, in which protein 961 is expressed and/or purified in tetrameric form.
35. The method of claim 32, in which protein 287 is expressed and/or purified in dimeric form.
36. The method of claim 32, in which protein 919 is expressed and/or purified in monomeric form.
- 20 37. A method for the heterologous expression of a protein of the invention, in which the protein is expressed as a lipidated protein.
38. The method of claim 37, in which the protein of the invention is 919, 287, ORF4, 406, 576, or ORF25.
- 25 39. A method for the heterologous expression of a protein of the invention, in which (a) the protein's C-terminus region is mutated and, optionally, (b) no fusion partner is used.

40. The method of claim 39, wherein the mutation is a substitution, an insertion, or a deletion
41. The method of claim 40, wherein the protein of the invention is 730, ORF29 or ORF46.
42. A method for the heterologous expression of a protein of the invention, in which the protein's leader peptide is mutated.
- 5 43. The method of claim 42, in which the protein of the invention is 919.
44. A method for the heterologous expression of a protein, in which a poly-glycine stretch within the protein is mutated.
45. The method of claim 44, wherein the protein is a protein of the invention.
46. The method of claim 45, wherein the protein of the invention is 287, 741, 983 or Tbp2.
- 10 47. The method of claim 46, wherein (Gly)₆ is deleted from 287 or 983.
48. The method of claim 46, wherein (Gly)₄ is deleted from Tbp2 or 741
49. The method of claim 47 or claim 48, wherein the leader peptide is also deleted.
50. The method of any preceding claim, in which the heterologous expression is in an *E.coli* host.
- 15 51. A protein expressed by the method of any preceding claim.
52. A heterologous protein comprising the N-terminal amino acid sequence MKKYLFSA.

1/13

FIGURE 1**FIGURE 2**

2/13

FIGURE 3**ELISA: POSITIVE**


3/13

FIGURE 4


M1 961




TP OMV



PURIFICATION



WESTERN BLOT






BACTERICIDAL ASSAY

FACS

ELISA: POSITIVE

4/13

FIGURE 5**FIGURE 6****FIGURE 9**

5/13

FIGURE 7

<A-----<A1
 MC58 1 MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLSPKPAAPVSEKETEAKEKEDAPQAGSQG
 2996 1 MFKRSVIAMACIFALSACGGGGGGSPDVKSADTLSPKPAAPVSEKETEVKEDAPQAGSQG

-----<A2
 MC58 61 QGAPSAQGSQDMAAVSEENTGNGCAVTADNPKNEDEVAQNDMPQNAAGTDSSTPNHTPDP
 2996 61 QGAPSTQGSQDMAAVSAENTGNGCAATIDKPKNEDEGPQNDMPQN.....

-----<A3
 MC58 121 NMLAGNMENQATDAGESSQPANQPDMANAADGMQDDPSAGGQNAAGNTAAQGANQAGNNQ
 2996 106SAESANQTCNNQ

-----A><B-----
 MC58 181 AAGSSDPIPASNPAPANGGSNFGVRDLANGVLIDGPSQNTLTTHCKGDSGNNFLDEEV
 2996 118 PADSSDSAPASNPAPANGGSNFGVRDLANGVLIDGPSQNTLTTHCKGDSGNDMLLDEEA

-----B>
 MC58 241 QLKSEFEKLSADAKISNYKKDGKNDKFVGLVADSVMKGINOYTIIFYKPK..PTSFARFR
 2996 178 PSKSEFENLNESERIEKYKKDGKSDKFTNLVATAVQANGINKYVLIYKDKSASSSSARFR



-----<C-----
 MC58 299 RSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSNIFAPEGNYRYLTYGAEKLPGG
 2996 238 RSARSRRSLPAEMPLIPVNQADTLIVDGEAVSLTGHSNIFAPEGNYRYLTYGAEKLPGG

 MC58 359 SYALRVQGEPAKGEMLAGTAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSVDDGIIDS
 2996 298 SYALRVQGEPAKGEMLAGTAVYNGEVLHFHTENGRPYPTRGRFAAKVDFGSKSVDDGIIDS









 MC58 419 GDDLHMGTOKFKAIDGNGFKGTWTENGCGDVSGKFYGPAGEEVAGKYSYRPTDAEKGGF
 2996 358 GDDLHMGTOKFKAIDGNGFKGTWTENGCGDVSGRFYGPAGEEVAGKYSYRPTDAEKGGF

-----C>
 MC58 479 GVFAKGKEQD*
 2996 418 GVFAKGKEQD*




6/13

FIGURE 8**FIGURE 10**



7/13

FIGURE 11A**FIGURE 11B****FIGURE 12****961 (2996)**961 L (2996) ☒**961 (MC58)**961 L (MC58) ☐**961a (2996=MC58)****961b (2996)****961c (2996)**961c-L (2996) ☐**961c (MC58)**961c-L (MC58) ☐**961d (2996)****961-Δ1 (2996)**961Δ1-L ☐☒ Leader Peptide☒ Region present in 2996,
not in MC58☐ Coil-coiled segment☒ Membrane anchor




8/13

FIGURE 13**FIGURE 14****FIGURE 14A — ΔG287—919****FIGURE 14B — ΔG287—953**






9/13

FIGURE 14C — ΔG287—961**FIGURE 14D — ΔG287NZ—919****FIGURE 14E — ΔG287NZ—953****FIGURE 14F — ΔG287NZ—961****FIGURE 14G — ΔG983-ORF46.1**

10/13

FIGURE 14H — ΔG983-741**FIGURE 14I — ΔG983-961****FIGURE 14J — ΔG983-961c****FIGURE 14K — ΔG741-961****FIGURE 14L — ΔG741-961c**

11/13

FIGURE 14M — ΔG741-983**FIGURE 14N — ΔG741-ORF46.1****FIGURE 14O — ORF46.1-741****FIGURE 14P — ORF46.1-961****FIGURE 14Q — ORF46.1-961c**

12/13









FIGURE 14R — 961-ORF46.1**FIGURE 14S — 961-741****FIGURE 14T — 961-983****FIGURE 14U — 961c-ORF46.1****FIGURE 14V — 961c-741**

FIGURE 14W — 961c-983**FIGURE 14X — 961cL-ORF46.1****FIGURE 14Y — 961cL-741****FIGURE 14Z — 961cL-983**

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- ☒ BLACK BORDERS
- ☒ IMAGE CUT OFF AT TOP, BOTTOM OR SIDES
- ☐ FADED TEXT OR DRAWING
- ☐ BLURRED OR ILLEGIBLE TEXT OR DRAWING
- ☐ SKEWED/SLANTED IMAGES
- ☐ COLOR OR BLACK AND WHITE PHOTOGRAPHS
- ☒ GRAY SCALE DOCUMENTS
- ☐ LINES OR MARKS ON ORIGINAL DOCUMENT
- ☐ REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY
- ☐ OTHER: _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.